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Background—Ultrasmall superparamagnetic particles of iron oxide (USPIO) detect cellular 
inflammation on magnetic resonance imaging (MRI). In patients with abdominal aortic 
aneurysm, we assessed whether USPIO-enhanced MRI can predict aneurysm growth rates and 
clinical outcomes.
Methods—In a prospective multicentre open-label cohort study, 342 patients with abdominal 
aortic aneurysm (diamete by the presence of USPIO enhancement and
were monitored with serial ultrasound and clinical follow-up for at least 2 years. The primary 
endpoint was the composite of aneurysm rupture or repair.
Results—Participants (85% male, 73·1±7·2 years) had baseline aneurysm diameter of 49·6±7·7
mm, and USPIO enhancement was identified in 146 (42·7%) participants, absent in 191 (55·8%) 
and indeterminate in 5 (1·5%). During follow-up (1005±280 days), there were 17 (5·0%) 
abdominal aortic aneurysm ruptures, 126 (36·8%) abdominal aortic aneurysm repairs, and 48 
(14·0%) deaths. Compared to those without uptake, patients with USPIO enhancement have
increased rates of aneurysm expansion (3·1±2·5 versus 2·5±2·4 mm/year, p=0·0424) although 
this was not independent of current smoking habit (p=0·1993). Patients with USPIO 
enhancement had higher rates of aneurysm rupture or repair (47·3% versus 35·6%; difference 
11·7%, 95% confidence intervals 1·1 to 22·2%, p=0·0308): this was similar for each component
of rupture (6.8% versus 3.7%, p=0·1857) or repair (41.8% versus 32.5%, p=0·0782). USPIO 
enhancement was associated with reduced event-free survival for aneurysm rupture or repair 
(p=0·0275), all-cause mortality (p=0·0635) and aneurysm-related mortality (p=0·0590). Baseline 
abdominal aortic aneurysm diameter (p<0·0001) and current smoking habit (p=0·0446) also 
predicted the primary outcome, and the addition of USPIO enhancement to the multivariate 
model did not improve event prediction (c-statistic, 0·7935 to 0·7936). 
Conclusions—USPIO-enhanced MRI is a novel approach to the identification of aortic wall 
cellular inflammation in patients with abdominal aortic aneurysms, and predicts the rate of 
aneurysm growth and clinical outcome. However, it does not provide independent prediction of 
aneurysm expansion or clinical outcomes in a model incorporating known clinical risk factors.
Clinical Trial Registration—URL:http://www.isrctn.com/ Unique Identifier: ISRCTN76413758
EudraCT Number: 2012-002488-25
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What is new? 
In this proof-of-concept phase 2 study, we demonstrate for the first time that functional 
imaging of abdominal aortic aneurysms can predict disease progression and clinical 
events. 
Aortic wall inflammation detected by ultrasmall superparamagnetic particles of iron 
oxide (USPIO)-enhanced magnetic resonance imaging (MRI) predicts the rate of 
aneurysm growth, and the risk of aneurysm rupture or repair as well as being associated 
with all-cause and aneurysm-related mortality.
What are the clinical implications?
Multivariate analysis demonstrated that USPIO-enhanced MRI does not appear to 
improve risk stratification beyond current predictors of clinical outcome including 
ultrasound measures of aneurysm diameter. 
This technique may be a useful adjunctive imaging approach in those with high-risk or
borderline aneurysm sizes, or those with larger aneurysms where the balance of risk and 
benefit is uncertain.
This approach may also have utility in assessing candidate anti-inflammatory therapies 
targeted at reducing disease progression.









Abdominal aortic aneurysms have a prevalence of 5% in 65-74 year-old men and when ruptured, 
are associated with a mortality of up to 90%.1 At a population level, ruptured aortic aneurysms 
are a major cause of death being the thirteenth commonest cause of death and accounting for 
over 150,000 deaths in 2013.2 Pre-emptive elective open surgical or endovascular repair can be 
life-saving and is considered when the abdominal aortic aneurysm diameter exceeds 55 mm, is 
.3-5
Abdominal aortic aneurysms are usually associated with no symptoms and are often
identified incidentally or as part of an ultrasound-based screening programme. Population 
screening has been established in some countries and is associated with a halving of the mortality 
associated with abdominal aortic aneurysms.6,7 Continued surveillance of aneurysms is however 
challenging because of the non-linearity and unpredictability of expansion rates,8 although the 
best current predictor of aneurysm expansion and rupture is the baseline aneurysm diameter.1,9
Furthermore, the pathophysiological mechanisms underlying aneurysm expansion remain 
uncertain, and the role of cellular inflammation and macrophage infiltration has been debated.
Finally, up to one fifth of ruptured abdominal aortic aneurysms are <55 mm in diameter and 40%
of patients with aneurysm diameters between 70 and 100 mm do not experience aneurysm 
rupture.10 There is therefore an unmet clinical need to identify more reliable methods of 
identifying those patients at risk of abdominal aortic aneurysm expansion and rupture,11,12 and 
techniques that assess both the structure and biology of aneurysms hold considerable promise.
Ultrasmall superparamagnetic particles of iron oxide (USPIO) constitute a class of
magnetic resonance imaging (MRI) contrast agent that are taken up by tissue-resident 
macrophages and can be used to identify cellular inflammation within tissues13,14 including 
abdominal aortic aneurysms.15,16 In a small pilot study of 29 patients with abdominal aortic 









aneurysm,15 we have previously demonstrated that USPIO enhancement on MRI is associated 
with macrophage infiltration of the abdominal aortic aneurysm wall and more rapid rates of 
abdominal aortic aneurysm expansion. We therefore aimed to validate these preliminary findings 
in a larger multicentre cohort of patients, and to determine whether USPIO-enhanced MRI could 




The Magnetic resonance imaging using ultrasmall superparamagnetic particles of iron oxide in 
patients under surveillance for Abdominal Aortic Aneurysm to predict Rupture or Surgical repair
(MA3RS) study was a prospective multi-centre observational open-label cohort study of patients 
under routine ultrasound surveillance for abdominal aortic aneurysm. The research design and 
protocol has been described previously (ISRCTN76413758).17 The study was approved by the 
local research ethics committee (12/ES/0068) and the use of ferumoxytol was given Clinical 
Trial Authorisation by the Medicines and Healthcare products Regulatory Authority (MHRA) of 
the United Kingdom (EudraCT Number 2012-002488-25).
Study Population
Consecutive patients were recruited from three centres in Scotland, UK (Royal Infirmary of 
Edinburgh, Western Infirmary of Glasgow and Forth Valley Royal Hospital in Larbert) between 
8th November 2012 and 5th December 2014. Inclusion criteria were age >40 years, maximum
anteroposterior abdominal aortic aneurysm diameter 40 mm by abdominal ultrasound, and 
under ultrasound surveillance as part of routine clinical care. Exclusion criteria included patients 









with planned repair of abdominal aortic aneurysm, known inflammatory aneurysm, aneurysm
arising from a connective tissue disorder, women of child-bearing potential, renal failure 
m2) and contraindication to MRI or 
ferumoxytol. All participants gave written informed consent to participate in the study.
Study Protocol
Participants attended for a baseline assessment within 6 weeks of the screening abdominal 
ultrasound. Participant characterisation comprised of full clinical assessment, USPIO-enhanced 
MRI and computed tomography aortography. The scanning protocols and image analysis 
techniques have been described previously.15,17 In brief, patients underwent a baseline 3T MRI
(Magnetom Verio 3T, Siemens Healthcare, Erlangen, Germany) before receiving an intravenous 
infusion of a weight-adjusted dose of USPIO (4 mg/kg of ferumoxytol; Rienso®, Takeda Italia, 
Italy). A second MRI scan was performed 24-36 hours after USPIO administration. Two trained 
observers performed image analysis using bespoke software that compared pre- and post-contrast 
images using semi-automatic registration. To calculate the degree of USPIO enhancement, 
colour maps were generated to depict the percentage change in T2* which is the decay constant 
for the exponential decay of signal over time. Using the pre-
in T2*, each colour map was independently classified by two trained observers into patients with 
or without USPIO enhancement 15) within the wall of the abdominal 
aortic aneurysm (Figure 1). Discordant classifications were resolved by consensus.
Clinical Follow Up
Patients were reviewed every 6 months in the research clinic for a minimum of 24 months. 
Structured follow up data were collected on abdominal aortic aneurysm events, hospital 
admissions and other relevant clinical data. Clinical events were verified independently using 









electronic health records and public registry data as described previously.18,19 Serial maximum 
anteroposterior diameters were obtained by ultrasound in dedicated abdominal aortic aneurysm
surveillance clinics performed by trained specialist vascular practitioners who were blinded to 
USPIO-enhanced MRI findings. We have previously reported interobserver coefficient of 
variation of aortic diameter measurements of 3.5%.20 Participants unable to attend for subsequent
research visits were followed-up through electronic health records as described previously.18,19
Clinical Endpoints and Adjudication
Clinical data from clinic visits, research database, electronic health records, primary care 
contacts and General Register Office were reviewed and clinical endpoints adjudicated by an 
independent Clinical Endpoint Committee. The committee members were blinded to the MRI 
findings. Follow-up was censored at 21st November 2016 or at the time of event.  
Statistical Analysis
The primary endpoint was the composite of abdominal aortic aneurysm rupture or repair. We
estimated that 130 events would be required to have adequate sensitivity to determine the added 
value of USPIO-enhanced MRI to predict the occurrence of the primary endpoint. Previous data 
from the United Kingdom have suggested a two-year event rate of 41% in patients under 
surveillance for abdominal aortic aneurysm.21 We therefore aimed to recruit approximately 350
patients, with an expected drop-out rate of 10%, resulting in a minimum of 317 patients with 130 
events to be included in the final analysis.
Categorical data are presented using counts and percentages, continuous variables 
presented using mean±standard deviation and absolute differences with 95% confidence 
intervals. Comparisons in baseline characteristics were made using either a binomial test for 
proportions in the case of categorical data or by two-sample t-test for continuous data. Aneurysm 









growth rate was determined from serial ultrasound measurements using a linear regression model 
that was fitted to all available data and the slope used to determine the aneurysm growth rate per 
year. The primary and clinical event endpoints were assessed by log-rank test and are presented 
as Kaplan-Meier curves. Cox proportional hazards models were generated to include the baseline 
covariates of sex, smoking, systolic blood pressure and baseline aneurysm diameter determined 
by ultrasound. The additional value of USPIO enhancement was assessed by the c-statistic and 
net reclassification index.22-24 Statistical significance was taken as two-sided p<0·05.
Role of the Funder
The funder played no role in developing the study design, the collection, analysis, and 
interpretation of data, in the writing of the report, or in the decision to submit the paper for 
publication.
Results
We screened approximately two thousand patients attending the out-patient vascular clinics of
the study centres and identified 741 potentially eligible patients of whom ultimately 361 (48·7%)
were recruited into the study (Figure 2). Nineteen patients were subsequently withdrawn 
predominantly because they were unable to undergo repeated magnetic resonance imaging due to
claustrophobia. The final study population comprised of 342 participants who were 
predominantly elderly male current or ex-smokers with hypercholesterolaemia and hypertension 
(Table 1). There were no serious adverse events or reactions to intravenous ferumoxytol 
administration which was generally well tolerated by all participants. Mild asymptomatic 
hypotension that was possibly related to ferumoxytol was noted in one subject but required no 
action or intervention.









USPIO enhancement of the abdominal aortic aneurysm wall was identified in 146 
(42·7%) participants, was absent in 191 (55·8%) and was indeterminate in 5 (1·5%). USPIO 
enhancement was strongly associated with current smoking status as well as baseline abdominal 
aortic aneurysm diameter and the presence of a common iliac aneurysm (Table 1).
Aneurysm Growth Rate
On ultrasound, baseline maximum abdominal aortic aneurysm diameter was 49·6±7·7 mm and 
was slightly larger in patients with USPIO enhancement (Table 1). The abdominal aortic 
aneurysm growth rate during the trial was 2·8±2·4 mm/year (n=279) and was greater in patients 
with USPIO enhancement (3·1±2·5 versus 2·5±2·4 mm/year; difference 0·6 [95% confidence 
intervals (CI), 0·02 to 1·2] mm/year, p=0·0424). Current smoking status (p=0·0305), but not 
aneurysm diameter (p=0·1853), baseline systolic blood pressure (p=0.6994) or USPIO 
enhancement (p=0·1993), was an independent predictor of aneurysm growth rate.
Clinical Follow-up
All participants were followed up for a mean of 1005±280 days. Overall, the primary endpoint 
occurred in 140 (40·9%) subjects with 17 abdominal aortic aneurysm ruptures and 126
abdominal aortic aneurysm repairs (Table 2): 3 subjects underwent repair after rupture. There 
were 48 (14·0%) deaths of which a third was abdominal aortic aneurysm related (17 [35·4%])
and a quarter was due to other cardiovascular causes (12 [25·0%]).
Rupture or Repair
The primary endpoint occurred more frequently in participants with USPIO enhancement of 
abdominal aortic aneurysm (69/146=47·3% versus 68/191=35·6%; difference 11·7%, 95% CI 
1·1 to 22·2%, p=0·0308) and was associated with a reduced event-free survival (p=0·0275;
Figure 3). This was consistent for both components of the endpoint (Table 2). In contrast to 









female sex (hazards ratio 0·952, 95% confidence intervals 0·589 to 1·540; p=0·8413) and 
systolic blood pressure (hazards ratio 0·997, 95% confidence intervals 0·988 to 1·005; 
p=0·4492), baseline abdominal aortic aneurysm diameter (hazards ratio 1·077, 95% confidence 
intervals 1·061 to 1·094; p<0·0001) and current smoking habit (hazards ratio 1·464, 95% 
confidence intervals 1·001 to 2·120; p=0·0433) were the main predictors of the primary 
endpoint. The addition of USPIO enhancement to the model (hazards ratio 1·003, 95% 
confidence intervals 0·700 to 1·439; p=0·9849) did not improve the prediction of events (c-
statistic, 0·7924 to 0·7926) or the unconditional net reclassification (-13·5%, 95% confidence 
intervals -36·4% to 9·3%). This was true for both components of the endpoint: (a) aneurysm 
rupture, c-statistic, 0·6317 to 0·6304 and net reclassification 29·9% (95% confidence intervals, -
22·0% to 81·9%), and (b) aneurysm repair, c-statistic, 0·8000 to 0·7996 and net reclassification -
9·9% (95% confidence intervals, -33·4% to 13·7%).
All-cause and abdominal aortic aneurysm-related death appeared to be more frequent in 
participants with USPIO enhancement of the abdominal aortic aneurysm (Table 2 and Figure 3)
but fell short of statistical significance.
In post-hoc analysis, we explored whether USPIO enhancement varied according to 
aneurysm size. We dichotomised the population at the mean diameter into smaller (diameter 40-
The rate of USPIO 
enhancement was lower in patients with smaller aneurysms: 65 (35·1%) versus 81 (53·3%) in 
those with larger aneurysms, difference 18·2% (95% confidence interval, 7·7 to 28·9; 
p=0·0008). However, in patients with smaller aneurysms, USPIO enhancement was associated 
with a doubling in the rate of repair or rupture without an effect on mortality (Table 3) whereas 









in those with larger aneurysms, it was the reverse with a more than doubling of mortality but no 
effect on the primary endpoint (Table 4).
Discussion
In a prospective multicentre observational cohort study, we have demonstrated that USPIO-
enhanced MRI not only predicts the rate of aneurysm expansion but also the future risk of
abdominal aortic aneurysm rupture or repair. This is the largest prospective clinical study of 
magnetic resonance imaging in patients with abdominal aortic aneurysms, and is the first report 
of an imaging technique that not only identifies cellular inflammation, but also predicts disease 
progression and outcome. This suggests a central role of cellular inflammation in the 
pathophysiology, progression and outcome of abdominal aortic aneurysm disease.
Abdominal aortic aneurysm expansion is driven by several potential pathogenetic 
mechanisms that are associated with inflammation and tissue degradation.1,11 Macrophages are 
central to many of these processes25 and their depletion appears to prevent aneurysm formation 
or progression in preclinical models of abdominal aortic aneurysm.26 Non-invasive in vivo
imaging of tissue-resident macrophages would therefore seem an intuitive and promising 
approach in patients with abdominal aortic aneurysm but until now has not been prospectively 
tested in large clinical cohorts.11,12,27 We here report the first study in a large clinical cohort to 
image tissue-resident macrophages with USPIO-enhanced MRI, and demonstrate that USPIO 
enhancement is associated with more rapid abdominal aortic aneurysm growth rates and adverse 
clinical outcomes. This provides strong support for the concept that imaging the biology of 
abdominal aortic aneurysm may be a promising new approach to risk stratify and manage 
patients with this disease.11









The rate of abdominal aortic aneurysm growth has previously been shown to be predicted 
by smoking status, aneurysm size and the presence of common iliac aneurysms.9,28 Indeed, 
smoking habit is the principal modifiable risk factor for abdominal aortic aneurysm progression 
and rupture, and is the main focus of lifestyle modification in these patients. We here 
demonstrate that USPIO-enhanced MRI is associated with all of these three risk factors. In 
particular, current smoking was an independent risk factor for abdominal aortic aneurysm growth 
and intriguingly, USPIO enhancement was twice as frequent in current smokers. We know that 
smoking promotes inflammation, macrophage-mediated injury and vascular dysfunction.29-31
This suggests a potential mechanistic link between smoking and macrophage-driven abdominal 
aortic aneurysm inflammation. Indeed, components of cigarette smoke, such as 3,4-benzopyrene, 
promote macrophage infiltration of abdominal aortic aneurysm leading to increased matrix 
metalloproteinase expression and vascular smooth muscle apoptosis.32 Using adoptive transfer 
experiments, Jin and colleagues have further shown that in vivo exposure of leukocytes to smoke 
can accelerate the progression of aneurysm disease in smoke-free animals.33 In this context, our 
USPIO data suggest that macrophage-mediated inflammation may be the mechanistic link to
explain the association between smoking and disease progression in patients with abdominal 
aortic aneurysm.
The primary endpoint of the study was the rate of abdominal aortic aneurysm rupture or 
repair and although this was higher in patients with USPIO-enhancement on MRI, it was not 
independent of known predictors of outcome including baseline abdominal aortic aneurysm
diameter and smoking habit. Indeed, incorporation of USPIO-enhanced MRI did not improve the 
discrimination of a model incorporating these known clinical risk factors. This likely reflects the 
mutual interdependence and potential causal association of these factors, namely that USPIO-









enhancement highlights areas of smoking induced cellular inflammation within the aneurysm
which causes more rapid expansion and increase in the aneurysm diameter leading to aneurysm 
rupture or triggering of the threshold for repair.
Ultrasound measurements of abdominal aortic aneurysm diameter are the mainstay of 
clinical management and the principal determinant of the timing of elective surgical repair. Their
dominant effect on the primary endpoint is therefore perhaps not surprising, especially as most 
events were due to elective surgical repair. Given that the clinicians were blind to the results of 
the USPIO-enhanced MRI, it would be challenging to demonstrate that it could lead to any 
changes in the rate of elective surgical repair. We therefore explored other measures of outcome 
that were independent of elective surgical repair. We found that USPIO enhancement appeared 
to be greater in those with emergent abdominal aortic aneurysm-related events including 
abdominal aortic aneurysm rupture and abdominal aortic aneurysm-related mortality although 
the absolute number of events was small and fell just short of achieving statistical significance.
Given the small number of emergent events, our study did not have sufficient power to determine 
whether USPIO enhancement could provide clinically useful information that could 
independently predict emergent events. However, post-hoc analyses did suggest that USPIO-
enhanced MRI did predict overall mortality in patients with larger aneurysms.
Although USPIO-enhanced MRI was not an independent predictor of outcome across the 
whole study population, it did identify aneurysm disease activity, correlate with rates of 
aneurysm expansion and appear to predict clinical outcome including rupture and death. If future 
studies confirm the utility of USPIO-enhanced MRI, how would it be applied in the clinic? For 
some patients, treatment decisions are not straight forward. For example, abdominal pain in a 
patient with an aortic aneurysm may be due to other abdominal pathology and not the aneurysm 









itself. Urgent repair may be unhelpful in such circumstances and associated with considerable 
risk. Furthermore, decisions to undertake surgical repair can be challenging in those with high-
risk or morphologically atypical aneurysms below 55 mm, those with borderline aneurysm sizes 
of 50-55 mm (especially in women), or those with larger aneurysms where the balance of risk 
and benefit is uncertain. Additional information regarding disease activity that is tied to disease 
progression and adverse clinical outcome may be helpful in guiding such decisions. The value of 
USPIO-enhanced MRI may also differ according to aneurysm size with the prediction of future 
aneurysm repair greater in patients with smaller aneurysms, and the future mortality risk more 
marked in those with larger aneurysms. Although not directly tested here, USPIO-enhanced MRI 
may assist the clinician in making these difficult management decisions that are associated with 
significant potential benefits and hazards. This requires further investigation.
There are no definitive medical treatments that can impact on disease progression in this 
serious and potentially fatal condition. Novel anti-inflammatory or other disease modifying 
therapies are potential interventions that could address this unmet clinical need. USPIO-
enhanced MRI would provide a very useful surrogate biomarker of efficacy in such early proof-
of-concept clinical trials. Reduction in USPIO enhancement would be predicted to correlate with 
reduced cellular inflammation within the aneurysm and consequently reduced rates of expansion. 
This merits further investigation.
Our study has a number of strengths. It was a multicentre prospective observational 
cohort study that ensured blinding of the USPIO-enhanced MRI findings from the patients,
vascular technicians and attending clinicians, and was therefore independent of clinical decision 
making. It was an adequately sized phase 2 proof-of-concept trial that was ~10-fold larger than 
previous studies in this area.15,34 The study also achieved its predicted event rates and met its 









primary endpoint although not independent of known clinical predictors. However, the inclusion 
of elective surgical repair in the primary endpoint generates some challenges in interpretation 
because of the ultrasound and diameter-guided decision making for elective surgical repair. The 
prediction of emergent events appears promising but will require a much larger study with 
greater power to confirm these findings. Finally, USPIO-enhanced MRI is resource intensive and
was not possible in a small number of patients due to contraindications or claustrophobia.
However, it was a feasible, safe and deliverable clinical technique that was well tolerated in the 
vast majority of patients with no serious adverse effects of the MRI or contrast medium.
Moreover, we have demonstrated its applicability across multiple sites, and have developed 
robust computer algorithms and image analysis techniques than enables automated reporting of 
USPIO enhancement, lending itself to immediate clinical application.
In conclusion, in a multicentre prospective observational cohort study, we have 
demonstrated that USPIO-enhanced MRI predicts the rate of aneurysm expansion, and the risk of 
abdominal aortic aneurysm rupture and repair. Although it does not provide independent 
prediction of aneurysm expansion or clinical outcomes in a model incorporating known clinical 
risk factors, this is the first demonstration of a cellular imaging technique that can predict clinical 
events in patients with abdominal aortic aneurysm. Whether clinical outcomes can be improved 
by treatment decisions based on this novel imaging approach remains to be established.
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Age (years) 73·1±7·2 75·0±7·0 73·4±7·5 72·8±6·8 -0·6 (-2·2 to 0·9) 0·4330
Male 292 (85·4) 5 (100) 166 (86·9) 121 (82·9) -4·0 (-11·8 to 3·7) 0·3019
Blood pressure - systolic (mmHg) 139·6±21·2 151·6±5·3 140·3±21·3 138·2±21·3 -2·1 (-6·8 to 2·5) 0·3610
Blood pressure - diastolic (mmHg) 81·4 ±10·8 87·0±10·7 80·5±10·3 82·3±11·3 1·9 (-0·4 to 4·2) 0·1101
Heart rate (/min) 70·7±10·1 71·6±12·1 70·0±10·1 71·5±10·0 1·5 (-0·7 to 3·7) 0·1779
Body-mass index (kg/m2) 27·6±4·2 25·0±3·1 28·0±4·2 27·2±4·2 -0·8 (-1·7 to 0·1) 0·0729
Creatinine ( mol/L) 89·9±23·4 76·2±9·7 90·0±21·1 90·3±26·5 0·4 (-4·9 to 5·7) 0·8912
Cholesterol (mmol/L) 4·5±1·0 5·0±1·9 4·5±1·0 4·5±1·0 0·0 (-0·2 to 0·3) 0·7732
Smoking:  Current smoker 101 (29·5) 4 (80) 40 (20·9) 57 (39·0) 18·1 (8·3 to 27·9)* 0·0003*
                  Ex-smoker 195 (57.0) 1 (20) 120 (62.8) 74 (50.7)
                  Never smoker 46 (13.5) 0 (0) 31 (16.2) 15 (10.3)
Aneurysm
AAA diameter (mm) 49·6±7·7 54·4±12·3 48·2±6·6 51·4±8·4 3·2 (1·5 to 4·8) 0·0002
Concurrent iliac artery aneurysm 66 (19·3) 1 (20) 29 (15·2) 36 (24·7) 9·5 (0·8 to 18·1) 0·0289
Past Medical History
Hypertension 246 (71·9) 3 (60) 143 (74·9) 100 (68·5) -6·4 (-16·1 to 3·4) 0·1959
Hypercholesterolaemia 257 (75·1) 2 (40) 146 (76·4) 109 (74·7) -1·8 (-11·1 to 7·5) 0·7056
Diabetes Mellitus 47 (13·7) 0 (0) 31 (16·2) 16 (11·0) -5·3 (-12·6 to 2·0) 0·1663
Family history of AAA 61 (17·8) 0 (0) 32 (16·8) 29 (19·9) 3·1 (-5·3 to 11·5) 0·4626
Ischaemic heart disease 125 (36·5) 1 (20) 69 (36·1) 55 (37·7) 1·6 (-8·9 to 12·0) 0·7706
Peripheral vascular disease 66 (19·3) 1 (20) 34 (17·8) 31 (21·2) 3·4 (-5·1 to 12·0) 0·4288
Cerebrovascular disease 46 (13·5) 0 (0) 22 (11·5) 24 (16·4) 4·9 (-2·6 to 12·5) 0·1924
Baseline Medication
Anti-platelet therapy 224 (65·5) 2 (40) 127 (66·5) 95 (65·1) -1·4 (-11·7 to 8·8) 0·7847
Statin therapy 270 (78·9) 4 (80) 151 (79·1) 115 (78·8) -0·3 (-9·1 to 8·5) 0·9483
Anti-coagulant therapy 25 (7·3) 0 (0) 16 (8·4) 9 (6·2) -2·2 (-7·8 to 3·3) 0·4425
Beta blocker therapy 120 (35·1) 1 (20) 72 (37·7) 47 (32·2) -5·5 (-15·7 to 4·7) 0·2948
Mean±SD or n (%). 
*Current smoker versus combined ex-smoker and never smokers.
CI, confidence intervals; USPIO, ultrasmall superparagemagnetic particles of iron oxide; AAA, abdominal aortic aneurysm; ACE, angiotensin-converting 
enzyme.

























Abdominal Aortic Aneurysm Event
Rupture/repair 140 (40·9) 3 (60) 68 (35·6) 69 (47·3) 11·7 (1·1 to 22·2) 0·0308
Rupture 17 (5·0) 0 (0) 7 (3·7) 10 (6·8) 3·2 (-1·7 to 8·1) 0·1857
Repair 126 (36·8) 3 (60) 62 (32·5) 61 (41·8) 9·3 (-1·1 to 19·7) 0·0782
Type of repair:     EVAR 53 (15·5) 1 (20) 29 (15·2) 23 (15·8)
                                Open 73 (21·3) 2 (40) 33 (17·3) 38 (26·0)
Type of surgery:  Elective 120 (35·1) 3 (60) 58 (30·4) 59 (40·4)
                                Emergency 6 (1·8) 0 (0) 4 (2·1) 2 (1·4)
Death
All cause 48 (14·0) 1 (20) 21 (11·0) 26 (17·8) 6·8 (-0·8 to 14·4) 0·0736
Cardiovascular - AAA related 17 (5·0) 0 (0) 6 (3·1) 11 (7·5) 4·4 (-0·6 to 9·3) 0·0679
Cardiovascular – non-AAA related 12 (3·5) 0 (0) 8 (4·2) 4 (2·7)
Stroke 2 (0·6) 0 (0) 2 (1·0) 0 (0)
Myocardial infarction 8 (2·3) 0 (0) 4 (2·1) 4 (2·7)
Other cardiovascular 2 (0·6) 0 (0) 2 (1·0) 0 (0)
Non-cardiovascular 19 (5·6) 1 (20) 7 (3·7) 11 (7·5)
Malignancy 12 (3·5) 1 (20) 4 (2·1) 7 (4·8)
Other  7 (2·0) 0 (0) 3 (1·6) 4 (2·7)
n (%).
CI, confidence intervals; USPIO, ultrasmall superparamagnetic particles of iron oxide; AAA, abdominal aortic aneurysm; EVAR, endovascular 
aneurysm repair.

























Abdominal Aortic Aneurysm Event
Rupture/repair 42 (22·5) 0 (0) 20 (16·7) 22 (33·8) 17·2 (3·9 to 30·5) 0·0077
Rupture 4 (2·1) 0 (0) 2 (1·7) 2 (3·1) 1·4 (-3·4 to 6·2) 0·6136*
Repair 38 (20·3) 0 (0) 18 (15·0) 20 (30·8) 15·8 (2·9 to 28·7) 0·0113
Type of repair:     EVAR 19 (10·2) 0 (0) 9 (7·5) 10 (15·4)
                                Open 19 (10·2) 0 (0) 9 (7·5) 10 (15·4)
Type of surgery:  Elective 36 (19·3) 0 (0) 16 (13·3) 20 (30·8)
                                Emergency 2 (1·1) 0 (0) 2 (1·7) 0 (0)
Death
All cause 20 (10·7) 1 (50) 14 (11·7) 5 (7·7) -4·0 (-12·6 to 4·7) 0·3953
Cardiovascular - AAA related 4 (2·1) 0 (0) 2 (1·7) 2 (3·1) 1·4 (-3·4 to 6·2) 0·6136*
Cardiovascular – non-AAA related 8 (4·3) 0 (0) 7 (5·8) 1 (1·5)
Stroke 1 (0·5) 0 (0) 1 (0·8) 0(0)
Myocardial infarction 5 (2·7) 0 (0) 4 (3·3) 1 (1·5)
Other cardiovascular 2 (1·1) 0 (0) 2 (1·7) 0 (0)
Non-cardiovascular 8 (4·3) 1 (50) 5 (4·2) 2 (3·1)
Malignancy 4 (2·1) 1 (50) 3 (2·5) 0 (0)
Other  4 (2·1) 0 (0) 2 (1·7) 0 (0)
n (%). CI, confidence intervals; USPIO, ultrasmall superparamagnetic particles of iron oxide; AAA, abdominal aortic aneurysm;
EVAR, endovascular aneurysm repair. *Fisher’s exact test due to small numbers.
























Abdominal Aortic Aneurysm Event
Rupture/repair
Rupture 98 (63·2) 3 (100) 48 (67·6) 47 (58·0) -9·6 (-24·9 to 5·7) 0·2235
Repair 13 (8·4) 0 (0) 5 (7·0) 8 (9·9) 2·8 (-6·0 to 11·7) 0·5330
Type of repair:     EVAR 88 (56·8) 3 (100) 44 (62·0) 41 (50·6) -11·4 (-27·0 to 4·3) 0·1595
                                Open 34 (21·9) 1 (33) 20 (28·2) 13 (16·0)
Type of surgery:  Elective 54 (34·8) 2 (67) 24 (33·8) 28 (34·6)
                                Emergency 84 (54·2) 3 (100) 42 (59·2) 39 (48·1)
Death 4 (2·6) 0 (0) 2 (2·8) 2 (2·5)
All cause
Cardiovascular - AAA related 28 (18·1) 0 (0) 7 (9·9) 21 (25·9) 16·1 (4·3 to 27·9) 0·0108
Cardiovascular – non-AAA related 13 (8·4) 0 (0) 4 (5·6) 9 (11·1) 5·5 (-3·2 to 14·2) 0·2283
Stroke 4 (2·6) 0 (0) 1 (1·4) 3 (3·7)
Myocardial infarction 1 (0·6) 0 (0) 1 (1·4) 0 (0)
Other cardiovascular 3 (1·9) 0 (0) 0 (0) 3 (3·7)
Non-cardiovascular 0 (0) 0 (0) 0 (0) 0 (0)
Malignancy 11 (7·1) 0 (0) 2 (2·8) 9 (11·1)
Other  8 (5·2) 0 (0) 1 (1·4) 7 (8·6)
n (%). CI, confidence intervals; USPIO, ultrasmall superparamagnetic particles of iron oxide; AAA, abdominal aortic aneurysm;
EVAR, endovascular aneurysm repair. 










Figure 1. Magnetic resonance imaging of abdominal aortic aneurysm. A - T2-weighted HASTE 
sequence in the sagittal plane. B - Cross-sectional image (dashed line panel A) using a T2-
weighted fat saturated sequence to highlight intraluminal thrombus (white) within the aneurysm.
C - T2* map (blue) overlying the T2-weighted HASTE sequence of image B, demonstrating 
enhancement of the posterior aneurysm wall with ultrasmall superparamagnetic particles of iron 
oxide (red).
Figure 2. CONSORT diagram of participant recruitment.
Figure 3. Abdominal aortic aneurysm rupture or repair (primary endpoint; A), all-cause 
mortality (B) and aneurysm-related mortality (C) in participants with (red) and without (blue) 
ultrasmall superparamagnetic particles of iron oxide (USPIO) enhancement of the aneurysm 
wall. Cross-hairs represent individual censoring.
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BioPARR: A software system for 
estimating the rupture potential 
index for abdominal aortic 
aneurysms
Grand Roman Joldes  1,2,3, Karol Miller1,2,4, Adam Wittek1,2, Rachael O. Forsythe5, David E. 
Newby5 & Barry J. Doyle2,5,6
An abdominal aortic aneurysm (AAA) is a permanent and irreversible dilation of the lower region of the 
aorta. It is a symptomless condition that, if left untreated, can expand until rupture. Despite ongoing 
efforts, an efficient tool for accurate estimation of AAA rupture risk is still not available. Furthermore, 
a lack of standardisation across current approaches and specific obstacles within computational 
workflows limit the translation of existing methods to the clinic. This paper presents BioPARR 
(Biomechanics based Prediction of Aneurysm Rupture Risk), a software system to facilitate the 
analysis of AAA using a finite element analysis based approach. Except semi-automatic segmentation 
of the AAA and intraluminal thrombus (ILT) from medical images, the entire analysis is performed 
automatically. The system is modular and easily expandable, allows the extraction of information from 
images of different modalities (e.g. CT and MRI) and the simulation of different modelling scenarios 
(e.g. with/without thrombus). The software uses contemporary methods that eliminate the need for 
patient-specific material properties, overcoming perhaps the key limitation to all previous patient-
specific analysis methods. The software system is robust, free, and will allow researchers to perform 
comparative evaluation of AAA using a standardised approach. We report preliminary data from 48 
cases.
There are many limitations to the current clinical definition of ‘high-risk’ of rupture for AAA, based mainly on 
the maximum diameter of the AAA. Many researchers across both engineering and medical disciplines believe 
that biomechanics based patient-specific modelling (PSM) could have major clinical potential to provide more 
accurate patient-specific rupture risk assessment1–4.
With the advances in medical imaging technology and medical image analysis software, it became possible 
to create anatomically-correct reconstructions of the AAA, which were then used for computer simulations that 
have steadily increased in complexity3, 5–7. These simulations can compute the stress in the AAA wall due to the 
internal blood pressure. Mechanically-speaking, rupture of an artery occurs when the local wall stress exceeds 
the local wall strength. Vande Geest et al. proposed a useful statistical model for the non-invasive estimation of 
AAA wall strength8 and also introduced the rupture potential index (RPI)2. The RPI combines the estimated 
patient-specific AAA wall strength with the AAA wall stress computed using the finite element method. The 
RPI has since been implemented in several AAA rupture risk assessment studies3, 4, 9–11 and also in a commercial 
software for AAA analysis (VASCOPS)12.
The current approach to RPI computation, including that implemented in the VASCOPS software, uses rou-
tinely acquired computed tomography (CT) data of the AAA to create three-dimensional (3D) reconstructions 
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of the aneurysm. Despite some researchers developing algorithms and methods to measure AAA wall thickness 
from CT7, 13, 14, the poor soft tissue contrast of CT data compared to magnetic resonance imaging (MRI) limits 
the visibility of the AAA wall. Therefore, the vast majority of previous computational studies on AAA rupture 
risk assume a uniform wall thickness. A uniform wall is anatomically incorrect and results in inaccurate wall 
stress distributions, and thus RPI estimates. Therefore, RPI data based on uniform aortic wall thickness could be 
misleading in a clinical setting. Irrespective of uniform or variable wall thickness methods, the 3D reconstructed 
geometry is converted into a computational mesh of elements, typically tetrahedral elements due to the ease of 
automated mesh generation. Material properties must then be assigned to the model and are typically based on 
population-mean mechanical test data for the AAA wall tissue and the intraluminal thrombus (ILT)15, 16. A key 
obstacle in the translation of RPI to the clinic is the use of average material data, as in doing so, the model deviates 
away from a patient-specific simulation.
However, in some problems of biomechanics (and mechanics in general), material properties have negligible impact 
on wall stress17, 18. This occurs when the geometry to be analysed is already deformed, as is the case when examining 
arteries reconstructed from medical images. The medical image data represents the geometry under pressurisation 
from blood. Much effort has focussed on determining the pressure-free geometry using inverse procedures17, 19; how-
ever, what was observed when using the inverse method is that wall stress is almost independent of material properties. 
Building on from this, we have reformulated the mechanics of the AAA problem and demonstrated that AAA wall 
stress can be computed without knowledge of material properties and through a direct linear analysis19.
In this paper, we present our framework and describe the key algorithms and techniques that we have imple-
mented. An important aspect of our software is automation. Besides the semi-automatic 3D reconstruction of 
the AAA, the analysis is completely ‘push button’, thus eliminating potential inter-user variation and creating a 
standardised approach.
Figure 1. Diagram of the workflow. Only segmentation and wall thickness specification require user 
intervention; all other steps are automated. Multiple modelling scenarios are analysed (Scenario 1: pressure load 
on internal ILT wall; Scenario 2: no ILT included; scenario 3: ILT included and pressure load on internal AAA 
wall). MRI = magnetic resonance imaging, CT = computed tomography, FEM = finite element method.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 4641  | DOI:10.1038/s41598-017-04699-1
Results and Discussion
We have developed a semi-automatic, modular and easily extendable software system for analyzing the rupture 
potential of an AAA using a finite element analysis based rupture index. The software system, available for free 
download and usage20, consists of a collection of programs and scripts which perform the required steps in the 
AAA workflow, from image segmentation to geometry creation, meshing, finite element analysis and rupture 
potential index (RPI) computation (Fig. 1). The software is divided into several modules which perform spe-
cific tasks and are being run in sequence from a master script (batch) file. Data communication between these 
modules is performed using files in standard formats; this allows the user flexibility in changing or extending the 
functionality of the software, by replacing or adding additional modules.
To guarantee the accuracy of the results, the analysis by the finite element method (FEM) is conducted using 
the commercial finite element software Abaqus21. All the other modules consist of free or open source software 
programs. The software runs on 64Bit Windows operating systems and has been tested on Windows 7 and 8. We 
have created a series of tutorial training videos for each step of the analysis; the access link for these resources is 
included with the software.
Figure 1 shows the developed workflow. The software system allows the analyst to extract and combine data 
from images of different modality (such as CT and MRI), by using an inter-modality image registration algo-
rithm. The analyst has control over many parameters influencing the analysis results: the thickness of the AAA 
wall, inclusion of thrombus, geometry meshing, finite element type selection, and finite element simulation sce-
narios. The software can be used in the case when both CT and MRI data are available for a patient or, the more 
typical situation, when only CT is acquired.
We have automated the finite element analysis and so have removed the need for technical expertise in com-
putational mechanics. There is still the need to semi-automatically reconstruct the geometry, as this part of the 
workflow cannot be fully automated. However, this step takes approximately 45 minutes per case and, as with 
most manual tasks, the required time reduces with increasing familiarity. This segmentation time is comparable 
Figure 2. Example of RPI computation results. (a) ILT thickness [mm]. (b) Normalized diameter (NORD). (c) 
Wall strength for a female with family history of AAA [MPa]. (d) RPI for a female with family history of AAA.
www.nature.com/scientificreports/
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with that needed to segment AAA using the commercial VASCOPS software (~40 minutes)22. In the future, the 
segmentation time may be reduced by using better quality images (having enhanced contrast between AAA 
and the surrounding structures) or through the adoption of emerging image analysis techniques, such as those 
relying on machine learning23. An important aspect of our software is the fast return of data. Our computational 
approach removes non-linearities (both material and geometric) from the model. As such, the computation time 
is dramatically reduced and can fit into the clinical workflow.
Example results generated by our software are presented in Fig. 2. The program automatically generates 3D 
color-contoured visualizations of the key patient-specific components of the analysis, namely, ILT thickness (ILT), 
the normalized ratio of the maximum AAA diameter and the diameter in the proximal neck of the aneurysm 
(NORD), the estimated wall strength, and the final RPI. In this particular example, the patient was female with a 
family history of AAA; both gender and family history of the disease significantly affect the wall strength estima-
tion. Excluding the 3D geometry reconstruction time, the entire analysis of this scenario took approx. 6 minutes on 
an Intel(R) Core(TM) i7-5930K CPU @ 3.50 GHz with 64 GB of RAM running Windows 8 OS. The analysis time 
greatly depends on the problem size (i.e. size of the computational grid, in this case just under 200 k nodes and 740 k 
elements, and the type of elements used, in this case linear tetrahedrons) and the number of scenarios considered.
Figure 3. Case 2 used in reproducibility analysis. Axial (top) and sagittal (bottom) CT slices of the AAA. The 
poor contrast between the AAA and surrounding organs makes segmentation very challenging.
www.nature.com/scientificreports/
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In addition to its clinical potential, our software system can be used to answer research questions related to the 
evaluation of AAA rupture potential index, such as:
What is the influence of wall thickness and boundary conditions on the computed stress and RPI?
How many layers of finite elements and what type of elements should be used in the discretization to obtain 
convergence for the finite element analysis results?
What simulation scenario leads to the most accurate prediction of stress distribution?
What combination of simulation parameters leads to the most efficient and accurate RPI?
Finally, a major hurdle to translation of computational biomechanics methods to a clinical setting is robust 
statistical evidence. Until now, computational methods required intensive analyst time and expertise, and gener-
ally resulted in studies that lack statistical power. This problem is further compounded by the lack of standardi-
zation of computational methods24, which makes meta-analyses of studies difficult25. Without statistical evidence 
that the RPI closely correlates with the rupture risk, clinical uptake is unlikely. Therefore, we have made our soft-
ware freely available to all20, easily expandable and modifiable, and we hope this will enable multi-centre studies 
of large cohorts to generate statistical evidence.
In conclusion, we have created and offered a free software system for estimating the risk of rupture in abdom-
inal aortic aneurysms. All analysis steps have been automated, except image segmentation, which is impossi-
ble to perform automatically given the current image acquisition techniques and image processing algorithms. 
Therefore, once the software system has been configured, it can be run automatically for different segmented AAA 
cases and by different analysts without any user intervention; this reduces the analysis time, does not require tech-
nical knowledge from the user and generates reproducible results. Having a modular structure with data transfer 
between modules using standard file formats, the software system is easy to modify and expand.
We used our software system to analyse 48 cases acquired in the initial phase of the MRI in AAA to predict 
Rupture or Surgery (MA3RS) study26 – a multicentre observational cohort study of patients under surveillance 
for AAA with maximum diameter greater than 4 cm (EudraCT 2012-002488-25). It proved reliable and able to 
handle all cases, which included a large range of AAA sizes and shapes. Once follow-up data of the entire MA3RS 
cohort is available, we plan to analyse that data and collect the much needed statistical evidence regarding the 
accuracy of this AAA rupture risk analysis method. Some preliminary results from this analysis are presented in 
the following subsections, using the assumption of constant AAA wall thickness and a standard blood pressure of 
120 mmHg. We used second order tetrahedral elements, for accurate stress computation. The stresses computed 
near the top and bottom AAA boundaries (which are constrained) were excluded when extracting the maximum 
stresses or RPI, as stress concentrations occur in these areas.
Reproducibility of analysis results. Because the entire workflow after image segmentation is automated, 
the analysis following image segmentation is completely reproducible. Image segmentation involves manual user 
intervention and its reproducibility depends on the experience of the user and the quality of the images. We have 
performed the following study to quantify the effect of image segmentation on the computation results:
Three users with different levels of experience in AAA segmentation have each segmented the AAA and 
lumen from three CT datasets;
The segmentations were compared using the Dice Similarity Coefficient (DSC);
The segmentations were used as input to the analysis framework and the results compared;
The three users are marked as user A (experienced, with many hours of AAA segmentation and usage of 3D 
Slicer), user B (less experienced, with only a couple of AAA segmentations done using 3D Slicer) and user C (nov-
ice, no previous AAA segmentations). Users B and C were instructed by user A in the application of the software 
and given access to several online tutorials. The results obtained by user A were considered as the best and the 
results from the other users were compared against them.














1 48 A 1 1 19.8 2.2 0.69
B 0.982 0.997 20.3 (3%) 2.3 (5%) 0.62 (10%)
C 0.953 0.981 19.3 (3%) 2.5 (14%) 0.52 (24%)
2 54 A 1 1 19.6 1.8 1.05
B 0.952 0.983 19.6 (0%) 2.1 (17%) 1.0 (5%)
C 0.896 0.969 21 (7%) 1.6 (11%) 1.1 (5%)
3 48 A 1 1 16.4 1.8 0.62
B 0.955 0.961 16.1 (2%) 1.8 (0%) 0.58 (6%)
C 0.899 0.908 17.3 (5%) 1.7 (6%) 0.75 (21%)
Table 1. Reproducibility of analysis results. The relative differences between the results of users B and C and 
user A are shown in parenthesis. NORD = normalized diameter.
www.nature.com/scientificreports/
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Figure 4. RPI distribution for case 2 used in reproducibility analysis. The results are obtained based on the 
segmentations performed by user A (right), B (center) and C (left). Despite the visual differences in geometry 
from user to user, the difference between the maximum RPI is ~5%.
Figure 5. Influence of modelling scenario on the computed stress. Three scenarios are compared. There is little 
difference between the stresses computed using the “ILT pressure” and “Wall pressure” scenarios. The inclusion 
of ILT results in a significant reduction in the computed stress.
Figure 6. Influence of ILT thickness. (a) The distribution of maximum ILT thickness for the analysed cases. (b) 
Influence of maximum ILT thickness on the ratio between the maximum principal stresses computed in the “No 
ILT” and “ILT pressure” modelling scenarios.
www.nature.com/scientificreports/
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The accuracy of segmentation increases with the user experience, as indicated by the DSC coefficients;
Parts of the image with good contrast were easily segmented by all users (there is much smaller difference in 
the lumen DSC and maximum ILT thickness between users);
For the novice user, the differences in the computed maximum principal stress were less than 25%.
The differences between segmentations must be considered by taking into account the resolution of the CT 
images, of 0.625 mm × 0.625 mm × 2 mm (therefore, a one voxel segmentation error results in a 2.5% AAA radius 
error) and the lack of contrast in parts of the image, as illustrated in Fig. 3. However, despite the relatively large 
difference in peak wall stress calculated between users, the difference between the maximum computed RPI for 
this case is approximately 5%. This is due to the RPI calculation including information specific to the 3D recon-
struction (i.e. NORD and ILT thickness). The computed RPI for this case is presented in Fig. 4.
A more detailed study of inter-user and intra-user reproducibility of CT segmentation and its effect on the 
computation of wall stress is presented in Hyhlik-Durr et al.22. In that study the commercial VASCOPS software 
was used to perform semi-automatic segmentation of CT images having much higher resolution (in plane resolu-
tion 0.33 mm, slice thickness 0.7–1.0 mm). The authors reported a high reproducibility of volume and maximum 
diameter measurements in infrarenal AAAs. We note the fact that segmentations obtained using the VASCOPS 
software can also be used as inputs for our software system.
Comparison between different modelling scenarios. We used three different modelling scenarios and 
assumed the AAA wall was of uniform thickness (1.5 mm) and the ILT was a homogeneous material:
AAA with ILT and the blood pressure load applied on the ILT surface (ILT pressure);
AAA with ILT and blood pressure load applied on the internal wall surface, bypassing the ILT (Wall pressure);
AAA without ILT and blood pressure load applied on the internal AAA wall surface (No ILT).
A comparison between the maximum principal stresses obtained for each case is presented in Fig. 5. While 
the inclusion of ILT results in a significant reduction in the computed maximum principal stress, there is little 
Figure 7. Influence of AAA diameter. (a) The distribution of maximum AAA diameter for the analysed cases. 
(b) Variation of computed maximum principal stress with the maximum AAA diameter (R2 = 0.34). The “No 
ILT” scenario results are presented, to eliminate the influence of ILT thickness on the results.
Figure 8. Influence of AAA diameter, ILT, and family history of AAA on the computed RPI. (a) RPI computed 
in the “ILT pressure” scenario, with (R2 = 0.16) and without (R2 = 0.25) considering a family history of AAA 
for each case. (b) RPI computed in the “No ILT” scenario, with (R2 = 0.18) and without (R2 = 0.3) considering a 
family history of AAA for each case.
www.nature.com/scientificreports/
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difference between the stresses computed using the “ILT pressure” and “Wall pressure” scenarios, as previously 
reported27. The stresses computed using the “Wall pressure” scenario are slightly higher than those computed 
using the “ILT pressure” scenario, but the maximum difference across all cases is less than 3%. Therefore, there is 
no need to analyse these two scenarios separately, and only the “ILT pressure” scenario results will be considered 
in the following analysis.
To better understand the influence of ILT on the computed stress, we plotted the reduction in stress between 
the “No ILT” and “ILT pressure” modelling scenarios against the maximum ILT thickness in Fig. 6. We find that a 
larger ILT thickness leads to a larger reduction in the maximum principal stress (up to 8 times higher wall stress 
without ILT). Clearly, the decision on whether or not to include the ILT in the analysis has a major influence on 
the computation results, especially for cases with large ILT thickness.
Influence of AAA diameter on stress. The relation between the maximum AAA diameter and maximum 
principal stress for all the analysed cases is presented in Fig. 7. Only the “No ILT” scenario results are presented, to 
eliminate the influence of ILT thickness and only capture the influence of AAA diameter on the computed stress. 
There is a trend of increased maximum principal stress with increased AAA diameter, although there are other 
factors influencing the stress value (such as the shape of the AAA) which lead to a relatively large dispersion of 
the results (R2 = 0.34).
Relation between AAA diameter, ILT, family history of AAA and RPI. The variation of computed 
maximum RPI against the maximum AAA diameter for the “ILT pressure” and “No ILT” scenarios, with and 
without considering the family history of AAA for each case, is presented in Fig. 8. In each modelling scenario 
there is a trend of increased RPI with increased AAA diameter, especially when ILT is omitted from the model. 
Furthermore, without ILT, most RPI exceed the theoretical rupture value of 1.0, yet all AAAs were intact when 
Figure 9. Example segmentation of an AAA from CT (one CT slice in the coronal view). The contour of the 
AAA segmentation is shown in red and the lumen segmentation is in green. The region of interest has been 
extracted from an abdominal CT with a resolution of 0.625 mm × 0.625 mm × 2 mm and segmented using the 
FastGrowCut algorithm for the AAA and intensity thresholding for lumen (with manual seed creation and 
segmentation corrections).
www.nature.com/scientificreports/
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images were acquired. This further supports the necessity to include ILT into the risk assessment models. We 
also found that the parameters influencing the wall strength, such as family history of AAA, have a major impact 
on the RPI computation (the wall strength is computed based on a statistical model8, as described in the section 
“Rupture Potential Index Computation”), reducing the correlation between RPI and maximum diameter, as indi-
cated by the smaller R2 values.
In all the presented results, although some trends can be identified, there is a large dispersion of the data. Due 
to the influence of multiple parameters on the computed stress/RPI, simplistic conclusions such as “larger ILT 
thickness leads to a smaller stress” or “larger AAA diameter leads to larger stress” cannot be drawn. The obtained 
results suggest that patient-specific analysis is needed in each case.
Methods
Image segmentation. The high variability in AAA geometry, as well as low discrimination between the 
AAA and the surrounding tissue in parts of the image, make automatic AAA segmentation practically impos-
sible. Therefore, we have used the segmentation tools available in the free, open source image analysis software 
3D Slicer28. Any other segmentation software can be used. We have found that using the 3D Slicer extension 
FastGrowCut for segmentation29 can help reduce the segmentation time. Manual intervention is still required 
in defining the region of interest in the image, cropping, defining the seeds for the FastGrowCut algorithm and 
performing corrections and smoothing of the resulting label maps. Using this method, we can easily extract the 
AAA from CT or MRI (Fig. 9). In the preliminary data presented in this work, we have segmented the AAA from 
immediately below the renal arteries to the iliac bifurcation.
Inter-modality image registration. Registering inter-modality images allows the user to extract 
geometrical information, such as the AAA wall thickness, from medical images from different imaging 
Figure 10. MRI to CT registration. (a) A sagittal slice of an AAA in a contrast-enhanced CT image (top) and 
the corresponding slice in the MR image (bottom). The contours of the AAA segmentations are shown in green. 
The two images occupy different positions in space and need to be registered. (b) The segmentations of the 
CT (top) and MR (bottom) images. The two label maps are registered and the resulting transform is saved. (c) 
The transform obtained from the label map registration is used to register the MRI dataset to the CT dataset. 
A checkerboard display of the two images is used to verify the registration result in axial (top) and sagittal 
(bottom) views, with the contour of the AAA segmentation shown in green.
www.nature.com/scientificreports/
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systems. Registration involves aligning different images into the same coordinate system. Automatic regis-
tration of inter-modality images is practically impossible most of the time, because different image modali-
ties can reveal and represent very different information about an organ. In order to overcome this difficulty, 
we implemented a label map based registration algorithm and used it to register MRI to CT images. The 
basic principle of the algorithm is to register the AAA label maps extracted from MRI and CT and then use 
the obtained transform to bring the MRI image in the same coordinate system as the CT image (Fig. 10), 
using the following steps:
Figure 11. Example of thickness interpolation for an AAA. (a) Thickness measurements points. (b) Areas of 
the surface discretization associated with each measurement point (similar to a Voronoi diagram in plane) – the 
thickness at the measurement point will be extended to these areas. In this image the colors are determined by 
the measurement point id – for illustration purposes, only a limited number of measurement points are defined 
in order to have a clear separation of these areas. (c) Thickness values (using 10 smoothing iterations) [mm].
Figure 12. Example of geometry creation. (a) Geometry extracted from label map. (b) Re-meshed geometry. 
(c) Final geometry (AAA exterior surface in blue, interior surface in yellow and ILT surface in red).
www.nature.com/scientificreports/
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Segment the AAA from both CT and MRI (Fig. 10a), resulting in 2 binary images defining the label maps 
(Fig. 10b);
Register the MRI label map to the CT label map and extract the resulting transform;
Use the transform to register the MRI image to the CT image (Fig. 10c).
These steps are performed using the general registration and resampling algorithms (BRAINSFit and 
BRAINSResample) available in 3D Slicer. The registration algorithm has been implemented in a Python script so 
it can be run without user intervention. One disadvantage of this registration method is that it cannot take into 
consideration local deformations; therefore only rigid registration is implemented.
Wall thickness specification. Although wall thickness has a great influence on the stress distribution 
within the AAA wall19, accurate extraction from medical images remains problematic due to the low image res-
olution and soft tissue contrast. This uncertainty is why many authors have used constant wall thickness in their 
analyses. It is nevertheless important to understand the effect of such an assumption on the computed rupture 
potential index (RPI). Therefore, we offer the possibility of specifying wall thickness at multiple points on the 
AAA surface.
Measuring surface thickness from medical images or excised tissue samples is difficult and usually results in 
measurements only at sparse locations on the AAA surface. Therefore, we devised a new method of generating 
the thickness information for all points of the AAA surface using interpolation and smoothing of the sparse 
measurements (Fig. 11).
Thickness information can be specified in different ways. One possibility is to measure the wall thickness at 
different locations with the ruler tool available in 3D Slicer on the registered images (i.e. CT and MRI), and then 
save the measurements as 3D Slicer annotation files. The software can read the thickness from these files. Another 
option is to generate the annotation files (which are simple text files) containing thickness information using 
some other method. For example, ex vivo measurements of excised tissue can be performed30 or wall thickness 
can be estimated from CT13 and the thickness data entered into the annotation files. If only one file containing 
thickness information exists, a constant thickness AAA wall will be created. In the preliminary data presented in 
this study, we used a constant thickness of 1.5 mm.
Geometry creation. The label maps segmented from the images and the wall thickness information are used 
to create the AAA geometry. The following surfaces are automatically created: the external AAA wall surface, the 
internal AAA wall surface and the internal intraluminal thrombus (ILT) surface. The ILT surface is only created 
if the lumen label map is available. In few cases of AAA (~5%), there is no ILT present31.
The AAA geometry is created in three stages. The first stage is performed using 3D Slicer and consists of label 
map manipulation (to make sure the lumen label map is contained within the AAA label map), subtraction of the 
lumen label map from the AAA label map, and surface extraction using the 3D Slicer module Model Maker32. 
Because the resulting tessellated surface discretisation is only intended for visualization, it has many triangles of 
different sizes and bad aspect ratios (Fig. 12a). This leads to problems in creating the internal AAA wall surface 
in the third stage. Therefore, in the second stage, the surface is automatically re-meshed using the surface mesh 
resampling software ACVDQ33–35 (Fig. 12b).
In the third stage, a custom command line interface (CLI) 3D Slicer module is used to generate the discretised 
surfaces. The module uses the re-meshed AAA surface from the previous stage to separate the exterior AAA wall 
surface from the ILT surface (if it exists), interpolates the thickness measurements over the external AAA wall 
surface, creates the internal AAA wall surface by displacing the nodes of the external AAA wall surface along the 
Figure 13. Example of meshing. The AAA wall is meshed using 2 layers of elements (configurable). The ILT is 
meshed using a minimum of 2 layers of elements (configurable); the element size is increased in the middle of 
the ILT layer to reduce the number of elements in the mesh.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7: 4641  | DOI:10.1038/s41598-017-04699-1
surface normal, modifies the internal ILT surface to make sure that the ILT has a configured minimum thickness 
(to simplify ILT meshing, the default value is 1 mm), computes the ILT surface thickness, and outputs the created 
surfaces (in standard STereoLithography. STL file format) and element size information to be used for meshing.
The element size is computed based on the local wall and ILT thickness, so that a configured number (default 
value of 2) of element layers are generated over the thickness of the wall. The element size information is gen-
erated for all the points of a 1 mm spaced structured grid which covers the entire AAA geometry and saved in a 
format readable by the meshing software.
Meshing. Meshing of the AAA wall and ILT, based on the surfaces and element size configuration from 
the previous step, is performed in three stages using custom command files for the free, open source meshing 
software Gmsh36, 37. In the first stage, the surfaces are meshed using the generated element size information. 
Additional constraints on the element size can be included by modifying the command files, such as curvature 
dependent element sizing. In the second stage, the volumes of the AAA wall and ILT are created by generating 
end surfaces between the external and internal AAA wall surfaces, and between the internal AAA wall surface 
and the ILT surface. We perform this necessary step to ensure the geometry consists of watertight closed surfaces, 
as this is not guaranteed by the VTK toolkit38 used to create surfaces in the previous step. In the third and final 
stage, a tetrahedral volumetric mesh is created using the element size information generated in the previous step 
(Fig. 13). This process ensures a conforming mesh between the ILT and AAA wall. The generated meshes are 
saved as standard.vtk files.
This new meshing approach maintains the geometric accuracy of the meshed surfaces by using very small 
elements on these surfaces. At the same time, by increasing the element size inside the ILT volume and in the 
thicker areas of the AAA wall, it reduces the mesh size and, therefore, the computational cost of the finite element 
analysis.
Figure 14. Example of Abaqus model, showing constraints applied on the top and bottom surfaces of the AAA. 
Definitions of the important surfaces in the model (where loads and boundary conditions are applied) are 
created by the software and available to the user in the generated input files.
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Finite Element Model Creation. A custom CLI 3D Slicer module reads the volumetric mesh files created 
in the previous step and generates input (.inp) files for the finite element software Abaqus21 containing the AAA 
wall and the ILT meshes as parts. The surfaces necessary for defining loads and boundary conditions are automat-
ically detected and included in the generated files and the element type can be configured as linear or quadratic, 
displacement only or hybrid displacement-pressure formulation. The generated files are then copied into separate 
folders for each simulation scenario that needs to be analysed.
Three analysis scenarios are currently included: (i) AAA with ILT and the blood pressure load applied on the 
ILT surface; (ii) AAA with ILT and blood pressure load applied on the internal wall surface, bypassing the ILT; 
and (iii) AAA without ILT and blood pressure load applied on the internal AAA wall surface. These scenarios 
are a result of uncertainty in the role of ILT. The ILT is believed to buffer the blood pressure being applied to the 
wall16, thus reducing wall stress. However, in vivo measurements with a pressure probe placed directly into the 
ILT showed no reduction in pressure39. Therefore, the ILT is thought to act similar to a series of ropes, anchoring 
the AAA wall but enabling pressure transmission27, 40. For each scenario, an Abaqus input file defines the simula-
tion parameters and includes the generated AAA wall and ILT mesh files in order to define the geometry, loading 
and boundary conditions (Fig. 14). Therefore, the user has complete control over each simulation scenario by 
simply editing the Abaqus input file corresponding to that scenario. More information on how to edit, add or 
remove a simulation scenario is included in the configuration instructions accompanying the software.
Finite Element Analysis. The finite element analysis is performed using the commercial finite element 
software Abaqus, for each configured simulation scenario. The simulations are carried out using the procedure 
described in Joldes et al.19, which allows the computation of stress in the AAA wall without exact knowledge 
of the material properties. The approach exploits the fact that the geometry of an AAA extracted from medical 
images represents the deformed geometry (under internal blood pressure). The AAA in the deformed configura-
tion is a statically determined structure. Therefore, the internal stress has to balance the externally applied forces; 
the stress is determined by the applied load and the AAA geometry and is very weakly dependent on the material 
properties. This is of great practical significance, as patient-specific material properties for the AAA wall and ILT 
are difficult to obtain in vivo. Removing the dependency on material properties is a major innovation in AAA bio-
mechanics research. For a detailed discussion of the problem of obtaining solutions without knowing mechanical 
properties of tissues please see also Miller et al. and Wittek et al.18, 41.
The results of the finite element simulation (maximum principal stresses in the AAA wall) are extracted using 
the Abaqus scripting interface and saved in a.vtk file (Fig. 15).
Rupture Potential Index Computation. We used the statistical model for AAA wall strength proposed by 
Vande Geest et al.8, which has subsequently been used in several AAA rupture risk assessment studies3, 4, 9–11. The 
wall strength at any point of the AAA surface is determined based on the following variables: local ILT thickness 
(ILT), normalized AAA diameter (NORD), sex of the patient and whether or not the patient has family history 
Figure 15. Example of stress computation results. The maximum principal stress [MPa] is computed at each 
node of the finite element mesh.
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of AAA. NORD is the ratio of the maximum AAA diameter to the diameter at the proximal aorta distal to the 
renal arteries.
By combining the computed wall stress with the wall strength information, the rupture potential index (RPI) 
can be computed at any point of the AAA surface as the ratio between wall stress and wall strength2. A RPI of one 
is the theoretical point of rupture as the local stress higher has exceeded the local strength; therefore, values above 
one imply a high likelihood of rupture.
The RPI is computed using a custom CLI 3D Slicer module, and the results (including intermediate variables 
used for wall strength computation, such as ILT thickness and normalized diameter) are saved in a Visualisation 
Toolkit Polygonal data (.vtp) file for visualization and assessment (see Fig. 2).
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Abstract. Volumetric and 3D tortuosity, curvature and asymmetry measure-
ments were assessed for the first time from magnetic resonance (MR) data 
against ultrasound (US)-derived diameters, in a pilot cohort of 26 patients with 
abdominal aortic aneurysm (AAA) disease. We demonstrated that MR multidi-
mensional analysis can better detect morphologic aneurysmal differences over 
time compared to diameters extracted from US imaging, which is the current 
clinical standard method for assessing AAA progression. Our 3D descriptors 
correlated more strongly with MR volumes, compared to US diameters at base-
line and over time. Following further assessments in a larger patient cohort, this 
multidimensional analysis may enhance rupture risk prediction and improve 
clinical decision making. 
Keywords: Abdominal aortic aneurysm, Magnetic Resonance Imaging, Ultra-
sound, Multidimensional assessments. 
1 Introduction 
Abdominal aortic aneurysm (AAA) disease is an important cause of morbidity that 
affects up to 5% of men aged 65-74 years in Western Europe, with a mortality rate 
that can be greater than 80% when rupture occurs [1]. In the clinical setting, decision 
making must take into account significant risks associated with elective AAA repair, 
with a 30-day mortality rate of up to 5% [2]. It is therefore important, that for the 
clinical management of a patient with AAA, the risks of elective repair must be 
weighed against the risk of rupture [1, 2]. 
The current guidelines suggest that the risk of rupture in an AAA increases with its 
size [3]. Elective repair should be considered when the AAA exceeds 5.5 cm in an-
teroposterior diameter, or expansion exceeds 0.7 cm per six months, or 1 cm per year 
[4]. Despite these guidelines, up to 1 in 5 ruptured AAAs occur in small aneurysms 
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(<5.5 cm), whilst there are many patients under surveillance with aneurysms far ex-
ceeding 5.5 cm in diameter that do not rupture [2, 4].  
Ultrasound (US) is the reference standard technique for assessing AAA diameter 
growth rates accurately, with no radiation exposure and at low cost. However, other 
than visual morphological assessments, it is not possible to provide additional quanti-
tative information about AAA volume and morphology [5]. Computed tomography 
(CT) data analysis has recently showed that AAA volume may better predict aneu-
rysm growth rate [6], whilst correlated more strongly with increasing estimated bio-
mechanical rupture risk, than maximum diameter [3]. These data suggest that aneu-
rysms exhibit non-linear, discontinuous growth patterns and hence, morphological 
changes beyond US-derived diameter growth rates must be assessed [3, 5, 6].  
Magnetic resonance (MR) imaging is widely accepted as a diagnostic imaging tool 
for cardiovascular diseases but its utility in monitoring volumetric as well as asym-
metry AAA changes has not been rigorously examined [7]. Furthermore, although 
some AAA diameter and volume [3, 6], 2D tortuosity indices [8, 9] and asymmetry 
[10] have been assessed (using CT imaging), more advanced multidimensional AAA 
morphological changes such as 3D tortuosity and curvature have not been extensively 
investigated.  
We assessed growth rates and correlations between AAA volumes derived from 
MR images versus US-derived diameters in a pilot cohort of patients. We also as-
sessed for the first time multidimensional 3D tortuosity, curvature and asymmetry 
estimated from MR imaging versus US-derived diameters and MR-derived volumes 
in this pilot cohort. 
2 Methods 
2.1 Study population 
26 patients with asymptomatic AAA (diameter 38-56 mm on ultrasound examination) 
and with aneurysmal expansions <1 cm per year (24 males, 2 females), were retro-
spectively selected from the MA3RS study database (full cohort N=350) [11]. After 
informed consent, MR imaging was acquired in all patients. AAA volumes and multi-
dimensional 3D geometrical descriptors (3D tortuosity, curvature, asymmetry) were 
extracted from the MR images and comparisons as well as correlations with clinical 
standard US-derived diameters were assessed.   
2.2 Ultrasound and MR acquisition 
Standard US imaging was carried out in an accredited clinical vascular science la-
boratory. Participants underwent US evaluation of the maximum anteroposterior di-
ameter of the abdominal aorta by an expert ultrasonographer using a 3.5 MHz linear 
array transducer.  
MRI scans were performed on a 3T Magnetom Verio scanner (Siemens, Erlangen, 
Germany), as previously described [11]. T2-weighted multi-slice Half Fourier Acqui-
sition Single Shot Turbo Spin Echo (HASTE) sequences were used to identify the 
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extent of the aneurysm and anatomical data were obtained using a respiratory-gated 
T2-weighted turbo spin echo sequence. US and MR protocols were implemented for 
baseline and 1-year follow up imaging. 
2.3 Image and 3D geometrical analysis  
Maximum anteroposterior diameters (US_Diam) were extracted from the US images 
by an expert clinician. AAAs from MR images were manually segmented by an expe-
rienced user, using dedicated segmentation software (SliceOmatic, TomoVision, Can-
ada). Regions or interest (ROIs) for the lumen, thrombus and aortic wall were manu-
ally defined across all slices for which abdominal aortas were MR visible (Fig. 1a, 11-
25 slices depending on the length of abdominal aortas). MR data were anatomically 
landmarked by an expert clinician and matching slices from the same anatomical 
areas for both baseline and 1-year follow up data were analysed for each subject.    
AAA volumes and 3D geometrical descriptors were calculated using in-house 
software developed in Matlab (Mathworks, USA). From the SliceOmatic data, the 
centroids for the lumen ROIs (Lum) and the combined ROIs (Com=lumen + throm-
bus + aortic wall) were derived for all MR slices across all subjects (Fig. 1b) and were 
then used to derive 3D tortuosity, curvature and asymmetry measurements. AAA 
volumes and 3D geometrical descriptors were calculated for Lum and Com ROIs and 
centrelines (Fig 1b, each centreline connects consecutive centroids) respectively. 
AAA volumes for Lum and Com ROIs are described as Vol_Lum, Vol_Com respec-
tively.  
For 3D tortuosity measurements, the distance measure (DM) algorithm was origi-
nally developed for retinal 2D data analysis, as previously described [12]. To adapt 
the DM algorithm for 3D tortuosity measurements, the lengths of the 3D vectors (3D 
Euclidean distances) connecting consecutive centroids were calculated and summed 
across both the Lum and Com centrelines (Fig 1c, Lc=Lc1+Lc2+…Lcn). Further-
more, the length of the 3D vector connecting the two end points of each Lum and 
Com centreline was measured (Lx). DM tortuosity algorithm was finally calculated in 
the 3D space for both Lum and Com centrelines (abbreviated as Tor_Lum, Tor_Com 






DM   (1) 
The curvature was measured for both Lum and Com centrelines (Cur_Lum, 
Cur_Com respectively). To devise 3D curvature measurements, singular value de-
composition was used to fit osculating circles at each centroid in 3D space (see equa-
tion 2 and Fig. 1d). For the singular value decomposition, the following factorisation 
was used: 
                                                         
TVUA                                                         (2) 
 
where A is an 3 x 3 matrix, in which each column represents a 3D centroid point 
across the Lum and Com centrelines. In matrix A, the second column corresponds to 
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the local 3D centroid point in which the osculating circle was fitted, whilst the first 
and third columns describe the 3D centroid points before and after the local 3D cen-
troid point, across each centreline. U and V represent orthogonal matrices describing 
the left and right singular vectors respectively, with VT denoting the transpose of V. Σ 
denotes the diagonal matrix in decreasing order. Following singular value decomposi-
tion, the first and second unit orthogonal vectors in U were extracted and multiplied 
by the matrix A. The product of this multiplication defined two 3D unit vectors which 
were subsequently used to fit an osculating circle for each local 3D centroid point.    
The radius of each osculating circle (r) is also the radius of the curvature (κ), whilst 
curvature equals the reciprocal of radius r (see also equation 3) [13]. The smaller the 
radius r of the circle, the higher the curvature is and vice versa. (note: curvature is 0 





  (3) 
Two types of asymmetry measurements were derived. The first type has been pre-
viously described by Doyle et al [14] and is based on calculating the perpendicular 
distance from each centroid to the straight line connecting the AAA end points 
(Fig.1e). This asymmetry type was calculated for both the Lum and Com centrelines 
(Ass_Lum, Ass_Com respectively). The second type of asymmetry is introduced by 
the authors, defined as centroid asymmetry (Ass_Cen). The lengths of the 3D vectors 
connecting paired (corresponding to the same slice) Lum and Com centroids were 
calculated, summed across all centroids and normalised to the Com centreline length 
for each AAA (Fig. 1f). In a vessel with no aneurysmal expansion, the lumen and 
outer wall are approaching concentricity and Ass_Cen tends to 0. 
2.4 Statistical analysis 
Statistical analysis was performed using R software (R Foundation for statistical 
computing, Vienna, Austria). A non-linear growth model (NLGM) was used to assess 
growth (for AAA expansion measurements: diameter, volumes, asymmetry) and 
change rates (for 3D tortuosity, curvature), between baseline and 1-year follow-up 
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in which M is an US or MR estimate and t is the time (in months) between baseline 
and follow-up measurements. The Shapiro-Wilk test was used to assess normality of 
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the data and comparisons were assessed using paired and unpaired Student’s t-tests as 
appropriate. Box and whisker plots investigated growth/change rates across all US 
and MR measurements. Linear regression and Pearson’s correlation coefficients were 
used to investigate correlations between MR AAA volumes versus US-derived diame-
ters, and between MR 3D geometrical descriptors versus diameters and volumes (two-
sided P value <0.05 were considered significant). 
 
Fig. 1. (a) Lumen (red), thrombus (green) and outer wall (blue) segments shown from a patient 
with AAA disease at baseline. (b) Centrelines for Lum (lumen, with red) and Com (com-
bined=lumen + thrombus + outer wall, with blue) regions of interest, from the same patient data 
set. (c) Tortuosity DM algorithm applied across 6 example centroids, where Lc1-n and Lx (dot 
blue line) are the 3D vectors connecting consecutive centroids and end points in centrelines, 
respectively. (d) Curvature measured by fitting osculating circles in 3D space. (e) and (f) two 
different types of vessel asymmetry metrics (in c-f. the solid red centrelines represent the Lum 
centreline, in f. the dot blue line shows the Com centreline). 
3 Results  
26 patients (2 females, 24 males) with AAA were included in the analysis. The medi-
an time between baseline and follow up US and MR imaging was 12 months (inter-
quartile range (IQR), 11-13 months). MR imaging was acquired within 1-week from 
the day of US imaging. The mean(SD) US-derived AAA diameter was 45(4) mm and 




3.1 Growth and change rates 
Increased growth rates were observed for all parameters describing AAA expansion 
(Fig. 2). For US_Diam, median diameter growth rate was 3.32 %/year (IQR were 0.00 
to 8.56 %/year). For Vol_Lum and Vol_Com, median volume growth rates were 7.18 
and 8.23 %/year (IQRs were 0.38 to 18.54, 4.59 to 13.67) respectively. The growth 
rates for Vol_Com showed a significant difference versus US_Diam (P<0.05). For 10 
patients who showed no diameter increases, Vol_Com showed a significant growth 
rate increase (P<0.001).  
Median growth rates for Ass_Lum and Ass_Com were 9.52 and 5.71 %/year (IQRs 
were -8.60 to 33.90, -9.92 to 24.90 %/year) respectively. Ass_Cen demonstrated the 
largest growth rate (median was 12.74 % /year; IQR was -0.40 to 34.52 %/year, Fig. 
2). The growth rate for Ass_Cen showed a significant difference versus US_Diam 
(P<0.05). For 10 patients who showed no diameter increases, Ass_Cen showed a sig-
nificant growth rate increase (P<0.01). No other significant differences were observed 
between growth rates.  
Change rates for 3D tortuosity and curvature were not significantly increased (all 










Fig. 2. Growth rates for US and MR measurements demonstrating aneurysmal expansions 
across all subjects (US_Diam: ultrasound-derived diameters, Vol_Lum: MR-derived volumes 
of the lumen, Vol_Com: volumes of the combined regions of interest, Ass_Lum: asymmetry for 
the lumen centreline, Ass_Com: asymmetry for the combined centreline, Ass_Cen: centroid 
asymmetry). Significant growth rate increases in patients with no diameter changes are indicat-
ed with *. 
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3.2 Correlations at baseline 
Initially, correlations across all measurements were examined at baseline. Vol_Lum 
and Vol_Com showed significant, strong correlations with US_Diam (Fig. 3a-b). A 
significant, strong correlation was also observed between Vol_Com and Ass_Cen 
(Fig. 3c, all P<0.001). There was also a moderate but significant correlation between 
US_Diam and Ass_Cen (r=0.46, P<0.05). 
All 3D geometrical descriptors (tortuosity, curvature, asymmetry) for both Lum 
and Com centrelines correlated positively (r=0.51-0.59, P<0.001), with Tor_Com 
versus Ass_Com reaching the highest correlation (r=0.83, P<0.001). 
 
Fig. 3. Significant, strong correlations shown at baseline (Vol_Lum: MR-derived volumes of 
the lumen, Vol_Com: volumes of the combined regions of interest, Ass_Cen: centroid asym-
metry). 
3.3 Correlations between growth and change rates 
Subsequently, correlation coefficients were investigated between growth rates for US 
derived diameters and MR derived volumes versus change rates for all 3D geomet-
rical descriptors. The strongest correlation was observed between Vol_Com and 
Cur_Com (r=0.63, P<0.001, Fig.3). There were also moderate but significant correla-
tions between US_Diam and Cur_Lum and between Vol_Com and Tor_Com (r=0.45, 
0.50 respectively, P<0.05). 
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Significant, strong correlations were finally observed between change rates of 3D 
geometrical descriptors. Specifically, between Tor_Lum and Cur_Lum (r=0.60), 
Tor_Com and Cur_Com (r=0.60), Tor_Com and Ass_Com (r=0.71, all P<0.01). All 
other correlations at both baseline and 1-year follow-up growth/change rates demon-
strated weaker non-significant relationships. 
 
Fig. 4. Significant, strong correlations for growth/change rates. Vol_Com: volume, Cur_Com: 
curvature, Tor_Com: tortuosity, Ass_Com: asymmetry, of the combined regions of interest 
(Com). 
4 Discussion 
We investigated growth rates for US diameters as well as MR volumes and asymme-
tries derived from a pilot cohort of AAA patients. MR-derived volumes and centroid 
asymmetries demonstrated significant growth rate increases in patients with small 
asymptomatic aneurysms and low US diameter increases. We also assessed all 3D 
geometrical descriptors versus US diameters and MR volumes and demonstrated sig-
nificant correlations both at baseline and over time (between baseline and 1-year). 
4.1 Growth rates of AAA expansion measures 
This is the first study assessing MR derived volumes and asymmetries against US 
reference standard diameter measurements. The AAA structural integrity can be com-
promised by fast AAA growth and may increase the risk of AAA rupture [6, 15, 16]. 
Monitoring the growth rate of small AAAs can therefore be crucial for decision mak-
ing in surveillance programs. In our analysis, we showed that MR-derived volumes 
may better detect morphologic aneurysmal differences over time compared to US 
diameters, the current clinical standard method for monitoring AAA changes. This is 
in agreement with a previous CT study suggesting that volume can better predict 
AAA growth rate than diameter [3].  
Similarly, we demonstrated that centroid asymmetry, our novel 3D asymmetry de-
scriptor, can better represent morphologic aneurysmal changes compared to US diam-
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eters. Centroid asymmetry can identify morphological differences beyond diameter 
and longitudinal growths across the AAA (accounted for by volumetric analysis), 
describing both areas of thrombus increases and aortic lumen dislocations inside the 
AAA over time. Moreover, centroid asymmetry demonstrated increased growth rate 
compared to asymmetry of the combined centreline (Fig. 2), which has previously 
been suggested as a potentially useful adjunct to diameter using CT data analysis [10].  
In our pilot cohort, we also showed for the first time significant, strong correlations 
between MR-derived volumes and US diameters at baseline (Fig. 3a-b), whilst 
demonstrated that baseline centroid asymmetry correlated with both US diameters and 
MR volume. The above correlations at baseline were not observed when the respec-
tive growth rates were assessed, which can suggest that volume and centroid asym-
metry may follow different growth patterns compared to maximum US diameters 
(Fig. 2). These results can suggest that MR volume and centroid asymmetry estimates 
may be able to detect morphological abnormalities at baseline as well as changes over 
time, and improve decision making in surveillance programs. 
4.2 Further assessment of 3D geometrical descriptors 
Our analysis demonstrated that changes in the curvature and tortuosity are associated 
with diameter and volume increases. The strongest correlation was observed between 
MR volume and curvature of the combined ROIs. Although there was a significant 
correlation between US diameters and curvature of the lumen, curvature and tortuos-
ity correlated more strongly with MR volume of the combined ROIs. Significant, 
strong correlations were also shown between change rates of 3D geometrical de-
scriptors (tortuosity and curvature of the lumen, tortuosity and curvature, tortuosity 
and asymmetry of the combined ROIs). To our knowledge, this is the first study as-
sessing 3D tortuosity and curvature algorithms in AAAs using medical imaging data. 
Previous studies have mainly assessed 2D tortuosity indices [8, 9], or have focused in 
biomechanical analysis using peak wall stress [3, 10, 17, 18]. In the context of biome-
chanical analysis, studies have suggested that AAAs predominantly dilate (thrombotic 
expansion) in the anterior plane due to spinal cord constraints in the posterior direc-
tion and thus, peak wall stress is frequently increased in areas of the posterior wall [3, 
17, 18]. Molacek et al. investigated the elastic properties of AAAs by performing a 
distensibility study using CT data and suggested that thrombotic morphologies may in 
some cases act protectively against the risk of rupture [19]. Further investigation of 
our 3D descriptors may provide additional quantitative information to biomechanical 
analysis, for which cases thrombus morphologies may act as risk [17, 18] or protec-
tive factors [19] of rupture.  
In conclusion, we showed that MR multidimensional analysis can better detect 
morphologic aneurysmal differences over time compared to US diameters. In addi-
tion, our 3D descriptors correlated more strongly with MR volumes, compared to US 
diameters at baseline and over time. Further evaluation is underway in our larger pa-
tient cohort (N=350) to further assess our 3D geometrical descriptors and evaluate 
their ability in predicting rupture risk and disease progression. 
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Although carotid endarterectomy reduces risk of ipsilat-eral stroke in people with symptomatic carotid artery 
stenosis, the number needed to treat to prevent one stroke is 
large,1,2 especially in asymptomatic stenosis.3 Furthermore, 
the pathological event that leads to cerebral thromboembo-
lism (atherosclerotic plaque rupture) is not necessarily cor-
related with luminal stenosis severity.4 Other pathological 
features, such as inflammation, cell death, and microcalci-
fication, are important in driving both plaque formation and 
instability.5–7 New imaging biomarkers of these processes are 
therefore needed to improve risk stratification and clinical 
Background—Combined positron emission tomography (PET) and computed tomography (CT) can assess both anatomy 
and biology of carotid atherosclerosis. We sought to assess whether 18F-fluoride or 18F-fluorodeoxyglucose can identify 
culprit and high-risk carotid plaque.
Methods and Results—We performed 18F-fluoride and 18F-fluorodeoxyglucose PET/CT in 26 patients after recent transient 
ischemic attack or minor ischemic stroke: 18 patients with culprit carotid stenosis awaiting carotid endarterectomy and 8 
controls without culprit carotid atheroma. We compared standardized uptake values in the clinically adjudicated culprit 
to the contralateral asymptomatic artery, and assessed the relationship between radiotracer uptake and plaque phenotype 
or predicted cardiovascular risk (ASSIGN score [Assessing Cardiovascular Risk Using SIGN Guidelines to Assign 
Preventive Treatment]). We also performed micro PET/CT and histological analysis of excised plaque. On histological and 
micro PET/CT analysis, 18F-fluoride selectively highlighted microcalcification. Carotid 18F-fluoride uptake was increased 










0.29±0.10 versus 0.12±0.11, P=0.001). 18F-Fluoride uptake correlated with high-risk plaque features (remodeling index 
[r=0.53, P=0.003], plaque burden [r=0.51, P=0.004]), and predicted cardiovascular risk [r=0.65, P=0.002]). Carotid 
18F-fluorodeoxyglucose uptake appeared to be increased in 7 of 16 culprit plaques, but no overall differences in uptake 
were observed in culprit versus contralateral plaques or control patients. However, 18F-fluorodeoxyglucose did correlate 
with predicted cardiovascular risk (r=0.53, P=0.019), but not with plaque phenotype.
Conclusions—18F-Fluoride PET/CT highlights culprit and phenotypically high-risk carotid plaque. This has the potential 
to improve risk stratification and selection of patients who may benefit from intervention.  (Circ Cardiovasc Imaging. 
2017;10:e004976. DOI: 10.1161/CIRCIMAGING.116.004976.)
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Circ Cardiovasc Imaging is available at http://circimaging.ahajournals.org DOI: 10.1161/CIRCIMAGING.116.004976
Received May 2, 2016; accepted January 12, 2017.
From the BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (A.T.V., W.S.A.J., A.M., G.S., R.O.F., N.L.M., E.J.R.v.B., 
M.R.D., D.E.N.); Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (A.I., J.R., A.P.D.); and Clinical 
Research Imaging Centre (T.C., G.R., A.F., C.L., E.J.R.v.B., M.R.D., D.E.N.) and Centre for Clinical Brain Sciences (R.A.-S.S., M.D., W.W.), University 
of Edinburgh, United Kingdom.
The Data Supplement is available at http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.116.004976/-/DC1.
Correspondence to Alex T. Vesey, MD, Centre for Cardiovascular Science, University of Edinburgh, Room SU 305, Chancellor’s Bldg., 49 Little France 
Crescent, Edinburgh, EH16 4SB, United Kingdom. E-mail: avesey@staffmail.ed.ac.uk
18F-Fluoride and 18F-Fluorodeoxyglucose Positron  
Emission Tomography After Transient Ischemic  
Attack or Minor Ischemic Stroke
Case–Control Study
Alex T. Vesey, MD; William S. A. Jenkins, MD; Agnese Irkle, PhD; Alastair Moss, MD;  
Greg Sng, MD; Rachael O. Forsythe, MD; Tim Clark, MSc; Gemma Roberts, MSc;  
Alison Fletcher, PhD; Christophe Lucatelli, PhD; James H. F. Rudd, MD, PhD;  
Anthony P. Davenport, PhD; Nicholas L. Mills, MD, PhD; Rustam Al-Shahi Salman, MA, PhD;  
Martin Dennis, MD, PhD; William N. Whiteley, MD, PhD; Edwin J. R. van Beek, MD, PhD;  
Marc R. Dweck, MD PhD; David E. Newby, MD, PhD, DSc
Molecular Imaging
© 2017 The Authors. Circulation: Cardiovascular Imaging is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, 
Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited.
See Editorial by Tawakol et al 
See Clinical Perspective








































































2  Vesey et al  18F-Fluoride and 18F-FDG PET After TIA/Ischemic Stroke
decision-making. Such biomarkers could also assess the 
response of plaque biology to novel pharmacological inter-
ventions and provide a way of identifying culprit lesions in 
patients with multiple plaques.
Hybrid positron emission tomography and computed 
tomography (PET/CT) is a molecular imaging modality that 
has high sensitivity for noninvasive in vivo detection of radio-
labeled biomolecules tuned to a variety of pathophysiological 
processes. In carotid atherosclerosis imaging, the most widely 
used tracer has been 18F-fluorodeoxyglucose (18F-FDG)8–14: 
Recently, we have described another radiotracer, 18F-fluoride, 
in atherosclerosis imaging.15,16 We15–18 and others19–23 have 
shown that this tracer has major potential in cardiovascular 
disease. 18F-Fluoride can highlight culprit plaque in patients 
after myocardial infarction and high-risk plaques in patients 
with apparently stable coronary heart disease.16 We have 
shown that this is because 18F-fluoride can highlight areas 
of microcalcification indicative of necrotic atheroma.24 The 
ability to identify high risk or culprit plaque in the cephalic 
circulation has the potential to improve risk stratification in 
patients at high risk of stroke with a view to more targeted 
interventions. Our study aims were to compare and contrast 
the identification of clinically adjudicated culprit and high-




Two cohorts of people with a recent transient ischemic attack (TIA) or 
minor ischemic stroke were recruited: a case cohort with a high-grade 
internal carotid artery stenosis (≥50% by North American Symptomatic 
Carotid Endarterectomy Trial25 criteria for men, ≥70% for women) 
scheduled to undergo carotid endarterectomy and a control cohort 
in whom the cause of stroke was not attributed to carotid atheroma. 
Participants were recruited from outpatient clinics in National Health 
Service Lothian between January 2013 and June 2014 (for exclusion 
criteria, see Appendix in the Data Supplement). Research ethics com-
mittee approval (National Health Service West of Scotland Research 
Ethics Committee: 12/WS/0227) and the written and informed consent 
of all participants were obtained.
Baseline Assessment
Participants underwent clinical assessment at baseline including 
standard hematologic and biochemical indices. Serum C-reactive 
protein concentration was measured using the MULTIGENT CRP 
Vario assay on the high-throughput ARCHITECT system (Abbott 
Laboratories, Abbott Park, IL). Predicted cardiovascular risk was es-
timated using the ASSIGN score: a validated Scottish cardiovascular 
risk score that is similar to the Framingham risk score but includes 
additional factors, such as social deprivation and family history.26
PET/CT Protocol
Static 18F-FDG PET/CT was acquired using a hybrid scanner 
(Biograph mCT, Siemens Medical Systems, Erlangen, Germany) 90 
minutes after the intravenous administration of a target dose of 200 
MBq. A rigid neck collar was fitted to minimize movement and stan-
dardize position. An attenuation-correction CT scan (nonenhanced, 
low dose 120 kV, 50 mAs) was then performed followed by PET ac-
quisition covering 2 bed positions with the first upper bed centered 
over the carotid bifurcation in 3-dimensional mode for 20 minutes per 
bed. Patients were fasted for 6 hours before scanning.
18F-Fluoride PET/CT was undertaken the subsequent day 60 min-
utes after administering 250 MBq 18F-fluoride. A neck collar was 








n 18 8  
Age, y 71.7±12.3 66.1±12.5 0.30
Men, n (%) 12 (66.7) 4 (50) 0.67
BMI, kg·m−2 26.2±5 27.3 (23.38–36) 0.40
Systolic blood pressure 
(mm Hg)
137±25 154±16 0.08
Diastolic blood pressure 
(mm Hg)
78±18 85±3.4 0.34
ASSIGN score 31±15.5 21.1±13.1 0.13
Presenting syndrome, n (%)   0.22
  Stroke 8 (44) 6 (75)  
  TIA/amaurosis fugax 10 (56) 2 (25)  
CEA side, right (%) 8 (44)   
Cardiovascular history, n (%)
  Coronary artery disease 10 (56) 2 (25) 0.22
  Myocardial infarction 5 (28) 1 (13) 0.63
Risk factors, n (%)
  Hypertension 11 (61) 7 (88) 0.36
  Diabetes 1 (6) 0 1
  Hypercholesterolemia 13 (72) 5 (63) 0.67
  Current smoker 6 (33) 2 (25) 0.67
Medication, n (%)
  Single antiplatelet 
therapy
14 (78) 6 (88) 1
  Dual antiplatelet therapy 3 (17) 0 0.53
  Anticoagulant 1 (6) 2 (25) 0.22
  Statin 17 (94) 6 (75) 0.22
  ACEi/AIIRB 7 (39) 2 (25) 0.20
  Βeta-antagonist 7 (39) (131) 0.36
  Calcium antagonist 7 (39) 2 (25) 0.67
  Other antihypertensive 6 (39) 3 (38) 1
Hematology
  Hemoglobin, g/L 139.8±19 142.6±12.3 0.71
  White cell count, ×109/L 8±1.4 6.4 (3.8–7.9) 0.06
  Platelet count, ×109/L 259±64 273±63 0.60
Biochemistry
  Creatinine, mmol/L 88.5 (78–97.5) 76.8±13.5 0.07
  Total cholesterol, mg/dL 117.9±34.8 181.7±54.1 0.81
  C-reactive protein, mg/L* 3.1±2.6 2.4±3.5 0.66
Parametric data presented as mean±SD. Nonparametric data presented 
as median (IQR). Categorical data presented as number (%). ACE indicates 
angiotensin converting enzyme; AIIRB, angiotensin 2 receptor antagonists; BMI, 
body mass index; CAD, coronary artery disease; CEA, carotid endarterectomy; 
IQR, interquartile range; and transient ischemic attack.
*C-reactive protein values > 10 excluded as per AHA guidelines.
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fitted and an attenuation-correction CT scan was performed. This was 
followed by PET acquisition covering 2 similar bed positions to the 
18F-FDG scan allowing 15 minutes per bed. A subset of 5 patients 
underwent fully dynamic 18F-fluoride PET/CT with pharmacokinetic 
analysis as described previously.24 Dynamic PET provides a quantita-
tive assessment of uptake and these data were used to validate the 
semiquantitative static imaging data.
After PET acquisition, a CT carotid angiogram was performed 
without moving the subject (Care Dose 4D, 120 kV, 145 mA, rotation 
time 0.5 seconds, pitch 0.8. Contrast: 50 mL Niopam 370).
Static PET data were reconstructed using the Siemens UltraHD 
algorithm: ordered subset expectation maximization+point spread 
function modeling+time-of-flight; 2 iterations and 21 subsets; matrix 
size 200×200; 5 mm full-width half-maximum Gaussian smoothing. 
Dynamic PET data were similarly reconstructed but only using coin-
cident events from the 60- to 75-minute time-bin. Dynamic data were 
analyzed as reported previously24 and a K
i
 value was calculated using 
Patlak analysis.27,28
Tissue Collection, Micro PET/CT, and Histology
At the time of endarterectomy, plaques were collected immediately 
after excision, photographed, and snap frozen. A random selection 
(n=8) of specimens was analyzed by micro PET/CT and histology 
to explore 18F-fluoride binding patterns (see Appendix in the Data 
Supplement for detailed methods).
Image Analysis
Positron Emission Tomography/Computed Tomography
Static analysis of 18F-FDG and 18F-fluoride uptake was performed 
on an OsiriX workstation (OsiriX version 3.5.1 64-bit; OsiriX 
Imaging Software, Geneva, Switzerland). PET/CT data were re-
viewed alongside the CT angiogram. Scans were qualitatively as-
sessed for registration, image quality, patient movement, and visual 
evidence of radiotracer uptake. PET and CT data were individually 
and carefully manually coregistered by lining up fiducial markers 
apparent on both modalities (eg, cervical spine, mandible and hyoid 
on 18F-fluoride imaging; skin, spinal cord, and brain on 18F-FDG 
imaging). No formal inter-PET registration was performed. Three 
regions of interests (ROIs) were drawn on the carotid of interest on 
adjacent 3-mm axial slices. If a plaque was present, the ROIs were 
centered on the area of highest uptake. If there was no plaque, the 
uptake in the proximal 1 cm of internal carotid artery, just distal to 
the bifurcation was quantified. From these, standardized uptake val-
ues (SUVs; maximum, mean maximum, and mean) were recorded. 
Blood pool activity was determined from the average of 5 ROIs 
within the lumen of the superior vena cava to calculate target to 
background ratios.
Uptake in the proximal left common carotid artery was quantified 
to explore the relationships between arterial 18F-FDG and 18F-fluoride 
uptake in a site unaffected by an acute plaque event. Three ROIs were 
placed around this vessel and uptake was recorded.
Inter- and intraobserver reproducibility of 18F-fluoride uptake mea-
surements were determined using a random selection of 12 patients (24 
carotids) by 2 experienced observers (A.T.V., G.S.) who were blinded to 
the clinical data during analysis.
Computed Tomography
The CT angiogram was assessed for image quality, plaque presence, 
location, and characteristics. Analysis was undertaken on a cardio-
vascular workstation (Vital Images, Minnetonka, MN). A blinded and 
experienced observer (A.V.) performed the semiautomated CT plaque 
analysis.
Statistical Analysis
Radiotracer uptake, expressed as mean and maximum SUV, was 
compared between the clinically adjudicated culprit carotid plaque 
and the contralateral side. Continuous variables are expressed as 
mean±standard deviation for normally distributed data and median 
(interquartile range) for skewed distributions. Skewed datasets un-
derwent logarithmic transformation to normalize their distribution. 
Parametric (unpaired and paired t-tests) and nonparametric (Mann–
Whitney U or Wilcoxon matched-pairs signed rank) tests were used 
for normally distributed and skewed data, respectively. Categorical 
Figure 1.  18F-Fluoride and 18F-fluorodeoxyglucose (FDG) positron emission tomography of carotid arteries. Example of 18F-fluoride (A, B, C) 
and 18F-FDG (D, E, F) positron emission tomography (PET)/computed tomography (CT) of 1 patient before surgery for symptomatic carotid 
stenosis. A, 18F-Fluoride PET axial slice. B, Registered CT angiogram axial slice. C, Fused PET/CT image. White arrow, Ruptured plaque 
showing 18F-fluoride uptake. D–F, Same slice but with 18F-FDG. Culprit shows uptake, but the contralateral side is obscured by uptake in the 
right longus colli (green star). An oblique computed tomography carotid angiogram reformat of the culprit (G). The operative specimen (H).
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data are presented as n (%) and were compared using Fisher’s exact or 
Chi-squared tests. Correlation was undertaken with either Pearson’s 
r or Spearman’s ρ subject to the normality of the variables tested. 
To quantify inter- and intraobserver reproducibility of 18F-fluoride 
uptake measurement, the intraclass correlation coefficient was calcu-
lated and Bland-Altman analysis was undertaken.
Statistical analyses were performed with the use of SPSS ver-
sion 18 (SPSS Inc, Chicago, IL) and Graph Pad Prism version 6.0 
(GraphPad Software Inc, San Diego, CA). Statistical significance was 
defined as a 2-sided P<0.05.
Results
Study Population
We recruited 26 patients: 18 in the carotid endarterectomy 
cohort and 8 in the control cohort (Figure I in the Data Supple-
ment). Baseline characteristics (Table 1) were similar in both 
cohorts. Twenty patients completed all the imaging techniques 
(Figure 1). A minority did not receive all scans because of the 
technical and feasibility challenges of completing our multi-
modality imaging protocol in the very short time frame before 
surgery. Actual doses and uptake times are specified in Table I 
in the Data Supplement. There were no adverse events during 
the study. There were 3 withdrawals.
Micro PET/CT and Histology
18F-Fluoride was observed to selectively highlight areas of 
pathologically high-risk microcalcification (Figure 2 and 
Supplementary Movie I in the Data Supplement). Both on auto-
radiography and micro PET/CT, 18F-fluoride was observed to 
bind avidly to areas of microcalcification but only to the sur-
face of large volume stable macrocalcifications. Our previous 
studies24 would suggest that this was because of the inability 
of the fluoride ion to penetrate to the deeper layers of a large 
crystalline mass (with a low surface-area-to-volume ratio). In 
contradistinction, the powdery deposits of microcalcification 
(not visible on CT) provide a large area (high surface-area-to-
volume ratio) for the fluoride ion to bind.
Imaging
When comparing the 18F-fluoride uptake on static imaging 
with full dynamic modeling, K
i
 was most strongly correlated 
with the SUV
mean
 (r=0.93 [95% confidence interval 0.64–0.99], 
P=0.001; Figure 3). There were no fixed or proportional biases 
in the SUV measurements within and between observers (Table 
II in the Data Supplement). These assessments also demon-
strated high intraclass correlation coefficients (all >0.90).
Assessment of Uptake: Culprit Compared With 
Contralateral and Controls
18F-Fluoride uptake was variably present in most plaques with 
all culprits showing uptake on visual assessment. In the large 
majority of patients undergoing carotid endarterectomy who 
were scanned (87%; 13/15), there was more visual uptake 
of 18F-fluoride in the culprit compared with the contralateral 
Figure 2.  18F-Fluoride micro positron emission tomography (PET)/computed tomography (CT), autoradiography, and alizarin red staining. 
Two examples of ex vivo 18F-fluoride micro PET/CT are shown (A–D, F). A, Coronal micro CT slice; B, corresponding micro PET; C, fused 
image; D, the plaque. Green arrow, Adherent thrombus over plaque rupture. Red arrow, Associated area of 18F-fluoride uptake (microcal-
cification). Black arrows, Areas of macrocalcification showing comparatively little uptake (A, C, F). These examples show that 18F-fluoride 
provides information of the presence of microcalcification and does not simply highlight all calcification. E, An example of micro CT slice 
registered to an alizarin red-stained section and the corresponding autoradiogram from a specimen that had been incubated whole in 
18F-fluoride. It can be seen that the tracer is unable to penetrate the deeper layers of macrocalcification (black arrow), but is able to high-
light microcalcification beyond the resolution of even micro CT (red arrow), thus explaining the findings in the micro PET/CT images.
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side. In the 2 patients without discriminatory uptake, there 
was heavy uptake bilaterally but more 18F-fluoride uptake on 
the contralateral side. One patient had grossly ossified carot-
ids and the second, at the time of surgery, was found to have 
a fibrous stenosis (low signal side) and was subsequently 
admitted with a fatal ischemic stroke on the contralateral side 
(high signal side, Figure 3J). 18F-Fluoride uptake was focal 
and readily identifiable with excellent signal to background 
discrimination. Spillover from the hyoid bone, thyroid carti-
lage and cervical vertebrae occasionally made drawing ROI 
difficult, but only 1 vessel was rendered uninterpretable. 
On SUV analysis, the clinically adjudicated culprit showed 










 0.29±0.10 versus 0.12±0.11, P=0.001) 
irrespective of the method of quantification (Table 2 and Fig-
ures 3 and 4).
Of note, in patients with a stroke in whom the imaging 
extended to encompass the affected territory of the brain (n=3), 
intense 18F-fluoride uptake was noted in regions of cerebral 
infarction (SUV
mean
 4.8±1.98 versus SUV
mean
 of 0.07±0.02 for 
contralateral noninfarcted brain, P<0.001; Figure 3B and 3C, 
Movie II in the Data Supplement).
Seven of the 16 culprit carotid plaques demonstrated 
clear and discernible increased 18F-FDG uptake. However, 
this uptake was generally more diffuse than 18F-fluoride and 
analysis was more frequently hampered by overspill from 
sternocleidomastoid, longus colli, tonsillar tissue, and the 
submandibular salivary glands (Figure 1). This rendered 5 
vessels noninterpretable. In the remaining 4 culprit vessels, 
no increase in 18F-FDG uptake could be observed. Overall 
on semiquantitative analysis, 18F-FDG uptake was not higher 
in the clinically adjudicated culprit compared with either the 
paired contralateral (SUV
mean
 1.83±0.55 versus 1.81±0.46, 
P=0.269) or control vessels (SUV
mean
 1.83±0.55 versus 
2.08±0.33, P=0.269) irrespective of the method of quantifica-
tion (Table 2 and Figure 4).
Uptake Compared With Plaque Features and 
Baseline Characteristics
18F-Fluoride uptake was correlated with several plaque char-
acteristics on CT plaque analysis (Table 3). The strongest 
Figure 3.  Dynamic positron emission tomography (PET) acquisition and examples of 18F-fluoride uptake. A, Correlation between stati-
cally derived standardized uptake value (SUV)mean and dynamically measured Ki (dotted line is 95% confidence interval). Photograph 
shows a dynamic PET study in process. B, C, 18F-Fluoride uptake into areas of cerebral infarction. D–F, From 1 patient. D, Axial image 
from computed tomography carotid angiogram; E, Fused axial 18F-fluoride PET/computed tomography (CT; white arrow, culprit plaque); 
F, Oblique reconstruction. G–I, Similar reconstructions from a different patient. J, Obliquely reformatted PET/CT image from a patient 
who developed a fatal stroke (ipsilateral to the lesion marked by a white arrow) 2 weeks after this scan. The contralateral side, which had 
shown minimal uptake, had been deemed the culprit based on duplex assessment.
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correlation was with the Agatston score (SUV
mean
 r=0.72, 
P<0.001), although there were also strong correlations with 
high-risk features such as plaque burden (SUV
mean
 r=0.51, 
P=0.003) and positive remodeling (wall-distal internal carotid 
artery lumen ratio, with SUV
mean
 r=0.53, P=0.003).
In terms of baseline cardiovascular risk indices, uptake 
of both tracers in the vasculature correlated with age (18F-
FDG SUV
meanmax
 r=0.48, P=0.037; 18F-fluoride SUV
mean
 
r=0.59, P=0.007) and the cardiovascular risk score (18F-FDG 
SUV
meanmax
 r=0.53, P=0.019; 18F-fluoride SUV
mean
 r=0.65, 
P=0.002) but neither was associated with serum C-reactive 
protein concentration.
Discussion
We have shown that the culprit plaques of patients with recent 
TIA or minor ischemic strokes enhance with 18F-fluoride on 
PET/CT. Uptake was focal, readily identifiable, and discrimi-
nated between culprit and nonculprit. 18F-Fluoride uptake was 
associated with high-risk plaque phenotype and predicted 
cardiovascular risk. In contrast, while 18F-FDG uptake was 
present in plaque and correlated with cardiovascular risk, it 
was more diffuse and prone to spillover and therefore less dis-
criminatory. 18F-FDG also failed to correlate with established 
high-risk plaque morphological features.
We have previously shown that 18F-fluoride uptake is 
associated with increased intraplaque markers of cell death, 
procalcific proteins, inflammation, and high-risk features in 
the coronary circulation in vivo and the carotid system ex 
vivo.16 Here, we confirm our previous observations24 (which 
we have also recently reviewed29) that this is explained by the 
ability of 18F-fluoride to report microcalcification. Why is this 
the case? Far from a passive and degenerative process, vessel 
mineralization is a controlled response to a variety of insults, 
particularly oxidized inflammatory lipid (as in the calcific 
response to tuberculosis infection where lipid-rich bacterial 
cell walls become oxidized through leukocyte action). It is 
therefore perhaps no surprise that direct links between ath-
erosclerosis and the induction of extraskeletal osteogenesis 
have been identified.30,31 The presence of cellular necrosis and 
apoptosis32 is also likely to potentiate this relationship further. 
Hydroxyapatite nanocrystals themselves may also further 
drive the inflammatory cycle by setting up a positive feedback 
loop of increasing calcification, increasing inflammation, and 
increasing cell death.30 Furthermore, by accumulating in the 
surface of thin fibrous caps, microcalcifications may focally 
increase mechanical stress and thus promote structural cap 
failure and plaque rupture.7,33,34 18F-Fluoride can demonstrate 
this pathologically important microscopic calcific response.
Table 2. Radiotracer Uptake: Comparative Data
 Culprit  Vessel
Contralateral  
Vessel
P Value for 
Culprit vs 
Contralateral Control
P Value for 





2.56 (2.35–3.54) 2.18 (1.94–3.01) * 1.78 (1.55–2.22) *
  SUV
meanmax
2.42 (2.24–3.24) 1.97 (1.78–2.74) * 1.67 (1.41–2.08) *
  SUV
mean
1.92 (1.71–2.46) 1.64 (1.39–1.98) * 1.41 (1.10–1.53) *
  TBR
max
2.75 (2.39–3.21) 2.42 (2.02–2.82) * 2.44 (1.715–2.48) *
  TBR
meanmax
2.61 (2.24–2.90) 2.32 (1.74–2.58) * 2.29 (1.61–2.37) *
  TBR
mean


































2.32±0.78 2.32±0.77 0.675 2.61±0.53 0.375
  SUV
meanmax
2.21±0.72 2.24±0.74 0.755 2.51±0.46 0.317
  SUV
mean
1.83±0.55 1.81±0.46 0.346 2.08±0.33 0.269
  TBR
max
1.88±0.31 1.81±0.31 0.496 1.86±0.27 0.848
  TBR
meanmax
1.80±0.29 1.74±0.29 0.554 1.79±0.20 0.925
  TBR
mean
1.49±0.19 1.44±0.19 0.358 1.48±0.10 0.922
Parametric data presented as mean±SD. Nonparametric data presented as median (IQR). FDG indicates 
fluorodeoxyglucose; SUV, standardized uptake value; TBR, target to background ratio; and IQR, interquartile range.
*Statistical testing performed on the normalized log
10
 transformed data.
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Figure 4.  18F-Fluoride and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography uptake. Dynamic PET 
acquisition and examples of 18F-fluoride uptake. Uptake in clinically adjudicated culprit vs contralateral and vs controls. Tukey box and whisker 
plots. A, B, 18F-Fluoride uptake into culprit (red) and contralateral (blue) plaque using the standardized uptake value (SUV)mean and target to back-
ground ratio (TBR)mean measurements, respectively. C, D, Each demonstrate comparison in 
18F-fluoride uptake between carotid endarterectomy 
(CEA) patients (red) and controls (blue); uptake is reported by SUVmean in C and TBRmean in D. E–H, The same comparisons but using 
18F-FDG.
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This is the first observation of 18F-fluoride uptake in 
necrotic brain tissue and merits consideration. Uptake of 
this and other bone metabolism markers has previously been 
observed in tissue necrosis.33,35 This is likely to be because of 
cell membrane disruption with influx of calcium and forma-
tion of nanoscale calcium phosphate complexes. These offer a 
substrate to which 18F-fluoride can adsorb, allowing us to visu-
alize the microcalcification associated with necrosis. We have 
also observed the same process in myocardial tissue postin-
farction (Figure II in the Data Supplement).
We confirmed identification of culprit plaque in 2 ways. 
First, we compared the culprit to the ideal internal control, 
the contralateral carotid artery (which is almost invariably 
diseased). Second, we compared the culprit against a valid 
external control; patients with a TIA or minor ischemic stroke 
not attributed to carotid plaque. This shows that 18F-fluoride 
may have real potential in helping to identify culprit plaque 
thus helping decision-making. This is exemplified by the case 
where a plaque with high uptake deemed nonculprit subse-
quently caused a fatal ischemic stroke.
We compared uptake of 18F-fluoride with 18F-FDG. Unlike 
18F-fluoride, overall, 18F-FDG uptake was not significantly 
higher in culprit lesions. Moreover, on a per-lesion basis, 18F-
FDG failed to correlate with high-risk plaque morphological 
features, whereas 18F-fluoride uptake correlated with plaque 
burden, positive remodeling, and luminal stenosis: all estab-
lished markers of plaque risk. Other studies have explored the 
utility of 18F-FDG alone in carotid atherosclerosis9–11,14,36–39 and 
a few have directly compared clinical culprit with nonculprit 
plaques.8,12,13 Our results are consistent with these previous 
findings with significant uptake noted in some but not all cul-
prit plaques, in part because of spillover from adjacent muscle. 
Our observations are also influenced by the ubiquity of statin 
therapy, potentially blunting 18F-FDG uptake. We did, however, 
note that proximal carotid uptake correlated with cardiovascular 
risk indicating that 18F-FDG does reflect a major aspect of ves-
sel pathobiology. As others suggest,38,40 it may be that 18F-FDG 
better reflects generalized vascular inflammation and that the 
relationship between the tracer and a single advanced and acute 
plaque is more complicated. There are increasing data available 
concerning other more specific markers of inflammation, such 
as those targeting the macrophage-specific somatostatin recep-
tor.41 These will theoretically be less hampered by overspill.
Our findings confirm those of a smaller study of 9 patients 
by Quirce et al23 that explored 18F-fluoride and 18F-FDG 
uptake in symptomatic patients. They showed that 18F-fluoride 
uptake appeared to be higher in the symptomatic carotid and 
that 18-FDG uptake was nondiscriminatory. Taken together 
with our current larger series, this suggests that 18F-fluoride 
has the potential to be a useful and robust clinical tool to iden-
tify culprit atherosclerotic plaque. Vascular 18F-fluoride imag-
ing could therefore guide clinical management better than the 
current standard of care, and lead to trials of plaque-specific 
interventions that go beyond simple assessments of anatomic 
luminal stenosis severity.
Limitations
This was a small pilot observational study (recruitment is 
very challenging given the time pressure to intervene) and 
findings should be regarded as preliminary. The true utility 
of 18F-fluoride PET/CT will need to be evaluated by pro-
spective studies with patients randomized to intervention 
based on imaging. 18F-Fluoride PET/CT will need to be 
Table 3. Plaque Analysis by CT and PET
 All Patients
Calcium score
  Patients with AC CT usable for calcium score 24
  Carotid bifurcations analyzed for calcium score 48




  Calcium volume, mm3 150 (15.75–404)
CT plaque analysis
  Patients with analyzable CT angiogram 17
  Internal carotid artery plaques analyzed 33
  CT diameter stenosis, % 50 (0–77)
  Wall-distal ICA lumen ratio, % 90 (54–173)
  Plaque burden, % 49.4±16.4
  Lipid/necrosis volume, mm3 37.5 (8.6–79.5)
  Lipid/necrosis % volume 6.7 (2.4–15.8)
  Fibrofatty volume, mm3 201 (96–313)
  Fibrofatty % volume 42.8±15.6
  Calcium volume, mm3 211 (124–358)




 r P Value
  vs CT Agatson score 0.79 <0.001
  vs CT diameter stenosis 0.54 0.002
  vs plaque burden 0.51 0.004
  vs wall-distal ICA lumen ratio 0.53 0.003
  vs lipid/necrosis volume 0.32 0.080
  vs fibrofatty volume 0.29 0.126




 r P Value
  vs CT Agatson score −0.14 0.469
  vs CT diameter stenosis −0.10 0.620
  vs plaque burden −0.03 0.873
  vs wall-distal ICA lumen ratio 0.00 0.996
  vs lipid/necrosis volume −0.19 0.315
  vs fibrofatty volume −0.15 0.457
  vs calcium volume 0.01 0.918
Parametric data presented as mean±SD. Nonparametric data presented 
as median (IQR). AC indicates attenuation correction; AU; arbitrary units; 
CT, computed tomography; FDG, fluorodeoxyglucose; ICA, internal carotid 
artery; IQR, interquartile range; PET, positron emission tomography; and SUV, 
standardized uptake value.
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compared with other techniques42 (in particular MR or PET/
MR) which have the advantages of improved soft tissue 
definition, reduced radiation, and lack of iodinated contrast. 
We did not perform prolonged-delayed 18F-FDG imaging 
which some authors have suggested is advantageous.43 We 
also acknowledge that quantitative vascular PET has some 
potential limitations because of the partial volume effects 
of small vascular structures. Finally, as vascular 18F-fluoride 
imaging is developed, consideration must be given to har-
monizing acquisition and reconstruction protocols,44 as well 
as achieving consensus on the uptake parameter of choice 
(SUV versus target to background ratio versus volumet-
ric parameters45) and whether to use manual or automated 
methods to define ROI. This will reduce variation between 
scanners and research groups and permit meaningful multi-
center studies.
Conclusion
We have shown that 18F-fluoride PET/CT is able to identify 
culprit or high-risk carotid plaque. In comparison, 18F-FDG, 
the most widely used tracer in cardiovascular PET imaging, 
did not reliably identify culprit plaque and did not correlate 
with high-risk morphological features. 18F-Fluoride PET has 
major potential to improve how we assess and manage the risk 
of stroke in patients with atherosclerosis.
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CLINICAL PERSPECTIVE
Stroke remains the leading global cause of disability and is responsible for huge healthcare costs. It is commonly caused by 
thromboembolism from extracranial atherosclerotic plaque. In addition to medical therapy, invasive carotid artery interven-
tion (by endarterectomy or stenting) has a role in reducing the chances of subsequent stroke. However, intervention itself 
is associated with significant risk and the decision to proceed with surgery is still based principally on stenosis severity, an 
outdated parameter. This report shows that by selectively demonstrating intraplaque microcalcification, a pathologically 
high-risk process that reflects ongoing inflammation and cell death, 18F-fluoride PET/CT may be able to identify plaque at 
particular risk of causing future stroke. The technique, as part of a multimodal risk stratification strategy, may help to ensure 
the appropriate planning of surgical intervention. This would potentially avoid unnecessary surgery on quiescent yet tightly 
stenosed plaques and conversely permit the identification and removal of high-risk plaques that currently do not meet criteria 
for intervention. 18F-Fluoride PET/CT also offers the possibility of noninvasively assessing the response to existing or novel 
pharmacological agents permitting the personalization of therapy to maximize benefit and minimize risk of complications.
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A	  modified	  Rankin	  score	  >3	  (due	  to	  the	  burden	  of	  participation	  in	  those	  with	  limited	  
mobility),	  insulin-­‐dependent	  diabetes	  mellitus	  (due	  to	  the	  variability	  of	  18F-­‐FDG	  uptake),	  
women	  of	  child-­‐bearing	  potential,	  severe	  chronic	  kidney	  disease	  (estimated	  glomerular	  
filtration	  rate	  <30	  mL/min/1.73	  m2),	  known	  allergy	  to	  iodine-­‐based	  contrast	  media,	  prior	  
ipsilateral	  internal	  carotid	  artery	  intervention,	  prior	  neck	  irradiation,	  or	  those	  unable	  to	  
provide	  informed	  consent.	  
	  
MicroPET/CT	  
Carotid	  artery	  specimens	  were	  stored	  at	  -­‐80	  degree	  Celsius	  following	  removal	  during	  carotid	  
endarterectomy.	  Thawed	  non-­‐decalcified	  carotid	  artery	  specimens	  were	  incubated	  for	  60	  
minutes	  in	  18F-­‐sodium	  fluoride	  104.89kBq/mL	  solution	  (10.5MBq	  18F-­‐NaF	  in	  99.5mLs	  0.9%	  
NaCl).	  Samples	  were	  twice	  washed	  in	  100mLs	  0.9%	  NaCl	  for	  2	  minutes	  to	  remove	  unbound	  
18F-­‐Fluoride.	  Carotid	  artery	  specimens	  were	  scanned	  using	  high-­‐resolution	  micro-­‐positron	  
emission	  tomography	  and	  non-­‐contrast	  computed	  tomography	  [50kVp	  tube	  voltage,	  
300msec	  exposure	  time]	  (Mediso	  nanoScan	  PET/CT,	  Mediso	  Medical	  Imaging	  Systems,	  
Hungary).	  PET-­‐CT	  images	  were	  analysed	  on	  an	  OsiriX	  workstation	  (OsiriX	  version	  7.5.1,	  64-­‐
bit,	  OsiriX	  Imaging	  Software,	  Geneva,	  Switzerland).	  
Autoradiography	  and	  Histology	  
To	  perform	  18F-­‐fluoride	  autoradiography,	  18F-­‐fluoride	  was	  diluted	  to	  1	  x	  10-­‐11	  M.	  Whole	  
carotid	  plaque	  specimens	  were	  thawed	  in	  5	  mL	  PBS	  for	  1	  h,	  and	  then	  placed	  in	  5	  mL	  of	  the	  
diluted	  18F-­‐fluoride	  solution	  for	  1	  h	  at	  room	  temperature.	  They	  were	  then	  washed	  in	  PBS	  
three	  time	  and	  dipped	  in	  distilled	  water.	  Specimens	  was	  then	  embedded	  in	  the	  OCT	  
Compound	  (CellPath,	  Powys,	  UK)	  and	  20	  μm	  thick,	  serial	  sections	  were	  cut	  on	  a	  Bright	  
(Huntingdon,	  UK)	  cryostat	  and	  placed	  on	  Superfrost	  Plus	  slides	  (VWR,	  Lutterworth,	  UK).	  
After	  drying,	  sections	  were	  placed	  on	  a	  charged	  phosphor	  screen	  (Perkin	  Elmer,	  Waltham,	  
Massachusetts)	  and	  left	  overnight.	  The	  next	  day	  screens	  were	  read	  using	  PerkinElmer's	  
Cyclone	  Plus	  Phosphor	  Imager	  (Waltham,	  Massachusetts)	  and	  data	  analysed	  with	  
OptiQuantTM	  software	  (Packard	  Instrument,	  Meriden,	  Connecticut).	  	  
	  
Alizarin	  Red	  (Alfa	  Aesar,	  Heysham,	  UK)	  was	  employed	  to	  stain	  calcium.	  Sections	  were	  fixed	  
in	  acetone	  (4	  °C)	  for	  ten	  minutes	  then	  washed	  in	  PBS	  at	  room	  temperature.	  After	  washing,	  
300	  μL	  Alizarin	  Red	  was	  applied	  to	  each	  section	  for	  one	  minute.	  Samples	  were	  then	  
transferred	  to	  acetone	  for	  1	  min,	  before	  being	  washed,	  in	  acetone:xylene	  (50:50)	  for	  1	  min.	  
Sections	  were	  then	  incubated	  in	  xylene	  for	  at	  least	  1	  h.	  Tissue	  was	  then	  mounted	  using	  
DePeX	  mounting	  medium	  Gurr	  (VWR,	  Lutterworth,	  UK)	  and	  glass	  coverslips	  (Menzel-­‐Gläser,	  
Braunschweig,	  Germany)	  were	  applied.	  	  Slides	  were	  imaged	  using	  Wild	  Heerbrugg	  M3Z	  










Abbreviations:	  CAS,	  carotid	  artery	  stenosis,	  CEA,	  carotid	  endarterectomy;	  CT,	  computed	  
tomography;	  FDG,	  fluorodeoxylucose;	  PET,	  positron	  emission	  tomography.	  
Supplementary	  Figure	  2:	  18F-­‐Fluoride	  Uptake	  in	  a	  Patient	  with	  a	  Large	  Anterior	  ST-­‐elevation	  
Myocardial	  Infarction	  
	  
Panels	  A-­‐D:	  CT	  coronary	  angiogram	  in	  long	  axis	  (A)	  and	  short	  axis	  (B-­‐D)	  reformats.	  Panels	  E	  
and	  F:	  Fused	  18F-­‐fluoride	  PET	  CT	  image	  in	  long	  (E)	  and	  short	  (F)	  axis	  reformats.	  Panel	  G:	  16	  
segment	  map	  of	  myocardial	  perfusion	  during	  stress.	  The	  hypoattenutating,	  hypoperfused	  
infarcted	  areas	  visible	  on	  the	  CT	  angiogram	  and	  perfusion	  map	  can	  be	  seen	  to	  co-­‐localise	  




Supplementary	  Table	  1:	  Baseline	  Scanning	  Protocol	  and	  Radiation	  Dose	  Data	  
	   All	  Patients	  
Target	  18F-­‐FDG	  Dose	  (MBq)	   200	  
Actual	  18F-­‐FDG	  Dose	  (MBq)	   199.8	  (194.7-­‐203.7)	  
Actual	  18F-­‐FDG	  Dose	  range	   184-­‐206	  
	   	  
Target	  18F-­‐Fluoride	  Dose	  (MBq)	   250	  
Actual	  18F-­‐Fluoride	  Dose	  (MBq)	   244.5±12.66	  
Actual	  18F-­‐Fluoride	  Dose	  range	   218	  –	  266	  
	   	  
Target	  18F-­‐FDG	  Uptake	  Time	  (min)	   90	  
Actual	  18F-­‐FDG	  Uptake	  Time	   94.1±5.5	  
Actual	  18F-­‐FDG	  Uptake	  Time	  range	   84.9-­‐109.8	  
	   	  
Target	  18F-­‐Fluoride	  Uptake	  Time	  (min)	   60	  
Actual	  18F-­‐Fluoride	  Uptake	  Time	  (min)	   64.6±5.6	  
Actual	  18F-­‐Fluoride	  Uptake	  Time	  range	   56.0	  -­‐80.5	  
	   	  
Interval	  between	  18F-­‐FDG	  and	  18F-­‐Fluoride	  (days)	   1	  (1-­‐2)	  
	   	  
Effective	  Radiation	  Dose	   	  
Average	  CT	  dose	  (mSv)	   4.1	  
Average	  dose	  from	  18F-­‐Fluoride	  (mSv)	   5.8	  
Average	  dose	  from	  18F-­‐FDG	  (mSv)	   4	  
Average	  total	  dose	  (mSv)	   12.9	  
	  
Parametric	  data	  are	  presented	  as	  mean±SD.	  Non-­‐parametric	  data	  are	  presented	  as	  median(IQR).	  Categorical	  
data	  are	  presented	  as	  number	  (percentage).	  Abbreviations:	  FDG,	  fluorodeoxyglucose;	  MBq,	  megabecquerels;	  
MSv,	  millisieverts.	  *One	  patient	  was	  accidentally	  given	  an	  oncologic	  dose	  (368.9MBq)	  so	  the	  actual	  18F-­‐FDG	  
dose	  data	  are	  skewed	  (this	  patient	  has	  been	  excluded	  from	  the	  range)	  
	  
	  
Supplementary	  Table	  2:	  Interobserver	  And	  Intraobserver	  Reproducibility	  Studies	  For	  
18F-­‐Fluoride	  Uptake	  At	  The	  Internal	  Carotid	  Artery	  And	  The	  Blood	  Pool	  
Interobserver	   Bias	   SD	  of	  bias	   95%	  LoA	  	   ICC	  (95%CI)	  
ICA	  SUVmax	   0.04	   0.22	   -­‐0.39	  –	  0.47	   0.98	  (0.96	  –	  0.99,	  p<0.001)	  
ICA	  SUVmeanmax	   0.04	   0.28	   -­‐0.50	  –	  0.59	   0.97	  (0.93	  –	  0.99,	  p<0.001)	  
ICA	  SUVmean	   -­‐0.002	   0.26	   -­‐0.51	  –	  0.51	   0.93	  (0.84	  –	  0.97,	  p<0.001)	  
Blood	  pool	  SUVmean	   0.004	   0.18	   -­‐0.35	  –	  0.36	   0.85	  (0.54	  –	  0.96,	  p	  =	  0.001)	  
	  
Intraobserver	   Bias	   SD	  of	  bias	   95%	  LoA	  	   ICC	  (95%CI)	  
ICA	  SUVmax	   0.04	   0.25	   -­‐0.44	  –	  0.53	   0.97	  (0.93	  –	  0.99,	  p<0.001	  
ICA	  SUVmeanmax	   0.01	   0.22	   -­‐0.41	  –	  0.44	   0.97	  (0.94	  –	  0.99,	  p<0.001	  
ICA	  SUVmean	   -­‐0.10	   0.15	   -­‐0.39	  –	  0.19	   0.97	  (0.92	  –	  0.99,	  p<0.001	  
Blood	  pool	  SUVmean	   0.04	   0.12	   -­‐0.19	  –	  0.27	   0.96	  (0.86	  –	  0.99,	  p<0.001	  
	  
ICC	  –	  intra-­‐class	  correlation	  co-­‐efficient	  (calculated	  used	  a	  2-­‐way	  random	  effects	  model	  to	  assess	  
absolute	  agreement)	  
	  
Supplementary	  Movie	  Titles	  and	  Legends	  
	  
Supplementary	  Movie	  1:	  Explanted	  Culprit	  Carotid	  Plaques	  As	  Seen	  On	  18F-­‐Fluoride	  
MicroPET/CT	  	  
	  
Two	  examples	  of	  carotid	  plaques	  scanned	  using	  18F-­‐Fluoride	  microPET/CT.	  The	  
relationship	  between	  calcium	  deposits	  visible	  on	  microCT	  and	  the	  areas	  of	  tracer	  
uptake	  is	  clearly	  complex.	  The	  tracer	  is	  clearly	  not	  merely	  highlighting	  areas	  of	  
calcium,	  but	  rather	  micocalcification	  not	  resolved	  by	  even	  microCT.	  
Supplementary	  Movie	  2:	  Examples	  Of	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Three	  sequential	  examples	  of	  patients	  with	  established	  cerebral	  infarction	  showing	  
intense	  uptake	  of	  18F-­‐Fluoride.	  Each	  patient	  has	  a	  run	  of	  2-­‐dimensional	  axial	  fused	  
PET/CT	  images	  followed	  by	  a	  3-­‐dimensional	  render	  of	  the	  18F-­‐fluoride	  uptake.	  The	  
uptake	  is	  remarkably	  high;	  greater	  indeed	  than	  the	  adjacent	  skull.	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Benefits of local anaesthesia 
for ruptured abdominal 
aortic aneurysm repair
RO Forsythe and RJ Hinchliffe
Introduction
Ruptured abdominal aortic aneurysms represent the 13th commonest cause of 
death in the UK, with an overall mortality of over 80%.1 If untreated, a ruptured 
abdominal aortic aneurysm is almost always fatal and of those patients who survive 
long enough to reach hospital, 41.6% are too unwell to undergo attempted repair.2 
Moreover, even if a patient reaches the operating theatre, repair using either open 
or endovascular (EVAR) techniques carries a high mortality that has seen relatively 
little improvement over the past few decades.  
Conversely, the outcomes of elective abdominal aortic aneurysm repair have 
shown great improvement, with an operative mortality of 4.3% and 1.8% for open 
repair and EVAR, respectively.3 
Given that more than 80% of abdominal aortic aneurysm deaths are the result of 
rupture,4 new strategies are required to help address the persistently high mortality 
associated with this condition.  
Recent data from the IMPROVE trial suggest that perioperative mortality for 
ruptured abdominal aortic aneurysms remains high and that a strategy of using 
EVAR where possible (compared with open surgery) does not appear to improve 
30-day mortality—36.4% versus 40.6% in patients with confirmed rupture.5  In 
addition, even though the instructions for use are sometimes relaxed in the context 
of ruptured aneurysms, only around 65% of aneurysms are deemed morphologically 
suitable for EVAR according to liberal instructions for use (proximal neck length 
≥10mm, diameter ≤32mm and angle <60 degrees),6 yet the mortality for EVAR-
suitable patients (who are intrinsically lower risk) remains high at 20–25% for 
either open or endovascular repair.7,8     
Whilst the IMPROVE trial did not suggest a significant perioperative survival 
advantage for an EVAR strategy compared to open repair, it did highlight an 
important observation—that patients undergoing EVAR under local anaesthesia 
may be three to four times more likely to survive than those patients requiring 
general anaesthesia, even after adjustment for age, sex, Hardman index and other 
potential confounders.9  
In the elective setting, general anaesthesia has been demonstrated to be an 
independent risk factor for operative complications including death (OR=5.1, 
95% CI 1.9–13.3),10 whilst the EUROSTAR registry (comprising more than 
5,500 patients in 164 centres undergoing EVAR) confirmed that patients appear to 
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benefit from locoregional anaesthesia in elective EVAR to treat infrarenal abdominal 
aortic aneurysms.11 EVAR under local anaesthesia may therefore represent a 
potential opportunity to reduce the perioperative mortality in ruptured abdominal 
aortic aneurysms.
Local anaesthesia versus general anaesthesia in elective  
and emergency surgery
There is increasing awareness of the limitations and potential negative impact on 
outcomes for surgical patients undergoing general anaesthesia, particularly those 
that are high-risk or with serious comorbidities. The use of alternatives to general 
anaesthesia (including local and regional anaesthesia), have been explored in 
various surgical contexts, particularly in the emergency situation.  Two substudies 
of the Swedish Hernia Registry have demonstrated improved outcomes for local 
anaesthesia in elective and emergency hernia surgery. A multicentre randomised 
trial comparing local versus regional anaesthesia versus general anaesthesia included 
10 non-specialised hospitals (616 patients) and demonstrated that local anaesthesia 
was associated with reduced postoperative pain and nausea when compared to 
general anaesthesia (mean visual analogue scale scores—1.8 vs. 3.3 for pain and 
1.1 vs. 1.7 for nausea; p<0.0001), a reduced frequency of early postoperative 
complications (15% vs. 44%; p<0.0001) and mean hospital stay (3.1 vs. 6.2 
days; p<0.0001).12 Further analysis of the Swedish Hernia Registry (comprising 
237 patients who died within 30 days of elective or emergency hernia surgery) 
demonstrated that local anaesthesia was used rarely for elective operations (3%) but 
more commonly for emergency operations (13%). Although used less commonly 
than either general anaesthesia or regional anaesthesia, local anaesthesia was used 
less frequently in those who subsequently died perioperatively (13% vs. 17% in 
elective surgery, p<0.001; 3% vs. 5% in emergency surgery, p=0.02).13 However, 
no multivariate analysis was performed in this study, therefore confounding factors 
may be undetected.
The use of local anaesthesia in patients undergoing surgery for peripheral vascular 
disease has been of increasing interest in recent years. A post-hoc substudy analysis 
of a study investigating the use of an endovascular intervention for acute stroke, 
the NASA (North American Solitaire stent retriever acute stroke) registry, found 
that local anaesthesia was associated with good 90-day neurological outcomes 
(modified Rankin Scale ≤2, p=0.01, OR 1.4 [1.1–1.8]) and that general anaesthesia 
was associated with mortality in multivariate analysis (OR 3.3 [1.6–7.1], p=0.001), 
in 281 patients who underwent mechanical embolectomy using the Solitaire stent-
retrieving device.14 In contrast, in the GALA (General anaesthesia versus local 
anaesthesia for carotid surgery) trial (a multicentre randomised controlled trial of 
3,526 patients with carotid stenosis), no definite benefit of local anaesthesia was 
demonstrated; however, three events (stroke, myocardial infarction or death within 
30 days) per 1,000 patients were prevented under local anaesthesia, although this 
finding failed to reach statistical significance.15 Carotid endarterectomy under local 
anaesthesia is common practice in many UK vascular centres – a large prospective 
cohort study in the UK (published in 2011) demonstrated that roughly half 
of all operations were performed under local anaesthesia, with a conversion to 
general anaesthesia rate of 1.4%.16 This number is likely to have increased in the 




















































well by vascular patients, surgeons and anaesthetists and is the best method of 
intraoperative monitoring of brain function. Therefore, the precedent is set for use 
in other vascular operations.
Regional anaesthesia (versus general anaesthesia) for hip fracture surgery in 
elderly patients has also been associated with reduced early mortality and fewer 
postoperative complications such as deep vein thrombosis and acute confusion in 
at least one large systematic review comprising more than 18,000 patients with 
hip fractures,17 although definitive evidence for regional anaesthesia as standard 
preference to general anaesthesia in hip fracture surgery is limited.
Outcomes of elective EVAR under local anaesthesia
The use of local anaesthesia for elective EVAR has been mooted for over a 
decade,18,19 and the benefits of this approach were confirmed in the EUROSTAR 
registry, where patients undergoing EVAR under local anaesthesia had a shorter 
operation time (115.7±42.2 minutes vs. 133.3±59.1 minutes, p<0.0001), a 
shorter hospital stay (3.7±3.1 days vs. 6.2±8.5 days, p=0.007), were less likely to 
require intensive therapy unit (2% vs. 16.2%, p<0.0001) and had fewer systemic 
complications (6.6% vs. 13.0%, p=0.0015) than those who underwent EVAR 
under general anaesthesia,11 when adjusted for possible confounders. A more 
recent meta-analysis confirmed that local anaesthesia in elective EVAR is faster 
than general anaesthesia, associated with reduced postoperative complications but 
failed to demonstrate a reduction in 30-day mortality.20  A “local anaesthesia first 
strategy” may be applied to the majority of patients undergoing elective EVAR 
and is thought to be feasible in up to 75% of patients with infrarenal abdominal 
aortic aneurysms, as demonstrated in one observational study of more than 200 
patients in a high-volume EVAR centre.21  
Despite evidence of the feasibility and improved outcomes for elective 
EVAR under local anaesthesia,11,20,22 there has not been widespread uptake of 
the technique, possibly due to the traditional surgical preference for operating 
under general anaesthesia. Therefore, translating this approach in the setting 
of ruptured abdominal aortic aneurysms may be arguably more challenging; 
however, patients with ruptured aneurysms represent the highest risk group 
who are perhaps more likely to develop complications associated with general 
anaesthesia. Some highly specialised centres already advocate local anaesthesia for 
ruptured aneurysms where possible,23 demonstrating that the majority of their 
patients have been successfully treated using local anaesthesia, with favourable 
outcomes.24 However, there remain no randomised trials to assess the feasibility 
and effectiveness of EVAR under local anaesthesia for ruptured aneurysms in an 
unselected population.
Benefits of EVAR under local anaesthesia for ruptured 
abdominal aortic aneurysms
Observational data suggest that 30-day mortality is reduced for patients who 
undergo EVAR under local anaesthesia for ruptured abdominal aortic aneurysms, 
compared to EVAR under general anaesthesia for ruptured aneurysms (13–15% 
and 33%, respectively; OR 0.27, 95% CI 0.10–0.70).9 Local anaesthesia in the 
elective setting is associated with a reduction in cardiac events (0.8% versus 6.4%, 









p=0.02),22 and whilst this has not been formally investigated in the setting of 
ruptured abdominal aortic aneurysms, the use of local anaesthesia in other vascular 
emergencies (such as endovascular intervention for stroke) has been associated 
with improved cardiovascular outcomes and survival (as demonstrated by the 
Solitaire registry).14
Local anaesthesia can be offered to the sickest patients who would otherwise be 
turned down for general anaesthesia, which avoids the inherent risks associated 
with general anaesthesia including the loss of sympathetic and abdominal wall 
tone on induction and the cardiorespiratory effects of artificial ventilation, 
whilst increasing the proportion of patients suitable for attempted repair. 
Spontaneous ventilation during local anaesthesia procedures improves venous 
return, decreasing pulmonary morbidity25 and local anaesthesia allows improved 
immediate postoperative analgesia. Importantly, in the context of ruptured 
aneurysms, the use of local anaesthesia potentially allows more rapid aneurysm 
exclusion (haemorrhage control) and reduces the operative duration, which in 
turn reduces risks of prolonged metabolic disturbance, thromboembolism and 
increased venous blood loss. A reduction in hospital stay and requirement 
for intensive therapy unit stay has also been demonstrated in the setting of 
elective EVAR.11
It is important to note that the use of regional anaesthesia is generally regarded 
as unsuitable in ruptured abdominal aortic aneurysms due to the potential 
for loss of sympathetic tone and further cardiovascular collapse in the already 
compromised patient.
Feasibility, technical considerations and drawbacks of  
EVAR under local anaesthesia in ruptured abdominal  
aortic aneurysm
Not all patients are suitable for EVAR under local anaesthesia. Firstly, the aneurysm 
must be morphologically and technically suitable for a bifurcated endograft. Those 
who require an aortouni-iliac graft and femoro-femoral crossover (to revascularise 
the contralateral leg) are unsuitable for the local anaesthesia approach; however, 
this is still a common configuration of stents used in ruptured abdominal aortic 
aneurysms, especially if the operator is less experienced or the patient particularly 
unstable—of those patients in the IMPROVE trial who complied with the 
allocated EVAR-first strategy, 23.3% required an aortouni-iliac graft.5  
The patient must also be suitable for this approach, which necessitates 
a compliant, conscious and co-operative patient – which may be challenging 
in ruptured abdominal aortic aneurysms. The patient also needs to be able to 
lie flat and comply with regular breath-holding instructions; confusion and 
agitation associated with hypoxia and metabolic disturbance may impede this. 
The surgeon needs to be comfortable and confident in obtaining vascular access 
even in the haemodynamically-compromised patient with potentially impalpable 
femoral pulses. Access vessels must be readily accessed; patient obesity and narrow 
access vessels can be a barrier to this; however, improved technology (including 
narrower delivery systems) has gone some way to address these issues.
Preliminary evidence from the National Vascular Registry suggests that 50% 
of UK vascular centres currently use local anaesthesia for EVAR of ruptured 




















































service, an experienced team is required, with adequate training to address the 
various drawbacks of local anaesthesia for EVAR in ruptured aneurysms. 
In addition, good anaesthesia input will be required throughout the procedure, 
in order to minimise the pain associated with performing an endovascular 
intervention without general anaesthesia. If extensive groin dissection is 
required, the pain of the procedure may not be tolerable or may necessitate 
heavy sedation. However, percutaneous access and the use of closure devices can 
overcome this problem.
Some patients may experience ongoing and unacceptable abdominal pain 
from the expanding haematoma, which may subsequently lead to respiratory 
insufficiency due to increased intra-abdominal pressure causing restriction of 
chest wall movements. Pain at the time of stent deployment, in addition to 
ischaemic leg and buttock pain from prolonged occlusion of access vessels, may 
be difficult to control.  
Movement artefact from an awake patient may compromise image quality, as 
will insufficient breath-holding. In the case of a complex EVAR leading to a 
longer operative duration, local anaesthesia may not be tolerated for a prolonged 
period and the cardiovascular instability associated with ruptured aneurysms may 
cause anaesthesia difficulties that are difficult to address in an awake patient. 
Finally, the conversion to general anaesthesia in a high-risk patient previously 
deemed unsuitable for general anaesthesia raises difficult questions; certainly 
the benefit of local anaesthesia is not sustained in those patients who start local 
anaesthesia but require conversion to general anaesthesia.
Future prospects
The IMPROVE trial suggests that EVAR, where possible, is associated with faster 
recovery and cost-effectiveness; therefore increasingly more EVARs are likely to 
be performed for ruptured aneurysms in the future.26 In addition, recent data 
demonstrate an increasing prevalence of acute abdominal aortic aneurysm events 
in the older population (>75 years of age)27 who may avoid detection during the 
single screening ultrasound offered at the age of 65 in the UK. We may therefore 
see an increasing number of elderly patients presenting with ruptured aneurysms, 
who are likely to have significant medical comorbidities that contribute to greater 
perioperative risk and are perhaps the most likely to benefit from EVAR and a local 
anaesthesia approach.
Better strategies to reduce the stubbornly high mortality associated with ruptured 
aneurysm intervention are required. The benefits of local anaesthesia for elective 
EVAR have been widely documented, and observational data for emergency EVAR 
in favour of local anaesthesia are emerging.
Local anaesthesia is often used for the sickest patients, therefore if there 
is a survival advantage in this selected group (as suggested in recent 
literature), this may potentially translate to the entire population and could 
go some way to address the sustained high mortality associated with ruptured 
aneurysm intervention.
Local anaesthesia may in future be the first choice approach (where possible) 
for EVAR in ruptured aneurysms; however, further confirmation should be sought 
from randomised trials, which should be robustly designed, using an intention-to-
treat strategy.










• An EVAR-first strategy for ruptured abdominal aortic aneurysms is commonly 
performed; however, the mortality rate remains high. 
• Local anaesthesia has been associated with improved clinical outcomes 
(compared to general anaesthesia) for elective EVAR and other elective and 
emergency operations.
• Recent observational data suggest a significant reduction in 30-day  
mortality for local anaesthesia in EVAR for ruptured aneurysms, compared  
to general anaesthesia.
• Other potential benefits of local anaesthesia in EVAR for ruptured  
aneurysm include shorter operative time, reduced intensive therapy unit 
and hospital stay, fewer cardiorespiratory complications and improved 
postoperative analgesia.
• EVAR for ruptured aneurysms is performed under local anaesthesia in 
approximately half of the UK vascular centres.
• Robust randomised evidence is required to more fully investigate local 
anaesthesia as a strategy to improve outcomes in ruptured aneurysms.
• The use of local anaesthesia for ruptured aneurysms may increase the 
proportion of patients offered repair, and may go some way to improve the 
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at 1.5 and 3T
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Abstract
Background: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging
(MRI) can detect tissue-resident macrophage activity and identify cellular inflammation. Clinical studies using this
technique are now emerging. We aimed to report a range of normal R2* values at 1.5 and 3 T in the myocardium
and other tissues following ferumoxytol administration, outline the methodology used and suggest solutions to
commonly encountered analysis problems.
Methods: Twenty volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2* and late gadolinium enhanced
(LGE) MRI was conducted at baseline with further T2* imaging conducted approximately 24 h after USPIO infusion
(ferumoxytol, 4 mg/kg). Regions of interest were selected in the myocardium and compared to other tissues.
Results: Following administration, USPIO was detected by changes in R2* from baseline (1/T2*) at 24 h in myocardium,
skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and bone at 3 T
(p < 0.05 for all). Myocardial changes in R2* due to USPIO were 26.5 ± 7.3 s-1 at 1.5 T, and 37.2 ± 9.6 s-1 at 3 T (p < 0.0001
for both). Tissues showing greatest ferumoxytol enhancement were the reticuloendothelial system: the liver, spleen and
bone marrow (216.3 ± 32.6 s-1, 336.3 ± 60.3 s-1, 69.9 ± 79.9 s-1; p < 0.0001, p < 0.0001, p = ns respectively at 1.5 T, and
275.6 ± 69.9 s-1, 463.9 ± 136.7 s-1, 417.9 ± 370.3 s-1; p < 0.0001, p < 0.0001, p < 0.01 respectively at 3 T).
Conclusion: Ferumoxytol-enhanced MRI is feasible at both 1.5 T and 3 T. Careful data selection and dose administration,
along with refinements to echo-time acquisition, post-processing and analysis techniques are essential to ensure reliable
and robust quantification of tissue enhancement.
Trial registration: ClinicalTrials.gov Identifier - NCT02319278. Registered 03.12.2014.
Keywords: Cardiac, MRI, Inflammation, USPIO
Background
Iron oxide nanoparticles are a class of magnetic reson-
ance imaging (MRI) contrast agents that are generating
interest as a method of detecting tissue inflammation.
Historically, these nanoparticles were initially used for
gastrointestinal, reticuloendothelial system and lymph
node imaging [1–3], and subsequently in hepatic and
cardiac imaging [4–7]. Recently however, it is in their
use as an MRI contrast agent for detecting tissue-
resident macrophages that clinical applications are now
emerging [8–15].
T2* MRI has been successfully used for over a decade
in diagnosing and grading severity of iron accumulation
in transfusion-dependent thalassaemia major, and has
been instrumental in guiding therapy that improves
prognosis, and allows serial disease monitoring [16, 17].
T2* MRI in the assessment of iron accumulation is easily
quantifiable, well validated, highly reproducible, clinically
robust, and is achievable in a single breath hold [18–22].
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Ultrasmall superparamagnetic particles of iron oxide
(USPIO) consist of an iron oxide core surrounded by a
carbohydrate or polymer coating. These particles can ex-
travasate through damaged capillaries, where they are
engulfed and concentrated by tissue-resident macrophages
[23]. Gradient echo T2*-weighted (T2*W) sequences are
highly sensitive to magnetic field inhomogeneities such as
susceptibility artifacts due to the presence of iron, includ-
ing USPIO. Accumulation of USPIOs in macrophages can
be quantified and visualized using T2*W MRI [8, 9] and
calculation of, and observing the reduction in, T2*
relaxation time due to the presence of iron. Thus USPIO-
enhanced MRI can detect tissue-resident macrophage ac-
tivity and identify localized cellular inflammation within
tissues.
In this present study we aimed to observe and quantify
the distribution ferumoxytol enhancement following
intravenous administration at 1.5 and 3 T MRI and es-
tablish a range of normal values for healthy myocardium
and other tissue. We also aimed to develop our method-
ology and describe commonly encountered problems in
T2* image analysis of USPIO.
Methods
This was an open-label observational multi-centre
cohort study using human volunteers recruited as part
of a larger trial, recruiting patients with cardiac inflam-
mation. The study was performed in accordance with
the declaration of Helsinki, the approval of the Scotland
A research ethics committee, and the written informed
consent of all participants.
Subjects
Participants were aged over 18 years of age. Exclusion
criteria were contraindication to MRI or ferumoxytol
infusion, any systemic inflammatory comorbidity (eg
rheumatoid arthritis), renal failure (estimated glomerular
filtration rate <30 mL/min), pregnancy, breastfeeding
and women of child-bearing age not ensuring reliable
contraception.
Magnetic resonance imaging
MRI was performed using 3 T and 1.5 T scanners (Magne-
tom Verio and Avanto respectively, Siemens Healthcare
GmbH, Erlangen, Germany), with dedicated cardiac array
coils. All images were acquired using electrocardiogram-
gated breath-hold imaging. Routine steady state free preces-
sion (TrueFISP) sequences were used to acquire long-axis
and short-axis images of the heart. Standard cardiac slice
widths (6-mm width with 4-mm gap) and 8 echo times
(2.1–17.1 ms range) with matrix size of 256 × 115 were ac-
quired in order to generate T2* maps. The in-plane reso-
lution differed as required for larger or smaller subjects;
generally, a field of view of 400 × 300 mm was used with an
in-plane resolution of 2.6 × 1.6 mm. T2* relaxation maps
were generated before and approximately 24 h after admin-
istration of USPIO.
Immediately after the baseline T2* and SSFP cine im-
aging, breath-held inversion enhancement images were
acquired following an intravenous administration of gado-
linium contrast medium (0.1 and 0.15 mmol/kg at 3 T and
1.5 T respectively; Gadovist, Bayer Plc, Germany).
Fig. 1 MRI protocol
Table 1 Participant characteristics
1.5 T 3 T
Number 9 10
Male;Female 3:6 4:6
Age (years) 52 [45.5–61.5] 50 [45.25–53]
Body-mass Index (kg/m2) 22.9 [20.1–26.9] 25.9 [22.5–29.4]
Ejection Fraction (%) 63.6 ± 4.9 61.1 ± 4.1
N (%), mean ± SD, or median [interquartile range]
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Optimal inversion time (TI) was determined on a slice-by-
slice basis using standard late-enhancement TI-scout
protocols. The inversion-recovery late-enhancement
short-axis slices were acquired using similar slice positions
to the myocardial T2* imaging. The T2* acquisitions also
included imaging of the liver, spleen and spine to allow
quantification of USPIO accumulation within organs of
the reticuloendothelial system.
USPIO
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg;
Rienso®, Takeda Italia, Italy) was performed immediately
following the baseline magnetic resonance scan over at
least 15-min using a concentration of 2–8 mg/mL, di-
luted in 0.9 % saline or 5 % dextrose. Hemodynamic
monitoring was conducted throughout.
Study protocol
Volunteers received 2 MRI scans approximately 24 h
apart (Fig. 1).
Image analysis
All T2*-weighted multi-gradient-echo images for each pa-
tient were analyzed using Circle CVI software (Circle
CVI42, Canada). Regions of interest (ROI) were drawn in
the heart using standard cardiac segmentation [24], and
panmyocardial values averaged using segments 1–16. Fur-
ther ROI were drawn in skeletal muscle, kidney, liver,
spleen, blood pool (from LV cavity) and bone marrow.
An experimentally determined threshold used in previ-
ous work [8] for the coefficient of determination (r2 >
0.85) was used to exclude data that did not have an ac-
ceptable exponential decay when signal intensity (SI) was
plotted against echo time. The inverse of the mean T2*
(R2*) for each ROI was then calculated to assess the up-
take of USPIO, where the higher the value, the greater the
USPIO accumulation.
Late gadolinium enhancement (LGE), ventricular vol-
ume and functional analyses were performed using Circle
CVI software (Circle CVI42, Calgary, Canada). T2* data
were collected immediately prior to USPIO administra-
tion. USPIO-enhanced T2* data were collected 24–25 h
following ferumoxytol administration.
Statistical analysis
All statistical analysis was performed with GraphPad
Prism, version 6 (GraphPad Software, San Diego, CA).
To assess uptake of USPIO in tissues following single
administration, R2* increase from pre to 24 h following
USPIO were compared using repeated measures one-
way ANOVA. Statistical significance was defined as two-
sided p < 0.05.
Results
Twenty volunteer patients were recruited in total (10 at
1.5 T, 10 at 3 T). Forty MRI scans and 20 infusions of
ferumoxytol were completed over the course of the
study. Data from one participant at 1.5 T has been re-
moved due to the presence of LGE, (which was included













Panmyocardial average 33.5 ± 5.4 60.5 ± 7.2 26.5 ± 7.3 46.9 ± 4.1 84.2 ± 12.4 37.2 ± 9.6
Skeletal muscle 34.7 ± 4.2 44.9 ± 4.7 10.2 ± 5.8 55.5 ± 17.1 59.8 ± 6.6 4.3 ± 16.3
Kidney 16.6 ± 2.0 81.2 ± 15.2 64.6 ± 16.1 43.5 ± 39.1 115.2 ± 28.1 71.8 ± 48.8
Liver 36.0 ± 7.2 252.3 ± 34.3 216.3 ± 32.6 65.3 ± 21.2 340.9 ± 57.8 275.6 ± 69.9
Spleen 22.0 ± 7.7 358.3 ± 59.5 336.3 ± 60.3 51.2 ± 21.1 515.1 ± 137.4 463.9 ± 136.7
Blood 11.3 ± 4.1 96.0 ± 26.6 84.7 ± 27.2 18.8 ± 5.3 91.5 ± 20.9 72.6 ± 18.3
Bone 84.4 ± 29.2 154.3 ± 62.0 69.9 ± 79.9 330 ± 168.7 747.9 ± 277.8 417.9 ± 370.3
Mean ± SD
Fig. 2 Myocardial R2* pre- and post-USPIO administration at 1.5 and
3 T. Following administration, USPIO was detected by an increase in
R2* at 24 h in the myocardium at both 1.5 and 3 T.
(**** = p < 0.0001, ** = p < 0.01)
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in the cardiac MR protocol so that we could exclude vol-
unteers with any detectable cardiac MR abnormalities
according to standard cardiac MR protocols). All other
volunteers that were included had structurally normal
hearts. One participant was prescribed antihypertensive
medication but had a normal cardiac MR study and was
normotensive so the data was retained for analysis. Ad-
ministration of ferumoxytol was well tolerated with no
adverse reactions reported during or immediately after
administration in any of the participants.
Participants were predominantly middle aged, with
greater numbers of women in both groups (Table 1).
There were no differences between 1.5 T and 3 T groups
in BMI or ejection fraction at baseline.
A summary of results is shown in Table 2. At baseline,
panmyocardial R2* values were greater at 3 T than 1.5 T
(46.9 ± 4.1 versus 33.5 ± 5.4 s-1, Fig. 2, p < 0.01) as ex-
pected. Baseline R2* values were also greater at 3 T in
bone (P < 0.0001) but no baseline differences were seen
between magnetic field strength in all other tissues (Fig. 3,
p > 0.05 for all). USPIO increased panmyocardial R2*
values at 24 h in both 1.5 T and 3 T scanners (p < 0.0001
for both). Post-USPIO panmyocardial R2* values were
again greater at 3 T than 1.5 T, as expected (84.2 ± 12.4
Fig. 3 Tissue R2* pre- and post-USPIO administration at 1.5 and 3 T. Following administration, USPIO was detected by an increase in R2*, 24 h
after administration in skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and kidney, liver, spleen, blood and bone at 3 T. (**** = p < 0.0001,
*** = p < 0.001, ** = p < 0.01, * = p < 0.05)
Stirrat et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:46 Page 4 of 9
versus 60.5 ± 7.2 s-1, p < 0.0001). Panmyocardial change in
R2* between baseline and 24 h post USPIO at 1.5 T was
26.5 ± 7.3 s-1 and at 3 T was 37.2 ± 9.6 s-1 (p < 0.0001 for
both). Detectable increases in R2* were also observed at
24 h post-USPIO in skeletal muscle, kidney, liver, spleen
and blood at 1.5 T, and kidney, liver, spleen, blood and
bone at 3 T. (Fig. 3, p < 0.05 for all). BMI correlated with
the panmyocardial R2* changes due to USPIO contrast
(Fig. 4; r = 0.72, p < 0.001).
Discussion
For the first time, we report a range of normal T2*
values in the healthy human heart and other tissues 24 h
after ferumoxytol administration at 1.5 and 3 T. We also
report problems, solutions and guidance in ferumoxytol-
enhanced T2* image analysis.
Following administration, USPIO is detectable by T2*
imaging in the myocardium and other tissues at both 1.5
and 3 T. Tissues with small increases in R2* (less than
the blood pool) are likely to represent detection of
USPIOs within the intravascular space and include skel-
etal muscle (at 1.5 T only), myocardium and kidney. In
contrast, R2* changes that are greater than the blood
pool must be due to accumulation of USPIO, either
through iron storage, uptake by macrophages or other
phagocytes, or sequestered within tissue interstitium. In
the absence of tissue biopsies, we cannot be certain, but
as the most pronounced R2* changes were seen in the
spleen, liver and bone marrow - organs of the reticulo-
endothelial system - it would appear likely that USPIO is
incorporated quickly into tissue-resident phagocytes and
macrophages.
Detection of USPIO enhancement in skeletal muscle at
1.5 T but not 3 T is due to generally noisier data seen
across all tissues at 3 T. Due to wider data confidence inter-
vals, a larger sample size would be required to detected the
same mean change in R2*. The variation in data at 3 T is
partly artifact in the images, but also because of the lower
values at 3 T (USPIO has a faster T2* decay time at 3 T).
With the same sampling echo times, there are fewer data
points to construct the decay curve at 3 T than 1.5 T so
our error in estimation also increases.
We chose 24 h post USPIO to re-image participants as
myocardial signal attenuation at 24 h has shown to be
optimal in the myocardium compared to later time
points [8, 9]. In view of this, scanning appointments
were generally separated by 25 h, and in practice, this re-
gime worked well for both participants and MRI plan-
ning. According to previous work [8], we chose a
weight-adjusted USPIO dose of 4 mg Fe/kg body weight.
However acknowledging that the distribution of USPIO
following administration is predominantly in the organs
of the reticuloendothelial system and blood pool, this
may not be the optimum administration strategy as
blood volume does not increase linearly with weight. We
found a correlation between BMI and myocardial R2*
change, probably due to increased blood pool USPIO
concentration in those with higher BMI. We therefore
suggest that a fixed dose approach may also be appropri-
ate depending on the application.
Artifacts were commonly encountered with USPIO-
enhanced T2* imaging and made data analysis challenging.
Post contrast artifacts at the blood-pool to myocardial
interface were commonly seen and needed careful exclu-
sion when selecting myocardial ROI. (Fig. 5A) This limited
the assessment of USPIO accumulation at the endocar-
dium. Similarly, blooming artifacts from nearby organs with
high iron or blood pool USPIO content, such as lung and
liver, commonly created signal deficits within the myocar-
dium. In this situation, examination of T2* decay curves
and excluding echo times influenced by artifact aided T2*
decay curve fitting (Fig. 5).
The advantage of MRI mapping techniques is that visual
assessment and objective quantification can be made using
the same image, and these are now entering clinical prac-
tice. It seems likely that if UPSIO-enhanced MRI is adopted
into clinical practice to detect tissue inflammation, T2*
mapping would be used for image interpretation. However
based on our experiences, we would recommend caution in
interpreting maps alone. Signal attenuation seen on the T2*
map may be interpreted as tissue USPIO accumulation, but
may be due to blooming artifact from nearby susceptibility
effects, and close examination of the T2* decay curve, and
individual echoes if possible is suggested in order to distin-
guish accurately between tissue USPIO accumulation and
artifact. In theory, setting an r2 threshold as we did helps to
exclude areas grossly affected by artifact. In practice how-
ever, regions with a seemingly acceptable R2 may still be in-
fluenced by artifact (Fig. 5). Manual exclusion of later
echoes (influenced by artifact) from the curve may result in
an improvement in R2 (a measure of how well the data
Fig. 4 Body-mass Index vs Panmyocardial R2* change at 1.5 and
3 T. Body-mass index correlates with panmyocardial R2* change
pre- and post-USPIO
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Fig. 5 (See legend on next page.)
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points fit the curve), however there is the danger that redu-
cing the number of fitting points will in fact reduce the
overall sampling accuracy. Clearly, automated software
capable of detecting and excluding artifact would be
advantageous. This could be achieved by excluding, or ap-
plying less weight, to later echo times especially data points
at a large distance from the initial decay curve trajectory
[25, 26]. It should be noted that like all other MRI se-
quences, poor data quality heavily influenced by breathing
or movement artifact is generally non-interpretable and
post processing using automated T2* decay curve fitting
software is not likely to provide a remedy.
Echo times in this study were specific for cardiac im-
aging and were selected appropriately. Therefore they
were not optimal for imaging tissues with T2* values
substantially higher or lower than myocardium. Native
blood pool and post USPIO bone marrow (Fig. 6) pro-
vide examples of low and high T2* values respectively
that we had difficulty accurately fitting a T2* decay
curve. With high T2* values, only a short part of the
decay curve is plotted over the echo sampling time
period, and often the signal has not decayed sufficiently
for an accurate decay curve to be plotted. In contrast,
regions with particularly short T2* decay times have
decayed to a level expected from background noise be-
fore sufficient data sampling has been made. Therefore
fitting a decay curve from a small number (2–4) of echo
times is clearly difficult, and often too much emphasis is
(See figure on previous page.)
Fig. 5 Inferior Blooming artifact. Example illustrating the challenge in assessing whether the inferior myocardial signal attenuation seen arrowed
on the T2* colourmap (a, scale 0-60 ms) is true or caused by artifact. Drawing a region of interest (b) and examining the decay curve (c) along
with visualising individual echos (d1-8) helps determine that this is a ‘blooming artifact’ from outside the heart is seen to influence echos 4-8.
These can be manually removed, forming a new decay curve (e) with improvement in curve fitting (R2 value), although with fewer fitting points
Fig. 6 Example of high and low T2* values. Regions of Interest with excessively low or high T2* value (pre-contrast blood pool, a, and post
USPIO bone marrow, b, respectively) can often be difficult to generate an accurate T2* decay curve. Imaging with tissue-spcific echo times will
help generate more accurate T2* decay curves
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placed upon data decayed to the baseline level of back-
ground noise in order to generate a decay curve. Allow-
ances can be made for background noise but are of
limited value in this instance. We strongly advise apply-
ing tissue-specific echo times tailored to the expected
T2* value in order to achieve the most accurate decay
curves possible.
Limitations
There are some limitations that should be taken into ac-
count when interpreting these data. First, this study has
small numbers and a larger cohort of participants should
be studied to further validate these normal values. Fur-
thermore, due to geographical reasons, it was not feas-
ible to scan the same participants at both centres so
comparison cohorts at 1.5 T and 3 T were different. Des-
pite this, both were healthy volunteers groups and dis-
played no differences at baseline so we do not feel this
has impacted on the results. Finally, due to problems in
interpreting high and low T2* values as mentioned
above, we recommend caution in interpreting some high
non-cardiac R2* values; especially in the organs of the
reticuloendothelial system at 3 T. In these organs, the
spread of R2* data above the median value appears wide.
This is possibly caused by artifact and most evident at
3 T, and may additionally explain why these regions have
disproportionally high R2* values.
Conclusion
We have shown that ferumoxytol-enhanced MRI is feasible
at both 1.5 T and 3 T, and suggest a range of expected nor-
mal values post-ferumoxytol in a range of tissues. Refine-
ments of dose administration, optimization of acquired
echo-times, careful image analysis, and development of
post-processing and analysis software capable of excluding
common artifacts, are essential to ensure reliable and ro-
bust quantification of tissue enhancement.
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Abdominal aortic aneurysms (AAAs) are an important
cause of morbidity and, when ruptured, are associated
with >80% mortality. Current management decisions are
based on assessment of aneurysm diameter by
abdominal ultrasound. However, AAA growth is non-
linear and rupture can occur at small diameters or may
never occur in those with large AAAs. There is a need to
develop better imaging biomarkers that can identify the
potential risk of rupture independent of the aneurysm
diameter. Key pathobiological processes of AAA
progression and rupture include neovascularisation,
necrotic inflammation, microcalcification and proteolytic
degradation of the extracellular matrix. These processes
represent key targets for emerging imaging techniques
and may confer an increased risk of expansion or rupture
over and above the known patient-related risk factors.
Magnetic resonance imaging, using ultrasmall
superparamagnetic particles of iron oxide, can identify
and track hotspots of macrophage activity. Positron
emission tomography, using a variety of targeted tracers,
can detect areas of inflammation, angiogenesis, hypoxia
and microcalcification. By going beyond the simple
monitoring of diameter expansion using ultrasound,
these cellular and molecular imaging techniques may
have the potential to allow improved prediction of
expansion or rupture and to better guide elective
surgical intervention.
INTRODUCTION
Abdominal aortic aneurysm (AAA) disease affects
up to 5% of men aged between 65 and 74 years in
Western Europe and may pass undetected until a
patient presents with rupture. The mortality rate of
ruptured AAA is over 80%,1 with a minority of
patients surviving long enough to undergo emer-
gency repair. The risks associated with elective
AAA repair are also significant, with a 30-day mor-
tality rate of up to 5% for elective endovascular or
open repair.2 Decision-making at an individual
patient level is therefore paramount to ensure the
best clinical outcome, particularly as AAA shares
risk factors for, and typically coexists with, athero-
sclerotic disease processes that confer substantial
perioperative risk.
When planning management of a patient with
an AAA, the risks of elective surgery must be
weighed against the risk of rupture without inter-
vention. Various risk prediction models have been
developed to help evaluate perioperative and post-
operative risk. While these scores may help evalu-
ate risk when operative intervention is being
considered, the prediction of aneurysm expansion
and rupture risk in patients under surveillance
remains challenging. Current knowledge of AAA
progression is largely based on the tenet that
rupture rate rises with increasing aneurysm diam-
eter. However, up to one in five ruptured AAAs
occur in small aneurysms (<5.5 cm),3 while many
patients have far larger aneurysms that never
rupture and a substantial proportion of patients
die of non-AAA-related causes while under surveil-
lance. We would therefore suggest that prediction
of disease progression using simple measures and
thresholds, such as aneurysm diameter, is too
simplistic.
RISK FACTORS FOR DISEASE OCCURRENCE
AND PROGRESSION
Various risk factors for the development and
progression of AAA disease have been identified,
although it remains unclear why some patients
develop AAA and others, with identical risk pro-
files, do not. AAA occurrence is associated with
advancing age and male sex. However, female
sex is also an independent predictor of acceler-
ated disease progression. Indeed, in comparison
to men, women have an increased rate of aneur-
ysm expansion and a threefold higher risk of
rupture.4 Moreover, when rupture takes place in
women, it occurs at smaller aneurysm
diameters.5
Cigarette smoking is the most important modifi-
able risk factor associated with development,
expansion and rupture of AAA: more than 90% of
patients with AAA are current or ex-smokers. The
relative risk of aneurysm development in current
smokers is at least 2,6 with an increased rate of
expansion of the order of 15–20% in patients who
continue to smoke.7
Although it is often said that AAA shares much
of its pathophysiology with atherosclerosis, it has a
number of distinct features. While traditional ath-
erosclerotic risk factors (such as hypertension and
hypercholesterolaemia) are also associated with
AAA formation, diabetes mellitus is protective
against its development.8 The reason for this
remains incompletely understood but may relate to
diabetes-mediated inhibition of the matrix metallo-
proteinases (MMPs)9 that are responsible for pro-
teolytic degradation of the extracellular matrix in
AAA disease. The pleiotropic effects of antidiabetic
medications, including lipid homeostasis, may also
be important.10
A strong genetic component to the development
of AAA is suggested by the observation that
patients with a family history of AAA have the
highest risk of AAA development.11 Connective
tissue diseases, such as Marfan’s syndrome and
Ehlers–Danlos syndrome, are also associated with
AAA development.
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TOWARDS IMPROVED EVALUATION OF DISEASE
PROGRESSION
Current evaluation of AAA disease progression is based on mor-
phological risk factors for expansion—primarily, aneurysm
diameter. Serial ultrasound examination is the standard method
of monitoring the natural history of AAA disease, using
population-derived data to predict the future expansion of an
individual patient’s aneurysm. The establishment of population-
based ultrasound screening in the UK has been associated with a
40–50% decrease in aneurysm-related mortality.1 Overall, the
rate of expansion and risk of rupture generally rises with
increasing AAA diameter, and current guidelines recommend
that elective repair should be considered when the AAA exceeds
5.5 cm in maximum anteroposterior diameter, or expansion
exceeds 1.0 cm/year.
Recent data have demonstrated that many aneurysms exhibit
a non-linear, discontinuous staccato growth pattern, with
periods of expansion and dormancy.12 The specific biomechan-
ical and biological factors that lead to this variable and patient-
specific AAA expansion patterns cannot be accounted for by
current aneurysm diameter measurements and recent growth
trends alone. Despite this, maximum anteroposterior diameter,
as measured on ultrasound or computed tomography (CT), is
still considered the best clinical predictor of AAA expansion and
rupture.7
Morphological features associated with disease progression
include vessel asymmetry13 and a short, narrow neck configur-
ation.14 The role of intraluminal thrombus in disease progres-
sion remains controversial, although plausibly a large thrombus
load may induce local wall hypoxia, triggering further inflam-
matory activity and inducing changes in local wall strength,15
potentially leading to rupture. However, beyond maximum
diameter none of these is validated as part of standard monitor-
ing of patients with AAA.
As a tool for aneurysm growth surveillance, ultrasound is
ideally suited since it is relatively inexpensive, readily available
and avoids ionising radiation. CT offers the additional anatom-
ical information required for surgical planning and can diagnose
rupture. However, neither modality offers insight into the bio-
logical status of the aneurysm that determines disease progres-
sion. Future developments in the assessment of AAA disease
should go beyond simple morphological parameters with the
aim of predicting more accurately the likely evolution of the
aneurysm for an individual patient.
PATHOBIOLOGICAL ACTIVITY AS TARGETS FOR DISEASE
MONITORING: BIOLOGICAL ‘HOTSPOTS’
Aneurysmal degeneration of the aorta involves inflammation,
neovascularisation, microcalcification and proteolytic degrad-
ation of the extracellular matrix culminating in medial thinning
and loss of the structural integrity of the vessel wall. Once
again, there are common pathological processes involved in
both AAA and atherosclerosis, but also some clear differences
(figure 1). Perhaps, the most striking difference is that athero-
sclerosis affects the arterial intima, causing luminal narrowing,
whereas aneurysmal degradation of the vessel wall predomin-
antly affects the media and adventitia, causing vessel dilatation.
Furthermore, while aneurysm disease affects only the distal
abdominal aorta in 90% of cases, atherosclerosis is typically
widespread involving the coronary, cerebral and peripheral cir-
culation systems.
In studies of coronary atherosclerosis, the term ‘vulnerable
plaque’ has been coined to describe plaques at risk of rupture
precipitating clinical events. Such plaques are characterised by
pathological features that include a thin fibrous cap, large lipid
core, increased infiltration of macrophages and a reduction in
smooth muscle cells.16 Analogous to this concept, ‘hotspots’
have been described in AAA, reflecting the focal and intense bio-
logical activity that occurs in specific regions of the aortic wall.
Within these hotspots, focal neovascularisation is associated
with increased inflammation and proteolysis and is present at
the site of rupture.17 In contrast, the tensile strength of the
aortic wall is not uniform and is impaired in areas of increased
proteolytic activity,18 which varies across the aneurysm sac.
These biological hotspots appear to represent areas of the aortic
wall that are prone to further expansion and rupture.
A number of serum biomarkers of inflammatory and proteo-
lytic activity have been investigated in patients with AAA includ-
ing MMPs (MMP-2, MMP-8, MMP-9), interleukins (IL-6,
IL-10), CRP and other potential mediators (including TNF-α
and TIMP-1) that may contribute to connective tissue degrad-
ation and depletion of collagen and elastin stores. Increased
levels of MMP-8 and MMP-9 have also been identified at the
site of AAA rupture.19 However, measurement of plasma con-
centrations of these biomarkers has not been demonstrated to
be of value in clinical risk prediction of patients and this likely
reflects a lack of sensitivity. Ultimately plasma concentrations
will represent activity of the entire vasculature rather than
potentially small areas of focal vascular injury.
The identification of biological hotspots within the aortic wall
using non-invasive imaging may prove to be a more valuable
approach that could enable risk prediction and, in addition to
the other known risk factors for AAA progression, could form
part of a patient-specific risk prediction model. However, this
cannot be achieved using conventional cross-sectional imaging
techniques and contrast agents. Molecular imaging techniques
have the potential to provide such functional biological informa-
tion and, when used in combination with structural anatomical
data, may provide regional and patient-specific information on
disease activity. Capitalising on our increased knowledge of the
pathogenesis of cardiovascular disease, the field of ‘molecular
imaging’ is one area that has expanded rapidly over the past few
decades. Molecular imaging techniques apply both positron-
emission tomography (PET) and magnetic resonance imaging
(MRI) to identify cell-specific or process-specific probes that
assess the biological function of small-scale molecular events,
such as gene transcription, or identify surrogate markers for
disease activity, such as inflammation and calcification.
Knowledge of a relevant biological ‘target’ is a prerequisite. A
suitable tracer needs to be able to bind to the target, be clinically
available and offer compatibility with a clinically available
imaging modality that provides appropriate spatial and tissue
resolution for the disease process. Such techniques have been
used in coronary artery disease and valvular heart disease to
describe key processes involved in atherosclerosis including
inflammation, angiogenesis and apoptosis.20 21 These techniques
can often define and identify evolving disease states at an earlier
stage than conventional imaging such as the identification of
vulnerable lesions associated with plaque rupture and myocar-
dial infarction. Similarly, the identification, localisation and
tracking of disease activity in patients with AAA may provide
incremental risk prediction in addition to known risk factors for
disease progression (figure 2).
MACROPHAGE ACTIVITY AND MRI
MRI offers high spatial resolution, avoids ionising radiation and
results in excellent soft tissue contrast. Molecular MRI
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techniques allow coregistration of molecular information with
detailed anatomical information and can also be fused with CT
data. Paramagnetic MRI agents (such as gadolinium) are used
widely in clinical practice. When used as a blood pool agent in
AAA, T2-weighted gadolinium-enhanced MRI delineates mor-
phological features such as the blood pool, thrombus and
fibrous cap22 whereas late enhancement reveals areas of fibrosis
within vascular tissues. More recently, ultrasmall superparamag-
netic particles of iron oxide (USPIOs) have been used as ‘smart’
contrast agents in cardiovascular molecular MRI studies.23 24
USPIOs exhibit a dual benefit, in that they can be used both as
an initial T1 blood-pool contrast agent as well as visualise tissue
inflammation using delayed T2 and T2* imaging. Moreover,
USPIOs can be safely used in patients with renal failure,
whereas the use of gadolinium is contraindicated in patients
with renal failure, due to the risks of nephrogenic systemic
fibrosis. With a mean particle diameter of <50 nm, USPIOs are
small enough to evade immediate uptake by the reticuloendo-
thelial system and persist in the blood pool with a half-life of
10–15 h. They translocate into tissues and are slowly taken up
by tissue-resident macrophages thereby accumulating at sites of
inflammation. As such, they have been used to identify and
track macrophage activity in situations of cardiovascular disease.
In particular, they have been shown to accumulate in vulnerable
and ruptured atherosclerotic plaques, but not stable plaques,
and atorvastatin therapy reduces USPIO uptake and inflamma-
tion in symptomatic carotid plaques.25 More recently, a small
pilot study of 29 patients with asymptomatic AAA (diameter
between 4 and 6.6 cm) has demonstrated that focal areas of
USPIO uptake in the aortic wall are associated with more rapid
AAA expansion.23 A large, prospective multicentre trial
(ISRCTN76413758) of USPIO to predict AAA rupture or
surgery in patients with asymptomatic AAA (n=350) is currently
in progress.26 This will establish whether this imaging approach
has any potential clinical utility in patient monitoring (figure 3).
Further development of MRI-based techniques may include
development of agents that can detect subgroups of macro-
phages, in addition to other aspects involved in the process of
atherosclerosis and AAA disease progression.
MACROPHAGE ACTIVITY AND PET
There is a wide range of PET tracers available that can target
different disease processes, many of which could be used in car-
diovascular disease. PET has lower spatial resolution (∼5 mm)
when compared with MRI or CT, and on its own cannot
provide optimal anatomical information for detailed evaluation.
However, fusion techniques (PET-CT and PET-MRI) allow the
integration of molecular information obtained through PET
with anatomical detail gained from CT or MRI. Macrophage
activity may be tracked using cell-specific PET tracers (table 1).
Figure 1 Comparison of pathobiological characteristics of atherosclerosis and abdominal aortic aneurysm (AAA) disease. While AAA disease shares
similar pathobiological processes involved in atherosclerotic disease, there are notable distinctions. In particular, the location of the disease
processes is an important difference, with atherosclerosis affecting primarily the vessel intima, whereas AAA disease has a predilection for the media
and adventitia. The resulting clinical manifestation is that AAA disease causes vessel dilatation and rupture, whereas atherosclerosis leads to vessel
stenosis occlusion. However, the common ground between these two pathological conditions means that molecular imaging techniques thus far
used in the study of atherosclerotic vessels (such as the coronary and carotid arteries) may prove useful in the study of AAA disease.
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18F-Fluorodeoxyglucose
The most widely used clinical PET tracer is
18F-fluorodeoxyglucose (18F-FDG): a glucose analogue that is
taken up by glucose transporters and accumulates in glucose-
metabolising cells. It is used as a surrogate marker for metabolic
activity and is widely used to identify tumour metastases and
monitor response to cancer treatment. In addition, its value in
atherosclerosis imaging (by identifying metabolically active
macrophages as a marker of inflammation) has been explored
largely in the coronary and carotid arteries, as it accumulates
within active atherosclerotic plaques.27
18F-FDG imaging is the only clinically available tracer that
has been explored in AAA disease but its value remains unclear.
One small study found that AAA wall biopsies from patients
with 18F-FDG uptake showed significantly increased inflamma-
tory infiltrate and a reduction in the number of smooth muscle
cells compared with samples from patients with no 18F-FDG
uptake.28 Another small study showed that patients undergoing
open repair of symptomatic AAA (n=3) had higher 18F-FDG
uptake than asymptomatic patients (n=12), and increased
18F-FDG uptake correlated with histological evidence of
increased inflammatory activity.29 Increased 18F-FDG uptake
within the AAA was associated with more aneurysm-related clin-
ical events compared with patients with no 18F-FDG uptake,
and interestingly areas of 18F-FDG uptake correlated with
increased wall stress on biomechanical modelling.30 The authors
of these papers suggest a potential role of 18F-FDG PET
imaging in predicting AAA expansion or rupture.
However, the value of 18F-FDG uptake remains controversial.
Data sets are generally small and often derived retrospectively
from oncology patient cohorts. Moreover, one larger study has
demonstrated no difference in 18F-FDG uptake among patients
with AAA when compared with matched controls (n=310).31
An inverse relationship between 18F-FDG uptake and future
AAA expansion has been demonstrated in a small study, suggest-
ing that aneurysms with lower metabolic activity may actually
be more prone to expand.32
The primary drawback of 18F-FDG PET imaging is that the
effect of local cellular hypoxia on glucose uptake may confound
the PET signal that is otherwise attributed to macrophage activ-
ity,33 as well as the potential for spillover from adjacent struc-
tures that are metabolically active, such as muscle and liver.
Thus, 18F-FDG PET imaging of AAA entails many potential
confounding factors, lacks specificity and there is currently
insufficient evidence to support its routine clinical use in pre-
dicting future AAA expansion or rupture risk.
Although other experimental PET tracers have been investi-
gated in studies of inflammation in the context of atherosclerotic
plaque, few have been investigated in AAA disease. As aneurysm
disease shares some of the common pathways involved in ath-
erosclerosis, some of these tracers may prove useful in the evalu-
ation of AAA disease.
Figure 2 Biological targets and potential molecular imaging techniques in abdominal aortic aneurysm (AAA) disease. As well as patient factors
(such as smoking, hypertension and advancing age) that contribute to the risk of AAA formation, biological processes have been identified that are
implicit in aneurysm formation. The key processes are illustrated above, along with the corresponding molecular imaging techniques (written in
green arrows) that have been used in experimental or clinical studies to date (primarily in the coronary arteries). The combination of patient-related
risk factors and biological processes leads to increased wall stress and decreased wall strength (which can be investigated using computational
modelling techniques), and all of these factors lead to aneurysm expansion and vulnerability to rupture.
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68Ga-DOTATATE
68Ga-DOTATATE (68Ga-[1,4,7,10-tetraazacyclododecane-N,N0,
N00,N0-tetraacetic acid]-d-Phe1,Tyr3-octreotate) has a specific
binding affinity for somatostatin receptors, which play a role in
the modulation of inflammation and angiogenesis. Activated
macrophages and damaged endothelial cells can cause overex-
pression of somatostatin receptors (subtype 2), and
68Ga-DOTATATE (which binds to these receptors) exhibits
macrophage-specific binding properties that may be more valu-
able than 18F-FDG. Murine studies have demonstrated
68Ga-DOTATATE uptake in atherosclerotic plaques,34 while
clinical imaging studies have demonstrated an association
between 68Ga-DOTATATE uptake in coronary arteries and
known cardiovascular risk factors such as the presence of
calcified plaques and hypertension.35 Of note, focal uptake of
68Ga-DOTATATE does not always correlate with 18F-FDG
uptake in one comparison study, suggesting that these tracers
target slightly different pathobiological pathways. There have
been no studies to date investigating the role of
68Ga-DOTATATE in AAA disease progression; however, the
abundance of macrophages seen in aneurysmal aortic wall sug-
gests that this may be a suitable tracer for evaluation.
11C-PK11195 and GE180
11C-PK11195 and GE180 selectively bind to the translocator
protein (TSPO) and have been used primarily in the assessment
of neuronal damage. However, TSPO are also highly expressed
by activated macrophages. Studies have demonstrated the
Figure 3 Magnetic resonance imaging (MRI) using ultrasmall superparamagnetic particles of iron oxide (USPIO) in abdominal aortic aneurysm
disease. This technique is currently being investigated in the MA3RS study (MRI in Abdominal Aortic Aneurysms to Predict Rupture or Surgery—
ISRCTN76413758).




process Cellular target Molecular target
Current clinical
use Applications and limitations
18F-FDG27–33 Inflammation Macrophage Glucose analogue Yes—oncology,
neurology and
cardiology
Uptake influenced by local hypoxia and other resident cell
types, therefore may have limited value. Widely used in
cardiovascular research; has been studied in AAA disease
68Ga-DOTATATE34–35 Inflammation Macrophage Somatostatin
receptor (subtype 2)
Experimental No physiological uptake seen in myocardium, therefore
clearly detects macrophage accumulation
11C-PK1119536 Inflammation Macrophage TSPO receptor Experimental Non-specific binding and low arterial signal density may
preclude its use in clinical setting
GE18047 Inflammation Macrophage TSPO receptor Experimental Binding heterogeneity—10% of the population may lack
binding potential due to variant in receptor
18F-FMCH37–39 Inflammation Macrophage Choline receptor Yes—oncology High uptake in liver may obscure analysis in suprarenal
aorta. Lower tissue-to-background ratios than FDG,
however, may identify areas of evolving inflammation
distinct from areas of established calcification
18F-fluciclatide47 Angiogenesis Endothelium,
fibroblasts
Integrin αvβ3 Experimental Has been investigated in autoradiography studies of AAA
disease
18F-FMISO48 Hypoxia Macrophage Macromolecules in
hypoxic cells
Experimental Has been used in carotid studies
18F-HX448 Hypoxia Macrophage Macromolecules in
hypoxic cells
Experimental Has been used in carotid studies
18F-NaF46 Microcalcification – Hydroxyapatite Yes—oncology Overspill from nearby bone can interfere with uptake
interpretation
AAA, abdominal aortic aneurysms; DOTATATE, 68Ga-[1,4,7,10-tetraazacyclododecane-N,N0,N00 ,N0-tetraacetic acid]-D-Phe1,Tyr3-octreotate; FDG, fluorodeoxyglucose; FMCH,
fluoromethylcholine; FMISO, fluoromisonidazole; HX4, (3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3,-triazol-1-yl)-propan-1-ol); NaF, sodium fluoride; PET,
positron-emission tomography; TSPO, translocator protein.
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potential use of 11C-PK11195 in localising vascular inflamma-
tion in atherosclerotic disease states such as symptomatic carotid
artery disease and inflamed aortic plaques.36 GE180 has a
superior signal-to-noise ratio compared with 11C-PK11195;
however, around 10% of people may have a genetic variant in
the GE180 receptor, which leads to poor binding of the ligand.
Binding heterogeneity would be a barrier to widespread use of
GE180, as it would require pre-emptive genotyping. Neither
tracer has been investigated in AAA disease to date.
18F-Fluoromethylcholine
18F-Fluoromethylcholine (18F-FMCH) binds to choline recep-
tors and was introduced as a radiotracer for neuroimaging and
prostate cancer. However, increased choline uptake is also seen
in activated macrophages. 18F-FMCH uptake has been seen in
murine atherosclerotic plaques, with a higher sensitivity than
18F-FDG,37 while one retrospective clinical study in oncology
patients demonstrated 18F-FMCH uptake in structurally abnor-
mal aortic wall,38 but not in areas that only exhibited established
calcification. This suggests that 18F-FMCH may identify areas of
current biological activity, distinct from areas of macroscopic
calcification that are biologically inert. However, a comparison
study of rat AAA has demonstrated that 18F-FMCH achieved
lower tissue-to-background ratios than 18F-FDG, which was
more sensitive when detecting activated macrophages.39
CALCIFICATION IN AAAS
Vascular calcification is associated with increased cardiovascular
risk. Molecular imaging studies have suggested that inflamma-
tion and calcification occur at different stages of the atheroscler-
otic disease process.40 18F-FDG does not always colocalise with
areas of calcification seen on CT,41 and it is postulated that vas-
cular calcification occurs as part of the healing response to nec-
rotic inflammation, and is regulated in a similar manner to bone
formation.42 Established deposits of vascular calcification are
considered part of a chain of pathological processes relating to
atherosclerosis.41 Therefore, macroscopically visible vascular cal-
cification (macrocalcification) may correlate with overall disease
burden and can be visualised on CT.
Mural calcification is common in AAA disease, is a predictor
of future cardiovascular events and may also be linked with an
increased risk of rupture.43 Calcification, resulting from necrotic
inflammation, may therefore cause aneurysm wall weakness.44
Although widespread macrocalcification is very common in
AAA disease, macrocalcification on CT does not identify those
at high risk of AAA events. However, early evolving areas of cal-
cification (microcalcification) could be a more significant and
useful measurement of biological activity in the aneurysm wall,
as microcalcification precedes the laying down of macrocalcifica-
tion. Recent evidence suggests that plaque vulnerability is
inversely associated with calcification density—established dense
calcification may stabilise a plaque whereas less dense, spotty
areas of microcalcification can trigger plaque rupture by causing
a disproportionate increase in local stresses in the thin collage-
nous plaque, leading to a mismatch in compliance and vulner-
ability to rupture.45 Identifying and localising microcalcification
are beyond the resolution of CT scanning and require a molecu-
lar imaging approach to detect its presence.
MICROCALCIFICATION AND 18F-NAF PET IMAGING
The PET radiotracer 18F-sodium fluoride (18F-NaF) has been
used as a bone tracer for decades in the clinical arena. 18F-NaF
acts as a novel marker of vascular calcification activity, by
binding to hydroxyapatite, which is a key component of bone
and vascular calcification. 18F-NaF preferentially binds to areas
of developing calcification (microcalcification) and has been
used to identify high-risk coronary plaques and culprit lesions
in acute myocardial infarction.46 18F-NaF may also be useful in
Figure 4 18F-NaF positron emission tomography–computed tomography (PET-CT) in abdominal aortic aneurysm disease. This technique is currently
being investigated in the SoFIA3 study (Sodium Fluoride Imaging (18F-NaF PET-CT) in Abdominal Aortic Aneurysms—NCT02229006).
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patients with AAA to identify those with increased biological
activity. Microcalcification represents necrotic inflammation
which, in turn, weakens the vessel wall and may predispose to
aneurysm expansion or rupture. By combining 18F-NaF PET
with CT and CT angiography, identification of hotspots of
increased microcalcification in the aneurysm wall could allow
identification of high-risk AAAs. These data, when combined
with known clinical risk factors for disease progression, may
allow patient-specific evaluation of AAA expansion or rupture
risk. This is currently being investigated as part of the prospect-
ive sodium fluoride imaging (18F-NaF PET-CT) in AAAs
(SoFIA3) study (NCT02229006) (figure 4).
OTHER TARGETS FOR MONITORING BIOLOGICAL ACTIVITY
Other potential PET tracers that may be useful in evaluating
AAA disease do exist,47 although research has so far been con-
fined largely to preclinical autoradiography studies.
18F-fluciclatide binds to integrins and has a high affinity for
αvβ3, which is expressed on endothelial cells, fibroblasts and
inflammatory cells, and is known to be upregulated in angiogen-
esis. One autoradiography study demonstrated that
18F-fluciclatide detects areas of angiogenesis in AAA in vitro.47
18F-FMISO (fluoromisonidazole) and 18F-HX4 are radiotracers
that selectively identify areas of hypoxia and have been used to
localise high-risk carotid artery plaque reflecting increased
macrophage activity.48 Proteolytic degradation of collagen and
elastin in the extracellular matrix is another key component in
AAA formation. Gadolinium-based contrast agents, using MRI
tropoelastin-binding probes, have recently shown promise in
imaging impaired elastinogenesis in atherosclerotic mice49 and
in humans following myocardial infarction.50
CONCLUSIONS AND FUTURE CHALLENGES
Current evaluation of AAA disease (using the basic morpho-
logical parameter of maximum aneurysm diameter) facilitates
only a generic, population-based estimate of future aneurysm
progression. However, more sophisticated methods of risk pre-
diction are now required to plan timely surgical intervention, to
allow appropriate screening intervals during AAA surveillance
and to rationalise health resources.
While aneurysm disease shares some of the common path-
ways of atherosclerosis, its unique and, as yet, incompletely
understood pathobiology means that further AAA-specific
research is required to assess the value of promising imaging
techniques that have been explored in the carotid and coronary
arteries. There is a pressing need to understand the evolving
biology of AAAs and its contribution to future AAA-related
events. Emerging molecular imaging techniques offer the poten-
tial to add this additional biological information to the estab-
lished risk factors for disease progression and may facilitate
individual patient risk assessment.
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ABSTRACT
Introduction: Population screening for abdominal
aortic aneurysms (AAA) halves the associated mortality
and has led to the establishment of national screening
programmes. Prediction of aneurysm growth and
rupture is challenging and currently relies on serial
diameter measurements with ultrasound. Recently,
a novel MRI-based technique using ultrasmall
superparamagnetic particles of iron oxide (USPIO) has
demonstrated considerable promise as a method of
identifying aneurysm inflammation and expansion.
Methods and analysis: The MA3RS study is a
prospective observational multicentre cohort study
of 350 patients with AAA in three centres across
Scotland. All participants will undergo MRI with USPIO
and aneurysm expansion will be measured over 2 years
with CT in addition to standard clinical ultrasound
surveillance. The relationship between mural USPIO
uptake and subsequent clinical outcomes, including
expansion, rupture and repair, will be evaluated and
used to determine whether the technique augments
standard risk prediction markers. To ensure adequate
sensitivity to answer the primary question, we need to
observe 130 events (composite of rupture or repair)
with an estimated event rate of 41% over 2 years of
follow-up. The MA3RS study is currently recruiting and
expects to report in 2017.
Discussion: This is the first study to evaluate the use of
USPIO-enhanced MRI to provide additional information
to aid risk prediction models in patients with AAA. If
successful, this study will lay the foundation for a large
randomised controlled trial targeted at applying this
technique to determine clinical management.
Trial registration number: Current Controlled Trials:
ISRCTN76413758.
INTRODUCTION
Abdominal aortic aneurysm (AAA) disease is
particularly prevalent in elderly men,
KEY MESSAGES
What is already known about this subject?
▸ Current techniques for estimation of rupture risk
in abdominal aortic aneurysm disease rely solely
on diameter measurements from ultrasound.
However, the absolute diameter of the aneurysm
is not the sole determinant of the risk of rupture.
▸ USPIO-enhanced MRI can be used to detect
focal hotspots of inflammation in asymptomatic
aneurysms, and mural USPIO uptake is asso-
ciated with more rapid expansion of aneurysms.
What does this study add?
▸ The aim of the MA3RS study is to examine the
relationship between mural USPIO uptake and
subsequent clinical outcomes.
How might this impact on clinical practice?
▸ This technique may provide an improved method
of risk stratification of patients with abdominal
aortic aneurysms that extends beyond simple
anatomical measurements of aneurysm diameter.
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affecting 5% of men over the age of 65 years1 and
causing 2–3% of deaths within this group.2 Aneurysm
rupture is associated with a mortality rate in excess of
80%.3 4 Population screening halves the mortality asso-
ciated with AAA and has led to the establishment of
national screening and surveillance programmes.1
However, once an aneurysm has been diagnosed, there is
currently no accurate method of predicting which
patients are at risk of rupture and would benefit from
elective surgical or endovascular intervention.
The aetiology of AAA is multifactorial, with environ-
mental and genetic factors playing a part. Aneurysms
typically occur in patients with atherosclerosis and there
are a number of common risk factors, however, there
are also distinct differences between the two disease pro-
cesses. Atherosclerotic lesions are predominantly located
within the tunica intima, whereas aneurysm disease
affects the media and also the adventitia. Aneurysm
disease is most commonly confined to the infrarenal
aorta, whereas atherosclerosis is generally more wide-
spread throughout the arterial tree. In aneurysm
disease, cigarette smoking and hypertension are more
strongly correlated with incidence and risk of rupture.5
The combined effects of biomechanical factors and bio-
logical processes weaken the aortic wall, and lead to aneur-
ysm formation, expansion and rupture. Histopathologically,
the aneurysmal aortic wall is characterised by focal
medial neovascularisation, infiltration of inflammatory cells
(principally macrophages) and fragmentation of elastin
and collagen fibres within the extracellular matrix. Regions
of intense biological activity represent sites of potential
rupture, and can be considered as putative targets for novel
imaging techniques to predict aneurysm expansion and
assess the risk of rupture. In addition, tissue and wall stresses
vary spatially within the aneurysm, and tensile strength
varies in different parts of the aneurysm sac.6 7 It is likely
that expansion and rupture occur where regions of high
biomechanical stress coincide with these biological ‘hot-
spots’ in the aneurysm wall that have become weakened.
Indeed, there is strong evidence that aneurysm rupture is
seen in those patients with more rapid aneurysm expansion
rates.8 9
MRI
MRI is increasingly being used as an investigative tool
for cardiovascular disease, enabling distinction between
the different atherosclerotic plaque components, such
as the lipid-rich necrotic core, fibrous cap and areas of
calcification.10 Standard gadolinium-based MRI is able
to identify areas of thrombus formation and fibrosis in
AAA.11 However, recent innovations in cellular and
molecular imaging methods have enabled the detection
of key biological processes and vessel characteristics that
may correlate with aneurysm disease progression.12–14
Superparamagnetic particles of iron oxide (SPIO) are
part of a novel class of MRI contrast agents that provide
additional biological and functional information
through the detection of cellular inflammation within
tissues. Current preparations of ultrasmall SPIO
(USPIO) are biodegradable and safe for clinical admin-
istration.15–17 USPIO are phagocytosed by macrophages
within vascular and lymphatic tissues,18–21 and can be
used to detect tissue inflammation. USPIO accumulate
in ruptured and vulnerable carotid plaques, and
USPIO-enhanced MRI can detect a reduction in plaque
inflammation following treatment with high-dose ator-
vastatin.22 USPIO uptake has also been demonstrated in
other regions of the vasculature, including the aorta, in
preclinical models and also in small clinical studies.23 24
We have recently conducted a series of MRI studies in
patients with AAA and shown that uptake of USPIO in
the aortic wall correlates with macrophage activity, and
identifies cellular inflammation.25 Using a 3 T MR
scanner, patients with asymptomatic AAA (n=29; aneur-
ysm diameter 4.0–6.6 cm) attending our surveillance
programme were imaged before and 24–36 h after intra-
venous administration of USPIO. Histological examin-
ation of aneurysm tissue confirmed co-localisation and
uptake of USPIO in areas of macrophage infiltration.
Patients exhibiting USPIO uptake and inflammation
within the wall of their aneurysm had a threefold higher
aneurysm expansion rate (n=11, 0.66 cm/year; p=0.020)
than patients with no (n=6, 0.22 cm/y) or non-specific
(n=8, 0.24 cm/y) USPIO uptake, despite similar baseline
anteroposterior diameters.25 Indeed, one patient with a
hotspot of USPIO uptake and biological activity within
the wall of an aneurysm, died suddenly 2 months after
scanning, from presumed aneurysm rupture.
We have shown that USPIO-enhanced MRI holds
major promise as a new method of risk-stratification of
patients with AAA and extends beyond simple anatom-
ical measurements of aneurysm diameter. The aim of
this present study is to validate this technique within a
larger multicentre cohort study and to examine the rela-
tionship between baseline USPIO uptake and subse-
quent aneurysm expansion, requirement for elective
repair and incidence of rupture.
METHODS AND ANALYSIS
Study design
The study is a prospective observational multicentre
cohort study of patients with AAA disease under routine
clinical surveillance, and will assess the role of MRI with
USPIO to predict clinical disease progression.
Study objectives
Our previous proof-of-concept study25 demonstrated
that MRI with USPIO had the potential to predict clin-
ical disease progression in patients with asymptomatic
AAA. The aim of this study is to validate these findings,
focusing on the relationship between baseline USPIO
uptake and the subsequent clinical outcome and aneur-
ysm expansion rates.
The primary objective of the study is to determine
whether mural uptake of USPIO in AAA provides
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incremental risk prediction in addition to standard risk
markers such as aneurysm diameter, smoking and blood
pressure.
Secondary objectives of the study are to ascertain
whether mural uptake of USPIO in AAA: (1) correlates
with the rate of aneurysm expansion; (2) occurs more
commonly in patients who progress to surgery or whose
aneurysm subsequently ruptures; (3) co-localises with, or
relates to, areas of biomechanical stress and (4) occurs
in a reproducible manner.
We will also investigate other inter-related mechanisms
associated with aneurysm growth. We will specifically
explore the added value of biomechanical stress model-
ling as we suspect co-localisation of USPIO uptake and
areas of high mechanical stress could act synergistically,
and cause more marked aneurysm growth. We will also
examine correlates with other blood biomarkers includ-
ing regulators of extracellular matrix turnover (such as
matrix metalloproteinases and tissue inhibitors of metal-
loproteinases) and vascular inflammation (such as C
reactive protein and interleukin 6).
Reproducibility of the technique will be assessed in a
subgroup (n=20) of study participants (from the
Edinburgh study centre) who will undergo repeat MRI
and USPIO administration at <1 month and 1 year.
Short-term (<1 month) reproducibility is likely to reflect
the variability in USPIO uptake whereas long-term
(1 year) reproducibility is likely to represent the vari-
ation in biology of the aortic aneurysm with time.
This will lay the foundation for a large multicentre
randomised controlled trial targeted at applying this
technique to determine clinical management and surgi-
cal intervention. This will be particularly important
given the fact that screening programmes for the detec-
tion of AAA are being rolled out in many countries and
this is likely to increase substantially the number of
patients being entered into surveillance programmes.
Study end points
The primary endpoint of the study will be the composite
rate of aneurysm rupture or repair. The following sec-
ondary endpoints will be evaluated: (1) the rate of
aneurysm rupture; (2) the rate of surgical or endovascu-
lar repair of the aneurysm; (3) the aneurysm growth
rate and (4) all-cause and aneurysm-related mortality.
We will conduct exploratory analyses examining the
interactions between mural USPIO uptake, biomechan-
ical stress, clinical risk factors, and serum biomarkers of
extracellular matrix turnover and inflammation.
Study population
Participants will be identified from clinical surveillance
programmes and databases at three centres: Royal
Infirmary of Edinburgh, Western Infirmary in Glasgow
and Forth Valley Royal Hospital (FVRH). We will recruit
350 participants over a 24-month period with recruit-
ment having begun on 6 November 2012. Recruitment
rate and summary statistics can be viewed at online sup-
plementary appendix 2.
Inclusion criteria will be: (1) AAA measuring ≥4.0 cm
in anteroposterior diameter on ultrasound scanning and
(2) age ≥40 years. Patients under the age of 40 years will
be excluded since they may have a connective tissue dis-
order accounting for their disease.
Exclusion criteria will be: (1) patients expected to
undergo imminent elective or emergency surgical or
endovascular repair; (2) contraindication to MRI scanning
identified from MRI safety questionnaire; (3) patients
refusing or unable to give informed consent; (4) women
with childbearing potential or who are breast feeding will
not be enrolled into the study (women who are currently
pregnant or have experienced menarche but are preme-
nopausal and have not been sterilised will be excluded);
(5) intercurrent illness including patients with a systemic
inflammatory disorder or underlying malignancy (life
expectancy <2 years); (6) renal dysfunction (estimated
glomerular filtration rate ≤30 mL/min/1.73 m2); (7) poly-
cythaemia; (8) contraindication to ferumoxytol (evidence
of known iron overload, haemochromatosis, known hyper-
sensitivity to ferumoxytol or its components or anaemia
not caused by iron deficiency) and (9) contraindication to
iodine-based contrast.
Participant selection and enrolment
Eligible participants will be identified from the clinical
aneurysm surveillance database and will be approached
by a member of the study team at their ultrasound
appointment. Participants will be supplied with the study
information sheet either in person or by post. Written
informed consent will be obtained from patients willing
to participate in the study. Participants are free to with-
draw from the study at any point or the investigator can
choose to withdraw a participant. If a participant has
consented for the study and then wishes to withdraw,
providing they have not been administered ferumoxytol,
another participant will be recruited in their place.
Study drug
Ferumoxytol
Ferumoxytol (Rienso) is composed of USPIO coated
with polyglucose sorbitol carboxymethylether. It is sup-
plied as an aqueous colloidal product that is formulated
with mannitol and presented in single use vials ready for
intravenous infusion. Each vial contains 510 mg of elem-
ental iron in a volume of 17 mL of mannitol.
The ferumoxytol dose (4 mg/kg) is removed from the
vial and administered intravenously at a rate of up to
1 mL/s. The single dose is given immediately following
the baseline MRI and 24–36 h before the postcontrast
scan. Blood pressure is recorded before and 30 min
after administration to monitor for hypotension. In a
subset of patients (n=20), MRI scanning and USPIO
administration will be repeated at <1 month and 1 year
(up to a total of 3 doses of ferumoxytol in 1 year). Each
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dose of ferumoxytol equates to approximately 7% of
total body iron.
The study drug is manufactured by AMAG
Pharmaceuticals Inc (Lexington, Massachusetts, USA), and
distributed and released by Takeda Italia Farmaceutica SPA
in Europe.
Buscopan
Intravenous Buscopan (hyoscine butylbromide) 20 mg
will be administered before each MRI to reduce artefact
from bowel peristalsis in patients who do not have a
contraindication (allergic reaction, narrow angle glau-
coma, paralytic ileus, myasthaenia gravis, obstructive
prostatic hypertrophy).
Study assessments and data collection
Online supplementary appendix 1 outlines the assess-
ments performed at each study visit. Figure 1 shows
the study flow chart. Patients recruited in Edinburgh
and Glasgow will undergo all study investigations in
their respective centre. For patients recruited from
FVRH, they will have the choice of attending the
study in either Edinburgh or Glasgow. They will con-
tinue to have their surveillance ultrasound scan at
FVRH.
Clinical assessment
Patients will have a full formal and standardised clin-
ical assessment at baseline that will include history,
examination and documentation of cardiovascular
risk factor profile (smoking status, family history,
hypertension, hyperlipidaemia, diabetes mellitus).
Concomitant medications (antihypertensive medica-
tion, etc) will be recorded at baseline and at the end
of the study.
Figure 1 Study flow chart (i.v.,
intravenous).
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Blood sampling
Blood samples (20 mL on each visit) will be collected at
baseline and at 24 months, for routine haematology and
biochemistry including full blood count, urea, creatinine
and electrolytes, liver function tests, total cholesterol
and glucose.
For patients recruited and imaged in the Edinburgh
centre, a further blood sample (9 mL) will be collected
at baseline and at 6, 12, 18 and 24 months. Samples will
be processed (plasma and serum) and stored at −80°C
for later analysis of potential extracellular matrix and
inflammatory biomarkers.
Pulse wave analysis and velocity
Pulse wave analysis and velocity will be measured in trip-
licate in fasted patients using applanation tonometry
(SphygmoCor, AtCor Medical, Sydney Australia). This
will facilitate the measurement of central aortic pressure
to assist in the modelling of biomechanical stress within
the aneurysm. This will be measured at baseline and at
6, 12, 18 and 24 months.
Ultrasound of the abdominal aorta
Patients will undergo ultrasound imaging as part of the
standard clinical surveillance programme with measure-
ment of the maximum anteroposterior diameter of the
aneurysm. Ultrasound scans will be performed every 6
±2 months. A 3.5 MHz linear array transducer will be
used to provide standard real time longitudinal B-scan
images of the AAA at the point of maximum diameter.
Maximum anteroposterior AAA diameter and distensibil-
ity (pressure strain elastic modulus and stiffness) will be
assessed. Scans will be undertaken by accredited clinical
vascular scientists with interobserver coefficient of vari-
ation of aortic diameter measurements of 3.5% in our
laboratory.26
CT of the abdominal aorta
Contrast-enhanced images of the abdominal aorta will
be obtained using a 320-multidetector (Edinburgh;
Aquilion ONE; Toshiba) or 64-multidetector CT scanner
(Glasgow; Brilliance 64; Philips), at baseline and 2 years.
These data will be reconstructed into three dimensions
(3D) using volumetric matrices to enable a more com-
prehensive assessment of the aneurysm geometry and
growth than that provided by the ultrasound assessment
of the unidimensional aortic anteroposterior diameter.
In cases where study participants undergo emergency
repair of a ruptured AAA, a CT scan may not be per-
formed. In the event of patients not receiving the CT
scan at baseline it will be performed within 1 month of
the baseline visit.
MRI of the abdominal aorta
MRI will be conducted using a 3 T Siemens Magnetom
Verio scanner (Siemens, Erlangen, Germany) before
and 24–36 h after administration of the USPIO in
Edinburgh or Glasgow. Scanning protocols from the two
centres were validated prior to study initiation. The MRI
safety questionnaire will be applied to identify patients
with a contraindication to scanning. Patients will be
given intravenous Buscopan (hyoscine butylbromide)
prior to imaging to minimise bowel motion artefacts.
Routine clinical coronal and sagittal breath-held
T2-weighted (T2W) multislice HASTE sequences will be
used to identify the position and extent of the aneur-
ysm, following which a respiratory-gated, T2W turbo spin
echo sequence will be used to acquire detailed anatom-
ical data (TR/TE 2500/252 ms; matrix 365×384; field of
view 300×400 mm; slice width 5 mm). These data are
acquired with and without Spectral Attenuated Inversion
Recovery fat suppression in order to allow segmentation
of aortic wall. A multiecho, gradient echo T2*W
sequence (TE 4.9, 7.7, 10.5, 13.3 ms; TR 133 ms; flip
angle 15°; matrix 192×256; field of view 400×400 mm;
slice width 5 mm) will be used to acquire contiguous
axial images of the entire aneurysm (from the neck of
the aneurysm down to the iliac bifurcation) with slice
positions corresponding to those of the T2W images.
Saturation bands are placed over the anterior abdomen
for the T2*W acquisition in order to minimise
breathing-related artefact.
Clinical management of AAA
The management of AAA in NHS Scotland follows inter-
national27 and national guidelines.28 Elective AAA repair
is considered when the anteroposterior diameter, as
measured by ultrasound scanning, reaches 5.5 cm, the
AAA grows >1 cm in 1 year or the AAA is symptomatic.
Furthermore, the decision for elective AAA repair will
be made by independent clinicians who will be unaware
of the USPIO-enhanced MRI. These clinicians do not
have routine access to the CT scans. However, clinically
important incidental findings will be communicated to
the clinicians. Study investigators will not be directly
involved in the patient’s care or treatment decisions. In
the case of patients undergoing surgery where repair of
the AAA is not the primary intention (eg, in the case of
repair of a common iliac aneurysm with concomitant
AAA), they will be included in the primary analysis on
an intention-to-treat analysis.
Follow-up for patients in certain circumstances
If a patient undergoes an open or endovascular repair
of their aneurysm, we will record the results of any scans
that are carried out for clinical reasons (such as extra
CT or ultrasound scans). Those undergoing open repair
will have aneurysm wall tissue collected and stored for
the assessment of tissue resident macrophages and
matrix metalloproteinases. These patients will be invited
to return every 6 months for blood tests but not ultra-
sound or pulse wave analysis or velocity.
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Proposed analysis
Image analysis of ultrasound
Cursors will be locked onto echoes representing the
anterior and posterior aortic walls and the movement of
both tracked with each cardiac cycle. The longitudinal
image will be used for analysis as experience with the
technique and data from formal reproducibility studies
indicate that the quality of the data obtained from a lon-
gitudinal section is superior to that obtained from a
transverse view. Images will be captured digitally for later
offline core laboratory review.
Image analysis of CT
CT of the abdominal aorta will be performed at baseline
and 2 years to assess regional and volumetric growth
rates. These two CT scans will be spatially co-registered
so that areas of expansion and growth can be more
accurately defined, and can permit correlation with
areas of USPIO uptake and finite element analysis
modelling.
Three-dimensional computer models will be gener-
ated from segmented, contrast-enhanced images, allow-
ing geometric indices to be quantified. Semiautomatic
segmentation is achievable due to the intensity differ-
ences between the aneurysm, and surrounding tissues
and structures. Intensity thresholding will be used to
identify the lumen. To detect the thrombus and com-
plete the segmentation, we will use a 3D deformable
model approach that utilises the level set algorithm as
well as modelling the thrombus contour as a radial func-
tion starting from the aortic centre line as calculated
from the lumen segmentation.
Image analysis of MRI
A region of interest encompassing the aortic wall and
thrombus but excluding the lumen will be drawn on
each slice of the precontrast T2W image. The precon-
trast T2W scan will be used as the base image to which
subsequent scans will be co-registered using a semi-
automatic rigid 3D voxel registration protocol utilising a
normalised mutual information algorithm. To minimise
the contribution of bowel and abdominal wall motion
in the MRI datasets, a region for registration will include
the aorta, vertebrae and spinal musculature that remain
relatively static during the respiratory cycle, but exclude
the more mobile abdominal wall and bowel.
The four echoes in the multiecho T2*W sequence will
be combined to generate T2* and R2* maps. The T2*
value is the decay constant for the exponential decay of
signal intensity with time and its inverse is the R2* value.
A 3×3 voxel Gaussian filter will be applied to the individ-
ual echoes to reduce noise, and the coefficient of deter-
mination will be used to exclude data that do not have
an acceptable straight line fit when the log of signal
intensity is plotted against echo time. Images will be
co-registered to allow direct comparison of the precon-
trast and postcontrast T2*W MRI. USPIO uptake will be
presented visually as a colour map of change in T2* or
R2* values between pre-USPIO and post-USPIO scans,
with our previously validated threshold of significance
applied (figure 2).25 The change in T2* or R2* colour
maps from the MRI will be spatially co-registered to the
CT datasets.
Finite element analysis
Using Abaqus/Complete Abaqus Environment, the
vessel wall will be modelled as a constant thickness layer
of 1.5 mm, with a hyperelastic constitutive model.
Thrombus will be modelled as homogeneous and iso-
tropic with Young’s modulus 0.1 MPa. The model will be
inflated from diastolic to systolic pressure using a homo-
geneous pressure-modelling regime. Peak wall stress and
other rupture indices will be calculated and compared
against areas of USPIO uptake.
Statistics and data analysis
Sample size calculation
The sample size is determined by the numbers required
to build robust prognostic models for rupture or surgical
Figure 2 Colour map of MRI of an abdominal aortic
aneurysm. Red and yellow pixels indicate areas of increased
T2* value, indicative of ultrasmall superparamagnetic particles
of iron oxide uptake.
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repair, and in particular to measure the additional prog-
nostic value of mural USPIO uptake when added to
such a prognostic model based only on conventional
clinical risk factors. There is a widely accepted ‘rule of
thumb’ that one needs at least 10 and ideally 20
outcome events per covariate to be included in a prog-
nostic model.29 As described in more detail below, we
plan to use the net reclassification index (NRI) as the
primary measure of the clinical relevance of the added
prognostic value of mural USPIO uptake.30 31 Based on
two recent papers using the NRI,32 33 and also taking
account of the Harrell ‘rule of thumb’, we estimate that
we need to observe 130 events (ie, the composite of
rupture or surgical repair) to have adequate sensitivity
to answer the primary question. With our estimated
event rate of 41% over the mean duration of follow-up
of 2 years,34 this equates to 317 patients. The estimated
event rate is based on a composite endpoint of rupture
and repair. This is taken from a previous study at our
centre,34 where rupture rates were 13% and elective
intervention rates were in the region of 30% over a
2-year period.
The sample size has been derived so that the study
will allow us to assess the ‘added value’ of USPIO uptake
over and above conventional clinical risk factors in pre-
dicting rupture and/or the need for surgical interven-
tion. As such, conventional type I and II errors are not
relevant. However, the approach we have adopted is
extremely conservative in terms of a conventional power
calculation. For example, if we assume that 40% of the
patients are ‘positive’ for USPIO uptake, and that their
event rate is 55%, compared with an event rate of 30%
in the uptake ‘negative’ patients, then the statistical
power to detect such an effect would be over 99% at the
5% significance level (2-sided). In other words, the
study has extremely high power to detect an effect of
the order that would be required if USPIO uptake is to
add usefully to conventional prognostic factors.
There should be very modest losses to follow-up for
the primary analysis, since all study recruits are already
enrolled in a surveillance programme. Moreover, we
shall seek consent at the time of recruitment to flag the
patients so that if any patients are lost to follow-up they
can be traced to identify any hospital admissions or to
identify if they have died. In addition, some patients will
drop out due to technical failure of the scan, such as
claustrophobia or a severe reduction in image quality
preventing analysis. Image quality will be assessed on a
four-point Likert scale (1=excellent; 2=mild reduction in
image quality; 3=moderate reduction in image quality;
and 4=severe reduction in image quality). We have,
therefore, conservatively accounted for a 10% drop out
rate and we will recruit 350 patients to the study.
Statistical analysis
The baseline assessment will include the baseline aneur-
ysm diameter, sex, smoking habit and blood pressure.
Using these covariates, a prognostic model predicting
the time to the composite outcome event of rupture or
surgical repair will be developed using Cox proportional
hazards regression. The added prognostic value of
adding mural USPIO uptake to this model will be
assessed using the increase in the area under the
receiver operator characteristic curve, the Nagelkerke
partial R2 and, primarily, the NRI.32 33 The NRI is a
direct measure of the clinical relevance of adding a cov-
ariate to a prognostic model. It is an overall measure of
how many patients move from a low predicted risk to a
high predicted risk when the covariate is added (and
whether these individuals are indeed high risk), and
how many move from a high predicted risk to a low pre-
dicted risk (and whether these individuals are indeed
low risk). For the primary analysis, the USPIO will be
taken as a binary covariate (as in Richards et al25), but a
sensitivity analysis will explore the potential for including
a quantification of the USPIO uptake. Some but not all
of the patients will also have a measure of current aneur-
ysm growth rate at baseline, and a further sensitivity ana-
lysis will explore using growth rate as a further
prognostic factor, using imputation when the estimated
growth rate is not available.
A secondary analysis will follow a similar analytical
strategy to that set out above, but using prognostic
models to predict aneurysm growth rate. This analysis
will be far more complex with the inclusion of serial
measures of aneurysm diameter and with these measure-
ments being censored on rupture or on surgical repair.
Further exploratory analysis will look at the predictive
ability of measures of wall stress and how these interact
with regional USPIO uptake.
The reproducibility of the technique will be assessed
with participants categorised with respect to the presence
or absence of USPIO uptake at 1 month and 1 year, to
define the proportionate agreement, with 95% CIs.
ETHICS AND DISSEMINATION
Research sponsorship is provided by the Academic and
Clinical Central Office for Research and Development
(ACCORD), a partnership between the University of
Edinburgh and NHS Lothian Health Board.
The results of the study will be submitted for publica-
tion in peer-reviewed journals.
Results will also be disseminated through presenta-
tions at national and international conferences.
DISCUSSION
The multicentre MA3RS study will assess the ability of
USPIO-enhanced MRI to augment standard risk
markers for AAA expansion or rupture in 350 patients
attending aneurysm surveillance clinics. This is the first
study to assess novel MRI-based imaging approaches to
improve risk prediction in this common and potentially
fatal condition.
Mortality from ruptured AAA is very high, at approxi-
mately 90%. In contrast, the risk of death from open
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surgical or endovascular repair is low, at 1–5%.35 The
aim is therefore to identify AAA prior to rupture and
consider surgery when the risk of rupture exceeds that
of elective repair. Aneurysm screening reduces the risk
of aneurysm-related death by 53–73%, and has been
introduced throughout the UK and in many countries
across the world.1 36 37 Evaluation of rupture risk is cur-
rently based on the maximum anteroposterior diameter
of the aneurysm. Elective aneurysm repair is offered to
patients with an aneurysm diameter of >5.5 cm or if
aneurysm expansion is >1.0 cm/year. However, while the
risk of rupture increases with diameter,8 38 39 the abso-
lute diameter of the aneurysm is not the sole determin-
ant of the risk of rupture,40 and elective repair when the
diameter is <5.5 cm offers no survival benefit over con-
tinued surveillance.41 Furthermore, 1 in 14 screen-
detected aneurysms <5.5 cm in diameter will rupture
within 3 years of detection, and up to one-fifth of rup-
tured AAA are <5.5 cm in diameter, while many patients
present with diameters considerably >5.5 cm without
prior symptoms or rupture.8 41 42 The increase in
patients under long-term surveillance with the introduc-
tion of nationwide screening, coupled with the unpre-
dictability and non-linearity of aneurysm growth,
highlight the need for an improved method of risk pre-
diction in aneurysm disease. This will then enable pre-
ventative surgical or endovascular repair to be targeted
to the high-risk patients.
We have previously demonstrated that the assessment
of USPIO uptake with MRI can be used to detect focal
hotspots of inflammation in asymptomatic aneurysms,
and that mural USPIO uptake is associated with more
rapid expansion of aneurysms.25 By assessing these bio-
logical processes and evaluating them with this novel
technique, the MA3RS study aims to develop an
improved method of assessing rupture risk in AAA in a
large prospective clinical study with a long duration of
follow-up.
We will model differing thresholds of risk predictors
that have the potential to inform future interventional
trials. For example, this study could define USPIO-
enhanced MRI features that predict aneurysm rupture.
This could lead to the design of a major interventional
trial whereby surgical intervention could be targeted at
those aneurysms that are vulnerable or prone to rupture.
This could include surgery in patients with aneurysms
<5.5 cm or mandate conservative management in those
with aneurysms >5.5 cm. A more sophisticated stratified
approach has the potential to save lives as well as avoid
unnecessary high-risk surgery in those who are unlikely to
come to harm.
Trial status
The study has been approved by the East of Scotland
Research Ethics Committee. Recruitment is underway at
all sites and two-thirds of the study population have
already been recruited. Completion of study enrolment
is anticipated in autumn 2014.
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Background: 18F-Sodium fluoride (18F-NaF) uptake is a marker of active vascular 
calcification associated with high-risk atherosclerotic plaque.   
Objectives: In patients with abdominal aortic aneurysm (AAA), we assessed whether 
18F-NaF positron emission tomography and computed tomography (PET-CT) predicts 
AAA growth and clinical outcomes. 
Methods: In prospective case-control (n=20 /group) and longitudinal cohort (n=72) 
studies, patients with AAA (aortic diameter >40 mm) and control subjects (diameter 
<30 mm) underwent abdominal ultrasound, 18F-NaF PET-CT, CT angiography and 
calcium scoring. Clinical endpoints were aneurysm expansion and the composite of 
AAA repair or rupture.   
Results: 18F-NaF uptake was increased in AAA compared to non-aneurysmal regions 
within the same aorta (p=0·004), or aortae of control subjects (p=0·023). Histological 
and micro-PET-CT analysis demonstrated that 18F-NaF uptake localised to areas of 
aneurysm disease and active calcification. In 72 patients within the longitudinal 
cohort study (age 73±7 years, men 85%, baseline aneurysm diameter 48·8±7·7 mm), 
there were 19 aneurysm repairs (26·4%) and 3 ruptures (4·2%) after 510±196 days.  
Aneurysms in the highest tertile of 18F-NaF uptake expanded 2·5 times more rapidly 
than those in the lowest tertile (3·10 [2·34-5·92] versus 1·24 [0·52-2·92] mm/year, 
p=0·008) and were nearly three times as likely to experience AAA repair or rupture 
(15·3% versus 5·6%, log-rank p=0·043).  
Conclusions: 18F-NaF PET-CT is a novel and promising approach to the 
identification of disease activity in patients with AAA, and is an additive predictor of 




18F-sodium fluoride uptake specifically localizes to areas of abdominal aortic 
aneurysm disease, and is a major predictor of aneurysm expansion and clinical 
outcome, independent of established clinical risk factors including aneurysm 
diameter. 18F-Sodium fluoride positron emission tomography may be a useful 
adjunctive test in patients with high-risk or borderline aneurysms, or those with larger 
aneurysms where the balance of risk and benefit is uncertain. Future clinical trials will 
be needed to validate this approach and to establish whether clinical and surgical 
decisions based on 18F-sodium fluoride positron emission tomography findings can 





AAA  Abdominal aortic aneurysm 
CT  Computed tomography 
ECG  Electrocardiogram 
18F-NaF  18F-Sodium fluoride  
MA3RS Magnetic resonance imaging in Abdominal Aortic Aneurysms to 
predict Rupture or Surgery  
MDS Most diseased segment 
PET  Positron emission tomography 
ROI  Regions of interest 
SUV  Standardized uptake value 




Abdominal aortic aneurysm (AAA) disease affects up to 5% of males aged 64 to 75 
years and its prevalence is increasing in more elderly populations (1). With 
progressive AAA expansion over time, there is an increasing risk of often fatal 
rupture, representing the twelfth commonest cause of death amongst older men (2). 
Consequently, patients with AAA enter an ultrasound-based surveillance programme, 
with the aim of facilitating pre-emptive elective aneurysm repair in order to avoid 
fatal rupture. AAA surveillance relies on serial measurements of aneurysm diameter, 
which is currently the best clinical predictor of further expansion and rupture (3,4). 
However, AAA growth is non-linear, unpredictable and influenced by biomechanical 
processes that cannot be predicted by conventional anatomical imaging alone (5). 
Indeed, aneurysms not infrequently rupture below the current threshold (55 mm 
diameter) for elective repair, and many patients with aneurysms larger than 70 mm 
never experience rupture (6). There is therefore a need to develop more reliable 
methods of identifying those patients at particular risk of abdominal aortic aneurysm 
expansion and rupture (7). 
 
In AAA disease, degradation of the extracellular matrix occurs in response to the 
accumulation of inflammatory cells, such as macrophages and lymphocytes, and the 
activation of matrix metalloproteinases. The resulting milieu of cellular inflammation, 
tissue destruction and necrosis can lead to cycles of further inflammation (8). Focal 
‘hotspots’ of such intense biological activity have been identified in active aneurysm 
disease and can occur at the site of rupture (9). We have recently demonstrated that 
the positron emitting radiotracer, 18F-sodium fluoride (18F-NaF), can identify areas of 
	 6	
early microcalcification (10) that occur in response to necrotic inflammation in 
ruptured or high-risk human carotid (11) and coronary (12) atherosclerotic plaques.  
This tracer has not been assessed in patients with AAA although loss of tissue 
integrity and necrotic inflammation may be central to its pathophysiology, underlie 
aneurysm expansion and ultimately predict disease progression and outcome (7). We 
hypothesized that 18F-NaF uptake on positron emission tomography (PET) would 
highlight areas of microcalcification and AAA disease activity, representing regions 
prone to expansion and rupture. The main aims of this study were to determine 
whether 18F-NaF uptake on combined PET and computed tomography (CT) is 
increased in AAA, and whether this is associated with aneurysm growth (primary 






Study Population  
Consecutive patients over 50 years of age under routine clinical surveillance with 
asymptomatic AAA (≥40 mm anteroposterior diameter) were recruited from the 
Magnetic resonance imaging in Abdominal Aortic Aneurysms to predict Rupture or 
Surgery (MA3RS) study (ISRCTN76413758) database (13). Control subjects were 
recruited through the NHS Lothian National Abdominal Aortic Aneurysm Screening 
Programme or the Vascular Laboratory at the Royal Infirmary of Edinburgh, and had 
a documented normal calibre aorta (<30 mm anteroposterior diameter).  
 
Study Design 
This was a prospective single-centre case-control and observational cohort study of 
patients with asymptomatic AAA, who were under ultrasound-based surveillance as 
part of routine clinical follow-up, and control subjects with a normal calibre 
abdominal aorta demonstrated on targeted screening ultrasound. The study 
(www.clinicaltrials.gov, NCT02229006) was conducted with the written informed 
consent of all subjects, approval by the Research Ethics Committee, and in 
accordance with the Declaration of Helsinki.  
 
Study Assessments  
Participants underwent a clinical evaluation including documentation of medical 
history, concomitant medications and family history as well as an ultrasound 
evaluation of the maximum anteroposterior abdominal aortic diameter. Ultrasound 
scans were carried out in an accredited clinical vascular science laboratory using a 
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standardized protocol with a known inter-observer variability of 3·4% (14). The AAA 
growth rate was determined using the AAA maximum anteroposterior diameter 
obtained at baseline and the last ultrasound performed during study follow-up. 
Abdominal aortic tissue was obtained at post-mortem or from patients undergoing 
elective AAA repair, and analysed by micro-PET-CT and histology (Supplementary 
Material). 
 
18F-Sodium Fluoride PET-CT 
Patients were administered a target dose of 125 MBq of 18F-NaF intravenously, and 
after 60 min, were imaged on a hybrid 128-detector array PET-CT scanner (Biograph 
mCT, Siemens) (10). A low-dose attenuation correction CT scan was performed (120 
kV, 50 mAs; 5/3 mm), followed by acquisition of PET data, using three 10-min bed 
positions to ensure coverage from the thoracic aorta to the aortic bifurcation. An 
ECG-gated calcium scoring CT scan (120 kV, 120 mAs, 3/3 mm; prospective ECG-
gating at 50% of the R-R interval) and a contrast-enhanced CT angiogram (120 kV, 
145 mAs; 3/3 mm, 400 field of view; and 1/1 mm, 300 field of view; triggered at 181 
HU) were performed, centred on the AAA (or abdominal aorta in control patients) 
and extending to the aortic bifurcation (Figure 1). 
 
To estimate 18F-NaF uptake, the maximum standardized uptake values (SUVmax, a 
validated measure of tissue radiotracer uptake) were quantified from regions of 
interest (ROI; Supplementary Material) (15). Maximum tissue-to-background ratios 
(TBRmax) were then calculated, after correction for blood pool activity using the 
averaged SUVmean values of 3 consecutive ROIs from the right atrium, according to 
our previously described technique (16). Although TBRmax was used for our primary 
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analysis (12), we also investigated other methods for quantification including SUVmax 
and the corrected SUVmax (cSUVmax; calculated by subtracting the blood pool activity 
from the SUVmax) (15). Finally, we adopted the ‘most-diseased segment’ (MDS) 
approach as suggested by others (11,16,18-20). The MDS TBRmax was calculated as 
the average TBRmax across three axial slices centred on the region of the aneurysm 
with the highest tracer activity (11).  
 
Clinical Endpoints and Adjudication 
Clinical data from clinic visits, research database, electronic health records, primary 
care contacts and General Register Office were reviewed and clinical endpoints 
adjudicated by an independent Clinical Endpoint Committee (Supplementary 
Material). The committee members were blinded to the PET-CT findings. Follow-up 
was censored at 10th January 2017 or at the time of event.   
 
Statistics and Data Analysis 
Baseline characteristics are reported as number (percentages) for categorical variables 
and mean ± standard deviation or median [interquartile range] for continuous 
variables, as appropriate.  We stratified our patient cohort by AAA MDS TBRmax 
tertiles to assess associations with aneurysm expansion (primary endpoint) and the 
clinical outcomes of aneurysm repair or rupture (secondary endpoint).  For the 
aneurysm growth and outcomes analysis, AAA expansion rate and MDS TBRmax 
were log-transformed [log2] to normalize the data.  One-way analysis of variance was 
used to compare continuous data across multiple factors, with post-hoc analysis using 
the Bonferroni test where appropriate. The Kruskall-Wallis test was used for non-
parametric continuous data and the log-rank test for comparisons of AAA event rate 
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and mortality between tertiles. Categorical data were compared using chi-squared or 
Fisher’s exact tests, and unpaired Student’s t-test was used to compare continuous 
outcomes between two independent groups. Two-tailed Pearson’s correlation and 
linear regression analysis were performed to investigate the relationship between 18F-
NaF uptake and aneurysm expansion. Finally, we performed Kaplan-Meier and Cox’s 
regression analysis to investigate time to AAA event by tertile, censored at the date of 
death. Statistical analysis was undertaken using IBM SPSS Statistics 23 and 






A total of 145 patients with AAA were screened for inclusion: 136 were approached 
and 76 patients ultimately attended for the scanning visit.  Four patients underwent 
protocol development scans, had incomplete data and were excluded from the final 
analysis, leaving a total of 72 patients with AAA and 20 control subjects (Figure 2). 
Patients were predominantly elderly (72·5±6·9 years) men (84·7%) with multiple 
cardiovascular risk factors including hypertension (65·3%) and hypercholesterolemia 
(81·9%; Table 1). Over 90% were current or ex-smokers (27·8% and 65·3% 
respectively) with a mean baseline AAA diameter of 48·8±7·7 mm. Control subjects 
were younger (65·2±2·8 years), but also predominantly (95·0%) men and 40% were 
current (25·0%) or prior (15·0%) smokers. 
 
Case-control Study  
Twenty AAA patients were matched for age, sex and smoking status with the 20 
control subjects (Table 1).  Background blood pool activity in the right atrium was 
similar between groups (log2SUVmean -0·570±0·517 versus -0·588±0·531; difference 
0·018 (95% confidence interval (CI) -0·340 to 0·376), p=0·919). 18F-NaF uptake was 
higher in the AAA when compared to the abdominal aorta of control subjects 
irrespective of the method of quantification (e.g. log2MDS TBRmax 1·712±0·560 
versus 1·314±0·489; difference 0·398 (95% CI 0·057 to 0·739), p=0·023; 
Supplementary Table 1). In contrast to control aortic tissue, AAA tissue demonstrated 
ex vivo 18F-NaF uptake that correlated with areas of tissue disruption with necrotic 
debris and active calcification (r=0·808, P=0·015; Figure 3). Areas of 18F-NaF uptake 
on PET were distinct from areas of macrocalcification on CT (Supplementary Movie). 
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Patients with AAA had more cardiovascular risk factors and higher abdominal aortic 
CT calcium scores (log2Agatston score, 11·444±1·760 versus 7·338±3·811; 
difference 4·105 (95% CI 2·013 to 6·198), p=0·001; Supplementary Table 1) than 
control subjects. However, no differences in 18F-NaF uptake were observed between 
these groups in either the descending thoracic aorta, or the non-aneurysmal abdominal 
aorta.  
 
Observational Cohort Study 
18F-NaF uptake was again higher in the aneurysm than in the non-aneurysmal portion 
of the abdominal aorta (log2TBRmax 1·647±0·537 versus 1·332±0·497; difference 
0·314 (95% CI 0·0685 to 0·560), p=0·004) and almost double the uptake observed in 
the descending thoracic aorta (log2TBRmax 1·647±0.537 versus 0·881±0.414; 
difference 0·766 (95% CI 0·517 to 1·011), p<0·0001). These differences were 
consistently observed regardless of the method of PET quantification.  
 
Across the tertiles of AAA MDS TBRmax, there were no differences in most risk 
factors for AAA disease including age, sex, smoking habit, aneurysm diameter, 
hypertension and hypercholesterolemia. Whilst there appeared to be some differences 
with respect to diastolic blood pressure, body-mass index and peripheral arterial 




18F-NaF Uptake and Aneurysm Growth 
During 510±196 days of follow-up, the median AAA expansion rate was 2·20 [0.96-
3.72] mm/year (Table 2).  Baseline 18F-NaF activity in the aneurysm was associated 
with future expansion regardless of the method of quantification (e.g. log2MDS 
TBRmax r=0·365, p=0·006). When stratified by tertiles, aneurysms in the highest 
tertile expanded 2.5 times more rapidly than those in the lowest tertile (3·10 [2.34-
5.92] mm/year versus 1·24 [0.52-2.92] mm/year, p=0·008; Figure 4). Moreover, in 
multivariable analysis, 18F-NaF activity in the AAA (MDS TBRmax) emerged as a 
predictor of growth independent of age, sex, baseline diameter, body-mass index, 
blood pressure, smoking, renal function or peripheral arterial disease (p=0·042; 
Supplementary Table 2). In contrast, the aneurysm Agatston score was not associated 
with future expansion (r=0·199, p=0·141). 
 
18F-NaF Uptake and Clinical Events 
In total, 22 (30·6%) patients met the composite endpoint of AAA repair or rupture.  
Of these 19 (26·4%) underwent elective AAA repair and 3 (4·2%) experienced AAA 
rupture, all of whom died without repair. Five other patients died during study follow-
up, all from non-AAA causes. 
 
Patients with aneurysms in the highest tertile of 18F-NaF uptake were more likely to 
experience AAA repair or rupture during follow up (15·3% versus 5·6%, log-rank 
p=0·043; Table 2).  They also had a reduced time to AAA event: 572 versus 735 days 
for AAA repair (log-rank p=0·014), and 572 versus 709 days for the composite of 
AAA repair or rupture (log-rank p=0·043; Figure 4). In those patients who 
experienced an AAA event, 18F-NaF activity was higher than those who continued 
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under surveillance without an event (log2MDS TBRmax 2·20±0·58 versus 1·87±0·54, 
difference 0·330 (95% CI 0·047 to 0·613), p=0·023). In unadjusted analysis, a 
doubling of 18F-NaF activity in the MDS was associated with a more than 2-fold risk 
of experiencing AAA rupture or repair (HR 2·16, 95% CI 1·03 to 4·50; p=0·041; 
Table 2).  When adjusted for age, sex, baseline diameter, systolic blood pressure, 
body-mass index and smoking, this risk remained (HR 2·49, 95% CI 1·07 to 5·78; 




In this prospective series of clinical studies, we have demonstrated for the first time 
that 18F-NaF uptake is specifically increased in AAA, and relates to areas of advanced 
aneurysmal disease. Moreover, 18F-NaF uptake is a major predictor of aneurysm 
expansion and clinical outcome that is additive to standard clinical risk factors 
including aneurysm diameter. This is the first study to demonstrate that an imaging 
biomarker of disease activity can add to the risk prediction of AAA and to suggest 
that this approach might refine clinical decisions regarding the need for surgery and 
improve patient outcomes (Central Illustration).  
 
Our studies have several major strengths and prominent observations. First, we have 
shown AAA tissue demonstrates markedly increased levels of 18F-NaF uptake that far 
exceeds those seen in control volunteers. Perhaps more importantly, uptake of the 
AAA also exceeds that observed in the non-aneurysmal aorta within the same patient. 
Second, we demonstrate that 18F-NaF uptake localized to areas of AAA disease, 
highlighting diseased areas of poor tissue integrity that may be susceptible to 
aneurysm expansion and clinical events. Third, we assessed the potential clinical 
value of this technique in a cohort of patients with extended follow-up where the 
clinicians responsible for the patient’s care were unaware of the PET-CT findings. It 
is therefore salient to note that 18F-NaF uptake predicted expansion and clinical 
outcomes in addition to clinical risk factors including AAA diameter, especially as the 
latter drives the decision for elective AAA repair. Four, this is the largest dedicated 
PET-CT study in AAA disease to date and the first clinical study to investigate 18F-
NaF PET-CT in AAA disease progression (21). Finally, this was a prospective 
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clinical cohort study which contrasts with many previous studies of PET-CT in 
patients with AAA that are based on retrospective data, often obtained from cohorts 
derived from oncological imaging practice.   
 
We have previously demonstrated that 18F-NaF selectively binds to microcalcification 
in coronary11 and carotid atherosclerotic plaques (10,11), and that this is associated 
with plaque vulnerability and rupture. We (11,12) and others (22) have also shown 
that 18F-NaF binds to areas of tissue necrosis associated myocardial and cerebral 
infarction. In our present study, histological and micro-PET-CT data indicate that this 
tracer is behaving in a similar fashion in AAA. Increased 18F-NaF uptake was most 
marked in AAA tissue with advanced disease and active calcification. We suggest that 
18F-NaF uptake again relates to microcalcification and is particular to the most 
diseased areas associated with tissue disruption and loss of integrity. Interestingly, we 
also showed that 18F-NaF was distinct from AAA macrocalcification detected by 
computed tomography, and that the latter is not associated with expansion or AAA 
events, suggesting that once established, dense calcified deposits represent a more 
stabilized biological state.  
 
Most previous clinical PET-CT studies of AAA disease have focussed on the use of 
18F-fluorodeoxyglucose (18F-FDG) to identify inflammation, with variable results and 
no clear clinical application.  Whilst some groups have suggested a potential role for 
18F-FDG PET-CT in predicting AAA expansion or rupture (23-25), others have 
disputed this and reported contradictory findings (26,27). This in part relates to the 
small study sample sizes and whether patients had symptomatic or inflammatory 
AAAs but to date there is no clear relationship between 18F-FDG and aneurysm 
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expansion or clinical outcome (22). Our current study was nested within another 
larger clinical cohort study, the MA3RS trial. This was a multicentre study of 342 
patients with AAA who underwent ultrasmall superparamagnetic particles of iron 
oxide (USPIO)-enhanced magnetic resonance imaging (MRI) to identify cellular 
inflammation within the aortic wall (13). This study recently reported and 
demonstrated that while USPIO-enhanced MRI did predict AAA expansion and 
clinical outcome, the association was modest and was not independent of established 
clinical factors including ultrasound AAA diameter (28). This suggests that imaging 
of cellular inflammation alone, either by 18F-FDG or USPIO-enhanced MRI, is 
insufficient to provide additive clinical information beyond established clinical risk 
factors and AAA diameter. In contrast, 18F-NaF PET-CT identifies focal areas of 
microcalcification indicative of more advanced aneurysm disease, and independently 
predicts both disease progression and clinical events. 
 
We have demonstrated an important clinical application of 18F-NaF PET-CT in AAA 
disease.  Until now, future prediction of aneurysm expansion has relied on the simple 
morphological parameter of aneurysm diameter. However it is clear that AAA growth 
is non-linear and cannot be predicted accurately from a simple anatomical measure, 
such as AAA diameter. While we know that larger aneurysms tend to expand more 
rapidly and are more prone to rupture, disease evolution is not straightforward. Better 
AAA disease prediction using 18F-NaF uptake could be particularly useful for patients 
in whom the decision to intervene is challenging. For example, those with high-
risk aneurysms below 55 mm, those with borderline aneurysm sizes, or those with 
larger aneurysms where the balance of risk and benefit is uncertain.  
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Our study has a number of limitations. This is a single-centre proof-of-concept study 
with a low number of rupture events that makes adjustment for potential confounders 
and covariates challenging. Although we observed no marked differences in gender 
across the tertiles of 18F-NaF uptake, our study population had a strong male bias 
(typical of this disease population) and we cannot be certain that our findings are truly 
representative for both men and women. The clinical impact of this technique has not 
been assessed, and would require a larger trial where clinical and surgical decisions 
would be influenced or dictated by the 18F-NaF PET-CT findings. The widespread 
implementation of this technique may be challenging, especially given the relative 
expense and complexity of PET-CT compared to ultrasound.  However, we have 
demonstrated the feasibility of this technique that uses a well-established, widely 
available and relatively cheap radiotracer.  Moreover, with the more widespread use 
and availability of PET-CT scanners, barriers to implementation are declining. There 
are also some inherent limitations of 18F-NaF image analysis that merit comment. 
Being a bone tracer, 18F-NaF is readily taken up by the vertebrae, which lie in close 
proximity to the abdominal aorta.  In our study, it was necessary to exclude some 
areas of the posterior aorta due to overspill of signal.  However, this is not unique to 
18F-NaF with similar issues seen with 18F-FDG uptake in regions of interest adjacent 
to bowel, muscle or other metabolically active tissues. Finally, further validation of 
the tissue binding characteristics and time course of change in 18F-NaF uptake in 
aneurysmal and non-aneurysmal aortae are needed and this would be interesting to 
explore in future studies. 
 
In conclusion, this novel proof-of-concept PET-CT study of patients with 
asymptomatic AAA demonstrates that 18F-NaF uptake identifies advanced 
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aneurysmal disease, and is associated with aneurysm growth and clinical AAA events 
independent of established clinical risk factors including aneurysm diameter. This 
technique holds major promise for the future management of patients with AAA 
disease.   
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Clinical Competency: 18F-Sodium fluoride uptake is specific to abdominal aortic 
aneurysm tissue, is proportional to the rate of aneurysm expansion, and predicts the 
risk of repair or rupture independent of aneurysm diameter. 
 
Translational Outlook: This is the first study to demonstrate that an imaging 
biomarker of disease activity can add to the risk prediction of abdominal aortic 
aneurysms, and to suggest that this approach might refine clinical decisions regarding 
the need for surgery and improve patient outcomes. This needs to be established in 





1. Howard DPJ, Banerjee A, Fairhead JF, et al. Age-specific incidence, risk 
factors and outcome of acute abdominal aortic aneurysms in a defined 
population. Br J Surg. 2015;102:907-915.  
2. Office for National Statistics. Leading causes of death 2013. Office for 
National Statistics. http://visual.ons.gov.uk/wp-
content/uploads/2015/02/Leading-Causes-of-Deaths-20131.csv. Published 
2013. Accessed February 16, 2017. 
3. Brady AR, Thompson SG, Fowkes FGR, Greenhalgh RM, Powell JT, UK 
Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk 
factors and time intervals for surveillance. Circulation. 2004;110:16-21.  
4. RESCAN Collaborators, Bown MJ, Sweeting MJ, Brown LC, Powell 
JT, Thompson SG. Surveillance intervals for small abdominal aortic 
aneurysms: a meta-analysis. JAMA. 2013;309:806-13.  
5. Kurvers H, Veith F, Lipsitz E, et al. Discontinuous, staccato growth of 
abdominal aortic aneurysms. J Am Coll Surg. 2004;199:709-715.  
6. Darling RC, Messina CR, Brewster DC, Ottinger LW. Autopsy study of 
unoperated abdominal aortic-aneurysms - case for early resection. Circulation. 
1977;56:161-164. 
7. Forsythe RO, Newby DE, Robson JMJ. Monitoring the biological activity of 
abdominal aortic aneurysms: beyond ultrasound. Heart. 2016;102:817-824. 
8. Golledge ALV, Walker P, Norman PE, Golledge J. A systematic review of 
studies examining inflammation associated cytokines in human abdominal 
aortic aneurysm samples. Dis Markers. 2009;26:181-188.  
9. Thompson MM, Jones L, Nasim A, Sayers RD, Bell P. Angiogenesis in 
abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1996;11:464-469. 
10. Irkle A, Vesey AT, Lewis DY, et al. Identifying active vascular micro-
calcification by 18F-sodium fluoride positron emission tomography. Nat 
Commun. 2015;6:1-11.  
11. Vesey AT, Jenkins W, Irkle A, et al. 18F-Fluoride and 18F-
Fluorodeoxyglucose positron emission tomography after transient ischemic 
attack or minor ischemic stroke.  case-control study. Circ Cardiovasc Imaging. 
2017;10:e004976. 
12. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission 
tomography for identification of ruptured and high-risk coronary 
atherosclerotic plaques: a prospective clinical trial. Lancet. 2014;383:705-713.  
13. McBride OMB, Berry C, Burns P, et al.  MRI using ultrasmall 
superparamagnetic particles of iron oxide in patients under surveillance for 
	 23	
abdominal aortic aneurysms to predict rupture or surgical repair: MRI for 
abdominal aortic aneurysms to predict rupture or surgery - the MA3RS Study. 
Open Heart 2015:2:e000190.  
14. Wilson KA, Hoskins PR, Lee AJ, Fowkes FG, Ruckley CV, Bradbury AW. 
Ultrasonic measurement of abdominal aortic aneurysm wall compliance: a 
reproducibility study. J Vasc Surg. 2000;31:507-513. 
15. Vallabhaneni SR, Gilling-Smith GL, How TV, Carter SD, Brennan JA, Harris 
PL. Heterogeneity of tensile strength and matrix metalloproteinase activity in 
the wall of abdominal aortic aneurysms. J Endovasc Ther. 2004;11:494-502. 
16. Pawade TA, Cartlidge TRG, Jenkins WSA, et al. Optimization and 
Reproducibility of aortic valve 18F-fluoride positron emission tomography in 
patients with aortic stenosis. Circ Cardiovasc Imaging. 2016;9:e005131. 
17. Chen W, Dilsizian V. PET assessment of vascular inflammation and 
atherosclerotic plaques: SUV or TBR? J Nucl Med. 2015;56:503-504.  
18. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on 
atherosclerotic disease using novel non-invasive multimodality imaging (dal-
PLAQUE): a randomised clinical trial. Lancet. 2011;378:1547-1559. 
19. Fayad ZA, Mani V, Woodward M, et al. Rationale and design of dal-PLAQUE: 
A study assessing efficacy and safety of dalcetrapib on progression or 
regression of atherosclerosis using magnetic resonance imaging and 18F-
fluorodeoxyglucose positron emission tomography/computed tomography. Am 
Heart J. 2011;162:214–221. 
20. Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in 
a rapid reduction in atherosclerotic inflammation results of a multicenter 
fluorodeoxyglucose-positron emission tomography/computed tomography 
feasibility study. J Am Coll Cardiol. 2013;62:909-917.  
21. Jalalzadeh H, Indrakusuma R, Planken RN, Legemate DA, Koelemay MJW, 
Balm R. Inflammation as a predictor of abdominal aortic aneurysm growth and 
rupture: a systematic review of imaging biomarkers. Eur J Vasc Endovasc 
Surg. 2016;52:333-342.  
22. Marchesseau S, Seneviratna A, Sjöholm AT, Qin DL, Ho JXM, Hausenloy 
DJ, Townsend DW, Richards AM, Totman JJ, Chan MYY. Hybrid PET/CT 
and PET/MRI imaging of vulnerable coronary plaque and myocardial scar 
tissue in acute myocardial infarction. J Nucl Cardiol. 2017; in press. doi: 
10.1007/s12350-017-0918-8. [Epub ahead of print] 
23. Courtois A, Nusgens BV, Hustinx R, et al. 18F-FDG uptake assessed by pet/ct 
in abdominal aortic aneurysms is associated with cellular and molecular 
alterations prefacing wall deterioration and rupture. J Nucl Med. 2013;54:1740-
1747.  
24. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein H-H, Krause B-J. Increased 
18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron 
	 24	
emission/computed tomography is associated with inflammation, aortic wall 
instability, and acute symptoms. J Vasc Surg. 2008;48:417-423. 
doi:10.1016/j.jvs.2008.03.059. 
25. Nchimi A, Cheramy-Bien J-P, Gasser TC, et al. Multifactorial relationship 
between 18F-fluoro-deoxy-glucose positron emission tomography signaling 
and biomechanical properties in unruptured aortic aneurysms. Circ Cardiovasc 
Imaging. 2014;7:82-91.  
26. Barwick TD, Lyons OTA, Mikhael NG, Waltham M, O'Doherty MJ. 18F-FDG 
PET-CT uptake is a feature of both normal diameter and aneurysmal aortic 
wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging. 
2014;41:2310-2318.  
27. Kotze CW, Groves AM, Menezes LJ, et al. What is the relationship between 
18F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J 
Nucl Med Mol Imaging. 2011;38:1493-1499. 
28. The MA3RS Study Investigators. Aortic wall inflammation predicts abdominal 









18F-Sodium Fluoride Uptake in Abdominal Aortic Aneurysms 
18F-Sodium fluoride uptake is specific to abdominal aortic aneurysm tissue, is 
proportional to the rate of aneurysm expansion, and predicts the risk of repair or 
rupture independent of aneurysm diameter. 
 
Figure 1 
Positron emission tomography and computed tomography images of abdominal 
aortic aneurysms. 
(A) Structural image of computed tomography (CT) angiogram, (B) 18F-sodium 
fluoride uptake on positron emission tomography (PET), and (C) fused PET-CT co-





The 20 patients for the case-control study were selected from within the cohort study 





Correlation of histology with micro-positron emission tomography and 
computed tomography of abdominal aortic tissue. 
Ex vivo micro-positron emission tomography and computed tomography (left panels), 
and histology (right panels) of aortic wall excised (A) at post-mortem in a patient 
without an aneurysm, and (B) during open abdominal aortic aneurysm repair. Regions 
of interest (dashed circle) of 18F-sodium fluoride (18F-NaF) uptake demonstrate 
atheromatous disease with necrosis (hematoxyin and eosin stain; magnification x100; 
B1) and calcification (black, Von Kossa stain; magnification x200; B2) in the aortic 
aneurysm tissue that is not apparent in control aorta (A1 and A2).  
 
Figure 4 
Prediction of disease progression and clinical outcome by 18F-sodium fluoride 
positron emission tomography 
Association of 18F-sodium fluoride (18F-NaF) uptake with disease progression and 
clinical outcome. (A) Rate of aneurysm expansion (mm/year: logarithm base 2 
transformed) across the tertiles of 18F-sodium fluoride uptake. The highest tertile 
expanded more rapidly than those in the lowest tertile (3·10 versus 1·24 mm/year 
respectively, p=0·008). Cumulative event rate (censored at date of death) across the 
tertiles of 18F-sodium fluoride uptake for (B) abdominal aortic aneurysm repair or 
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Patient Population: Exclusion Criteria 
Participants were excluded if they were unable to give informed written consent, or had 
contraindications to iodine-based contrast media, estimated glomerular filtration rate <30 
mL/min/1·73 m2, a collagen vascular disorder, an intercurrent illness, a life expectancy <1 
year, or were women of child-bearing potential without contraception. 
 
Tissue Collection and Micro-Positron Emission Tomography 
In two patients, aneurysmal aortic tissue was obtained during open abdominal aortic 
aneurysm (AAA) repair and was excised from the anterior wall of the native aorta prior to 
plication around the tube graft. Non-aneurysmal (control) aortic tissue was obtained during 
post-mortem examination of a sudden cardiac death victim, following written consent from 
relatives and the approval of the Research Ethics Committee.   
 
Aneurysmal and non-aneurysmal aortic tissues were incubated using optimized protocol 
conditions, specifically: 20-min incubation with 18F-sodium fluoride (100 kBq/mL, in 0.1 M 
phosphate buffer saline) at room temperature. Following incubation, samples were washed 
twice in assay buffer (1 min per wash) and mounted on a petri dish for micro-positron 
emission tomography (PET) and computed tomography (CT) imaging. This incubation 
protocol was designed to capture pseudo-secular equilibrium of 18F-sodium fluoride binding 
to calcium particles and aggregates in tissue, mimicking in vivo conditions, while minimizing 
tissue degradation during incubation process with the aim to retain tissue properties for 
subsequent histology. Incubation conditions were optimized using calcium phosphate 
particles (CPPs, 200-300 nm) and varying concentrations of 18F-sodium fluoride, as well as, 
incubation time with and without competing non-homologous inhibitor (alendronate 25 µM). 
In brief, results from those optimization experiments demonstrated that 18F-sodium fluoride 
total and specific binding to CPPs was rapid and reached pseudo-secular equilibrium at 20 
min following incubation. The affinity, KD, of 18F-sodium fluoride to CPPs was 1 nM. For 
molar activity of 18F-sodium fluoride of 100 GBq/µmol, incubations total volume of 200 mL 
and activity of 20 MBq equals 100 kBq/mL of 18F-sodium fluoride (i.e. 1 nM).           
    
Following incubation of the aortic specimen with 18F-sodium fluoride, a 30-min emission 
scan was obtained using a micro-PET-CT scanner (nanoPET/CT; Mediso, Hungary) in a 1:5 
co-incidence mode.  A CT scan was acquired (semi-circular full trajectory, maximum field of 
view, 720 projections, 55 kVp, 300 ms and 1:4 binning) for attenuation correction.  PET data 
were reconstructed using Mediso’s iterative Tera-Tomo 3D reconstruction algorithm using 4 
iterations, 6 subsets, full detector model, normal regularisation, spike filter on, voxel size 0.4 
mm and 400-600 keV energy window. 
 
Histopathological analysis 
Regions of interest (ROI) were identified on the reconstructed micro-PET-CT images of the 
AAA and control aortic specimens. Specimens of tissue corresponding to the site of each ROI 
were stained with hemotoxylin and eosin to determine cellular structure, and Von Kossa to 
identify focal calcification. 
 
 
18F-NaF PET-CT Image Analysis 
 Static PET-CT images were reconstructed with correction applied for attenuation, dead time, 
scatter and random coincidences, using an optimized iterative reconstruction algorithm (ultra-
HD; TrueX + TOF, matrix 200, zoom 1; Gaussian filter).  Scans were visually assessed for 
registration, patient movement, scan quality and tracer uptake, with minor adjustments in co-
registration made manually as required, using fixed boney landmarks.  PET analysis was 
performed using an OsiriX workstation (OsiriX, version 8·0·1 64 bit; OsiriX Imaging 
Software, Geneva, Switzerland). Care was taken to exclude tracer uptake that originated from 
nearby bone structures or from the urinary tract. 
 
CT Calcium Scoring 
CT Calcium scoring was performed by an experienced observer on a dedicated workstation 
(Vitrea Advanced, Vital Imaging, Toshiba Systems, Minnesota, USA).  Taking care to 
exclude calcium originating from the vertebrae, the aortic calcium burden was extracted 
using axial slices of the ECG-gated calcium scoring CT and recorded as the Agatston score. 
The cumulative Agatston score was used to determine the macroscopic calcium burden for 
each region of the aorta: descending thoracic aorta, non-aneurysmal abdominal aorta and the 
aneurysm (or infra-renal abdominal aorta in control subjects) using a threshold of 130 
Hounsfield Units.  
 
Clinical Endpoint Adjudication 
There are no consensus guidelines to direct investigators when adjudicating endpoints 
relating to death in patients with known abdominal aortic aneurysms who have no definitive 
proof of causality (such as post-mortem examination).  Most of the recently proposed 
classification systems relating to abdominal aortic aneurysms events require radiological or 
operative evidence to classify abdominal aortic aneurysms events.  In the event that no such 
confirmation was available, the end points were assessed and determined by each member of 
the end-point committee and any disagreement settled by consensus, with oversight from the 
Chairperson. ‘Cold pursuit’ of relevant data included obtaining information from primary 
care or hospital records as to likely cause of death, cause of death listed on death certificate 
obtained from public registry, and data from the Information and Statistics Division of NHS 
Scotland. The following guidelines and classification system were used as part of the 
assessment for adjudication of cause of death: 
 
Abdominal Aortic Aneurysms-related Events 
 
1) Abdominal aortic aneurysm-related death, confirmed 
• Death occurs in hospital following confirmed abdominal aortic 
aneurysm rupture on computed tomography, or intra-operative findings 
• Death occurs following treatment for abdominal aortic aneurysm 
during same admission (elective or emergency) 
• Death arising from complications relating to abdominal aortic 
aneurysm treatment 
• Death occurs out of hospital, confirmed abdominal aortic aneurysm 
rupture on post-mortem 
• Death occurs out of hospital, confirmed abdominal aortic aneurysm 
treatment related complication on post-mortem 
 
2) Abdominal aortic aneurysm-related death, probable 
• Death occurs in circumstances with high probability of abdominal 
aortic aneurysm rupture (e.g. patient admitted to hospital following 
collapse, known abdominal aortic aneurysm, hypotension, no other 
obvious cause of symptoms, death shortly after presentation) 
• Death occurs in circumstances with high probability of complications 
relating to abdominal aortic aneurysm treatment (e.g. known endoleak, 
suspected rupture post-endovascular aortic repair) 
• Death occurs out of hospital, no post-mortem performed but highly 
likely as no other obvious cause of death (e.g. witnessed collapse at home, 
known abdominal aortic aneurysm, sudden death, no other obvious cause) 
• Sudden unexplained death in a patient with known abdominal aortic 
aneurysm ≥7 cm, with no other cause of death identified 
 
3) Abdominal aortic aneurysm-related death, possible 
• Death occurs in hospital, no post-mortem performed and cannot be 
judged as highly likely to be abdominal aortic aneurysm-related, but no other 
circumstances to suggest other definitive cause 
• Death occurs out of hospital, no post-mortem performed and cannot be 
judged as highly likely to be abdominal aortic aneurysm-related, but no other 
circumstances to suggest other definitive cause 
 
Non-abdominal Aortic Aneurysm related events 
 
Cardiovascular death (non-abdominal aortic aneurysm): 
Death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart 
failure, death due to stroke, death due to cardiovascular procedures, death due to other 
cardiovascular causes (excluding abdominal aortic aneurysm-related deaths). 
 
Non-cardiovascular death: 






Expansion Rate and Clinical Outcomes According to Tertiles of 18F-Sodium Fluoride Uptake 
 



























       
 
AAA events 
     
 Composite events 22 (30·6) 4 (16·7) 7 (29·2) 11 (45·8) 0·043 
 Repair 19 (26·4) 3 (12·5) 5 (20·8) 11 (45·8) 0·014 
 Rupture 
 
3 (4·2) 1 (4·2) 2 (8·3) 0 (0·0)  
 
Deaths 
      
 All-cause 8 (11·1) 4 (16.7) 4 (16.7) 0 (0·0) 0·343 
 AAA-related 
 
3 (4·2) 1 (4·2) 2 (8·3) 0 (0·0) - 
Values are presented as n (%), median [interquartile range] 
AAA: abdominal aortic aneurysm 








Characteristics of Study Participants 
 
 Cohort study 
 



















Characteristics        
 Age (years) 72·5±6·9 73·3±7·2 72·8±7·5 71·4±6·1 0·640 66·2±2·6 65·2±2·8 
 Male 61 (84·7) 20 (83·3) 21 (85·7) 20 (83· 3) 1·000 19 (95·0) 19 (95·0) 
 Systolic blood pressure (mmHg) 136·7±18·3 142·1±18·2 132·5±16·2 135·6±19·9 0·178 138·1±22·5 141·6±14·2 
 Diastolic blood pressure (mmHg) 81·6±11·6 84·8±12·0 76·4±9·4 83·5±11·9 0·024 84·2±16·6 80·5±8·2 
 Heart rate (/min) 71±9 72±10 70±8 70±8 0·694 70·2±9·7 66·7±13·5 
 Body-mass index (kg/m2) 27·6±3·5 27·6±3·4 26·2±3·3 29·0±3·3 0·019 28·4±3·1 29·3±6·4 
 Current smoker 20 (27·8) 6 (25·0) 9 (37·5) 5 (20·8) 0·407 5 (25·0) 5 (25·0) 
Medical history        
 Hypertension 47 (65·3) 14 (58·3) 16 (66·7) 17 (70·8) 0·651 12 (60·0) 6 (30·0) 
 Hypercholesterolemia 59 (81·9) 21 (87·5) 21 (87·5) 17 (70·8) 0·264 15 (75·0) 7 (35·0) 
 Diabetes 10 (13·9) 3 (12·5) 4 (16·7) 3 (12·5) 1·000 1 (5·0) 2 (10·0) 
 Ischemic heart disease 22 (30·6) 7 (29·2) 7 (29·2) 8 (33·3) 0·937 5 (25·0) 1 (5·0) 
 Peripheral arterial disease 11 (15·3) 2 (8·3) 8 (33·3) 1 (4·2) 0·021 2 (10·0) 1 (5·0) 
 Cerebrovascular disease 10 (13·9) 1 (4·2) 4 (16·7) 5 (20·8) 0·316 1 (5·0) 0 (0·0) 
 Positive family history of AAA 9 (12·5) 2 (8·3) 4 (16·7) 3 (12·5) 0·903 3 (15·0) 2 (10·0) 
Medications        
 Anti-platelet 51 (70·8) 19 (79·2) 18 (75·0) 14 (58·3) 0·350 11 (55·0) 3 (15·0) 
 Statin 58 (80·6) 21 (87·5) 21 (87·5) 16 (66·7) 0·141 13 (65·0) 8 (40·0) 
 Anti-coagulant 2 (2·8) 1 (4·2) 0 (0·0) 1 (4·2) 1·000 0 (0·0) 1 (5·0) 
 Beta-blocker 19 (26·4) 8 (33·3) 5 (20·8) 6 (25·0) 0·711 6 (30·0) 2 (10·0) 
 ACE inhibitor 25 (34·7) 8 (33·3) 8 (33·3) 9 (37·5) 1·000 5 (25·0) 2 (10·0) 
Aorta        
 Aortic diameter (mm) 48·8±7·7 47·5±9·2 48·7±7·8 50·1±5·8 0·510 45·7±4·0 17·6±2·3 
 Concurrent iliac aneurysm 13 (18·1) 4 (16·7) 5 (20·8) 4 (16·7) 1·000 3 (15·0) 0·0 (0·0) 
Values are presented as n (%) or mean ± standard deviation. 
AAA: abdominal aortic aneurysm 
18F-NaF: 18F-Sodium fluoride 
MDS: most-diseased segment  
*P-value for trend across the tertiles 
 
Supplementary Table 1 
18F-Sodium Fluoride Uptake and Agatston Score in Patients with Abdominal Aortic Aneurysm and Control Subjects 
 
Region Uptake Measure 
[log2] 
Population  





(95% CI for difference) 
P-value 
Right atrium 
 SUVmean -0·570±0·571 -0·588±0·531 0·018 (-0·340 to 0·376) 0·919 
Descending thoracic aorta 
 SUVmax 0·281±0·316 0·268±0·473 0·013 (-0·250 to 0·275) 0·920 
TBRmax 0·851±0·415 0·856±0·418 -0·005 (-0·275 to 0·265) 0·970 
cSUVmax -1·089±0·684 -1·115±1·025 0·027 (-0·542 to 0·595) 0·925 
 MDS SUVmax 0·618±0·334 0·717±0·438 -0·099 (-0·348 to 0·150) 0·426 
 MDS TBRmax 1·156±0·450 1·306±0·443 -0·148 (-0·450 to 0·154) 0·328 
Abdominal aorta (non-aneurysmal) 
 SUVmax 0·762±0·316 0·726±0·366 0·037 (-0·186 to 0·259) 0·741 
 TBRmax 1·333±0·532 1·314±0·489 0·018 (-0·313 to 0·350) 0·911 
 cSUVmax -0·104±0·652 -0·1058±0·556 0·002 (-0·392 to 0·397) 0·991 
 MDS SUVmax 1·158±0·363 0·995±0·369 0·163 (-0·724, to 0·399) 0·170 
 MDS TBRmax 1·697±0·537 1·583±0·510 0·114 (-0·221 to 0·449) 0·494 
Abdominal aorta (AAA) 
 SUVmax 1·142±0·283 0·726±0·366 0·416 (0·203 to 0·629) <0·0001 
 TBRmax 1·712±0·560 1·314±0·489 0·398 (0·057 to 0·739) 0·023 
 cSUVmax 0·543±0·432 -0·1058±0·556 0·649 (0·324 to 0·973) <0·0001 
 MDS SUVmax 1·427±0·356 0·995±0·369 0·432 (0·197 to 0·668) 0·001 
 MDS TBRmax 1·997±0·568 1·583±0·510 0·414 (0·064 to 0·764) 0·022 
 Agatston score 11·444±1·760 7·338±3·811 4·105 (2·013 to 6·198) 0·001 
 
Values are logarithm base 2 transformed and presented as mean±standard deviation 
AAA, abdominal aortic aneurysm; 18F-NaF, 18F-sodium fluoride; MDS, most-diseased segment; CI, confidence interval  
 
Supplementary Table 2 
Multivariable Analysis of 18F-Sodium Fluoride Uptake and Clinical Outcomes 
 
 Increase in Expansion 
(mm/year; 95% CI) 
P-value Hazard Ratio (95% CI) for 
Composite AAA Events 
P-value 
Model 1 0·365 (0·34 to 1·90) 0·006 2·16 (1·03 to 4·51) 0·041 
Model 2 0·375 (0·39 to 1·91) 0·004 2·26 (1·97 to 4·76) 0·033 
Model 3 0·259 (0·029 to 1·56) 0·042 2·49 (1·07 to 5·78) 0·034 
Model 4 0.357 (0.315-1.880) 0.007 2.096 (1.004-4.375) 0.049 
Model 5 0.346 (0.295-1.834) 0.008 2.103 (1.002-4.412) 0.049 
Model 6 0.267 (0.052-1.589) 0.037 2.162 (0.970-4.819) 0.059 
Model 7 0.266 (0.026-1.597) 0.041 2.194 (0.955-5.028) 0.064 
 
Expansion rate was logarithm base 2 transformed 
 
Model 1: unadjusted 
Model 2: adjusted for age, sex 
Model 3: adjusted for age, sex, baseline diameter, body-mass index, systolic blood pressure, smoking 
Model 4: adjusted for diastolic blood pressure 
Model 5: adjusted for diastolic blood pressure, eGFR 
Model 6: adjusted for age, sex, body-mass index, diastolic blood pressure, smoking, diameter, eGFR 
Model 7: adjusted for age, sex, body-mass index, diastolic blood pressure, smoking, diameter, eGFR, peripheral arterial disease 
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SUMMARY 
 
Abdominal aortic aneurysms have a prevalence of 5% in 65-74 year-old men and when 
ruptured, are associated with a mortality of up to 90%. Ruptured aortic aneurysms are a 
common cause of death in the United Kingdom, being the thirteenth commonest cause of 
death and accounting for 6,800 deaths each year in England and Wales.1 Open surgical 
or endovascular intervention to prevent rupture is considered when the aortic aneurysm 
diameter exceeds 55 mm or expansion rates are greater than 10 mm/year. 
 
Population screening halves the mortality associated with abdominal aortic aneurysms1 
and has led to the establishment of a national screening and surveillance programme. 
Currently, abdominal aortic aneurysm surveillance is complex because of the non-linearity 
and unpredictability of expansion rates, although the best predictor of aneurysm 
expansion is the baseline aneurysm diameter. However, up to one fifth of ruptured 
abdominal aortic aneurysm are less than 55 mm in diameter2 and many patients present 
with diameters considerably greater than 55 mm without prior symptoms or rupture. Taken 
together, these data highlight the need for a more accurate method of rupture prediction 
that would better inform decisions to undertake preventative and potentially life-saving 
surgery. 
 
We have developed a novel magnetic resonance imaging method that is based upon the 
known biological processes underlying aneurysm expansion and rupture. For the first 
time, the MA3RS study proposes to assess this novel approach to identify aneurysms that 
are likely to expand more rapidly and potentially rupture. This technique would provide 
potentially important additional information to the current simplistic gold-standard of 
ultrasound measurement of aneurysm diameter. 
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Aortic aneurysms frequently occur in patients with atherosclerosis and the two disease 
processes share several common risk factors. However, there are distinct differences. 
Atherosclerotic lesions are pre-dominantly located in the intima, whereas the media and 
adventitia are primarily involved in aneurysms. Aneurysm disease is also much more 
closely associated with smoking and hypertension, and has a particular predilection for 
the abdominal aorta. 
 
The formation, growth and rupture of aneurysms are now recognised to be the result of a 
complex interplay between biological and mechanical factors. Aneurysm tissue is 
characterised by excessive medial neovascularisation, infiltration of inflammatory cells 
(principally macrophages) and irreversible remodeling of the extracellular matrix. These 
pathological processes do not affect the aorta uniformly but are focal in nature.  Shear 
wall stress varies spatially within the aneurysm3 and tensile strength varies in different 
parts of the aneurysm sac.4 Focal neovascularisation occurs at the site of rupture and its 
presence corresponds to the degree of inflammation. These biological ‘hotspots’ 
represent sites of potential rupture and are putative targets for novel imaging strategies 
aiming to predict aneurysm expansion and assess the risk of rupture. In addition, tissue 
and wall stresses vary spatially within the aneurysm and tensile strength varies in different 
parts of the aneurysm sac. Synergy between these biological 'hotspots' and areas of 
intense biomechanical stress may be the focal point precipitating aneurysm rupture. 
Indeed, there is strong evidence that aneurysm rupture is seen in those patients with more 
rapid aneurysm expansion rates.5, 6  
 
1.1.1 Magnetic Resonance Imaging 
 
Magnetic resonance imaging is emerging as a useful investigative tool for cardiovascular 
disease that can distinguish the different atherosclerotic plaque components, such as the 
lipid-rich core and areas of calcification.7 Standard gadolinium-based magnetic resonance 
imaging identifies areas of thrombus formation and fibrosis in abdominal aortic 
aneurysms.8 Newer contrast agents containing superparamagnetic particles of iron oxide 
(SPIO) have been developed that provide additional biological and functional information 
through the detection of cellular inflammation within tissues. Ultrasmall SPIO (USPIO), 
with particle sizes in the range 10-30 nm, escape immediate recognition by the reticulo-
endothelial system and persist for longer in the bloodstream allowing them to be used to 
assess the accumulation of macrophages within vascular and lymphatic tissues.9, 10, 11, 12, 
13 Current preparations are biodegradable and safe for clinical administration.14, 15, 16  
 
USPIO accumulate in the aortae of hypercholesterolaemic rabbits17 and in murine models 
of abdominal aortic aneurysms.18 In humans, USPIO accumulate in ruptured or rupture- 
prone carotid plaques rather than stable plaques,11, 12 and treatment with atorvastatin 
reduces both inflammation and USPIO uptake in carotid plaques.13  
 
We have recently conducted a series of magnetic resonance imaging studies in patients 
with abdominal aortic aneurysms and shown that uptake of USPIO in the aortic wall 
correlates with macrophage activity and identifies cellular inflammation.19, 20 Using a 3T 
magnetic resonance scanner, patients with asymptomatic abdominal aortic aneurysms 
(n=29; aneurysm diameter 4.0- 6.6 cm) attending our surveillance programme were 
imaged before and 24-36 hours after intravenous administration of USPIO. Histological 
examination of aneurysm tissue confirmed co-localization and uptake of USPIO in areas 
of macrophage infiltration (Figure 1).19  
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Figure 1.  Representative histological sections of the aortic wall. A, Haematoxoylin and eosin (x20) 
of the full thickness of the aortic wall including atherosclerotic plaque, adherent thrombus and 
periadventitial fatty tissue.  B, Elastin-van Gieson stain (x100) of the aortic wall showing complete 
destruction of the normal wall structure, including fibrosis (collagen, pink) of the media and 
adventitia and virtual absence of intact medial elastic fibers (black).  C, Prussian blue staining for 
iron demonstrating co-localisation of CD68-positive macrophages (x400; brown) with D, Ultrasmall 
super-paramagnetic particles of iron oxide particles (x400; blue), E, High power (x1000) Prussian 
blue staining shows intracytoplasmic accumulation of USPIO within macrophages. 
 
Furthermore, aortic aneurysms with mural USPIO uptake had a three-fold higher 
expansion rate when compared to abdominal aortic aneurysms with no or non-specific 
USPIO uptake despite similar baseline anteroposterior diameters (Figure 2).19 Indeed, 
one patient with substantial mural USPIO uptake died suddenly 2 months after scanning 
from presumed aneurysm rupture. We have therefore shown that this technique holds 
major promise as a new method of risk-stratification of patients with abdominal aortic 
aneurysm that extends beyond simple anatomical measurements of aneurysm diameter. 
 
 
Figure 2. USPIO uptake in the aortic wall (group 3; 45% of total population) predicted a 3-fold 




SPIO (USPIO), with particle sizes in the range 10-30 nm, escape immediate recognition by the reticulo-
endothelial system and persist for longer in the bloodstream allowing them to be used to assess the 
accumulation of macrophages within vascular and lymphatic tissues [Harisinghani et al, 2003; Heesakkers 
et al, 2008; Kooi et al, 2003; Trivedi et al, 2006; Tang et al, 2009]. Current preparations are biodegradable 
and safe for clinical administration [Bernd et al, 2009; Borrinet et al, 2006; Muller et al, 2007]. 
USPIO accumulate in the aortae of hypercholesterolaemic rabbits [Ruehm et al, 2001] and in murine models 
of abdominal aortic aneurysms [Turner et al, 2009]. In humans, USPIO accumulate in ruptured or rupture-
prone carotid plaques rather than stable plaques [Kooi et al, 2003; Trivedi et al, 2006], and treatment with 
atorvastatin reduces both inflammation and USPIO uptake in carotid plaques [Tang et al, 2009].  
 
We have recently conducted a series of magnetic resonance imaging studies in patients with abdominal 
aortic aneurysms and shown that uptake of USPIO in the aortic wall correlates with macrophage activity and 
identifies cellular inflammation [Richards et al, 2011a; Richards et al, 2011b]. Using a 3T magnetic 
resonance scanner, patients with asymptomatic abdominal aortic aneurysms (n=29; aneurysm diameter 4.0-
6.6 cm) attending our surveillance programme were imaged before and 24-36 hours after intravenous 
administration of USPIO. Histological examination of aneurysm tissue confirmed co-localization and uptake 
of USPIO in areas of macrophage infiltration (Figure 1) [Richards et al, 2011a].  
 
F rthermore, ortic aneurysms wit  mural USPIO uptake had a three-fold higher expansion rate when 
compared to abdominal aortic aneurysms with no or non-specific USPIO uptake despite similar baseline 
anter posterior diameters (Figure 2) [Richards et al, 
2011a]. Indeed, one patient with substantial mural 
USPIO uptake died suddenly 2 months after scanning 
from presumed aneurysm rupture. We have therefore 
shown that t is technique holds major promise as a 
new method of risk-stratification of patients with 
abdominal aortic aneurysm that extends beyond mere 
natomical measurements of aneurysm diameter.  
 
Figure 2. USPIO uptake in the aortic wall (group 3; 45% of total 
population) predicted a 3-fold increase in aneurysm expansion rate 
despite similar aortic diameters. 
 
To date, the assessment of USPIO uptake has been qualitative or based on relative changes in signal 
intensity within regions of interest defined by vessel quadrants [Trivedi et al, 2006; Tang et al, 2009]. 
However, this change in signal intensity can be caused by other factors including imaging artifacts.  During 
the process of our studies, we have developed a more robust semi-quantitative image acquisition 
methodology for the detection of iron nanoparticle accumulation in humans using 3T magnetic resonance 
imaging [Richards et al, 2011a; Richards et al, 2011b]. Here we apply a multi-echo gradient sequence to 
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To date, the assessment f USPIO uptake has been qualitative or based on relative changes in signal 
intensity within regions of interest defined by vessel quadrants [Trivedi et al, 2006; Tang et al, 2009]. 
However, this change in signal intensity can be caused by other factors including imaging artifacts.  During 
the process of our studies, we have developed a more robust semi-quantitative image acquisition 
methodology for the detection of iron nanoparticle accumulation in humans using 3T magnetic resonance 
imaging [Richards et al, 2011a; Richards et al, 2011b]. Here we apply a multi-echo gradient sequence to 
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To date, the assessment of USPIO uptake has been qualitative or based on relative 
changes in signal intensity within regions of interest defined by vessel quadrants.12, 13 
However, this change in signal intensity can be caused by other factors including imaging 
artifacts. During the process of our studies, we have developed a more robust semi-
quantitative image acquisition methodology for the detection of iron nanoparticle 
accumulation in humans using 3T magnetic resonance imaging.19, 20 Here we apply a 
multi-echo gradient sequence to define the T2* value of the tissue. Images before and 
after USPIO administration are then co-registered and the difference in T2* value 
quantified. Following repeatability measurements in patients with abdominal aortic 
aneurysms, we have identified a threshold of change in signal  
intensity (59%) that defines USPIO accumulation in tissues (Figure 3).20  
 
 
Figure 3. A. Signal intensity as percentage of first echo time (4.9 ms) within the multi-echo 
sequence of pre-contrast and post- contrast images in areas of no (black circles), low (green 
triangles) and high (red squares) USPIO uptake. B. Frequency of voxels with per cent change in 
T2* for patients who did (red) or did not (blue) receive USPIO. The upper 95% threshold of per 
cent change in T2* in the absence of USPIO was 59%. 
 
1.1.2  Biomechanical Stress 
 
Another potential predictive marker of aneurysm rupture is wall tissue stress. Information 
on aneurysm geometry is provided by computed tomography and magnetic resonance 
imaging, and this can be combined with finite element analysis to enable prediction of 
tissue stresses within the aneurysm wall.3, 21 Peak wall tissue stress is higher in patients 
with symptomatic aneurysms22 and co-localises with regions of inflammation identified by 
18F-fluorodeoxyglucose positron emission tomography.23  This suggests combining 
stress analysis with imaging of inflammation may provide added predictive value in the 
assessment of aneurysm expansion and potential rupture. 
 
1.2 RATIONALE FOR STUDY 
 
Ruptured AAA is the thirteenth commonest cause of death in the United Kingdom and 
accounts for 6,800 deaths each year in England and Wales. Population screening halves 
the mortality associated with AAA, and has led to the establishment of national screening 
and surveillance programmes. However, AAA surveillance is complex because of the non-
linearity and unpredictability of expansion rates. Although the best predictor of aneurysm 
expansion is the aneurysm diameter, up to one fifth of ruptured AAA are less than 55 mm 
in diameter, and many patients present with diameters considerably greater than 55 mm 
without prior symptoms or rupture. There is therefore a major unmet clinical need to 
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2.1.2 Biomechanical Stress 
 
Another potential predictive marker of aneurysm rupture is wall tissue stress. Information on aneurysm 
geometry is provided by computed tomography and magnetic resonance imaging, and this can be combined 
with finite element analysis to enable prediction of tissue stresses within the aneurysm wall [Raghavan et al, 
2000; Doyle et al, 2009]. Peak wall tissue stress is higher in patients with symptomatic aneurysms [Fillinger 
et al, 2002] and co-localises with regions of inflammation identified by 18F-fluorodeoxyglucose positron 
emission tomography [Xu et al, 2010]. This suggests combining stress analysis with imaging of inflammation 
may provide added predictive value in the assessment of aneurysm expansion and potential rupture.  
 




The risks to the participants of the trial are very modest and ar  mainly attributable to the magnetic 
resonance and computed tomography scans and their respective contrast agents.  
 
2.2.1.1 Magnetic Resonance Imaging 
 
Magnetic resonance imaging is a standard clinical imaging technique that is applied across the world. 
Contraindications for magnetic resonance imaging are the presence of certain metallic objects, electrical 
devices and claustrophobia. Patients with implanted electrical devices, such as pacemakers or defibrillators, 
will be excluded. We have the provision of a wide-bore scanner (diameter, 70 cm) that will minimise the risk 




Ferumoxytol (Feraheme, Advanced Magnetics, Inc., Cambridge, MA) was originally developed for the 
treatment of iron-deficiency anaemia in patients with chronic kidney disease. It consists of a suspension of 
MA3RS Protocol V 8.0 18th March 2015  
Page 11 of 37 Confidential 
predict aneurysm growth and rupture more accurately so that surgeons can better target 
preventative potentially life-saving surgery. We have developed a novel magnetic 
resonance imaging method that is based upon the known biological processes underlying 
aneurysm expansion and rupture. For the first time, this study proposes to assess this 
novel approach to identify aneurysms that are likely to expand more rapidly and potentially 
rupture. This technique would provide potentially important additional information to the 
current simplistic gold-standard of ultrasound measurement of aneurysm diameter. 
2 STUDY OBJECTIVES 
2.1 OBJECTIVES 
2.1.1 Primary Objective 
To determine whether mural uptake of USPIO provides incremental risk prediction in 
addition to standard risk markers such as aneurysm diameter, smoking and blood 
pressure. 
 
2.1.2 Secondary Objectives 
In patients under surveillance for abdominal aortic aneurysms, to determine whether 
mural uptake of USPIO: 
i. Correlates with the rate of aneurysm expansion 
ii. Occurs more commonly in patients who progress to surgery or whose aneurysm 
subsequently ruptures 
iii. Co-localises with, or relates to, areas of biomechanical stress 
iv. Occurs in a reproducible manner 
 
We will investigate other inter-related mechanisms associated with aneurysm growth. We 
will specifically explore the added value of biomechanical stress modeling as we suspect 
co-localisation of both USPIO uptake and areas of high mechanical stress could act 
synergistically and cause more marked aneurysm growth. We will also examine correlates 
with other blood biomarkers including regulators of extracellular matrix turnover (such as 
matrix metalloproteinases and tissue inhibitors of metalloproteinases) and vascular 
inflammation (such as C-reactive protein and interleukin-6). 
 
2.2 ENDPOINTS 
2.2.1 Primary Endpoint 
 
The primary end-point of the study will be the composite of aneurysm rupture or aortic 
aneurysm repair.  
 
2.2.2 Secondary Endpoints 
 
Secondary end-points will include: 
 
i. the rate of aneurysm rupture  
ii. the rate of surgical repair of the aneurysm 
iii. the aneurysm growth rate  
iv. all-cause and aneurysm-related mortality 
 
 
We will conduct exploratory analyses examining the interactions between mural USPIO 
uptake, biomechanical stress, clinical risk factors and serum biomarkers of extracellular 
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matrix turnover and inflammation. 
 
Clinicians involved directly with patient surveillance and care will be blinded to the 
magnetic resonance imaging findings of mural USPIO uptake. 
 
3 STUDY DESIGN 
The study will be a prospective observational cohort study of patients participating in 
abdominal aortic aneurysm surveillance programmes with blinded assessments of USPIO 
uptake. The study aims to recruit 350 participants in three study centres, with participants 
being followed up at six monthly intervals for 2 years.  
 
We aim to validate the findings of our previous proof-of-concept study,19 focusing on the 
relationship between baseline USPIO uptake and the subsequent clinical outcome and 
aneurysmal expansion rates. We will also look at the interplay between various risk factors 
affecting the growth rates and aneurysm-related adverse clinical events such as rupture, 
surgical repair, and death. This will lay the foundation for a large multicentre randomised 
controlled trial targeted at applying this technique to determine clinical management and 
surgical intervention. This will be particularly important given that screening programmes 
for the detection of abdominal aortic aneurysms are being rolled out across the United 
Kingdom and this is likely to increase substantially the number of patients being entered 
into surveillance programmes. 
 
Reproducibility of the technique will be assessed in a subgroup of study participants (from 
the Edinburgh study centre) who will undergo repeat magnetic resonance scanning and 
USPIO administration at 1 month and 1 year (n=20), 1 year(n=60) and 2 year (n=40). 
Short-term (1 month) reproducibility is likely to reflect the variability in USPIO uptake 
whereas long-term (1 and 2 year ) reproducibility is likely to represent the variation in 
biology of the aortic aneurysm with time. Patients recruited in Edinburgh who undergo 
elective surgery will also have AAA wall tissue collected and stored for the assessment of 
tissue resident macrophages and matrix metalloproteinases. Figure 4 shows the study 
flow chart. 
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 Final 2 year assessments  
                                +/- 8 weeks, assessments can be performed on separate days  
 Clinical assessment 
 Ultrasound scan 
 Computed Tomography scan 
 Blood sample collection 
 Pulse wave analysis 
 
 
Patients with abdominal aortic aneurysms (identified in surveillance program and 
other study site clinics) 
350 patients with abdominal aortic aneurysm > 40mm who meet inclusion and 
exclusion criteria AND who agree to take part 





 Clinical Assessment 
 Ultrasound scan (occurs as standard 
care and can occur up to 1 month prior 
to baseline assessment) 
 3T Magnetic resonance scan 
 i.v. ferumoxytol 
 Computed Tomography scan with 
contrast (can be done on day 2) 
 Blood sample collection (can be 
done on day 2) 
 Pulse wave analysis (can be done on 
day 2) 
Day 2 
(24-36 hours after Day 1): 
 
 3T Magnetic resonance scan (post 
ferumoxytol) * 
 
                                                     6 Monthly assessments (6, 12 and 18 months) 
  +/- 8 weeks, assessments can be performed on separate days 
Clinical assessment 
Ultrasound scan 
Blood sample collection (Edinburgh site only) 
Pulse wave analysis (Edinburgh site only) 
317 Patients with 2 year follow up (allowing for drop-outs) 
* 20 patients will undergo MRI reproducibility assessments at 1 month and 1 year,60 will 
have the assessment at 1 year only and 40 will have the assessment at 2 years only. 
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4 STUDY POPULATION 
 
Participants will be identified from the clinical surveillance program and given a patient 
information leaflet about the study. Eligible participants who are interested in the study will 
attend a baseline visit where they will provide written informed consent. All other study 
assessments for this baseline visit and the visits though-out the study are detailed in 
section 7.2 
 
4.1 NUMBER OF PARTICIPANTS 
 
We will recruit 350 patients with abdominal aortic aneurysms from the clinical surveillance 
program.  Patients will be recruited from three centres; Royal Infirmary of Edinburgh, 
Western Infirmary in Glasgow and Forth Valley Royal Hospital.  Patients recruited from 
Edinburgh will undergo limited additional procedures. Full details are in section 7.2.  
 
4.2 INCLUSION CRITERIA 
1.   Abdominal aortic aneurysms measuring ≥40 mm in anteroposterior diameter on 
ultrasound scanning. 
2.   Age ≥40 years. Patients with abdominal aortic aneurysms less than 40 years may 
have a connective tissue disorder and a different aetiology to their disease. 
 
4.3 EXCLUSION CRITERIA 
1. Patients expected to, or already received, imminent elective or emergency surgical 
or endovascular repair. 
2.  Contraindication to magnetic resonance imaging scanning identified from 
magnetic resonance imaging safety questionnaire 
3.  Patients refusing or unable to give informed consent 
4.  Woman with child-bearing potential and who are breastfeeding will not be enrolled 
into the trial (woman who have experienced menarche, are pre-menopausal, have not 
been sterilised or who are currently pregnant). 
5. Intercurrent illness including patients with a systemic inflammatory disorder or 
underlying malignancy (life expectancy < 2 years) 
6.  Renal dysfunction (eGFR ≤30 mL/min/1.73m2)  
7.   Polycythemia 
8.  Contraindication to ferumoxytol (evidence of known iron overload, 
hemochromatosis, known hypersensitivity to ferumoxytol or its components or anaemia 
not caused by iron deficiency)9.  Contraindication to Iodine. 
10.     Patients with any known history of drug allergy (including hypersensitivity) to other 
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5 PARTICIPANT SELECTION AND ENROLMENT 
5.1 IDENTIFYING PARTICIPANTS 
Patients will be identified from the clinical surveillance programmes and databases in 
Edinburgh, Glasgow and Forth Valley. 
 
5.2 CONSENTING PARTICIPANTS 
Written informed consent will be obtained by a suitably qualified member of the research 
team at study entry.  
 
5.3 SCREENING FOR ELIGIBILITY 
Once patients have been identified from the surveillance service database, they will be 
seen at their surveillance ultrasound appointment (standard clinical care) and eligibility 
will be assessed.  Eligibility will be confirmed prior to consent. If patients are not seen in 
the ultrasound appointment, the study will be discussed with the patient over the phone 
and study information sent to them in the post. An appointment will be made for a baseline 
visit (where consent takes place) for all patients who are eligible and are interested in 
taking part. 
 
5.4 INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
Ineligible and non-recruited patients will receive standard medical care. An anonymised 
log will be kept for patients who were screened for the study and subsequently found to 




Co-enrolment is permitted into the 18F-Sodium Fluoride Imaging of Abdominal Aortic 
Aneurysms (SoFIA3) substudy. Study participants at the Edinburgh site may be invited to 
take part in this sub-study, which is detailed in a separate protocol.   
Co-enrolment should not be considered with other interventional studies without prior 
discussion and agreement from the Sponsors and the Chief Investigators of both studies.  
 
5.6  PREMATURE WITHDRAWAL 
Participants are free to withdraw from the study at any point or a participant can be 
withdrawn by the investigator.  If withdrawal occurs, the primary reason for withdrawal will 
be documented in the participant’s Case Report Form (CRF). 
If a patient who has consented for the study states that they wish to be withdrawn from 
the study before they have been administered ferumoxytol, they will be withdrawn from 
the study and another participant will be recruited in their place.   
Clinicians should not withdraw participants who have received ferumoxytol but have not 
undergone the baseline MRI scanning protocol.  These participants should continue to be 
followed up.  
 
5.7 RANDOMISATION 
There is no randomisation in this study. 
 
 
6 INVESTIGATIONAL MEDICINAL PRODUCT AND PLACEBO 
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6.1 STUDY DRUG 
6.1.1 Study Drug Identification 
Rienso® (ferumoxytol) is composed of ultrasmall superparamagnetic particles of iron 
oxide (USPIOs) coated with polyglucose sorbitol carboxymethylether. It is supplied as an 
aqueous colloidal product that is formulated with mannitol and presented in single use 
vials 
 
6.1.2 Study Drug Manufacturer 
AMAG Pharmaceuticals Inc.Lexington, MA 02421, USA 
 
Takeda Italia Farmaceutici S.p.A. Via Crosa, 86, 28065 Cerano (NO), Italy are 
responsible for batch release. 
 
6.1.3 Marketing Authorisation Holder 
Takeda Pharma A/S, Langebjerg 1, DK-4000 Roskilde, Denmark 
 
6.1.4 Labelling and Packaging 
Rienso® is supplied in a labelled vial containing 510 mg of elemental iron in a volume of 
17mL of mannitol.  Each mL of the sterile colloidal solution contains 30 mg of elemental 
iron and 44 mg of mannitol. 
 
6.1.5 Storage 
Consistent with the Summary of Product Characteristics (November 2012), Rienso® will 
be stored in the original package in order to protect from light and will not be frozen. 
 
6.1.6 Summary of Product Characteristics or Investigators Brochure 
A copy of the latest version of the Summary of Product Characteristics (SmPC) is available 
in the Investigator Site File.  
 
6.2 PLACEBO 
No placebo will be used in this study. 
 
6.3 DOSING REGIME 
 
The single use vials are diluted and administered as an intravenous infusion over 15-30 
minutes.  The ferumoxytol dose (4.0 mg/kg) is diluted in sterile 0.9% sodium chloride up 
to a final concentration of 2-8 mg iron per mL. 
Patients should be reclined or in a semi-reclining position during infusion and for 30 
minutes thereafter.  Blood pressure (systolic and diastolic) will be recorded before 
ferumoxytol infusion and 30 minutes after the infusion to monitor for hypotension as 
detailed in the Summary of Product Characteristics.    
 
The single dose is given 24-36 hours before magnetic resonance imaging. 
In a subset of patients (n=20), repeated magnetic resonance imaging scans will be 
performed at 1 month and 1 year.  These patients will receive a further dose (4.0 mg/kg) 
of ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 3 
doses of ferumoxytol in one year).  
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A second subset of patients (n=60), repeated magnetic resonance imaging scans will be 
performed at 1 year only.  These patients will receive a further dose (4.0 mg/kg) of 
ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 2 doses 
of ferumoxytol in one year).  
In a further subset of patients (n=40), repeated magnetic resonance imaging scans will 
be performed at 2 years (±1 month).  These patients will receive a further dose (4.0mg/kg) 
ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 1 doses 
of ferumoxytol in 1 year). 
 
 
6.4 DOSE CHANGES 
All patients will receive the same dose (4.0 mg/kg) 24-36 hours before magnetic 
resonance imaging.   
In a subset of patients  (n=20), magnetic resonance imaging will be repeated at 1 month 
(± 1 week) and 1 year (± 1 month) to determine short and long-term reproducibility 
respectively. These patients will receive a further dose (4.0 mg/kg) of ferumoxytol 24 (±6h) 
-36 hours before each magnetic resonance imaging (total of 3 doses of ferumoxytol in one 
year).  
Another subset of patients (n=60), repeated magnetic resonance imaging scans will be 
performed at 1 year (± 1 month) only.  These patients will receive a further dose (4.0 
mg/kg) of ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total 
of 2 doses of ferumoxytol in one year).  
In a further subset of patients (n=40), repeated magnetic resonance imaging scans will 
be performed at 2 years (±1 month).  These patients will receive a further dose (4.0mg/kg) 
ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 1 doses 
of ferumoxytol in one year). 
All study participants who agree to be part of the reproducibility sub-study will consent for 
the extra scans.  Consecutive patients imaged in the Edinburgh centre will be approached 
until 20 patients have undergone repeated scanning at 1 month and 1 year, 60 patients 
have undergone repeated scanning at 1 year and 40 patients have undergone repeated 
scanning at 2 years. 
 
6.5 PARTICIPANT COMPLIANCE 
Responsibility for the infusion of ferumoxytol will be with the research team. Timing and 
volume of administration will be noted in the CRF. Any reason for non-administration of 
the ferumoxytol will be noted. 
If intolerable side effects are experienced during the infusion of Ferumoxytol, the infusion 
will be abandoned and appropriate medical care will be delivered to the participant. 
 
6.6 OVERDOSE 
Overdose is unlikely as ferumoxytol will be prescribed and administered in the hospital. If 
accidental overdose is suspected, the patient will be followed up for signs of iron excess 
and will be referred for specialist assessment if appropriate. 
 
For 270 patients, a single dose of ferumoxytol will be administered.  In a random subset 
of patients  (n=20) magnetic resonance imaging will be repeated at 1 month (± 1 week) 
and 1 year (± 1 month) to determine short and long-term reproducibility respectively. 
These patients will receive a further dose (4.0 mg/kg) of ferumoxytol 24 (±6h) -36 hours 
before each magnetic resonance imaging (a total of 3 doses of ferumoxytol in one year 
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and a total of 6 MRI scans). In a second subset of patients (n=60),  magnetic resonance 
imaging will be repeated at 1 year (± 1 month) only. These patients will receive a further 
dose (4.0 mg/kg) of ferumoxytol 24 (±6h) -36 hours before each magnetic resonance 
imaging (a total of 2 doses of ferumoxytol in one year and a total of 4 MRI scans). In a 
further subset of patients (n=40), repeated magnetic resonance imaging scans will be 
performed at 2 years (±1 month).  These patients will receive a further dose (4.0mg/kg) 
ferumoxytol 24 (± 6) - 36 hours before each magnetic resonance imaging (total of 1 doses 
of ferumoxytol in one year). 
The manufacturers have good evidence of repeated dosing of Ferumoxytol in more than 
200 patients, where repeat dosing occurred as short as 22 days, without adverse effect 
on the patient.  In addition, serial data from patients undergoing multiple MRIs over a 2-
week period, following a single dose of ferumoxytol show no residual ferumoxytol in the 
brain by 5-7 days. 
 
Each dose of ferumoxytol equates to approximately 7% of total body iron. 
 
 
6.7 OTHER MEDICATIONS 
6.7.1   Buscopan 
20mg of intravenous Buscopan  (hyoscine butylbromide) will be given before each MRI 
scan.  If patients have a contraindication (allergic reaction, narrow angle glaucoma, 
paralytic ileus, myasthenia gravis, obstructive prostatic hypertrophy) to this drug they will 
not receive it but will proceed with MRI scanning. 
 
6.7.2 Permitted Medications 
Any other medication necessary for clinical care can be taken.   
 
For patients taking Metformin refer to section 7.1. 
 
6.7.3 Prohibited Medications 
Any other medication necessary for clinical care can be taken.  
For patients taking Metformin refer to section 7.1. 
7 STUDY ASSESSMENTS 
7.1 SAFETY ASSESSMENTS 
 
In patients with no history of renal disease, hypertension or diabetes, a normal eGFR 
within the last six months will be considered to be acceptable. For patients with risk factors 
for renal dysfunction or no blood tests within the last 6 months, clinical biochemical 
analysis of a blood sample will be performed prior to receiving contrast agent. 
 
All patients are advised to drink water prior to their scan for adequate hydration. 
For patients with a normal eGFR (60 mL/min/1.73m2) and taking Metformin they should 
continue taking the medication up until the scan.  After the scan they should withhold 
Metformin for 48 hours and then have a blood test to check renal function.  They will be 
informed when they are to restart the Metformin following the result of this. 
 
For patients with an eGFR 30 – 60  mL/min/1.73m2 and taking Metformin they will be 
advised to stop the medication for 48 hours before and 48 hours after the scan.  They 
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will then have a blood test to check renal function and informed when they are to restart 
the Metformin following the result of this. 
 
These safety assessments are part of standard clinical care with regards to CT scanning 
with an intravenous contrast agent. 
 
The magnetic resonance imaging safety questionnaire will be applied to identify patients 
with a contraindication to scanning. 
Blood pressure (systolic and diastolic) will be recorded before ferumoxytol infusion and 
30 minutes after the infusion to monitor for hypotension as detailed in the Summary of 
Product Characteristics.   Patients should be reclined or in a semi-reclining position during 
infusion and for 30 minutes thereafter.   
 
7.2 STUDY ASSESSMENTS 
A preliminary assessment of eligibility will be conducted by a suitably qualified member of 




In patients that are to undergo elective repair of their aneurysms during the course of their 
follow-up, a repeat computed tomography scan may be performed immediately prior to 
surgery. 
 
Patients recruited in Edinburgh who undergo elective surgery will also have AAA wall 
tissue collected and stored for the assessment of tissue resident macrophages and 
matrix metalloproteinases.  Samples will not be collected for patients undergoing EVAR 
or from elective surgeries where unexpected complications arise.
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       
Medical History/Demographics and concomitant 
medications 
       
Consent 
       
Ultrasound of AAA (Standard clinical care) 
       
Clinical Assessment 
       
Pulse Wave analysis and velocity 
    **  **  **  
Blood sampling 
    **  **  **  
CT scan of AAA * 
        
MRI scan of AAA (pre-ferumoxytol) 
       
i.v. administration of ferumoxytol 
       
Post ferumoxytol MRI scan of AAA 
       
AE/SAE Reporting 
  
SV = surveillance clinic; BV(a) = Baseline visit (occurs within 1 month of SV); BV (b) Baseline visit part B; 
24-36 hours after part (a);  
 * Where patients are to undergo elective repair of their aneurysms during follow up, a repeat CT 
scan may be performed prior to surgery. 
 ** Bloods and pulse wave analysis will only occur every 6 months in Edinburgh only 
6 month follow-up visits, 24 month visits and reproducibility scans can be performed within +/- 8 weeks of 
the due date. 
 


































          
Medical History/Demographics and 
concomitant medications 
          
Consent 
          
Ultrasound of AAA (Standard clinical 
care) 
          
Clinical Assessment 
          
Pulse Wave analysis and velocity 
          
Blood sampling 
          
CT scan of AAA 
          
MRI scan of AAA (pre-ferumoxytol) 
          
i.v. administration of ferumoxytol 
          
Post ferumoxytol MRI scan of AAA 
          
AE/SAE Reporting 
  
SV = surveillance clinic; BV (a)= Baseline visit; BV (b) Baseline visit part B; 24-36 hours after part (a); RP 
= Reproducibility visit where (b) is 24-36 hours after RP (a) 
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8 DATA COLLECTION 
 
8.1 CLINICAL ASSESSMENT 
Patients will have a full formal and standardized clinical assessment at baseline that will 
include history, examination, documentation of cardiovascular risk factor profile (smoking 
status, family history, hypertension, hyperlipidaemia, diabetes mellitus) and concomitant 
medications (anti-hypertensive medication, etc).  Concomitant medication will be 
recorded at baseline and at end of trial. 
Brachial artery systolic and diastolic blood pressure, pulse pressure, and mean arterial 
pressure will be measured after a 30-min supine rest period using an automated 
oscillometric sphygmomanometer (model 711, Omron Healthcare GmbH, Hamburg, 
Germany). The mean of three recordings will be taken.  
 
8.2 BLOOD SAMPLING 
Blood samples (20 mL on each visit) will be collected at baseline and at 24 months for 
patients for routine biochemistry and haematology (including full blood count, U&Es, 
Liver Function Tests, total cholesterol and glucose) 
For patients recruited and imaged in the Edinburgh centre a blood sample will be 
processed (plasma and serum) and stored at -80°C for later analysis of potential 
extracellular matrix and inflammatory biomarkers.   This will happen at baseline, 6, 12,18 
and 24 months. Full details for processing and shipment of serum biomarker samples 
will be provided in the ISF.  
 
8.3 PULSE WAVE ANALYSIS AND VELOCITY 
Pulse wave analysis and velocity will be measured in triplicate using the SphygmoCorTM 
apparatus (AtCor Medical, Sydney Australia) as previously described [McLeod et al, 
2004]. This will facilitate the measurement of central aortic pressure to assist in the 
modelling of biomechanical stress within the aneurysm.  This will be measured at 
baseline and every 6 months (6,12,18 and 24 months) for the patients recruited at the 
Edinburgh centre. This procedure will be carried out at baseline and at 24 months for 
patients in other recruiting centres.  Pulse wave analysis and velocity measurements 
should always be done before the MRI scan and CT scans (this can be on day 1 or day 
2 of the baseline visit).  Patients will be fasted for this procedure. 
In some instances, it may not be possible to perform pulse wave analysis and pulse wave 
velocity on some of the study patients. For example, if they are in atrial fibrillation or a 
weak pulse. In these instances, we will record that it was not possible to obtain these 
measurements and no further measurements will be obtained at the relevant follow up 
timelines. 
 
8.4 ULTRASOUND OF THE ABDOMINAL AORTA 
 
Patients will undergo 6-month ultrasound imaging as part of standard care for the 
surveillance programme to measure the maximal anteroposterior diameter of the 
aneurysm (Ultrasound scans should be every 6 months ± 2 months from the last 
ultrasound scan) A 3.5-MHz linear array transducer will be used to provide standard real 
time longitudinal B-scan images of the abdominal aortic aneurysm at the point of 
maximum diameter. Maximum anteroposterior abdominal aortic aneurysm diameter and 
distensibility (pressure strain elastic modulus and stiffness) will be assessed. Scans will 
be undertaken by accredited clinical vascular scientists with interobserver coefficient of 
variation of aortic diameter measurements of 3.5% in our laboratory.24  
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8.5 COMPUTED TOMOGRAPHY OF THE ABDOMINAL AORTA 
 
Contrast enhanced images of the abdominal aorta will be obtained using a 320-
multidetector computed tomography scanner (Aquilion ONE; Toshiba) or a 64 slice multi-
detector computed tomography detector (Brilliance 64; Philips_at baseline and 2 years 
at either the Clinical Research Imaging Centre or the Western Infirmary of Glasgow. 
These data will be reconstructed into three dimensions using volumetric matrices to 
enable a more comprehensive assessment of the aneurysm geometry and growth than 
that provided by the ultrasound assessment of the unidimensional aortic anteroposterior 
diameter. In cases where study participants undergo emergency repair of a ruptured 
abdominal aortic aneurysm then a CT scan may not be performed. In the event of 
patients not receiving the CT scan at baseline (due to a CT scanner issue, or other 
clinical issue), the CT scan will be performed within 1 month of the baseline visit. 
 
8.6 MAGNETIC RESONANCE IMAGING OF THE ABDOMINAL AORTA 
 
Magnetic resonance imaging will be conducted using a 3T Siemens Magnetom Verio 
scanner (Siemens, Erlangen, Germany) before and 24-36 hours after administration of 
the USPIO in Edinburgh or Glasgow. Patients will be given intravenous buscopan 
(hyoscine butylbromide), prior to imaging to minimise bowel motion artifacts. Routine 
clinical coronal and sagittal breath-held T2-weighted multi-slice HASTE sequences will 
be used to identify the position and extent of the aneurysm following which a respiratory-
gated, electrocardiographically-triggered T2 weighted (T2W) turbo- spin echo sequence 
will be used to acquire detailed anatomical data (TR/TE 2R-R intervals/72 ms; flip angle 
180°; matrix 192 x 256; field of view 400 x 400 mm; slice width 5 mm). A multi-echo, 
gradient-echo T2*W sequence (TE 4.9, 7.7, 10.5, 13.3 ms; TR 133 ms; flip angle 15°; 
matrix 192 x 256; field of view 400 x 400 mm; slice width 5 mm) will be used to acquire 
contiguous axial images of the entire aneurysm (from the neck of the aneurysm down to 
the iliac bifurcation) with slice positions corresponding to those of the T2W images. 
 
8.7 FOLLOW UP FOR PATIENTS IN CERTAIN CIRCUMSTANCES 
If a patient undergoes an open or endovascular repair of their AAA they will not return 
routinely for US or pulse wave analysis or velocity every 6 months but  will be invited to 
return every 6 months for blood tests and at 2 years for a CT scan. 
If a patient is considered not fit for elective surgery then they would normally be 
discharged from the care of the Vascular Surgeons.  However, we will invite these 
patients to attend for the standard study assessments. 
 
9 STATISTICS AND DATA ANALYSIS 
9.1 SAMPLE SIZE CALCULATION 
The sample size is determined by the numbers required to build robust prognostic 
models for rupture and/or surgical repair, and in particular to measure the additional 
prognostic value of mural USPIO uptake when added to such a prognostic model based 
only on conventional clinical risk factors. There is a widely accepted ‘rule of thumb’ that 
one needs at least 10 and ideally 20 outcome events per covariate to be included in a 
prognostic model.25 As described in more detail below, we plan to use the net 
reclassification index (NRI) as the primary measure of the clinical relevance of the added 
prognostic value of mural USPIO uptake.26, 27 Based on two recent papers using the 
NRI,28, 29 and also taking account of the Harrell ‘rule of thumb, we estimate that we need 
to observe 130 events (i.e. the composite of rupture or surgical repair) to have adequate 
sensitivity to answer the primary question. With our estimated event rate of 41% over the 
mean duration of follow-up of two years,30 this equates to 317 patients.  
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There should be very modest losses to follow up for the primary analysis, since all 
study recruits are already enrolled on a surveillance programme. Moreover we shall 
seek consent at the time of recruitment to flag the patients so that if any patients are 
lost to follow up they can be traced to identify any hospital admissions or to identify if 
they have died. In addition, some patients will drop out due to technical failure of the 
scan, such as claustrophobia or poor image quality. We have therefore conservatively 
accounted for a 10% drop-out rate and we will recruit 350 patients to the study. 
 
9.2 PROPOSED ANALYSES 
 
9.2.1 Image analysis of ultrasound 
 
Cursors will be locked onto echoes representing the anterior and posterior aortic walls 
and the movement of both tracked with each cardiac cycle. The longitudinal image will 
be used for analysis as experience with the technique and data from formal 
reproducibility studies indicates that the quality of the data obtained from a longitudinal 
section is superior to that obtained from a transverse view. Images will be captured 
digitally for later off-line core laboratory review. 
 
9.2.2 Image analysis of computed tomography 
 
Computed tomography of the abdominal aorta will be performed at baseline and 2 years 
to assess regional and volumetric growth rates. These two computed tomography scans 
will be spatially co-registered so that areas of expansion and growth can be more 
accurately defined and permit correlation with areas of USPIO uptake and fine element 
analysis modeling. 
 
Three-dimensional computer models will be generated from segmented, contrast-
enhanced images allowing geometric indices to be quantified. Semi-automatic 
segmentation is achievable due to the intensity differences between the aneurysm and 
surrounding tissues and structures. Intensity thresholding will be used to identify the 
lumen. To detect the thrombus and complete the segmentation, we will use a 3-D 
deformable model approach that utilises the level set algorithm as well as modeling the 
thrombus contour as a radial function starting from the aortic centre line as calculated 
from the lumen segmentation. 
 
9.2.3 Image analysis of magnetic resonance imaging 
 
A region of interest (ROI) encompassing the aortic wall and thrombus but excluding the 
lumen will be drawn on each slice of the pre-contrast T2W image. The pre-contrast T2W 
scan will be used as the base image to which subsequent scans will be co-registered 
using a semi-automatic rigid three-dimensional voxel registration protocol utilising a 
normalised mutual information algorithm. To minimise the contribution of bowel and 
abdominal wall motion in the magnetic resonance imaging datasets, a region for 
registration will include the aorta, vertebrae and spinal musculature that remain relatively 
static during the respiratory cycle but exclude the more mobile abdominal wall and bowel. 
 
The four echoes in the multi-echo T2*W sequence will be combined to generate T2* and 
R2* maps. The T2* value is the decay constant for the exponential decay of signal 
intensity with time (Figure 3) and its inverse is the R2* value. A 3 x 3 voxel Gaussian 
filter will be applied to the individual echoes to reduce noise, and the co-efficient of 
determination will be used to exclude data that do not have an acceptable straight line 
fit when ln(signal intensity) is plotted against echo time. Images will be co-registered to 
allow direct comparison of the pre-and post-contrast T2*W magnetic resonance images. 
USPIO uptake will be presented visually as a colour map of per cent change in T2* or 
R2* values between pre- and post-USPIO scans, with our previously validated threshold 
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The change in T2* or R2* colour maps from the magnetic resonance images will be 
spatially co-registered to the computed tomography datasets. 
 
9.2.4 Finite element and stress analysis 
 
Using Abaqus, the vessel wall will be modeled as a constant thickness layer of 1.5 mm, 
with a hyperelastic constitutive model. Thrombus will be modeled as homogenous and 
isotropic with Young’s modulus 0.1 MPa. The model will be inflated from diastolic to 
systolic pressure using a homogeneous pressure-modeling regime. Peak wall stress and 
other rupture indices will be calculated and compared against areas of USPIO uptake. 
 
9.2.5 Statistical analysis 
 
The baseline assessment will include the baseline aneurysm diameter, sex, smoking 
habit and blood pressure. Using these covariates, a prognostic model predicting the time 
to the composite outcome event of rupture or surgical repair will be developed using Cox 
proportional hazards regression. The added prognostic value of adding mural USPIO 
uptake to this model will be assessed using the increase in the area under the receiver 
operator characteristic (ROC) curve, the Nagelkerke partial R2, and primarily, the net 
reclassification index.26, 27  The NCI is a direct measure of the clinical relevance of adding 
a covariate to a prognostic model. It is an overall measure of how many patients move 
from a low predicted risk to a high predicted risk when the covariate is added (and 
whether these individuals are indeed high risk), and how many move from a high 
predicted risk to a low predicted risk (and whether these individuals are indeed low risk). 
For the primary analysis, the USPIO will be taken as a binary covariate (as in Richards 
et al, 2011a), but a sensitivity analysis will explore the potential for including a 
quantification of the USPIO uptake. Some but not all of the patients will also have a 
measure of current aneurysm growth rate at baseline, and a further sensitivity analysis 
will explore using grown rate as a further prognostic factor, using imputation when the 
estimated growth rate is not available. 
 
A secondary analysis will follow a similar analytical strategy to that set out above, but 
using prognostic models to predict aneurysm growth rate. This analysis will be far more 
complex with there being serial measures of aneurysm diameter, and with these 
measurements being censored on rupture or on surgical repair. Further exploratory 
analysis will look at the predictive ability of measures of wall stress and how these 
interact with regional USPIO uptake. 
 
The analysis will be conducted by the study statistician, Catriona Graham (Senior 
Statistician Wellcome Trust Clinical Research Facility), under the supervision of Gordon 
Murray (Professor of Medical Statistics).  
 
Reproducibility of the technique will be assessed in a subgroup of study participants who 
will undergo repeat magnetic resonance scanning and USPIO administration at 1 month 
and 1 year (n=20), 1 year only (n=60) and at 2 years (n=40). Short-term (1 month) 
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on each slice of the pre-contrast T2W image. The pre-contrast T2W scan will be used as the base image to 
which subsequent scans will be co-registered using a semi-automatic rigid three-dimensional voxel 
registration protocol utilising a normalised mutual information algorithm. To minimise the contribution of 
bowel and abdominal wall motion in the magnetic resonance imaging datasets, a region for registration will 
include the aorta, vertebrae and spinal musculature that remain relatively static during the respiratory cycle 
but exclude the more mobile abdominal wall and bowel.  
 
The four echoes in the multi-echo T2*W sequence will be combined to generate a T2* map. The T2* value 
is the decay constant for the exponential decay of signal intensity with time (Figure 3). A 3 x 3 voxel 
Gaussi  filter will be applied to the individual echoes to reduce noise, and the co-efficient of determination 
will be used to exclude data that do not have an acceptable straight line fit when ln(signal intensity) is 
plotted against echo time. Images will be co-registered to allow direct comparison of 
the pre-and post-contrast T2*W magnetic resonance images. USPIO uptake will be 
presented visually as a colour map of per cent change in T2* values between pre- and 
post-USPIO scans, with our previously validated threshold of significance applied 
[Richards et al, 2011a; Richards et al, 2011b] (Figures 3 and 4). 
 
 
Figure 4. Colour map of magnetic resonance image of an abdominal aortic aneurysm. Red and yellow 
pixels indicate areas of increased T2* value indicative of USPIO uptake. 
 
The change in T2* colour maps from the magnetic resonance images will be spatially co-registered to the 
computed tomography datasets.  
 
7.5 Finite Element and Stress Analysis 
 
Using Abaqus, the vessel wall will be modeled as a constant thickness layer of 1.5 mm, with a hyperelastic 
constitutive model. Thrombus will be modeled as homogenous and isotropic with Young’s modulus 0.1 MPa. 
The model will be inflated from diastolic to systolic pressure using a homogeneous pressure-modeling 
regime. Peak wall stress and other rupture indices will be calculated and compared against areas of USPIO 
uptake. 
 
8. Assessment and follow up 
 
All subjects will undergo a standardised clinical assessment at baseline and every six months until study 
completion. The assessments will include risk factor profile, concomitant medications, blood pressure, pulse 
wave analysis, abdominal ultrasound and measurement of serum extracellular matrix and inflammatory 
markers. Magnetic resonance and USPIO uptake assessments of the abdominal aorta will be undertaken at 
baseline. In a random subset of patients (n=40), repeated magnetic resonance scans will be performed at 1 
month (short-term reproducibility) and 1 year (long-term reproducibility). This will define whether regions of 
USPIO uptake vary with time. Computed tomography of the abdominal aorta will be performed at baseline 
and 2 years to assess regional and volumetric growth rates. These two computed tomography scans will be 
spatially co-registered so that areas of expansion and growth can be more accurately defined and permit 
correlation with areas of USPIO uptake and fine element analysis modeling. Where patients are to undergo 
elective repair of their aneurysms during the course of their follow-up, a repeat computed tomography scan 
will be performed immediately prior to surgery.  
 
8.1 Assessment of efficacy and effectiveness 
 
The primary end-point of the study will be the composite of aneurysm rupture or aortic aneurysm repair. 
Efficacy will therefore be determined by whether the primary end-point event rate is higher in patients with 
mural uptake of USPIO. Secondary end-points will include: 
 
i. the rate of aneurysm rupture 
ii. the rate of surgical repair of the aneurysm 
Figure 4.  Colour m p of magnetic r sonance imaging 
of an abdominal aortic aneurysm.  R d a d yellow 
pixels indicate areas of increase T2* value, indicativ  of 
USPIO uptake. 
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repeatability is likely to reflect the variability in USPIO uptake whereas long-term (1 and 
2 years) reproducibility is likely to represent the variation in biology of the aortic aneurysm 
with time. Subjects will be categorised with respect to the presence or absence of USPIO 
uptake to define the proportionate agreement, with 95% confidence intervals.   
For the 2 year repro sub-study, missing data is expected to be minimal as participants 
will be recruited for this component of the study as they are attending their regular 2 year 
study visit.  A sample size has been determined as follows: 
The following table shows width of a two-sided 95% confidence interval around 
expected proportions from 0.5 [column 1] up to 0.9 [column 5] based on a sample size 
of 40.  
  Confidence interval for proportion using normal approximation (n large) 
  1 2 3 4 5 
  Confidence level, 1-   0.950   0.950   0.950   0.950   0.950 
  1 or 2 sided interval?    2    2    2    2    2 
      Expected proportion,   0.500  0.600  0.700  0.800  0.900 
  Distance from proportion to limit, 
 
    0.155     0.152     0.142     0.124     0.093 
  n  40  40  40  40  40 
As the expected proportion increases the width of the confidence interval decreases 
however with a sample size of 40 we would be able to express the proportional 
agreement to within ±0.155.  This is based on a proportional agreement of 0.5 as this 
represents the ‘worst-case scenario’ i.e. the point at which the width of the CI is as its 
widest. 
 
10 ADVERSE EVENTS 
The Investigator is responsible for the detection and documentation of events meeting 
the criteria and definitions detailed below.   
Full details of contraindications and side effects that have been reported following 
administration of the IMP can be found in the relevant Summary of Product 
Characteristics (SmPC). 
Participants will be instructed to contact their Investigator at any time after consenting to 
join the study if any symptoms develop.  All adverse events (AE) that require medical 
attention (for example, visit to a GP, hospital etc) which occur after having received 
ferumoxytol must be reported in detail in the Case Report Form (CRF) or AE form.  In 
the case of an AE, the Investigator should initiate the appropriate treatment according to 
their medical judgment.  Participants with AEs present at the last visit must be followed 
up until resolution of the event.  For patients that have an aneurysm rupture or repair 
(elective or emergency), this will be recorded in the AAA case report form and entered 
into the database (this is one of secondary outcomes).  This event will not be recorded 
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An adverse event (AE) is any untoward medical occurrence in a clinical trial participant 
which does not necessarily have a causal relationship with an investigational medicinal 
product (IMP). 
An adverse reaction (AR) is any untoward or unintended response to an IMP which is 
related to any dose administered to that participant.  
An unexpected adverse reaction (UAR) is an adverse reaction that is not consistent 
with the applicable product information for the IMP, e.g. the Investigator Brochure (IB) 
for a non licensed IMP or the SmPC for a licensed product. 
A serious adverse event (SAE), serious adverse reaction (SAR) or suspected 
unexpected serious adverse reaction (SUSAR) is any AE, AR or UAR that at any 
dose: 
 results in death; 
 is life threatening* (i.e. the participant was at risk of death at the time of the 
event; it does not refer to an event which hypothetically might have caused 
death if it were more severe); 
 requires in-patient hospitalisation or prolongation of existing hospitalisation; 
 results in persistent or significant disability or incapacity; 
 is a congenital anomaly or birth defect. 
 
10.2 DETECTING AEs AND SAEs 
All AEs and SAEs will be recorded from the time a participant signs the consent form to 
take part in the study until the last study visit.  
Participants will be asked about the occurrence of AEs/SAEs at every visit during the 
study.  Open-ended and non-leading verbal questioning of the participant will be used to 
enquire about AE/SAE occurrence.  Participants will also be asked if they have been 
admitted to hospital or had any accidents. If there is any doubt as to whether a clinical 
observation is an AE, the event will be recorded. 
AEs and SAEs may also be identified by support departments e.g. laboratories. 
 
10.3 RECORDING AEs AND SAEs 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the 
event.  The Investigator will then record all relevant information in the CRF and on the 
SAE form (if the AE meets the criteria of serious). 
Information to be collected includes dose, type of event, onset date, Investigator 
assessment of severity and causality, date of resolution as well as treatment required, 
investigations needed and outcome.   
10.4 ASSESSMENT OF AEs AND SAEs 
Seriousness, causality, severity and expectedness will be assessed as though the 
participant is taking active IMP.  The Investigator is responsible for assessing each AE.   
The Chief Investigator (CI) may not downgrade an event that has been assessed by an 
Investigator as an SAE or SUSAR, but can upgrade an AE to an SAE, SAR or SUSAR if 
appropriate. 
10.4.1 Assessment of Seriousness 
The Investigator will make an assessment of seriousness as defined in Section 10.1. 
 
10.4.2 Assessment of Causality 
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The Investigator will make an assessment of whether the AE/SAE is likely to be related 
to the IMP according to the definitions below.   
All AEs/SAEs judged as having a reasonable suspected causal relationship (e.g. 
possibly related or unrelated) to the IMP will be considered as related to the IMP 
(ARs/SARs).   
Where non Investigational Medicinal Products (NIMPs) e.g. rescue/escape drugs are 
given:  if the AE is considered to be related to an interaction between the IMP and the 
NIMP, or where the AE might be linked to either the IMP or the NIMP but cannot be 
clearly attributed to either one of these, the event will be considered as an AR/SAR. 
Unrelated: where an event is not considered to be related to the IMP. 
Possibly related: The nature of the event, the underlying medical condition, concomitant 
medication or temporal relationship make it possible that the AE has a causal relationship 
to the study drug. 
Probably related: The temporal relationship and absence of a more likely explanation 
suggest the event could be related to the study drug. 
Definitely related: The known effects of the study drug or its therapeutic class, or based 
on challenge testing, suggest that study drug is the most likely cause. 
Alternative causes such as natural history of the underlying disease, other risk factors 
and the temporal relationship of the event to the treatment should be considered and 
investigated.  
10.4.3 Assessment of Severity 
The Investigator will make an assessment of severity for each AE/SAE and record this 
on the CRF or AE form according to one of the following categories: 
Mild: an event that is easily tolerated by the participant, causing minimal discomfort and 
not interfering with every day activities. 
Moderate: an event that is sufficiently discomforting to interfere with normal everyday 
activities. 
Severe: an event that prevents normal everyday activities. 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or action 
criteria.  For example, a headache may be severe but not serious, while a minor stroke 
is serious but may not be severe. 
10.4.4 Assessment of Expectedness 
If an event is judged to be an AR/SAR, the evaluation of expectedness will be made 
based on knowledge of the reaction and the relevant product information documented in 
the SmPC/IB. 
The event may be classed as either: 
Expected: the AR is consistent with the toxicity of the IMP listed in the SmPC/IB. 
Unexpected: the AR is not consistent with the toxicity in the SmPC/IB. 
 
10.5 REPORTING OF SAEs/SARs/SUSARs 
Once the Investigator becomes aware that an SAE has occurred in a study participant, 
the information will be reported to the ACCORD Research Governance & QA Office 
immediately or within 24 hours. If the Investigator does not have all information 
regarding an SAE, they should not wait for this additional information before notifying 
ACCORD.  The SAE report form can be updated when the additional information is 
received. 
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The SAE report will provide an assessment of causality and expectedness at the time of 
the initial report to ACCORD according to Sections 10.4.2, Assessment of Causality and 
10.4.4, Assessment of Expectedness. 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may be 
transmitted by hand to the office. 
All reports faxed to ACCORD and any follow up information will be retained by the 
Investigator in the Investigator Site File (ISF). 
 
10.6 REGULATORY REPORTING REQUIREMENTS 
The ACCORD Research Governance & QA Office is responsible for pharmacovigilance 
reporting on behalf of the co-sponsors (Edinburgh University and NHS Lothian). 
The ACCORD Research Governance & QA Office has a legal responsibility to notify the 
regulatory competent authority and relevant ethics committee (Research Ethics 
Committee (REC) that approved the trial).  Fatal or life threatening SUSARs will be 
reported no later than 7 calendar days and all other SUSARs will be reported no later 
than 15 calendar days after ACCORD is first aware of the reaction.   
ACCORD will inform Investigators at participating sites of all SUSARs and any other 
arising safety information. 
An Annual Safety Report will be submitted to the regulatory competent authority and 
main REC listing all SARs and SUSARs. 
 
 
10.7 FOLLOW UP PROCEDURES 
After initially recording an AE or recording and reporting an SAE, the Investigator will 
follow each participant until resolution or death of the participant.  Follow up information 
on an SAE will be reported to the ACCORD office. 
AEs still present in participants at the last study visit will be monitored until resolution of 
the event or until no longer medically indicated. 
11. PREGNANCY 
Woman with child-bearing potential will not be enrolled into the trial (woman who have 
experienced menarche, are pre-menopausal, have not been sterilised or who are 
currently pregnant). 
12 TRIAL MANAGEMENT AND OVERSIGHT ARRANGEMENTS 
12.1 TRIAL MANAGEMENT GROUP 
The study will be coordinated by a Project Management Group, consisting of the grant 
holders (Chief Investigator and Principal Investigator in Edinburgh), Trial Manager and 
coordinating nurse. 
The Trial Manager will oversee the study and will be accountable to the Chief 
Investigator.  The Trial Manager will be responsible for checking the CRFs for 
completeness, plausibility and consistency.  Any queries will be resolved by the 
Investigator or delegated member of the study team.  
A Delegation Log will be prepared for each site, detailing the responsibilities of each 
member of staff working on the study.   
 
12.2 TRIAL STEERING COMMITTEE 
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A Trial Steering Committee (TSC) will be established to oversee the conduct and 
progress of the study, in particular the TSC will monitor the trial event rate. The terms of 
reference of the Trial Steering Committee, the draft template for reporting and the names 
and contact details are detailed in the TSC charter. 
 
12.3 DATA MONITORING COMMITTEE 
An independent Data Monitoring Committee (DMC) will not be convened for this study. 
The investigators will report all adverse events to the Sponsor and the Trial Steering 
Committee. As there is no blinded intervention and the investigational medicinal product 
will be given to all subjects, there is no risk to the scientific integrity of the study or 
requirement for a DMC. 
 
12.4 INSPECTION OF RECORDS 
Investigators and institutions involved in the study will permit trial related monitoring and 
audits on behalf of the sponsor, REC review, and regulatory inspection(s).  In the event 
of an audit or monitoring, the Investigator agrees to allow the representatives of the 
sponsor direct access to all study records and source documentation. In the event of 
regulatory inspection, the Investigator agrees to allow inspectors direct access to all 
study records and source documentation. 
 
12.5 RISK ASSESSMENT 
An independent risk assessment will be performed by an ACCORD Clinical Trials 
Monitor to determine if monitoring is required and if so, at what level. An independent 
risk assessment will also be carried out by the ACCORD Quality Assurance Group to 
determine if an audit should be performed before/during/after the study and if so, at what 




The risks to the participants of the study are very modest and are mainly attributable to 
the magnetic resonance and computed tomography scans and their respective contrast 
agents. 
 
12.5.1.1 Magnetic resonance imaging 
 
Magnetic resonance imaging is a standard clinical imaging technique that is applied 
across the world. Contraindications for magnetic resonance imaging are the presence of 
certain metallic objects, electrical devices and claustrophobia. Patients with implanted 
electrical devices, such as pacemakers or defibrillators, will be excluded. We have the 





Ferumoxytol (Rienso®) was originally developed for the treatment of iron-deficiency 
anaemia in patients with chronic kidney disease. It consists of a suspension of USPIO 
with an ultrasmall core (diameter ~7 nm) and a semi-synthetic carbohydrate coating 
giving an overall particle size of 30 nm. The size of the particle prevents any early 
redistribution outside the vascular space and therefore can act as a blood-pool imaging 
agent with a plasma elimination half-life of approximately 10 - 14 hours in humans. 
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Herborn and colleagues examined the utility of ferumoxytol for imaging atheroma in the 
aortae of hyperlipidaemic rabbits using a 1.5T magnetic resonance scanner.31 
Susceptibility artifacts were detectable in the aortic wall at day 2 to 3 post administration 
of contrast. Signal voids were observed as a result of T2/T2* effects and were more 
homogenous than those seen in similar animals administered ferumoxtran-10. Histology 
revealed the accumulation of iron particles under the endothelium and into the medial 
layer of diseased vessels.31  
 
Ferumoxytol has been administered safely as a bolus dose of 4 mg/kg for use as a 
magnetic resonance imaging contrast agent in humans.32, 33, 34, 35, 36 Most of these studies 
have examined and confirmed its utility as a blood-pool contrast agent. However, it has 
also been assessed for its use in lymph node imaging for cancer staging. In a study of 
patients with prostate cancer, ferumoxytol was administered at 4 mg/kg and imaging 
performed at baseline, 5, 8 and 24 hours post dose using a 1.5 T scanner. Maximum 
signal-to-noise ratio was observed in lymph nodes at 24 hours on T2*-weighted MR 
imaging.37  
 
Ferumoxytol is generally very well tolerated. We have administered ferumoxytol to 16 
patients with abdominal aortic aneurysms, 28 patients who have undergone coronary 
artery bypass surgery and 12 patients with a recent acute myocardial infarction. None 
have experienced any significant major side-effects or serious adverse events. One 
subject did experience brief muscle cramps; a previously reported mild side effect. 
Common reported side-effects of ferumoxytol include constipation, diarrhoea, dizziness 
and nausea. Reported severe reactions include serious hypersensitivity reactions and 
hypotension, but are rare. 
 
Buscopan is an anticholinergic drug and is generally used to provide relief from spasm 
of the genito-urinary tract or gastro-intestinal tract. In this study it is used to minimise 
bowel motion during the imaging protocol of this study to decrease artefacts seen due to 
digestive movements. Any side effects reported are uncommon or rare and consist of 
dry mouth and constipation. 
 
 
12.5.1.3 Computed tomography 
 
As part of the protocol, subjects will receive two extra computed tomography scans 
with intravenous contrast. This will expose the patient to ionising radiation (~6 mSv per 
scan for the Glasgow centre and 3mSv in Edinburgh centre) and the potential hazard of 
allergic reactions and transient renal dysfunction in response to the contrast agent. 
Thus the maximum total research protocol dose is 12 mSv. 
 
The level of dose is comparable to the average cumulated dose from 5 years of natural 
background radiation to the UK population. It is equal to 60% of the whole body dose 
limit for radiation workers. 
 
The associated excess risk of death from radiation induced cancer is approximately 1 
in 3000 compared with the cancer mortality rate in the UK of just over 1 in 4.  
 
The risks of exposure to the contrast medium include allergic reactions and impairment 
of kidney function. Amongst patients with moderate-to-severe chronic kidney disease, 
there is a 2-4% risk of kidney impairment after computed tomography angiography.38 The 
risk of contrast exposure in this study will be minimised by exclusion of high risk patients 
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Patients will benefit from inclusion in a clinical study that includes close clinical 
supervision. Based on our previous studies and the demographics of the study 
population, the study may identify other important clinical conditions that require 
intervention or treatment because of incidental findings on the magnetic resonance or 
computed tomography scans. This could be viewed as a potential risk but most patients 
are grateful if covert conditions are detected early and treated more promptly. In addition, 
patients will benefit from the additional and closer supervision and care that clinical 
studies deliver. 
 
Society and some of the participants will benefit if the findings of our study demonstrate 
that USPIO can successfully identify which patients are at risk of more rapid aneurysm 
expansion and clinical events. This is the main purpose of the study and we hope this 




The risks associated with the additional scans and the administration of contrast agents 
are very low and consistent with many routine clinical imaging procedures. Conversely, 
if this technique is proven to be successful, the major gains in risk stratification and better 
selection of patients with abdominal aortic aneurysms who should receive surgical 
intervention, could have major morbidity and mortality benefits. Deferring unnecessary 
major surgery or bringing forward potentially life-saving surgery will ensure appropriate 
use of limited health care resources for maximum patient benefit. 
 
12.6 STUDY MONITORING AND AUDIT 
An ACCORD Clinical Trials Monitor or an appointed monitor will visit the Investigator site 
prior to the start of the study and during the course of the study if required, in accordance 
with the monitoring plan if required. Investigator sites will be risk assessed by the 
ACCORD QA Manager, or designee, in order to determine if audit by the ACCORD QA 
group is required. 
 
13 GOOD CLINICAL PRACTICE 
13.1 ETHICAL CONDUCT 
The study will be conducted in accordance with the principles of the International 
Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP). 
A favorable ethical opinion will be obtained from the appropriate REC and local R&D 
approval will be obtained prior to commencement of the study. 
13.2 REGULATORY COMPLIANCE 
The study will not commence until a Clinical Trial Authorisation (CTA) is obtained from 
the appropriate Regulatory Authority. The protocol and study conduct will comply with 
the Medicines for Human Use (Clinical Trials) Regulations 2004, and any relevant 
amendments. 
13.3 INVESTIGATOR RESPONSIBILITIES 
The Investigator is responsible for the overall conduct of the study at the site and 
compliance with the protocol and any protocol amendments.  In accordance with the 
principles of ICH GCP, the following areas listed in this section are also the responsibility 
of the Investigator.  Responsibilities may be delegated to an appropriate member of study 
site staff.   
13.3.1 Informed Consent 
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The Investigator is responsible for ensuring informed consent is obtained before any 
protocol specific procedures are carried out.  The decision of a participant to participate 
in clinical research is voluntary and should be based on a clear understanding of what is 
involved. 
Participants must receive adequate oral and written information – appropriate Participant 
Information and Informed Consent Forms will be provided.  The oral explanation to the 
participant will be performed by the Investigator or qualified delegated person, and must 
cover all the elements specified in the Participant Information Sheet and Consent Form. 
The participant must be given every opportunity to clarify any points they do not 
understand and, if necessary, ask for more information.  The participant must be given 
sufficient time to consider the information provided.  It should be emphasised that the 
participant may withdraw their consent to participate at any time without loss of benefits 
to which they otherwise would be entitled. 
The participant will be informed and agree to their medical records being inspected by 
regulatory authorities and representatives of the sponsor(s) but understand that their 
name will not be disclosed outside the research team. 
The Investigator or delegated member of the study team and the participant will sign and 
date the Informed Consent Form(s) to confirm that consent has been obtained.  The 
participant will receive a copy of this document and a copy filed in the Investigator Site 
File (ISF) and participant’s medical notes. 
 
13.3.2 Study Site Staff 
The Investigator must be familiar with the IMP, protocol and the study requirements.  It 
is the Investigator’s responsibility to ensure that all staff assisting with the study are 
adequately informed about the IMP, protocol and their study related duties. 
13.3.3 Data Recording 
The Principal Investigator is responsible for the quality of the data recorded in the CRF 
at each Investigator Site. 
13.3.4 Investigator Documentation 
Prior to beginning the study, each Investigator will be asked to provide particular 
essential documents to the ACCORD Research Governance & QA Office, including but 
not limited to: 
 An original signed Investigator’s Declaration (as part of the Clinical Trial 
Agreement documents); 
 Curriculum vitae (CV) signed and dated by the Investigator indicating that it is 
accurate and current. 
The ACCORD Research Governance & QA Office will ensure all other documents 
required by ICH GCP are retained in a Trial Master File (TMF), where required, and that 
appropriate documentation is available in local ISFs. 
 
13.3.5 GCP Training 
All study staff must hold evidence of appropriate GCP training. 
  
13.3.6 Confidentiality 
All laboratory specimens, evaluation forms, reports, and other records must be identified 
in a manner designed to maintain participant confidentiality.  All records must be kept in 
a secure storage area with limited access.  Clinical information will not be released 
without the written permission of the participant.  The Investigator and study site staff 
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involved with this study may not disclose or use for any purpose other than performance 
of the study, any data, record, or other unpublished, confidential information disclosed to 
those individuals for the purpose of the study.  Prior written agreement from the sponsor 
or its designee must be obtained for the disclosure of any said confidential information 
to other parties. 
 
13.3.7 Data Protection 
All Investigators and study site staff involved with this study must comply with the 
requirements of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and will uphold the Act’s core 
principles. Access to collated participant data will be restricted to those clinicians treating 
the participants. 
Computers used to collate the data will have limited access measures via user names 
and passwords. 
Published results will not contain any personal data that could allow identification of 
individual participants. 
 
13.3.8 Sharing of anonymised data 
 
Toshiba Medical Visualisation Systems (TMVS) have requested permission to use some 
of the anatomical MA3RS MRI and CT imaging data for the purposes of developing and 
evaluating registration algorithms. This will enable development of a framework allowing 
quantitative comparison of various registration algorithms and will only look at the 
anatomical/structural data that is acquired during the MA3RS imaging protocol. No 
MA3RS primary outcome data will be included.  
 
The data provided will be fully anonymised (identifiable by MA3RS study ID only).  An 
agreement will be put in place so that only TMVS members that are named on the 
agreement will be allowed to access the data provided and TMVS will not publish without 
explicitly requesting consent.  Any further use of the data by TMVS for any purpose will 
require approval by the University of Edinburgh and the Trial Steering Committee. 
 
14 STUDY CONDUCT RESPONSIBILITIES 
14.1 PROTOCOL AMENDMENTS 
Any changes in research activity, except those necessary to remove an apparent, 
immediate hazard to the participant in the case of an urgent safety measure, must be 
reviewed and approved by the Chief Investigator.   
Amendments to the protocol must be submitted in writing to the appropriate REC, 
Regulatory Authority and local R&D for approval prior to participants being enrolled into 
an amended protocol. 
 
 
14.2 PROTOCOL VIOLATIONS AND DEVIATIONS 
Investigators will not implement any deviation from the protocol without agreement from 
the Chief Investigator and appropriate REC, Regulatory Authority and R&D approval 
except where necessary to eliminate an immediate hazard to study participants. 
In the event that an Investigator needs to deviate from the protocol, the nature of and 
reasons for the deviation will be recorded in the CRF.  If this necessitates a subsequent 
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protocol amendment, this should be submitted to the REC, Regulatory Authority and 
local R&D for review and approval if appropriate. 
 
14.3 SERIOUS BREACH REQUIREMENTS 
A serious breach is a breach which is likely to effect to a significant degree: 
(a) the safety or physical or mental integrity of the participants of the study; or 
b) the scientific value of the study. 
If a potential serious breach is identified by the Chief investigator, Principal Investigator 
or delegates, the co-sponsors (accord.seriousbreach@ed.ac.uk) must be notified within 
24 hours.  It is the responsibility of the co-sponsors to assess the impact of the breach 
on the scientific value of the study, to determine whether the incident constitutes a 
serious breach and take the appropriate action.  
Not every violation from the protocol needs to be reported to the regulatory authority as 
a serious breach.  If the sponsor(s) deem the incident to be a violation that does not 
constitute a serious breach from the protocol when identified, corrective and preventative 
actions will be taken where appropriate and they will be recorded in file notes, held within 
the TMF and ISF. 
 
14.4 STUDY RECORD RETENTION 
All study documentation will be kept for a minimum of 5 years from the protocol defined 
end of study point. When the minimum retention period has elapsed, study 
documentation will not be destroyed without permission from the sponsor. 
 
14.5 END OF STUDY 
The end of study is defined as the last participant’s last visit.   
The Investigators and/or the trial steering committee and/or the co-sponsor(s) have the 
right at any time to terminate the study for clinical or administrative reasons.  
The end of the study will be reported to the REC and Regulatory Authority within 90 days, 
or 15 days if the study is terminated prematurely.  The Investigators will inform 
participants of the premature study closure and ensure that the appropriate follow up is 
arranged for all participants involved. 
A summary report of the study will be provided to the REC and Regulatory Authority 
within 1 year of the end of the study. 
 
14.6 CONTINUATION OF DRUG FOLLOWING THE END OF STUDY 




14.7 INSURANCE AND INDEMNITY 
The co-sponsors are responsible for ensuring proper provision has been made for 
insurance or indemnity to cover their liability and the liability of the Chief Investigator and 
staff. 
The following arrangements are in place to fulfil the co-sponsors' responsibilities: 
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 The Protocol has been designed by the Chief Investigator and researchers 
employed by the University and collaborators.  The University has insurance in 
place (which includes no-fault compensation) for negligent harm caused by poor 
protocol design by the Chief Investigator and researchers employed by the 
University. 
 Sites participating in the study will be liable for clinical negligence and other 
negligent harm to individuals taking part in the study and covered by the duty of 
care owed to them by the sites concerned.  The co-sponsors require individual 
sites participating in the study to arrange for their own insurance or indemnity in 
respect of these liabilities. 
 Sites which are part of the United Kingdom's Nation Health Service will have 
the benefit of NHS Indemnity. 
Sites out with the United Kingdom will be responsible for arranging their own 
indemnity or insurance for their participation in the study, as well as for 
compliance with local law applicable to their participation in the study. 
15 REPORTING, PUBLICATIONS AND NOTIFICATION OF RESULTS 
15.1 AUTHORSHIP POLICY 
Ownership of the data arising from this study resides with the study team.  On completion 
of the study, the study data will be analysed and tabulated, and a clinical study report 
will be prepared in accordance with ICH guidelines.  
 
15.2 PUBLICATION 
The clinical study report will be used for publication and presentation at scientific 
meetings. Investigators have the right to publish orally or in writing the results of the 
study. 
Summaries of results will also be made available to Investigators for dissemination within 
their clinics (where appropriate and according to their discretion). 
 
15.3 PEER REVIEW 
The protocol has undergone extensive peer review by the funders (Medical Research 
Council, Efficacy and Mechanism Evaluation programme) and by the Trial Steering 
Committee of the study. 
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LIST OF ABBREVIATIONS 
 
AAA               Abdominal Aortic Aneurysm 
ACCORD       Academic and Clinical Central Office for Research and Development 
AE                  Adverse Event 
CI                    Chief Investigator 
CRIC              Clinical Research Imaging Centre, Edinburgh 
CRIF  Clinical Research Imaging Facility, Dundee 
CT                  Computed Tomography 
eGFR              estimated Glomerular Filtration Rate 
MA3RS           MRI in Abdominal Aortic Aneurysms to predict Rupture or Surgery 
MRI                Magnetic Resonance Imaging 
NHS                National Health Service 
NAAASP National Abdominal Aortic Aneurysm Screening Programme 
PET-CT          Positron Emission Tomography-Computed Tomography 
PI                    Principal Investigator 
REC                Research Ethics Committee 
R&D               Research and Development 
USPIO            Ultrasmall supramagnetic Particles of Iron Oxide 
USS                Ultrasound scan 
SAE                Serious Adverse Event 
18F-NaF         18F-Sodium Fluoride 
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Ruptured abdominal aortic aneurysms (AAAs) have a 90% mortality rate but there are 
currently no accurate methods of establishing the risk of rupture for an individual patient 
with an asymptomatic AAA. In vascular disease, microcalcification occurs in response to 
necrotic inflammation. Using computed tomography and positron emission tomography, 
we can identify early microcalcification using uptake of the radiotracer 18F-sodium 
fluoride. This can identify high risk-lesions in the aorta, coronary and carotid arteries, 
and  appears  to  be  indicative  of  necrotic  and  heavily  inflamed  tissue.  We  therefore 
propose to evaluate the ability of 18F-sodium fluoride to identify regions of necrotic 
inflammation in AAA and predict AAA expansion. We will also explore its value as part 
of an ongoing clinical trial assessing the identification of macrophage activity using 
magnetic resonance imaging (the MA3RS study). 
Confidential Page 6 of 25 









Abdominal aortic aneurysms (AAA) are the 13th  leading cause of death in the United 
Kingdom and other western countries, with around 6,800 deaths each year in the United 
Kingdom and 15,000 deaths annually in the United States1. The condition is most 
prevalent  amongst  men,  with  5-8%  of  men  over  the  age  of  65  years  affected.  The 
mortality of ruptured AAA is extremely high at ~90%. In contrast, the risk of death from 
elective open surgical or endovascular repair is low at 1-5%2. 
 
 
The focus is therefore to identify AAA before rupture and offer surgery when the risk of 
rupture exceeds that of elective repair. Indeed, the early identification of AAA through 
screening programmes can reduce aneurysm-related mortality by up to 50% and 
nationwide screening has recently been established in the United Kingdom. Currently, 
patients diagnosed with an aneurysm are entered into an ultrasound-based surveillance 
programme with a view to offering those at high risk of rupture preventative surgical or 
endovascular repair. Evaluation of rupture risk is currently based on the maximum 
anteroposterior diameter of the aneurysm. Aneurysms <55 mm in diameter have an 
annual risk of rupture of <1%, and early repair affords no survival benefit over continued 
surveillance in this group3. 
 
 
Elective aneurysm repair is offered to patients with an aneurysm diameter >55 mm or 
where the aneurysm expansion rate is >10 mm/year. However, up to one in five ruptured 
AAA has a diameter of <55 mm and many patients have aneurysms considerably larger 
than 55 mm without symptoms or rupture4. Furthermore, although aneurysm size is 
currently the best predictor of clinical risk, the unpredictability and non-linearity of 
aneurysm growth makes risk prediction complex. 
 
 
There is an urgent unmet clinical need for an improved method of predicting disease 
progression and rupture in patients with AAA so that preventative surgical or 
endovascular repair can be targeted at high-risk patients.   In this proposed study, we 
intend to conduct an exploratory analysis of the uptake of 18F-NaF in aneurysmal aortae 
and investigate whether there is a relationship with 18F-NaF uptake and AAA expansion. 
 
1.1.1    ANEURYSM BIOLOGY 
 
Aneurysm disease typically coexists with atherosclerosis and the two processes share a 
number  of  risk  factors.  However,  there  are  distinct  and  important  differences 5 . 
Atherosclerotic lesions originate in the tunica intima whilst aneurysmal degeneration 
affects the tunica media and adventitia6. Aneurysm disease has a particular predilection 
for the infrarenal abdominal aorta, whilst atherosclerotic disease is more widespread. 
Furthermore, aneurysm disease is more strongly associated with hypertension and 
smoking, and correlates negatively with the presence of diabetes mellitus7. 
 
 
Aneurysm disease results from a complex interaction between biomechanical factors and 
biological processes that include neovascularisation, inflammation and proteolytic 
degradation  of  the  extracellular  matrix 8 .    These  processes  do  not  affect  the  aorta 
uniformly but are focal in nature. Indeed biological and biomechanical “hotspots” are 
thought to represent regions of the aortic wall at risk of further expansion and rupture. 
Focal neovascularisation occurs at the site of rupture and corresponds to the degree of 
inflammation. Increased proteolytic activity occurs in regions of the wall with low tensile 
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strength and also at the site of rupture. Wall stresses vary in different parts of the 
aneurysm and it seems likely that rupture occurs where intense radial wall stress is 
applied to a biologically active and inflamed region of the aortic wall with reduced 
tensile strength9. 
 
1.1.2    VASCULAR SMOOTH MUSCLE CELL APOPTOSIS 
 
Vascular smooth muscle cells are the major source of extracellular matrix proteins 
including collagen and elastin. In atherosclerosis, vascular smooth muscle cells migrate 
into the intima, and can stabilise the plaque by maintaining the fibrous cap. Conversely, 
chronic vascular smooth muscle cell apoptosis is associated with plaque vulnerability and 
calcification as well as medial atrophy and aneurysm formation10 11. In aneurysm disease, 
wasting of the extracellular matrix occurs through both vascular smooth muscle cell 
apoptosis (reduced extracellular matrix production) and matrix metalloproteinase activity 
(degradation of existing collagen and elastin). Fragmentation and loss of first elastin and 
then collagen weakens the aortic wall leaving it vulnerable to expansion and rupture. In 
otherwise healthy arteries, vascular smooth muscle cell apoptosis is inconspicuous since 
phagocytic cells rapidly clear the cellular debris. In diseased arteries, however, apoptotic 
bodies appear to persist leading to a secondary pro-inflammatory necrotic response12. We 
hypothesise  that  it  is  the  balance  between  tissue  degradation  by  macrophages,  and 
extracellular matrix deposition by vascular smooth muscle cells that determines the 
initiation, progression and complications of AAA disease. 
 
1.1.3    CALCIFICATION 
 
In atherosclerotic disease, microcalcification is a key indicator of plaque vulnerability 
and its presence is associated with chronic vascular smooth muscle cell apoptosis and 
necrotic inflammation. Indeed coronary microcalcification is a strong predictor of plaque 
rupture and future cardiovascular events13. The relative risk of clinical events associated 
with coronary calcification is greater than that associated with established risk factors 
such as smoking, hypertension and diabetes mellitus, and is independently associated 
with a 3-4 fold increased risk of death14. 
 
 
Calcification is widely observed in aortic aneurysm disease and, like coronary atheroma, 
co-localises to areas of apoptosis and necrotic inflammation. In established aneurysm 
disease, regions of medial calcification contribute to increased Young’s elastic modulus, 
greater  aortic  stiffness  and  loss  of  mechanical  anisotropy15.  Load–bearing  becomes 
concentrated in regions of calcification causing heterogeneity in the distribution of wall 
stress across the aneurysm wall with an increase in the peak stresses. Irregular 
calcification therefore has the potential to induce aortic wall instability and increase 
vulnerability to rupture. We hypothesise that micro-calcification and later macro- 
calcification will occur at sites of vascular smooth muscle cell apoptosis and extracellular 
matrix depletion, and thereby localise to weakened areas of the aneurysmal aortic wall 
that are prone to expansion and rupture. 
 
1.1.4    IMAGING IN ANEURYSM DISEASE 
 
Current imaging techniques in aneurysm disease are limited to the assessment of 
aneurysm dimensions and morphology, and offer no prognostic information beyond size- 
based risk stratification. Molecular imaging techniques targeted against these biological 
‘hotspots’ in the aneurysm wall could allow the identification of patients with aneurysms 
at high risk of expansion and rupture. Positron emission and computed tomography 
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Figure 1: Fused PET-CT of atherosclerotic thoracic aorta. Upta 
fluoride in the wall of the ascending aorta, arch and descending aor 




(PET-CT) combine functional molecular imaging with high-resolution anatomical 
imaging. We have recently explored the PET radiotracer 18F -sodium fluoride (18F-NaF) 
as a marker of calcification activity in valvular heart disease and coronary 
atherosclerosis16 17. 18F-NaF has in fact been used as a bone tracer for >40 years, binding 
to hydroxyapatite, a key crystalline component of both bone and vascular calcification. 
The surface area of hydroxyapatite is much higher in regions of powdery, novel 
calcification compared to macroscopic field calcification (where much of the 
hydroxyapatite   is   internalized   and   not   available   for   binding)   so   that   18F-NaF 
preferentially binds to regions of developing calcification. It therefore acts as a marker of 
vascular calcification activity, providing complementary information to the presence of 
established calcium on CT and demonstrating a close correlation with 
immunohistochemical markers of calcification activity in excised aortic valve tissue 
(alkaline phosphatase: r=0.65, p=0.04)18. 
 
 
In previous studies we have established the methodology to measure 18F-NaF uptake in 
the cardiovascular system. In patients with aortic stenosis, 18F-NaF was detected within 
the aortic valve, often in areas of no macroscopic calcification or in areas adjacent to 
established macroscopic calcification. Moreover, baseline 18F-NaF uptake correlated not 
only with disease severity and histological measures of calcification activity, but also 
progression of valvular calcification over 1 year of follow-up 19 20. 
 
In  the  vasculature,  18F-NaF  acts  as  a  marker  of  novel  calcification  activity 21 22   23. 
Similar to other conditions, calcification in coronary atheroma occurs as a healing 
response to intense necrotic inflammation, making 18F-NaF a useful marker of high-risk 
atherosclerotic plaque. We have previously demonstrated increased uptake of this tracer 
in the coronary vasculature localising to individual coronary lesions and identifying 























ke of 18F -sodium 




More recently we have conducted a prospective study of 40 patients with myocardial 
infarction in whom 18F-NaF localised to the culprit plaque in over 90% of patients25. This 
finding was confirmed in 12 patients with a recent stroke undergoing carotid 
endarterectomy where 18F-NaF uptake was observed at the site of plaque rupture in 100% 
of patients and this uptake correlated with increased calcification activity and areas of 
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necrosis on histology. Finally we studied 40 patients with stable coronary artery disease. 
Increased uptake was observed in 45% of these patients and this again localised to 
individual coronary plaques. Interestingly these lesions were associated with multiple 
high-risk markers on radiofrequency and gray-scale intravascular ultrasound: necrotic 
core, positive remodelling and micro-calcification. 
 
During our cardiac studies, 18F-NaF uptake was observed incidentally in atherosclerotic 
regions of the thoracic and abdominal aorta as well as in aneurysmal aortae (Figure 1). 
This   activity   is   distinct   from   uptake   of   other   radiotracers,   such   as   18F- 
fluorodeoxyglucose, with which it correlated poorly26. We have also demonstrated 18F- 
NaF uptake in ex vivo autoradiography studies of human aortic wall tissue acquired from 
patients undergoing open AAA surgery and this maps to areas of tissue necrosis and 
degradation (Figure 2). Thus, as with atherosclerosis, 18F -NaF uptake identifies areas of 
tissue necrosis and apoptosis that is actively calcifying in order to limit and contain 
destructive tissue inflammation and degradation. Moreover, novel planes of calcification 
can serve to magnify and focus incident tissue stresses such that this may encourage 





























Figure  2:  18F  -NaF  is  seen  to  localise  to  areas  of  mineralisation  activity  and 
apoptosis in aneurysmal aortic wall. Histological and immunohistochemical staining of 
aortic wall for calcium (alizarin red), mineralisation metabolic activity (Alkaline 
phosphatase), osteocalcin (structural protein strongly associated with hydroxyapatite), 
apoptotic cells (cleaved caspase 3), macrophages (CD68) and smooth muscle cells (α- 
SMA).    The  computer  generated  segmentation  masks  clearly  demonstrate  positive 
staining.   The 18F-sodium fluoride autoradiography shows areas of high uptake (the 
green section outline is added to aid interpretation of co-localization). 18F-NaF can be 
seen to localise to areas of mineralisation activity and apoptosis. 
 
 
In our pilot study of 29 patients, we used magnetic resonance imaging (MRI) with 
ultrasmall superparamagnetic particles of iron oxide (USPIO) to identify cellular 
inflammation in the wall of AAA27. This approach exploits the fact that active tissue- 
resident macrophages phagocytose and concentrate the USPIOs that can then be detected 
using T2*-weighted MRI. This addresses the first mechanism of our hypothesis that 
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AAA disease initiation and progression is the result of tissue degradation by resident 
macrophages. Indeed, in this study, we were able to show that patients with focal USPIO 
uptake and inflammation in the wall of the AAA had an aneurysm expansion rate that 
was  three-fold  higher  than  those  who  did  not28. We  are  currently  confirming  these 
findings and investigating whether USPIO-MRI can predict rupture and the need for 
elective surgery in patients with AAA under surveillance (MA3RS study: MRI in AAA to 
predict rupture and the need for surgery; MRC EME   £2.2 million). As part of the 
MA3RS trial, we are currently recruiting 350 patients with AAA >40 mm in diameter 
who  will  undergo  MRI  scanning  with  USPIO  and  be  followed  up  for  2  years  to 




1.2 RATIONALE FOR STUDY 
 
The national screening programme for AAA (NAAASP) currently uses serial US 
assessments to identify patients with AAA and to monitor AAA expansion.   Elective 
surgical or endovascular AAA repair is offered to patients at high risk of rupture and this 
screening programme has reduced aneurysm-related mortality by 50% in the UK.   
Evaluation of rupture risk is currently based on aneurysm size; patients are offered 
elective repair if AAA maximum AP diameter is greater than 55 mm, or if AAA diameter 
expansion is found to exceed 10 mm per year.  However, the screening programme and 
risk evaluation are complex processes, as the growth rate of AAA is neither linear nor 
predictable.  18F-NaF PET-CT has been used in the coronary circulation to accurately 
identify atherosclerotic plaque at high risk of rupture.  We therefore propose to 
investigate the use of this imaging modality in AAA, to identify regions of necrotic 
inflammation and predict AAA expansion.  This study will run in parallel to the 
MA3RS Study, and will take advantage of some of the follow-up data that will 
already be collected for the 
MA3RS Study. 
 




2.1.1    Primary objective 
 
To  explore  whether  18F-NaF  uptake  in  the  aortic  wall  correlates  with  aneurysm 
expansion. 
 
2.1.2    Secondary objectives 
 




• occurs  in  regions  of  the  aneurysm  wall  that  show  evidence  of  active 
calcification, necrotic inflammation and proteolytic degradation 
•   is associated with focal areas of USPIO uptake on MRI 
•   corresponds with regions of high biomechanical stress 
 
2)  In volunteers who do not have an AAA, to determine whether 
there is any uptake of 18F-NaF and to compare these results 
with those patients who do have an AAA. 
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We aim to  investigate  whether  there  are  regions  of  18F-NaF  uptake  and  active 
calcification in the wall of abdominal aortic aneurysms and whether 18F-NaF uptake 
occurs in areas of mural inflammation (USPIO uptake on MRI, data to be obtained from 
The MA3RS Study), necrotic inflammation and extracellular matrix destruction. We 
propose to exploit the resources and platform of the MA3RS study to undertake 18F-NaF 
PET-CT imaging in a subset of the study cohort. This will allow us to detect any 
potential interaction between macrophage activity and necrotic inflammation, as well as 
assessing whether inflammation, vascular smooth muscle cell apoptosis and tissue necrosis 
contribute to the initiation, progression and complications of AAA disease. Through finite 
element analysis computational modelling, we will also be able to explore the relationship 
between 18F-NaF uptake and wall stresses. 
 
We will use data obtained from The MA3RS Study to assess peripheral blood biomarkers 
of inflammation (C-reactive protein and inflammatory cytokines) and protease activity 
(serum matrix metalloproteinases), as well as pulse wave analysis and an assessment of 
the  biomechanical  environment  within  the  aneurysm.    These  data  will  already  be 
collected from the MA3RS Study, however we will also collect blood for biomarkers at 
the time of the SoFIA3 Study, in order to gain real-time information about biomarkers 
present at the time of PET-CT scanning. All other information will be shared from the 
MA3RS Study results and outcome data. 
 
In addition, we will carry out a PET-CT, CT angiogram, a calcium scoring scan and Pulse 
Wave Analysis on 20 volunteers who have undergone an ultrasound as part of NAAASP 
who do not have an AAA.  This will allow comparison of age-matched controls with 
those patients who are known to have an AAA. 
 
The AAA patients will not be required to undergo any further pulse wave analysis as part 
of the study, as they will have already undergone this assessment during the MA3RS 
study visits.  The pulse wave data from AAA patients (obtained as part of MA3RS) will 




2.2.1    Primary endpoint 
 
•  Aneurysm expansion rate. 
 
2.2.2 Secondary endpoints 
 
•   Co-localisation of 18F-NaF with USPIO uptake on MRI scanning 
• Co-localisation   of   18F-NaF   with   histological   evidence   of   active 
calcification, necrotic inflammation and proteolytic degradation of the 
aneurysm wall 
•   Relationship with areas of high wall stress (finite element analysis) 
• Comparison of 18F-NaF uptake in people with AAA versus volunteers with 
no AAA 
• Comparison of Pulse Wave Analysis data in people with AAA versus 
volunteers with no AAA (using Pulse Wave Analysis data from AAA 
patients obtained as part of MA3RS) 
 
 
3          STUDY DESIGN 
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This will be a prospective observational cohort study. In patients with a known AAA, 
using 18F-NaF PET-CT, we will identify regions of active calcification and necrotic 
inflammation within the aortic aneurysm sac.  These data will be combined with data 
obtained from the MA3RS study, including histological analysis of tissue samples 
taken from participants who undergo open surgical aneurysm repair. AAA patients will 
continue to be followed up as part of the MA3RS study and will require only one 
additional visit to participate in this current study.   These results will be compared 
with the results from age-matched controls (ie volunteers who do not have an AAA).  See 
Figure 3 and Figure 4 for diagrams of patient and volunteer participation in this study. 
 






- Clinical:   PET-CT   scan   including   administration   of   IV   contrast   and 
administration of radiopharmaceutical 18F-NaF – this will take place either in 
the Clinical Research Imaging Centre (CRIC), Edinburgh or the Clinical 
Research Imaging Facility, Dundee (CRIF) 
-    Clinical: CT angiogram and calcium scoring CT – this will take place in the 
CRIC / CRIF 
- Clinical: Measurement of blood pressure and pulse – this will take place 
before the PET-CT scan at the CRIC / CRIF 
- Clinical: Withdrawal of 9ml of blood from cannula required for contrast 
injection.  Blood sampling will not require any additional needles. 
- Clinical (Volunteers only): Pulse Wave Analysis – this will take place at the 
CRF 
-    Non-clinical: Informed consent – written information will be given to the 
participant at the ultrasound surveillance clinic or via post.  Written informed 
consent will be taken at the baseline study visit prior to the scan at the CRIC / 




Total time for study visit: 60-90 minutes for AAA patients, 2-2.5 hours for volunteers 
 
We will conduct  exploratory  analyses  examining  the  interactions  between  18F-NaF 
uptake, biomechanical stress, clinical risk factors and serum biomarkers of extracellular 
matrix turnover and inflammation. 
 
Clinicians involved directly with patient surveillance and care will be blinded to the 
PET-CT findings of 18F-NaF uptake.
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• BP and pulse measurement 
- Blood sampling  
• 18F-NaF administration 
• PET-CT performed at 60 min 
• Calcium scoring CT 
• CT angiogram 

















Patients will continue to be followed up as part of the MA3RS study.  No further study 
visits required as part of SoFIA3. 
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Figure 4: VOLUNTEERS (no AAA) 
 
 
Volunteers who have had an ultrasound scan as part of the NAAASP and do not 

































 Baseline Assessment (1 day) 
 
• Consent 
• BP and Pulse Wave Analysis 
Blood sampling  
• 18F-NaF administration 
• PET-CT performed at 60 min 

















No further study visits or follow-up required as part of SoFIA3. 
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4    STUDY POPULATION 
 
Participants with AAA will be identified from the MA3RS study database.  Participants 
will already be enrolled and under follow up in the MA3RS study (ISRCTN76413758).  
Volunteers will be identified through the NAAASP ultrasound clinic – they will have 
attended for an ultrasound scan, which has demonstrated that they do not have an AAA. 
 
4.1.      Number of participants 
 
Patients with AAA: 
We aim to recruit 100 patients with AAA.  AAA patients will already be enrolled and 
under follow up in the MA3RS study.   Enrolment for the MA3RS study commenced in 
November 2012 and was completed in December 2014.  As part of the MA3RS study, a 
subset (n=80) of patients will undergo reproducibility MRI scans at 12 months.  We 
will also aim to carry out repeat MRI scans at 2 years in a further 40 patients.  The 
patients involved in repeat MRI scanning will also be approached for co-enrolment in 
SoFIA3.    
 
 
Volunteers with no AAA: 
We aim to recruit 20 volunteers with no AAA, as demonstrated on an ultrasound scan 
performed as part of the NAAASP. 
 
 
4.2       Inclusion criteria 
 
AAA patients: 
•   Patients already enrolled in the MA3RS study 
• Patients with abdominal  aortic  aneurysm  with  AP  diameter  >40  mm  on 
ultrasound 
• >50 years of age.  Patients <50 years of age may have a connective tissue disorder 
and a different disease aetiology 
 
Volunteers: 
• Participants who have attended for an ultrasound scan as part of the NAAASP who 
do not have an AAA 
• >50 years of age 
 
 




•   Patients expected to undergo imminent AAA repair 
•   Patients who refuse or are unable to give informed consent 
•   Women of child-bearing potential without contraception 
•   Patients who are unable to undergo PET-CT scan 
•   Patients with collagen vascular disease 
•   Intercurrent illness, malignancy or comorbidity with life expectancy <1 year 
•   Renal dysfunction (eGFR <30ml/min/1.73m2) 
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•   Contraindication to PET-CT or CTA 
•   Iodine allergy 
 
Volunteers: 
• Volunteers who refuse or are unable to give informed consent 
• Women of child-bearing potential without contraception 
•  Patients who are unable to undergo PET-CT scan 
• Participants with collagen vascular disease 
• Intercurrent illness, malignancy or comorbidity with life expectancy <1 year 
• Renal dysfunction (eGFR <30ml/min/1.73m2) 
• Contraindication to PET-CT or CTA 
• Iodine allergy 
 
 
5    PARTICIPANT SELECTION AND ENROLMENT 
 
5.1       IDENTIFYING PARTICIPANTS 
 
AAA participants will be identified from the participant list of the MA3RS study, 
which is based on ultrasound surveillance programme databases at the Royal Infirmary of 
Edinburgh.  Volunteers will be identified from the NAAASP database at the Royal 
Infirmary of Edinburgh. 
 
5.2       CONSENTING PARTICIPANTS 
 
Participants will be given written information (in the form of a Patient Information 
Leaflet)  at  the  time  of  screening  at  the  ultrasound  surveillance  clinic  or  via  
post, following initial contact with the PI.  Written informed consent will be taken 
by the PI (Dr Rachael Forsythe) prior to the PET-CT scan at the baseline scan visit.  
This will take place at the CRIC, Edinburgh or the CRIF, Dundee. 
 




AAA patients: Once AAA patients have been identified from the MA3RS database, 
they will be seen at their 12 month surveillance US appointment (standard clinical 
care) and eligibility will be assessed.  Eligibility will be confirmed prior to consent. If 
patients are not seen in the US appointment, the study will be discussed with the patient 
over the phone and study information sent to them in the post.  
 
Volunteers: Once volunteers have been identified from the NAAASP database, they 
will be assessed for eligibility after their NAAASP scan visit (standard clinical care).  If 
volunteers are not seen at the NAAASP visit, the study will be discussed over the phone 
and information sent to them in the post.   
 
All participants: An appointment will be made for a baseline visit (where consent 
takes place) for all patients and volunteers who are eligible and are interested in taking 
part. 
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5.4       INELIGIBLE AND NON-RECRUITED PARTICIPANTS 
 
 
Ineligible and non-recruited participants will receive standard medical care. An 
anonymised log will be kept for participants who were screened for the study and 
subsequently found to be ineligible or not recruited. 
 
 
5.5       PREMATURE WITHDRAWAL 
 
Participants are free to withdraw from the study at any point and a participant can also be 
withdrawn from the study by an investigator.  If withdrawal occurs, the primary reason 
for withdrawal will be documented in the participant’s Case Report Form (CRF). 
 
If a participant who has consented for the study states that they wish to be withdrawn 
from the study before they have been administered 18F-NaF, they will be withdrawn from 
the study and another participant will be recruited in their place. 
 
5.6       RANDOMISATION 
 
There is no randomisation in this study 
 
6    INVESTIGATIONAL MEDICAL PRODUCT AND PLACEBO 
 
This study does not involve investigational medical products 
 
7    STUDY ASSESSMENTS 
 
 
A preliminary assessment of eligibility will be conducted by a suitably qualified member 
of the research team.   See Table 1 for the assessments performed at each study visit. 
This table does not illustrate the assessments which will already be planned for the 





Screening/Eligibility! √!  
 
Consent  √ 
 
Blood sampling, PET-CT scan, calcium 
scoring scan and CT 
angiogram of AAA *! 
 √ 
 
Pulse Wave Analysis (volunteers only) 	  √  
 
AE/SAE Reporting! !    
Table 1 
SV = surveillance clinic visit; BV(a) = Baseline visit (occurs within 1 month of SV) 
* Where patients are to undergo elective repair of their aneurysms during follow up, a 
repeat CT scan will be performed prior to surgery. 
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7.1       Additional assessments: 
All AAA patients will already be enrolled in the MA3RS study, which involves additional 
assessments not detailed in this protocol.   These include MRI scan, CT angiogram, 
clinical assessment, pulse wave analysis, blood tests, tissue sampling.   Data from the 
MA3RS study will be shared with this current study, in order to reduce the number of 
additional assessments required.  Volunteers will not require any additional assessments. 
 
 
7.2       Safety assessments 
 
 
In participants with no history of renal disease, hypertension or diabetes, a normal eGFR 
within the last six months will be considered to be acceptable. For patients with risk 
factors for renal dysfunction or no blood tests within the last 6 months, clinical 




All participants are advised to drink water prior to their scan for adequate hydration. For 
participants with a normal eGFR (≥60 mL/min/1.73 m2) and taking metformin they 
should continue taking the medication up until the scan.  After the scan they should 
withhold metformin for 48 h and then have a blood test to check renal function.   They 
will be informed when they are to restart the Metformin following the result of this. 
 
 
For participants with an eGFR 30–60 mL/min/1.73 m2  and taking metformin they will 
be advised to stop the medication for 48 h before and 48 h after the scan.  They will then 
have a blood test to check renal function and informed when they are to restart the 
metformin following the result of this. 
 
 
These safety assessments are part of standard clinical care with regards to PET-CT 
scanning with an intravenous contrast agent. 
 
 
Participants will be advised to avoid close contact with children for 12 h following the 
PET- CT scan.  This is precautionary and is part of standard clinical care with regards 




8    DATA COLLECTION 
 
 
8.1       Clinical Assessment 
 
All AAA patients will undergo clinical evaluation as part of the MA3RS study.  Apart 
from blood pressure and pulse measurement before and after administration of 18F-NaF, 
no additional clinical assessment will be performed as part of the current study, 
however 
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clinical assessment information will be shared between the two studies.  This is in order 
to minimise duplication of assessments and to reduce the extra time required for 
participation in the SoFIA3 study. 
 
 
8.2       Blood and Tissue Assays 
 
 
Information from the MA3RS study will be shared with the current study.  A further 
sample of blood will be obtained from the cannula required for the SoFIA3 study, in order 




8.3       Positron emission and computed tomography (PET-CT) 
 
 
Participants will undergo combined positron emission tomography computed tomography 
(PET-CT) scanning 60 min after the administration of 18F-NaF. Previous studies have 
shown that this time point provides excellent contrast between the artery wall and blood 
pool. A scout CT scan will be followed by a low-dose computed tomography scan, to 
allow attenuation correction, and a calcium scoring CT scan Positron emission 
tomographic data will then be acquired over two bed positions centred over the aneurysm 
for 10 min each. Finally a CT angiogram will be acquired of the aneurysm following 
contrast  administration  to  provide  detailed  anatomical  information  on  which  to  co- 
register the PET data. 
 
 
8.4       Follow-up 
 
AAA patients will continue to be followed up as part of the MA3RS study.   They will 
also continue  with  standard  care  using  ultrasound  scanning  (baseline,  6  months  and  
12 months) to determine the aneurysm expansion rate.  Volunteers will not require any 
further follow up after the SoFIA3 scan visit. 
 
 
9          STATISTICS AND DATA ANALYSIS 
 
 
9.1       SAMPLE SIZE CALCULATION 
 
 
The sample size for the study is based on data from our previous pilot studies where the 
overall aneurysm growth rates were 4.2±4.0 mm/year.29 We have previously observed a 
difference in growth rate of 6.6 versus 2.2 mm/year in AAA with and without USPIO 
uptake  respectively.29   To  observe  a  more  conservative  effect  size  of  50%  of  this 
difference (2.2 mm/yr) at 80% power and assuming that half of all aneurysms will 
demonstrate 18F-NaF uptake (c.f. coronary atheroma [Joshi et al, 2014]), we will need a 




9.2       PROPOSED ANALYSES 
 
9.2.1    Image analysis of 18F-NaF PET-CT 
 
18F-NaF uptake: Static positron emission and computed tomographic images will be 
reconstructed with corrections applied for attenuation, dead time, scatter and random 
coincidences, using an optimised iterative reconstruction algorithm. To estimate 18F-NaF 
concentrations, 3D volumes of interest (VOI) will be drawn around the aorta on the 
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computed tomography images. From these VOI, we will derive the mean and maximum 
standardised uptake values (SUV): a widely used, validated measure of tissue 18F-NaF 
uptake. Tissue-to-background ratios (TBR) will be calculated after correction for blood 
pool activity in the superior vena cava. Increased 18F -NaF uptake will be defined as TBR 
≥1.25 as previously defined in a study using healthy controls to set the threshold.30  31 
We will explore the patterns of uptake throughout the AAA wall, to identify areas of 
active (TBR ≥1.25) and inactive (TBR <1.25) calcification.   We will explore whether 
there are focal areas of increased 18F–NaF uptake (TBR ≥1.25) that correspond to focal 
areas of USPIO uptake (as identified in the MA3RS study) and/or focal or overall 
aneurysm expansion. We also explore modelling of different thresholds to assess the 
optimum sensitivity for detecting higher aneurysm growth rates and we will identify the 
threshold which gives a 50:50 split of patients into those with and without uptake, to 
maximise the sensitivity of the primary comparison described in Section 9.1. 
 
 
Calcium Scoring: The aortic calcium score will be  calculated on axial scans using 
calcium score analysis software (VScore, Vital Images, Minnetonka, Minnesota). 
 
 
Computed tomography growth assessment: Three-dimensional computer models will be 
generated from segmented, contrast-enhanced images allowing geometric indices to be 
quantified. Semi-automatic segmentation is achievable due to the intensity differences 
between the aneurysm and surrounding tissues and structures. Intensity thresholding will 
be used to identify the lumen. To detect the thrombus and complete the segmentation, we 
will use a 3-D deformable model approach that utilises the level set algorithm as well as 
modelling the thrombus contour as a radial function starting from the aortic centre line as 
calculated from the lumen segmentation. 
 
 
Assessment of growth changes:  Changes in AAA growth will be determined using the 
measurement  of  AAA  maximum  AP  diameter  on  the  screening  ultrasound  scan 
performed 6 months prior to the SoFIA3 scanning visit (ie as part of normal clinical care) 
and the ultrasound scan performed 6 months after the SoFIA3 scanning visit (ie as part of 
normal clinical care). We will also explore the effect of 18F–NaF uptake on focal 
aneurysm expansion using baseline and final CT aortograms. 
 
 
9.2.2    Biomechanical analysis 
 
 
Using Abaqus, the vessel wall will be modelled as a constant thickness layer of 1.5 mm, 
with a hyperelastic constitutive model. Thrombus will be modelled as homogenous and 
isotropic with Young’s modulus 0.1 MPa. The model will be inflated from diastolic to 
systolic pressure using a homogeneous pressure-modelling regime. Peak wall stress and 
other rupture indices will be calculated and compared against areas of USPIO uptake. 
 
 
9.2.3    Statistical analysis 
 
 
Data sharing: A summary of demographics will be shared with the SoFIA3 study from 
the MA3RS study.   The SoFIA3  researchers will have access to the images obtained 
during the SoFIA3  scanning visit and the MRI images obtained during the MA3RS 
scanning visits.   The SoFIA3  study will require access to a cleaned, quality-checked 
extract of data from the MA3RS study, however this will not include clinical data 
pertaining to MA3RS primary outcomes. 
 
 
The primary end-point of AAA growth rate will be compared between those with and 
those without 18F-NaF uptake using an unpaired Student’s t-test. Statistical significance 
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will be taken at the two-sided 5% level. We will assess the level of agreement between 
18F-NaF uptake and histological evidence of necrotic inflammation and MRI USPIO 
uptake  using  regression  analysis  and  the  kappa  statistic.  Statistical  analysis  will  be 
carried out by the PI under the supervision of the CI and study statistician. 
 
 
We may also explore whether 18F-NaF uptake adds value to the MA3RS analysis in this 
small subset of patients, using clinical data obtained from the MA3RS study.  This would 
be on a strictly exploratory basis, as the SoFIA3  study is not sufficiently powered to 
predict clinical outcomes. 
 
 
10        ADVERSE EVENTS 
 
 
The Investigator is responsible for the detection and documentation of events meeting the 
criteria and definitions detailed below. 
 
Participants will be instructed to contact their Investigator at any time after consenting to 
join the study if any symptoms develop.  All adverse events (AE) that require medical 
attention (for example, visit to a GP, hospital etc) must be reported in detail in the Case 
Report Form (CRF) or AE form.  In the case of an AE, the Investigator should initiate the 
appropriate  treatment  according  to  their  medical  judgment.    Participants  with  AEs 
present at the last visit must be followed up until resolution of the event. 
 
 
10.1       DEFINITIONS 
 
An adverse event (AE) is any untoward medical occurrence in a clinical trial participant 
which does not necessarily have a causal relationship with an investigational medicinal 
product (IMP). 
 
A serious adverse event (SAE), is any AE: 
 
•       results in death; 
•       is life threatening* (i.e. the participant was at risk of death at the time of the event; 
it does not refer to an event which hypothetically might have caused death if it 
were more severe); 
•       requires in-patient hospitalisation or prolongation of existing hospitalisation; 
•       results in persistent or significant disability or incapacity; 





10.2       DETECTING AEs AND SAEs 
 
All AEs and SAEs will be recorded from the time a participant signs the consent form to 
take part in the study until the last study visit. 
 
Participants will be asked about the occurrence of AEs/SAEs at every visit during the 
study.  Open-ended and non-leading verbal questioning of the participant will be used to 
enquire about AE/SAE occurrence.   Participants will also be asked if they have been 
admitted to hospital or had any accidents. If there is any doubt as to whether a clinical 
observation is an AE, the event will be recorded. 
 
AEs and SAEs may also be identified by support departments e.g. laboratories. 
 
10.3       RECORDING AEs AND SAEs 
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When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation  (e.g.  hospital  notes,  laboratory  and  diagnostic  reports)  related  to  the 
event.  The Investigator will then record all relevant information in the CRF and on the 
SAE form (if the AE meets the criteria of serious). 
 
Information to be collected includes dose, type of event, onset date, Investigator 
assessment of severity and causality, date of resolution as well as treatment required, 
investigations needed and outcome. 
 
10.4       ASSESSMENT OF AEs AND SAEs 
 
The Investigator is responsible for assessing each AE. 
 
10.4.1    Assessment of Seriousness 
 
The Investigator will make an assessment of seriousness as defined in Section 10.1. 
 
10.4.2    Assessment of Severity 
 
The Investigator will make an assessment of severity for each AE/SAE and record this on 
the CRF or AE form according to one of the following categories: 
 
Mild: an event that is easily tolerated by the participant, causing minimal discomfort and 
not interfering with every day activities. 
 
Moderate: an event that is sufficiently discomforting to interfere with normal everyday 
activities. 
 
Severe: an event that prevents normal everyday activities. 
 
Note: the term ‘severe’, used to describe the intensity, should not be confused with 
‘serious’ which is a regulatory definition based on participant/event outcome or action 
criteria.  For example, a headache may be severe but not serious, while a minor stroke is 
serious but may not be severe. 
 
10.5       REPORTING OF SAEs 
 
Once the Investigator becomes aware that an SAE has occurred in a study participant, the 
information will be reported to the ACCORD Research Governance & QA Office 
immediately  or  within  24 hours.  If  the  Investigator  does  not  have  all  information 
regarding an SAE, they should not wait for this additional information before notifying 
ACCORD.   The SAE report form can be updated when the additional information is 
received. 
 
The SAE form will be transmitted by fax to ACCORD on +44 (0)131 242 9447 or may 
be transmitted by hand to the office. 
 
All reports faxed to ACCORD and any follow up information will be retained by the 
Investigator in the Investigator Site File (ISF). 
 
 
10.6       FOLLOW UP PROCEDURES 
 
After initially recording an AE or recording and reporting an SAE, the Investigator will 
follow  each  participant  until  resolution  or  death  of  the  participant.     Follow  up 
information on an SAE will be reported to the ACCORD office. 
 
AEs still present in participants at the last study visit will be monitored until resolution of 




11.       PREGNANCY 
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Woman with child-bearing potential will not be enrolled into the trial (woman who 








Study  management  will  be  overseen  by  the  Principal  Investigator,  who  will  be 
accountable to the Chief Investigator.  Any requirement for monitoring or audit by the 








12.1  PET-CT, calcium scoring CT and CT 
angiogram 
 
As part of the protocol, subjects will receive 18F-NaF PET-CT scans. This will expose 
the patient to ionising radiation and a mildly radioactive tracer (18F-NaF), as well as the 
potential hazard of allergic reactions and transient renal dysfunction in response to the 
contrast agent.  See Table 2 and Table 3. 
 
The risks of exposure to the contrast medium include allergic reactions and 
impairment of kidney function. Amongst participants with moderate-to-severe chronic 
kidney disease, there is a 2-4% risk of kidney impairment after computed 
tomography angiography.38 
The risk of contrast exposure in this study will be minimised by exclusion of high risk 
participants who have significant kidney disease (estimated glomerular filtration rate 
≤30 mL/min/1.73 m2). 
 
Participants undergoing PET-CT are routinely advised to avoid close contact with 
children for 12 hours following the scan.  This is to avoid any unnecessary exposure to 
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Type of investigation! PET-CT! 
Radionuclide! 18F! 
Chemical form! Fluoride! 
Proposed activity (mSv)! 125 MBq 
Route of administration! Intravenous! 
Number  of  administrations 
per participant! 
1! 
Effective   dose   or   target 












1 1 1 
Estimated procedure dosed 3 5 5 
 
    















a. ARSAC Notes for Guidance on the Clinical Administration of Radiopharmaceuticals and Use of Sealed Radioactive Sources -March 












Typical patient dose , based on average patient doses for study centre 
c 
Taken from Chuang et al. Academic Radiology. 20 (11) (pp 1422-1428) 2013, with uplift to account for variation between scanner 
models 
d Utilising scanner –specific dose-length product to effective dose conversion factor based on ICRP 103 tissue weighting factors 
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13. GOOD CLINICAL PRACTICE 
 
13.1 Ethical conduct 
 
A favourable ethical opinion will be obtained from the appropriate REC and local R&D 
approval will be obtained prior to commencement of this study. 
 
13.2 Investigator responsibilities 
 
The Chief Investigator will be responsible for the overall conduct of the study, however 
tasks may be delegated to other members of the team. 
 
13.3 Informed consent 
 
The Investigators are responsible for ensuring informed written consent is obtained prior 
to involvement in the study.   The decision to participate in the study is voluntary and 
should be based on a clear understanding of what is involved. 
 
Formal  written  and  verbal  information  will  be  given  to  prospective  participants, 
including Patient Information Sheets and Consent Forms, which will also be signed and 
dated by the person taking consent. 
 
Participants must be given every opportunity to ask questions before and during the study 
and to withdraw consent at any time. 
 
Participants will be aware that their medical records may be accessed for additional 
information and confidential data shared only with members of the study team.   Any 




All records must be identified in a manner designed to maintain confidentiality, in a 
secure area with limited access.   The study team members shall not disclose any 
confidential information for any other reason outside of this study. 
 
13.5 Data Protection 
 
All study team members must comply with the requirement of the Data Protection Act 
1998 with regards to the collection, storage, processing and disclosure of personal 
information and will uphold the Act’s core principles.  Access to participant data will be 
restricted to those clinicians directly involved in the study or patient care. 
 
Computers used to access participant details will have password protection and limited 
access. 
 
Published results will not include any patient identifiable data. 
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14. STUDY CONDUCT RESPONSIBILITIES 
 
14.1 Protocol amendments 
 
Any changes or amendments must be approved by the Supervising Investigator.   Any 
major amendments must be submitted for re-review. 
 
14.2 End of Study 
 
The  end  of  the  study  will  be  defined  by  the  participation  of  the  total  number  of 
participants required as per the power calculation. 
 
14.3 Insurance and indemnity 
 
Sites participating in the study will be liable for clinical negligence and covered by the 
duty of care owed to them by the sites concerned. 
There will be the benefit of NHS indemnity in sites which are part of the UK NHS. 
The details of indemnity and insurance will be clarified in the REC application. 
 
15. REPORTING, PUBLICATION AND NOTIFICATION OF RESULTS 
 
15.1 Authorship policy 
 




Results of this study may be used for publication and presentation at scientific meetings. 
The Principal Investigator has the right to publish the results of the study orally or in 
writing.   Summaries of the results may also be made available for dissemination in 
clinics, if appropriate. 
 
15.3 Peer review 
 
Prior to commencement of this study, it shall undergo peer review by the local REC. 
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atherosclerosis	of	 the	 internal	 carotid	 artery.2	Atherosclerosis	 is	 a	 complex	disease	of	 the	
large	 arteries	 characterised	 by	 persistent	 inflammation,	 lipid	 accumulation,	 angiogenesis,	
and	 necrosis.3	 In	 the	 carotid	 circulation,	 it	 usually	 remains	 asymptomatic	 until	 a	 critical	
burden	 of	 luminal	 atheroma	 is	 reached	 that	 may	 ultimately	 rupture,	 thrombose	 and	






suggest	 that	CEA	 is	 indicated	when	 luminal	stenosis	of	carotid	artery	exceeds	50%	 in	men	
and	70%	in	women,	as	at	this	threshold	the	recurrent	risk	of	stroke	equals	or	exceeds	the	
risk	 of	 surgery.10	 11	 Unfortunately,	 this	 anatomical	 quantification	 of	 luminal	 stenosis	 has	
limitations.	First,	it	does	not	take	account	of	positive	remodelling,	which	plays	an	important	
role	 in	 lumen	 preservation	 that	 is	 responsible	 for	 a	 delayed	 clinical	 manifestation	 of	
atherosclerosis.3	12	13	Thus,	it	may	underestimate	the	degree	of	cross-sectional	area	stenosis	
including	 associated	 risks.	 Second,	 luminal	 stenosis	 provides	 no	 information	 on	 the	
biological	 activity	 of	 the	 plaque.	 	 Histological	 data	 show	 that	 inflammation,	 cell	 death,	
microcalcification	 and	 intraplaque	 haemorrhage	 are	 key	 features	 in	 driving	 both	 carotid	
plaque	formation	and	instability.14-17	These	high-risk	plaques	add	to	the	independent	risk	of	
ipsilateral	TIA	or	ischaemic	stroke	provided	by	the	severity	of	carotid	artery	stenosis	alone.15	
18	 19	 Third,	 only	 50-60%	 of	 recently	 symptomatic	 carotid	 plaques	 removed	 during	 CEA	
demonstrate	rupture.6		
Strong	evidence	from	histological	and	imaging	derived	markers	of	risk	have	so	far	made	no	
impact	 on	 the	 North	 American	 Symptomatic	 Carotid	 Endarterectomy	 Trial	 (NASCET)	
recommendations.18-22	 These	 observations	 indicate	 that	 assessment	 of	 carotid	 artery	
stenosis	 remains	 complex	 and	 that	 ipsilateral	 plaque	 morphology	 requires	 re-evaluation.	
Selection	of	patients	based	 solely	on	 the	 severity	of	a	 stenosis	 is	no	 longer	adequate	and	










The	 ability	 to	 identify	 the	 culprit	 carotid	 plaque	 represents	 a	 key	 goal	 in	 carotid	 artery	
imaging.	However,	this	remains	challenging	for	number	of	reasons	including	the	suboptimal	
evaluation	 of	 carotid	 plaque	 morphology,	 disease	 activity	 and	 future	 stroke	 risk	
stratification.		
Current	 non-invasive	 imaging	 technologies	 have	 been	 validated	without	 any	 standardised	
methodology	 of	 grading	 the	 severity	 of	 carotid	 artery	 stenosis	 with	 the	 outdated	 intra-
arterial	 angiography	 often	 used	 as	 a	 reference	 point.23-26	 This	 has	 resulted	 in	 a	 biased	
consensus	in	the	literature	that	tends	to	overestimate	true	sensitivity	and	specificity	of	non-
invasive	 imaging	 techniques.26	 27	 Meta-analyses	 demonstrate	 that	 contrast-enhanced	
magnetic	 resonance	 was	 the	 most	 sensitive	 and	 specific	 technique	 for	 detection	 of	
symptomatic	 70-99%	 carotid	 artery	 stenosis	 when	 compared	 with	 Duplex	 Ultrasound,	
Computed	Tomography	Angiography	and	Magnetic	Resonance	Angiography.23	 26	However,	
each	 of	 the	 aforementioned	 imaging	 modalities	 demonstrated	 low	 sensitivity	 in	 the	
detection	 of	 	 moderate	 (50-70%)	 carotid	 artery	 stenosis.26	 This	 was	 particularly	 evident	
when	images	were	obtained	by	Duplex	Ultrasound	and	Magnetic	Resonance	Angiography.26	
This	 is	 an	 important	 issue	 because	 imprecise	 stenosis	 calculation	 can	 lead	 either	 to	




the	 risk	 of	 stroke	 remains	 unchanged.28	 Recent	 data	 have	 shown	 that	 patients	 with	
symptomatic	 mild	 (20-49%)	 carotid	 artery	 stenosis	 treated	 with	 optimal	 medical	 therapy	
(OMT)	had	a	higher	risk	of	recurrent	ipsilateral	stroke	of	7.4%	when	compared	with	both	an	
asymptomatic	 group	 with	 similar	 degree	 of	 stenosis	 and	 a	 symptomatic	 cohort	 with	
moderate	 or	 severe	 stenoses.29	 This	 implies	 that	we	 need	 to	 look	 beyond	 the	 traditional	
paradigm	where	 the	 basis	 for	 CEA	were	 formulated	 by	 an	 invasive	 imaging	modality	 that	
provided	no	information	on	the	arterial	wall	composition.30		
Finally,	 overwhelming	 histological	 data	 suggests	 that	 specific	 plaque	 components	 identify	
patients	at	high-risk	for	future	ipsilateral	stroke	and	cardiovascular	events.31	32	Although	an	
array	 of	 non-invasive	 imaging	 techniques	 can	 detect	 a	 wide	 spectrum	 of	 complementary	


























prior	 to	 any	 vascular	 intervention.	 CTA	 can	 delineate	 a	 heterogeneous,	 calcified30	 and	
ulcerated	 atheroma,30	 41	 and	 can	 identify	 intra-plaque	 haemorrhage	 and	 intra-luminal	
thrombus.31	42	When	colour	duplex	ultrasound	may	be	overestimating	the	degree	of	carotid	






lipid-rich	 necrotic	 core,	 intra-plaque	 haemorrhage,	 cap	 thickness,	 ulceration	 and	 plaque	
rupture.15	 31	 43	 44	 However,	 MRA	 use	 is	 limited	 by	 the	 exclusion	 of	 patients	 with	 certain	
metallic	implants	and	claustrophobia,	it	is	also	more	expensive,	takes	longer	to	perform,	and	
requires	 a	 greater	 degree	 of	 co-operation	 than	 either	 colour	 duplex	 ultrasound	 or	 CTA.31	




Overall,	 currently	 available	 imaging	 technologies	 have	 strengths	 but	 are	 unable	 to	
characterise	carotid	plaque	biology	and	activity	fully,	and	lack	the	capacity	to	identify	culprit	
carotid	 plaque	 reliably.	 This	 is	 fundamental	 to	 optimal	 risk-stratification	 and	 appropriate	








Positron	 emission	 tomography	 demonstrates	 high	 sensitivity	 for	 the	 non-invasive,	 in	 vivo	
detection	 of	 radiolabelled	 biomolecules	 in	 a	 variety	 of	 pathophysiological	 processes.	
Atherosclerotic	 calcification	 in	 carotid	 arteries	 occurs	 in	 response	 to	 unresolved	 chronic	
inflammation	 within	 the	 plaque	 and	 represents	 an	 attempt	 to	 contain	 and	 isolate	 the	
necrotic	area,	thus	preventing	plaque	rupture	with	its	thrombotic	consequences.	However,	
detection	 of	 early	 vascular	 calcification	 is	 difficult	 because	 we	 can	 only	monitor	 the	 late	
stages	 of	 the	 disease	 when	 calcium	 deposition	 has	 become	 confluent	 and	 large	 enough	
(macrocalcification,	 diameter	 >50	 μm)	 to	 be	 detected	 by	 computed	 tomography.	 Our	
research	group	has	pioneered	research	into	the	early	microcalcification	(<50	μm)	in	human	
diseased	cardiovascular	 tissue	using	 18F-Fluoride	by	validating	 the	mechanism	of	action	of	
18F-Fluoride	 in	 highlighting	 high-risk	 atherosclerotic	 plaque.	 We	 have	 shown	 that	 the	
phenomenon	is	 likely	to	be	mediated	by	the	ability	of	the	radiotracer	to	identify	early	and	
pathologically	high-risk	micro-calcification	well	beyond	 the	 resolution	of	clinical	 computed	
tomography.13	 We	 have	 demonstrated	 that	 18F-Fluoride	 Positron	 Emission	 Tomography-
Computed	 Tomography	 (18F	 PET-CT)	 identifies	 both	 culprit	 plaque	 in	 patients	 following	
myocardial	 infarction	and	plaques	with	high-risk	 features	 in	patients	with	 stable	 angina.12	
We	 have	 also	 confirmed	 18F-Fluoride	 uptake	 in	 the	 aortic	 valve	 correlates	 with	 stenosis	
severity	 and	 identifies	 areas	 of	 newly	 developing	 calcification	 that	 are	 beyond	 standard	
computed	tomography	resolution.		
We	have	recently	reported	ex	vivo	and	in	vivo	carotid	plaque	data	showing	high	18F-Fluoride	
uptake	 localises	 to	 areas	 of	 plaque	 rupture	 that	 showed	 greater	 immunostaining	 for	
markers	 of	macrophage	 infiltration,	 cell	 death	 and	 active	 calcification	when	 compared	 to	
areas	 of	 low	uptake.	 	Moreover,	we	have	 shown	
that	 in	 patients	 with	 carotid	 stenosis	 and	 recent	
neurovascular	 symptoms,	 18F	 PET-CT	was	 able	 to	
discriminate	 between	 culprit	 and	 non-culprit	
plaques	 (Figure	 1);	 the	 carotid	 ipsilateral	 to	 the	
affected	 cerebral	 hemisphere	 showed	 higher	
uptake	 of	 18F-Fluoride	 compared	 to	 either	 its	
contra-lateral	 partner	or	 to	 carotids	 from	control	
stroke	patients.	Carotid	uptake	of	18F-Fluoride	was	
focal,	 readily	 identifiable	 and	quantifiable.	 Tracer	
uptake	was	 also	 associated	with	 high-risk	 plaque	
features	 and	 with	 predicted	 cardiovascular	 risk.	
Therefore,	 we	 have	 shown	 that	 18F-Fluoride	
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and	 may	 thus	 identify	 high-risk	 ruptured	 carotid	 plaque	 in	 patients	 with	 recent	
cerebrovascular	events.		
1.4	Hybrid	Magnetic	Resonance	Imaging	-	18F-Fluoride	Positron	Emission	Tomography	
Positron	 Emission	 Tomography	 (PET)	 has	 traditionally	 been	 combined	 with	 computed	
tomography	(CT)	as	PET-CT,	but	recently,	novel	hybrid	systems	combining	PET	and	magnetic	
resonance	 imaging	 (MRI),	 have	 become	 available.14	 These	 systems	 have	 been	 developed	
with	 the	 specific	 intention	 of	 combining	 PET	with	 the	 generic	 advantages	 that	MRI	 holds	
over	 CT;	 principally	 improved	 soft	 tissue	 contrast,	 lack	 of	 radiation	 exposure,	 lack	 of	
requirement	for	iodine-based	contrast	media,	and	the	potential	for	full	motion	correction	of	
PET	data.	MRI	offers	multiple	other	 key	advantages	over	CT	when	 specifically	 considering	
the	 carotid	 arteries.	 CT	 is	 limited	 by	 “one-dimensional”	 plaque	 segmentation	 (i.e.	 based	
purely	 on	 photon	 attenuation)	 and	 blooming	 artefact	 from	 dense	 calcification.	 By	
comparison,	MRI	offers	superior	soft	tissue	detail	at	high	resolution	and	can	better	segment	
plaque	 by	 exploiting	 the	 varying	 T1/T2	 properties	 and	 proton	 density	 of	 different	 lesion	







increase	 in	 cerebrovascular	 events	 in	
patients	 with	 high-intensity	 carotid	
plaques	 on	 T1-weighted	 imaging.19	
Figure	 2	 shows	 an	 example	 from	 our	
institution	 of	 a	 recently	 symptomatic	
patient	 scanned	with	 both	 18F	 PET-CT	
and	MRI.	This	large	plaque	shows	both	
intense	 uptake	 of	 radiotracer	 and	
hyperintensity	 on	 T1-weighted	
imaging.	 At	 surgery,	 this	 lesion	 was	
ruptured	 with	 a	 large	 amount	 of	





of	 the	 brain	 parenchyma	 looking	 for	
acute	and	sub-clinical	evidence	of		
 
Figure	 2.	 Symptomatic	 carotid	 plaque	 on	 MRA	 (3T)	 and																
18F	 PET-CT.	 The	 red	 arrow	 denotes	 the	 lumen	 of	 the	 internal	
carotid	artery,	 and	 the	yellow	 star	denotes	 culprit	haemorrhagic	
plaque	 with	 intense	 18F-Fluoride	 uptake.	 (A)	 Axial	 time-of-flight	
















MRS	 identifies	 and	 quantifies	 various	 metabolites	 in	 tissues	 including	 liquid	 phase	
cholesteryl	 ester	 in	ex	 vivo	 atherosclerotic	 plaques.45	 47	 48	 This	 is	 of	 particular	 importance	
since	the	early	stages	of	atherosclerosis	are	characterised	by	the	deposition	of	cholesteryl	
ester	in	the	foam	cell	as	"fatty	streaks".49	50	Furthermore,	the	liquid	cholesteryl	ester	is	the	
major	 class	 of	 lipids	 found	 within	 the	 atheroma	 lipid-rich	 necrotic	 cores	 associated	 with	
plaque	 rupture.51	 Hence,	 quantification	 of	 specific	 lipid	 content	 can	 provide	 vital	
information	 central	 to	 the	 pathophysiology	 of	 atherosclerosis	 and	 potentially	 aid	 in	 the	
identification	of	culprit	carotid	plaque.			
Although	both	 cholesterol	 and	 cholesteryl	 ester	 accumulate	pathologically	 in	 the	 arteries,	
their	 imaging	 is	 challenging.	 MRI	 lacks	 the	 capacity	 to	 differentiate	 specific	 lipid	 plaque	
components.	In	general,	lipid	regions	are	inhomogeneous,	and	cholesterol	crystals	create	a	




that	 have	 been	 confirmed	 on	 histology.47-53	 Moreover,	 plaque	 lipids	 can	 undergo	
thermotopic	 transitions	 between	 liquid	 and	 solid	 phases,	 and	 the	 physical	 state	 of	
cholesteryl	ester	influences	enzymatic	activities,	lipids	transport,	and	storage;	all	which	are	
essential	 in	 atherogenesis.50	 There	 is	 no	 doubt	 that	 the	 chemical	 composition	 of	 plaque	
lipids	 influences	 the	 stability	 of	 a	 plaque	 as	 well	 as	 their	 potential	 for	 regression.52	
Ultimately,	 a	 better	 understanding	 of	 the	 arterial	 plaque	 lipid	 constituents	may	 form	 the	
basis	 for	 future	 treatment	 strategies	 and	 provide	 a	 means	 of	 assessing	 response	 to	
treatment.		
1.6	Transcranial	Doppler		
Transcranial	 Doppler	 (TCD)	 is	 a	 well	 established	 real-time	 imaging	 modality	 that	 detects	
microembolic	 signals	 (MES)	 in	 patients	with	 atherosclerotic	 disease	 of	 large	 arteries	who	
suffer	from	cerebral	or	retinal	ischaemia.54-57	It	is	a	non-invasive,	non-ionising,	portable	and	
safe	 technique	 that	 utilises	 an	 acoustic	 temporal	 bone	 window	 through	 which	 the	
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ultrasound	 beam	 can	 focus	 on	 the	 middle	 cerebral	 artery,	 which	 receives	 80%	 of	 an	
ipsilateral	internal	carotid	artery	inflow.54	58	59	Several	studies	have	shown	that	the	presence	
of	MES	is	associated	with	up	to	a	40-fold	increased	risk	of	future	neurological	events.56	60-63	
Furthermore,	 even	 patients	 following	 CEA	 remain	 at	 greater	 risk	 of	 MES-induced	
postoperative	 stroke.64	 65	 Moreover,	 MES	 correlates	 with	 a	 greater	 number	 of	 MRI	
detectable	 cerebral	 infarcts	 when	 compared	with	 patients	 free	 from	microembolism.62	 64	
Interestingly,	 the	 actual	 number	 of	 MES	 appears	 to	 be	 equally	 important.	 This	 was	
confirmed	 in	 a	 study	 where	 patients	 with	 10-30	 MES	 per	 30-min	 period	 suffered	 more	
severe	 neurological	 deficits	 than	 those	 with	 <10	 MES	 per	 30-min	 period.62	 Similarly,	
following	CEA,	microembolic	counts	>50	per	hour	were	associated	with	an	increased	risk	of	
neurological	 events.56	 Therefore,	 detection	and	prevention	of	 embolic	 events	may	have	a	
role	 in	 the	prediction	and	prevention	of	 future	stroke.57	Despite	 this,	no	centres	 routinely	
use	TCD	for	patient	triage	for	CEA.		
Although	the	pathological	events	that	lead	to	embolisation	into	the	cerebral	circulation	have	
been	 extensively	 investigated,	 the	 clinical	 consequences	 are	 not	 fully	 understood.	 Emboli	
generated	within	 large	 arteries	 such	 as	 the	 aortic	 arch	 and	 its	major	 branches	 can	 cause	
either	large	disabling	strokes	or	small	subclinical	events.57	The	embolic	material	may	consist	
of	 a	 thrombus,	 calcified	 plaque	 or	 other	 plaque	 constituents,	 and	 is	 often	 <0.1	 mm	 in	
diameter.	 If	 such	microemboli	pass	 into	 the	 small	 arteriolar	branches,	 the	 result	 can	be	a	
micro-infarction	of	brain	parenchyma.57	However,	not	all	microemboli	are	symptomatic,	and	
some	authors	suggested	that	this	phenomenon	may	explain	frequently	reported	subcortical	
ischaemic	 changes	 on	 CT	 or	 MRI	 in	 elderly	 patients	 with	 atherosclerotic	 risk	 factors.57	
Indeed,	 this	 may	 reflect	 the	 accumulated	 impact	 of	 asymptomatic	 microemboli	 over	 the	
years	leading	to	diffuse	brain	damage.57	62	In	contrast,	other	researchers	highlight	capillary	
dysfunction	as	a	primary	cause	for	the	cerebral	small	vessel	disease	that	manifests	on	MRI	







prevalent	 in	 patients	 with	 larger	 aortic	 plaques	 (>4	 mm).69	 However,	 no	 study	 has	
investigated	the	relationship	between	MES	and	recurrence	of	stroke	in	patients	with	a	non-
carotid	 artery	 source	 of	 embolism.	 We	 believe	 that	 TCD	 monitoring	 will	 add	 valuable	
information	regarding	the	correlation	between	MES	and	subsequent	stroke	risk	in	patients	










in	 subjects	without	 clinical	 stroke,	 the	most	 common	 subclinical	 pathology	 found	 on	MRI	
were	cerebral	and	lacunar	infarcts.70	71	Another	study	showed	that	patients	who	suffered	a	
minor	 stroke	 or	 TIA	 were	 diagnosed	 with	 silent	 early	 (33.7%)	 and	 late	 (22.1%)	 recurrent	
ischaemic	 lesions	 on	 diffusion-weighted	 imaging	 by	 MRI.72	 Even	 after	 carotid	
revascularisation	 procedures	 (CEA	 and	 stenting),	 patients	 develop	 silent	 new	 ischaemic	
infarcts.73		
Over	 the	 past	 decade,	 the	 intracranial	 atherosclerotic	 disease	 has	 not	 received	 the	 same	
amount	of	research	focus	as	the	extracranial	component	when	considering	the	aetiology	of	
neurovascular	 events.	 Interestingly,	 the	 intracranial	 disease	 that	 involves	 large	 arteries	 at	
the	base	of	 the	brain	 is	almost	as	common	as	carotid	artery	stenosis.68	More	 importantly,	
intracranial	 atherosclerosis	 is	 responsible	 for	 10%	of	 all	 strokes	 and	 TIAs.68	 Despite	OMT,	
patients	with	 severe	 (>70%)	 intracranial	disease	have	a	25%	 risk	of	 stroke	at	 two	years.68	
Although	 studies	 describe	 a	 high	 technical	 success	 rate	 with	 minimal	 complications	
following	 intracranial	angioplasty,	conflicting	data	exist	 regarding	a	post-procedural	stroke	
rate.68	 74-76	 Some	 authors	 report	 a	 low	 angioplasty	 stroke	 risk	 of	 between	 2-4%,	whereas	
others	 revealed	 stroke	 rates	 as	 high	 as	 14%	 that	 ultimately	 led	 to	 a	 termination	 of	 a	






Using	 a	 novel	 multimodal	 imaging	 approach,	 we	 propose	 to	 investigate	 a	 range	 of	 key	
pathobiological	pathways	(inflammation,	microcalcification,	necrosis	with	lipid-rich	core	and	
intraplaque	haemorrhage)	that	underlie	the	culprit	plaque	rupture	and	acute	neurovascular	
events.	 We	 hypothesise	 that	 18F-Fluoride	 PET-MRI	 (18F	 PET-MRI)	 will	 identify	 specific	
pathobiological	 pathways	 that	 will	 provide	 an	 ideal	 translational	 biomarker	 to	 identify	
culprit	 ruptured	 plaque	 and	 to	 test	 the	 plaque	 stabilising	 effects	 of	 novel	 therapeutic	
interventions.		
We	 plan	 to	 develop	 a	 “one-stop-shop”	 neurovascular	 18F	 PET-MRI	 protocol	 to	 assess	 the	
uptake	of	18F-Fluoride	and	plaque	MRI	characteristics	in	symptomatic	patients	with	carotid	
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ex	vivo	 to	 identify	 lipid	composition	and	correlate	the	results	with	18F-Fluoride	uptake	and	




will	 be	 able	 to	 differentiate	 clinically	 and	 surgically	 adjudicated	 culprit	 and	 non-culprit	
plaque.	 We	 also	 predict	 that	 18F-Fluoride	 uptake	 will	 be	 associated	 with	 high-risk	 MRI	


























be	 recruited	 as	 early	 as	 possible,	 but	 within	 14	 days	 of	 symptom	 onset.	 The	 diagnostic	
criteria	will	be	based	on	the	clinical	symptoms	and	radiological	evidence	of	infarction	in	line	
with	the	guidelines	produced	by	the	American	Heart	and	Stroke	Associations.		The	diagnosis	
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symptoms	 of	 a	 focal	 ischaemia	 will	 last	 <24	 hours	 with	 no	 evidence	 of	 infarction	 on	
imaging.78	 All	 patients	 will	 undergo	 careful	 clinical	 evaluation	 including	 carotid	 Doppler	
ultrasound	 assessment	 and	 magnetic	 resonance	 imaging	 of	 the	 brain.	 We	 will	 recruit	
patients	 who	 are	 scheduled	 to	 undergo	 carotid	 endarterectomy	 for	 symptomatic	 carotid	
artery	 stenosis	 (≥50%	 by	NASCET	 criteria	 for	men,	 ≥70%	 for	women).	 This	 cohort	will	 be	
identified	at	the	point	they	are	referred	to	a	vascular	surgeon	at	Edinburgh	Royal	Infirmary.	
After	 screening	 for	eligibility	by	 the	patient's	usual	 care	 team,	 the	 initial	 approach	will	be	




verbal	 description	of	 the	 study	 and	 go	over	 the	patient	 information	 sheet.	Any	questions	
that	arise	will	be	answered.	The	patient	will	be	contacted	at	least	24	hours	after	the	initial	


























This	 will	 be	 a	 prospective	 observational	 cohort	 study	 (See	 Appendix	 10a	 for	 study	 flow	
chart).	
3.2.1	Study	Visits	
For	 a	 flowchart	overview	of	 the	participant’s	pathway,	please	 refer	 to	Appendix	10b.	 The		
investigated	 cohort	 is	 composed	 of	 patients	 awaiting	 expedited	 surgery,	 and	 the	 imaging	
timetable	at	the	Edinburgh	Imaging	Facility	Queen’s	Medical	Research	Institute	(QMRI)	may	

































The	 18F	PET-MRI	will	 be	undertaken	using	 a	 Siemens	Biograph	mMR	hybrid	 scanner	using	









• Contrast-enhanced	 Magnetic	 Resonance	 angiography	 of	 the	 cerebral	 circulation	
including	aortic	arch	and	intracranial	vessels	centred	on	the	internal	carotid	artery	
• Coronal	 3D	 black	 blood	 T2-SPACE	 of	 the	 carotid	 bifurcation	 (and	 other	 plaques	 of	
interest)	
• High	 spatial	 resolution	 multi-contrast	 MRI	 will	 be	 performed	 using	 standard	































and	 geometry	will	 be	 preserved	 as	much	 as	 possible.	 Specimens	will	 be	 photographed	 in	
detail	to	permit	subsequent	assessment	by	independent	and	blinded	reviewers.	Dr	Maurits	
Jansen	 (Edinburgh	University)	who	has	expertise	 in	 the	 field	of	 the	MRI	and	 spectroscopy	
will	collaborate	with	us	regarding	an	ex	vivo	plaque	MRS.	The	excised	tissue	will	be	oriented	
and	labelled	in	such	a	manner	as	to	permit	orientation	in	the	carotid	artery	axis	and	will	be	
transported	 to	 the	 Edinburgh	 Pre-clinical	 Imaging	 suite	where	 7.4	 T	MRS	will	 take	 place.	
Subsequently,	carotid	plaque	will	be	transported	back	to	the	QMRI	where	specimen	will	be	
snap	 frozen	 in	 liquid	 nitrogen.	 Specimens	 will	 subsequently	 be	 prepared	 and	 stained	




























7.4	T	using	a	horizontal-bore	Agilent	MRI	 scanner	 to	 identify	either	 lipid-rich	or	 lipid-poor	
plaque	regions.	Specimens	will	be	placed	in	a	26-mm	diameter	imaging	coil	and	loaded	into	
the	 isocenter	 of	 the	magnet.	 The	 plaque	will	 be	 heated	 by	 air	 exchange	 to	 37⁰C	 20	min	
before	 initiation	 of	 the	 imaging	 protocol	 to	 permit	 thermal	 equilibration.	 High-resolution	





acquire	 a	 complete	 set	 of	 either	 T1W	or	 T2W	 images	will	 bet	 typically	 between	45	 to	 60	
min.	 Following	 image	 acquisition,	 a	 colourized	 polar	 map	 of	 the	 ratio	 of	 T1/T2	 image	
intensity	(based	solely	upon	the	signal	and	dependent	upon	T1/T2	contrast	weighting)	will	
be	 generated	 using	 the	 algebraic	 function	 of	 Paravision.	 This	 polar	map	will	 highlight	 the	
signal	 intensity	 differences	 between	 the	 T1	 and	 T2	 images	 and	 will	 be	 utilised	 to	 select	
regions	for	proton	spectroscopy.		
MRS		
Subsequently,	 image-guided	 proton	MRS	will	 be	 performed	 from	 3	mm3	 voxels	 using	 the	
PRESS	 technique	 (point-resolved	 spectroscopy)	 of	 voxel	 selection	 (Bruker	 sequence	
VSEL_SE_	SPEC).	Following	identification	of	the	region	of	interest,	a	larger	5mm	3	voxel	will	
be	placed	over	the	region	to	permit	shimming	of	Bₒ	on	the	water	peak	and	optimisation	of	




region	 of	 interest.	 Spectroscopy	 parameters	 will	 be	 as	 follows:	 spectral	 width,	 10K;	
acquisition	 size,	 2048;	 TR,	 500ms;	 TE,	 15ms;	 and	 Number	 of	 Excitations	 (NEX),	 600.	
Additional	spectroscopic	measurements	will	be	made	with	 identical	parameters	except	for	
TR	 of	 2,000	 ms.	 Spectral	 acquisition	 time	 is	 anticipated	 to	 take	 5	 minutes.	 A	 second	
spectrum	 from	 the	 same	 voxel	 position	 will	 be	 acquired	 without	 water	 suppression	 for	
standardisation.	This	technique	of	voxel	selection	and	the	signal	acquisition	will	be	applied	
to	phantom	samples	of	pure	cholesteryl	ester	and	triacylglycerol	to	test	the	sensitivity	of	the	
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the	 integrated	 water	 peak	 without	 presaturation	 (assigned	 to	 1.0).	 Ratios	 from	 a	 priori-
identified	 lipid-rich	 and	 lipid-poor	 plaque	 regions	 will	 be	 compared	 statistically	 using	 an	










acquires	 spectra	 from	 multiple	 regions	 of	 interest	 surrounding	 and	 over	 the	 plaque	 of	
interest.47	The	sequence	parameters	will	be	as	follows:	TR/TE	=	1100/30	ms,	FOV	=	80	mm2,	
matrix	 =	 160×160	 mm,	 voxel	 dimensions	 =	 5×5×5	 mm.47	 As	 for	 the	 ex-vivo	 spectra,	 the	
water	peak	will	be	assigned	to	4.7	ppm.	Spectral	analysis	will	be	carried	out	using	the	Java	
Magnetic	Resonance	User	 Interference	(JMRUI)	software	package	for	advanced	analysis	of	













presented	 as	 n	 (%)	 and	 will	 be	 compared	 using	 Fisher’s	 exact	 or	 Chi-squared	 tests.	
Correlation	will	 be	 undertaken	with	 either	 Pearson’s	 r	 or	 Spearman’s	 Rho	 subject	 to	 the	
normality	 of	 the	 variables	 tested.	 To	 quantify	 inter	 and	 intra-observer	 reproducibility	 of	
imaging	measurements,	the	intra-class	correlation	coefficient	will	be	calculated	and	Bland-
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T1	MRI-detected	thrombus.	We	will	assess	 the	relative	 frequencies	of	 their	co-localisation	
and	 levels	of	 agreement	with	 surgical	 findings	using	 intra-class	 correlation	 coefficient	 and	
kappa	 statistics.	We	will	 further	 explore	 the	 relative	 frequencies	 of	 co-localisation	 of	 18F-
Fluoride	uptake	and	T1	MRI-detected	thrombus	in	culprit	and	non-culprit	plaques	using	the	
chi-squared	 test.	 We	 will	 also	 compare	 microembolic	 signals	 detected	 on	 TCD	 with	 18F-




are	 further	 associations	 between	 our	 panel	 of	 exploratory	 imaging,	 spectroscopic	 and	
histologic	biomarkers.	
3.2	Sample	Size	
Data	 will	 be	 analysed	 to	 address	 the	 question	 of	 whether	 18F-fluoride	 uptake	 can	
differentiate	ruptured	from	non-ruptured	carotid	plaque.	Based	on	recent	data,	we	have	a	
variance	 (standard	deviation)	of	 0.13	 for	 TBRmax	with	mean	values	of	 1.88	 for	 18F-fluoride	
uptake.82	 We	 have	 previously	 seen	 a	 difference	 of	 0.08	 between	 culprit	 and	 non-culprit	















research	 subject	 will,	 therefore,	 be	 provided	 through	 the	 existing	 NHS	 and	 University	 of	
Edinburgh	 schemes.	 	 Both	 will	 provide	 cover	 for	 such	 harm	 arising	 from	 the	 design,	
management	or	conduct	of	the	research.	
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for	 publication	 in	 peer-reviewed	 journals.	 	 A	 lay	 summary	 of	 the	 results	 will	 also	 be	
disseminated	by	post	to	participants	who	wish	to	wish	to	receive	it.	
7.	Gadolinium	Contrast	Safety	Assessment	and	Related	Procedures	












Patients	 on	 metformin	 with	 an	 eGFR	 30–60	 ml/min/1.73m2	 will	 be	 advised	 to	 stop	
metformin	for	48	hours	before	and	after	the	scan.		They	will	then	have	a	blood	test	to	check	
renal	function	and	be	advised	on	when	to	restart	metformin.	
These	 safety	 assessments	 represent	 standard	 clinical	 care	 with	 respect	 to	 Gadolinium			
contrast.	
8.	Adverse	Events	








An	adverse	event	 (AE)	 is	any	untoward	medical	occurrence	 in	a	trial	participant	that	does	
not	 necessarily	 have	 a	 causal	 relationship	 with	 gadolinium-based	 contrast	 media	 or	 18F-
Fluoride.	
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Information	 to	 be	 collected	 includes	 dose,	 type	 of	 event,	 onset	 date,	 PI	 assessment	 of	




















The	 PI	 will	 make	 an	 assessment	 of	 severity	 for	 each	 AE/SAE	 and	 record	 this	 on	 the	 CRF	
according	to	one	of	the	following	categories:	
Mild:	 an	event	 that	 is	 easily	 tolerated	by	 the	participant,	 causing	minimal	discomfort	and	
not	interfering	with	every	day	activities.	





knowledge	 of	 the	 reaction	 and	 the	 relevant	 product	 information	 documented	 in	 the	
Summary	of	Product	Characteristics.	
The	event	may	be	classed	as	either:	








should	 not	 wait	 for	 this	 additional	 information	 before	 notifying	 ACCORD.	 	 The	
SAE/SAR/SUSAR	report	form	can	be	updated	when	the	additional	information	is	received.	
The	SAE/SAR/SUSAR	report	will	provide	an	assessment	of	causality	and	expectedness	at	the	
time	of	 the	 initial	 report	 to	ACCORD	according	 to	 Sections	 3.6.6,	Assessment	of	 Causality	
and	3.6.8,	Assessment	of	Expectedness.	
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The	 ACCORD	 Research	 Governance	 &	 QA	 Office	 is	 responsible	 for	 pharmacovigilance	
reporting	on	behalf	of	the	co-sponsors	(Edinburgh	University	and	NHS	Lothian).	
Although	 this	 study	 is	 not	 a	 Clinical	 Trial	 of	 an	 Investigational	 Medicinal	 Product,	 the	
ACCORD	Research	Governance	&	QA	Office	will	notify	 the	competent	regulatory	authority	
and	 relevant	 ethics	 committee	 (Research	 Ethics	 Committee	 (REC)	 that	 approved	 the	 trial)	
where	appropriate.	 	 Fatal	or	 life-threatening	SUSARs	will	 be	 reported	no	 later	 than	 seven	















Demographic,	 clinical,	 laboratory	 and	 all	 electronic	 radiological	 data	will	 be	 collected	 and	
stored	 in	 a	 linked-anonymous	 format.	 	 The	 Principal	 and	 Chief	 Investigators	 (Mr	 Jakub	
Kaczynski	 and	 Professor	 Newby)	 will	 have	 access	 to	 a	 master	 sheet	 linking	 the	 subjects’	
names	to	their	unique	patient	 identifier.	This	master	sheet	will	be	stored	electronically	on	
the	NHS	password-protected	 computer.	A	hard	 copy	will	 also	be	 kept	 in	 a	 locked	 cabinet	
within	the	NHS	premises.	
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aortic	 disease	 will	 not	 be	 included.	 	 Tissue	 will	 be	 collected	 through	 our	
collaboration	 with	 the	 Edinburgh	 Brain	 Bank.	 	 We	 will	 not	 request	 access	 to	



































scan	 will	 be	 obtained	 and	 a	 CT	 scan	 will	 then	 be	 acquired	 for	 attenuation	
correction.			
The	specimen	will	be	left	overnight	to	allow	complete	radiotracer	decay.			
The	 intact	 specimen	will	 then	be	 incubated	 in	 18F-NOTA-RGDfK	 for	30	minutes	
and	the	PET	protocol	will	be	repeated	as	above.	
	
PET	 data	 will	 be	 reconstructed	 using	 a	 3D	 reconstruction	 algorithm,	 with	
correction	for	randoms,	scatter	and	attenuation.		Volumes	of	interest	(VOIs)	will	
be	 manually	 drawn	 on	 the	 images,	 and	 radioactive	 concentration	 will	 be	
measured	for	each	radiotracer.	
	
Specimens	will	subsequently	be	sectioned	for	autoradiography	and	histological	
analysis.	
The	EdinVasc	ex	vivo	Imaging	Study	v1.0;	040417	
	
Autoradiography	Protocol	
Tissue	sections	will	be	pre-washed	in	cold	buffer	for	15	minutes,	then	the	
sections	will	be	incubated	in	1nM	[3H]PK11195	for	60	minutes	or	2.5	nM	
[3H]NS14490	for	120	minutes	at	room	temperature.	The	reaction	will	be	
terminated	by	two	5	minutes	washes	in	cold	buffer	and	the	slides	will	be	left	to	
dry	overnight.	The	nonspecific	binding	will	be	determined	by	adding	10	µM	
PK11195	or	10	µM	NS14490.	Slices	will	then	be	left	to	dry	overnight	in	a	
desiccator	at	room	temperature	before	being	exposed	to	a	BAS	TR240	tritium	
sensitive	imaging	plate	for	5	to	15	days	and	then	imaged	using	a	FLA-5000	
scanner.	Tritium	standards	will	be	used	for	quantification	of	binding.		
	
Histological	Analysis	
Where	possible,	histological	analysis	will	be	performed	following	the	PET-CT	and	
autoradiography	protocols,	focussing	on	the	identification	of	markers	of	
inflammation,	angiogenesis,	mineralisation	and	apoptosis.	
	
POTENTIAL	FUTURE	APPLICATIONS	
	
This	is	an	exploratory	study	that	aims	to	firstly	validate	our	recent	in	vivo	results	
demonstrating	that	18F-NaF	uptake	on	PET-CT	is	increased	in	patients	with	
abdominal	aortic	aneurysm	and	can	predict	AAA	growth	and	clinical	outcomes.		
In	addition,	we	will	explore	the	application	of	other	novel	PET	tracers	in	
identifying	disease	activity	ex	vivo	in	aortic	disease	and	in	peripheral	artery	
occlusive	disease.	
	
This	study	will	provide	further	insight	into	the	pathobiology	of	aortic	disease	and	
PAD	and	will	allow	evaluation	of	potential	new	imaging	biomarkers.		Successful	
identification	of	new	PET	tracers	that	identify	relevant	disease	processes	ex	vivo	
would	translate	into	future	in	vivo	studies	to	investigate	the	feasibility	and	
efficacy	of	clinical	PET-CT	in	predicting	disease	outcomes.	
	
The	EdinVasc	ex	vivo	Imaging	Study	v1.0;	040417	
Based	on	the	findings	of	this	study,	we	intend	to	apply	for	further	funding	to	
support	larger	clinical	studies	of	patients	with	aortic	disease	and	PAD.		In	
particular,	if	ex	vivo	characterisation	of	AAA	tissue	using	18F-NaF	supports	the	
findings	in	our	recent	clinical	study,	we	will	propose	a	larger	clinical	feasibility	
study	of	18F-NaF	PET-CT	in	predicting	AAA	growth.		If	successful,	this	could	lead	
to	a	randomised	trial	evaluating	early	intervention	in	AAA	disease,	based	on	18F-
NaF	PET-CT	findings.		Taken	together,	this	has	the	potential	to	change	
management	of	patients	with	AAA.	
	
In	addition,	results	from	this	study	would	help	us	to	support	future	clinical	
studies	using	other	the	novel	PET	radiotracers	described	in	this	protocol	that	
have	not	previously	been	investigated	in	aortic	disease	or	PAD.		This	could	lead	
to	a	number	of	other	proof-of-concept	clinical	studies,	and	beyond.	
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